<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> Syros Pharmaceuticals, Inc. (Form: S-1/A, Received: 06/20/2016 07:15:15) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_REGISTRATION_FEE **FIS_SUBJECT_STOCK_INFO **FIS_TABLE_OF_CONTENTS **FIS_PROSPECTUS_SUMMARY **FIS_THE_OFFERING **FIS_FINANCIAL_DATA **FIS_RISK_FACTORS **FIS_FORWARD_LOOK **FIS_PROCEED_USE **FIS_DIVIDEND_POLICY **FIS_CAPITALIZATION **FIS_DILUTION **FIS_BENEFICIAL_OWNERS **FIS_FINANCIAL_DATA_2 **FIS_MANAGEMENTS_DISCUSSION **FIS_OPTIONS **FIS_LIQUIDITY **FIS_MARKET_RISK **FIS_BUSINESS **FIS_COMPETITION **FIS_EMPLOYEES **FIS_MANAGEMENT **FIS_NAME_AND_TITLE **FIS_COMMITTEE_INTERLOCKS **FIS_EXECUTIVE_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_STOCK_PLANS **FIS_DIRECTOR_COMPENSATION **FIS_CERTAIN_TRANSACTIONS **FIS_CERTAIN_TRANSACTIONS_2 **FIS_STOCKHOLDERS **FIS_BENEFICIAL_OWNERS_2 **FIS_SECURITIES_DESCRIPTION **FIS_TRANSFER_AGENT **FIS_FUTURE_SALE **FIS_TAXATION **FIS_UNDERWRITING **FIS_MARKET **FIS_LEGAL_MATTERS **FIS_EXPERTS **FIS_MORE_INFORMATION **FIS_FINANCIAL_STATEMENTS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_PART_II **FIS_OFFERING_EXPENSE **FIS_INDEMNIFICATION **FIS_SALE_OF_UNREGISTERED_SECURITIES **FIS_EXHIBITS **FIS_UNDERTAKINGS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_1 FIS_EXHIBIT_3 **FIS_CERTIFICATE_OF_INCORPORATION FIS_EXHIBIT_5 FIS_EXHIBIT_23 ">
<META NAME="DETECTED PAGES" CONTENT="80">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="A2228976ZS-1A_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<BR>
<P>
<FONT SIZE=3>
	Use these links to rapidly review the document
<BR>
<A HREF="#A2228976ZS-1A_HTM_BG79601_TABLE_OF_CONTENTS">
	TABLE OF CONTENTS
</A>
<BR>
<A HREF="#A2228976ZS-1A_HTM_FA79601_INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMENTS">
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</A>
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	As filed with the Securities and Exchange Commission on June&nbsp;20, 2016
</B>
</FONT>
</P>
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Registration No.&nbsp;333-211818
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 3.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:3.0PT;">
</DIV>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 1.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:4.0PT;">
</DIV>
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	UNITED STATES
<BR>
	SECURITIES AND EXCHANGE COMMISSION
<BR>
</B>
</FONT>
<FONT SIZE=1>
<B>
	Washington, D.C. 20549
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=1>
<B>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Amendment No.&nbsp;1 to
<BR>
</B>
</FONT>
<FONT SIZE=4>
<B>
	FORM S-1
<BR>
</B>
</FONT>
<FONT SIZE=1>
<B>
	REGISTRATION STATEMENT
<BR>
	UNDER
<BR>
	THE SECURITIES ACT OF&nbsp;1933
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=1>
<B>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	SYROS PHARMACEUTICALS,&nbsp;INC.
<BR>
</B>
</FONT>
<FONT SIZE=1>
	(Exact name of registrant as specified in its charter)
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="31%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="31%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Delaware
</B>
</FONT>
<FONT SIZE=1>
<BR>
	(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of
<BR>
	incorporation&nbsp;or&nbsp;organization)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	2834
</B>
</FONT>
<FONT SIZE=1>
<BR>
	(Primary Standard Industrial
<BR>
	Classification Code Number)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	45-3772460
</B>
</FONT>
<FONT SIZE=1>
<BR>
	(I.R.S. Employer
<BR>
	Identification No.)
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	620 Memorial Drive, Suite&nbsp;300
<BR>
	Cambridge, Massachusetts 02139
<BR>
	(617)&nbsp;744-1340
</B>
</FONT>
<FONT SIZE=1>
<BR>
	(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=1>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Nancy Simonian, M.D.
<BR>
	President and Chief Executive Officer
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
<BR>
	620 Memorial Drive, Suite&nbsp;300
<BR>
	Cambridge, Massachusetts 02139
<BR>
	(617)&nbsp;744-1340
</B>
</FONT>
<FONT SIZE=1>
<BR>
	(Name, address, including zip code, and telephone number, including area code, of agent for service)
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=1>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="46%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="46%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Copies to:
</B>
</FONT>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<BR>
<FONT SIZE=1>
<B>
	Steven D. Singer
<BR>
	Cynthia T. Mazareas
<BR>
	Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP
<BR>
	60 State Street
<BR>
	Boston, Massachusetts 02109
<BR>
	Telephone: (617)&nbsp;526-6000
<BR>
	Fax: (617)&nbsp;526-5000
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
<BR>
	&nbsp;
</B>
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
<BR>
	Divakar Gupta
<BR>
	Nicole C. Brookshire
<BR>
	Richard C. Segal
<BR>
	Cooley&nbsp;LLP
<BR>
	1114 Avenue of the Americas
<BR>
	New York, New York 10036
<BR>
	Telephone: (212)&nbsp;479-6000
<BR>
	Fax: (212)&nbsp;479-6275
</B>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=1>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Approximate date of commencement of proposed sale to the public:
<BR>
	As soon as practicable after this Registration Statement is declared effective.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
	1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
	the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
	registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act
	registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
	definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:100%;MARGIN-LEFT:0%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="116PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="8%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="89PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="8%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="126PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="8%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="136PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Large accelerated filer
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Accelerated filer
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Non-accelerated filer
<FONT FACE="WINGDINGS">
	&#253;
</FONT>
<BR>
</FONT>
<FONT SIZE=1>
	(Do not check if a
<BR>
	smaller reporting company)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Smaller reporting company
<FONT FACE="WINGDINGS">
	&#111;
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<EFX_REGISTRATION_FEE>
<A NAME="FIS_REGISTRATION_FEE"></A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	CALCULATION OF REGISTRATION FEE
</B>
</FONT>
</P>
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="60%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="111" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="111" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:4PT;TEXT-INDENT:-4PT;">
<FONT SIZE=1>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Title of Class of Securities
<BR>
	Being Registered
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Proposed Maximum
<BR>
	Aggregate
<BR>
	Offering Price(1)(2)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	Amount of
<BR>
	Registration Fee(3)
</B>
</FONT>
<BR>
</TH>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
	&nbsp;
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:4PT;TEXT-INDENT:-4PT;">
<FONT SIZE=1>
<B>
</B>
</FONT>
<FONT SIZE=1>
	Common Stock, $0.001 par value per share
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$73,600,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	$7,412
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1.5PT;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:DOUBLE #000000 2.25PT;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:4PT;TEXT-INDENT:-4PT;">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	(1)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	In
	accordance with Rule&nbsp;457(o) under the Securities Act of 1933, as amended, the number of shares being registered and the proposed maximum offering
	price per share are not included in this table.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Estimated
	solely for purposes of computing the amount of the registration fee pursuant to Rule&nbsp;457(o) under the Securities Act of 1933, as amended.
	Includes the offering price of shares that the underwriters have the option to purchase to cover overallotments, if any.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	The
	Registrant previously paid $6,949 of this amount in connection with the initial filing of this Registration Statement.
</FONT>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=1>
<B>
	The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
	file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or
	until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;LINE-HEIGHT:1PT;MARGIN-LEFT:18PT;">
<FONT>
</FONT>
<FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
	&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 1.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:3.0PT;">
</DIV>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 3.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:4.0PT;">
</DIV>
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=679071,FOLIO='BLANK',FILE='DISK124:[15ZCT1.15ZCT79601]BA79601A.;39',USER='GPEARMO',CD='17-JUN-2016;20:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_TXTHEX,"" -->
</FONT>
<FONT COLOR="#FF4040" SIZE=2>
<B>
	The information in this preliminary prospectus is not complete and may be changed. We may not sell these
	securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not
	soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.
</B>
</FONT>
</P>
</EFX_REGISTRATION_FEE>
<EFX_SUBJECT_STOCK_INFO>
<A NAME="FIS_SUBJECT_STOCK_INFO"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- COMMAND=ADD_TXTHEX,"" -->
</B>
</FONT>
<FONT COLOR="#FF4040" SIZE=2>
<B>
	PROSPECTUS (Subject to completion) Dated June&nbsp;20, 2016
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=2>
<B>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	4,000,000&nbsp;Shares
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G778263.JPG" ALT="LOGO" WIDTH="631" HEIGHT="130">
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is the initial public offering of our common stock. We are offering 4,000,000&nbsp;shares of our common stock. We have applied to list our
	common stock on The NASDAQ Global Market under the symbol "SYRS." We expect that the initial public offering price for our common stock will be between $14.00 and $16.00&nbsp;per share.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are an "emerging growth company" under applicable Securities and Exchange Commission rules and will be eligible for reduced public company disclosure requirements for this prospectus
	and future filings. See "Summary&#151;Implications of Being an Emerging Growth Company."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=3>
<B>
	Our business and investment in our common stock involve significant risks. These risks are described in the section titled "Risk Factors"
	beginning on page&nbsp;13 of this prospectus.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon
	the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:100%;MARGIN-LEFT:0%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Per Share
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Initial public offering price
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- -->
	$
</B>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- -->
	$
</B>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
<B>
</B>
</FONT>
<FONT SIZE=2>
<B>
	Underwriting discounts and commissions(1)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- -->
	$
</B>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- -->
	$
</B>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
<B>
</B>
</FONT>
<FONT SIZE=2>
<B>
	Proceeds, before expenses, to Syros Pharmaceuticals, Inc.&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- -->
	$
</B>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<!-- -->
	$
</B>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:0%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	(1)
</FONT>
</DT>
</EFX_UNIDENTIFIED_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	We
	refer you to the section entitled "Underwriting" beginning on page 184 for additional information regarding total underwriting compensation.
</FONT>
</DD>
</DL>
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our existing principal stockholders have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million in shares of our common stock in this offering
	at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares
	to any of these potential
	purchasers and any of these potential purchasers could determine to purchase more, less or no shares in this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters may also purchase up to an additional 600,000&nbsp;shares from us at the initial public offering price, less the underwriting discounts and commissions, within
	30&nbsp;days from the date of this prospectus to cover overallotments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters expect to deliver the shares against payment in New York, New York on or about July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:100%;MARGIN-LEFT:0%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	Cowen and Company
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	Piper Jaffray
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=4>
<B>
	JMP Securities
<BR>
	Wedbush PacGrow
<BR>
</B>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;LINE-HEIGHT:1PT;MARGIN-LEFT:18PT;">
<FONT>
</FONT>
<FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
	&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=2,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=572571,FOLIO='BLANK',FILE='DISK124:[15ZCT1.15ZCT79601]BC79601A.;58',USER='KSEAMON',CD='19-JUN-2016;10:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_BG79601_1_1">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_SUBJECT_STOCK_INFO>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
</A>
</FONT>
</P>
<EFX_TABLE_OF_CONTENTS>
<A NAME="FIS_TABLE_OF_CONTENTS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_BG79601_TABLE_OF_CONTENTS">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	TABLE OF CONTENTS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_BG79601_TOC">
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Page
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_CA79601_SUMMARY">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Summary
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_CA79601_SUMMARY">
<FONT SIZE=2>
	1
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DA79601_RISK_FACTORS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Risk Factors
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DA79601_RISK_FACTORS">
<FONT SIZE=2>
<BR>
	13
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_SPECIAL_NOTE_REGARDING_FORWARD__SPE02700">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Special Note Regarding Forward-Looking Statements and Industry
	Data
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_SPECIAL_NOTE_REGARDING_FORWARD__SPE02700">
<FONT SIZE=2>
<BR>
	62
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_USE_OF_PROCEEDS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Use of Proceeds
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_USE_OF_PROCEEDS">
<FONT SIZE=2>
<BR>
	64
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_DIVIDEND_POLICY">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Dividend Policy
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_DIVIDEND_POLICY">
<FONT SIZE=2>
<BR>
	65
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_CAPITALIZATION">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Capitalization
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_CAPITALIZATION">
<FONT SIZE=2>
<BR>
	66
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_DILUTION">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Dilution
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DM79601_DILUTION">
<FONT SIZE=2>
<BR>
	68
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DO79601_SELECTED_CONSOLIDATED_FINANCIAL_DATA">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Selected Consolidated Financial Data
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DO79601_SELECTED_CONSOLIDATED_FINANCIAL_DATA">
<FONT SIZE=2>
<BR>
	71
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DO79601_MANAGEMENT_S_DISCUSSION_AND_AN__MAN03466">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Management's Discussion and Analysis of Financial Condition and
	Results of Operations
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DO79601_MANAGEMENT_S_DISCUSSION_AND_AN__MAN03466">
<FONT SIZE=2>
<BR>
	73
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DS79601_BUSINESS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Business
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_DS79601_BUSINESS">
<FONT SIZE=2>
<BR>
	92
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EA79601_MANAGEMENT">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Management
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EA79601_MANAGEMENT">
<FONT SIZE=2>
<BR>
	143
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EC79601_EXECUTIVE_COMPENSATION">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Executive Compensation
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EC79601_EXECUTIVE_COMPENSATION">
<FONT SIZE=2>
<BR>
	151
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EE79601_TRANSACTIONS_WITH_RELATED_PERSONS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Transactions with Related Persons
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EE79601_TRANSACTIONS_WITH_RELATED_PERSONS">
<FONT SIZE=2>
<BR>
	164
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EE79601_PRINCIPAL_STOCKHOLDERS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Principal Stockholders
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EE79601_PRINCIPAL_STOCKHOLDERS">
<FONT SIZE=2>
<BR>
	168
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EG79601_DESCRIPTION_OF_CAPITAL_STOCK">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Description of Capital Stock
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EG79601_DESCRIPTION_OF_CAPITAL_STOCK">
<FONT SIZE=2>
<BR>
	173
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EG79601_SHARES_ELIGIBLE_FOR_FUTURE_SALE">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Shares Eligible for Future Sale
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EG79601_SHARES_ELIGIBLE_FOR_FUTURE_SALE">
<FONT SIZE=2>
<BR>
	177
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EG79601_MATERIAL_U_S__FEDERAL_INCOME_A__MAT03574">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Material U.S. Federal Income and Estate Tax Considerations for
	Non-U.S. Holders of Common Stock
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EG79601_MATERIAL_U_S__FEDERAL_INCOME_A__MAT03574">
<FONT SIZE=2>
<BR>
	179
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_UNDERWRITING">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Underwriting
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_UNDERWRITING">
<FONT SIZE=2>
<BR>
	183
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_LEGAL_MATTERS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Legal Matters
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_LEGAL_MATTERS">
<FONT SIZE=2>
<BR>
	190
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_EXPERTS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Experts
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_EXPERTS">
<FONT SIZE=2>
<BR>
	190
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_WHERE_YOU_CAN_FIND_MORE_INFORMATION">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Where You Can Find More Information
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_EI79601_WHERE_YOU_CAN_FIND_MORE_INFORMATION">
<FONT SIZE=2>
<BR>
	190
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FA79601_INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMENTS">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Index to Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FA79601_INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMENTS">
<FONT SIZE=2>
<BR>
	F-1
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
	should rely only on the information contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. We have not, and the underwriters have not,
	authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriters
	are not, making an offer to sell these securities in any jurisdictions where the offer and sale is not permitted. You should assume that the information appearing in this prospectus is accurate only
	as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since such date. Information contained on our website is
	not a part of this prospectus. Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where
	action for that purpose is required, other than in the United States. You are required to inform yourselves about, and to observe any restrictions relating to, this offering and the distribution of
	this prospectus outside of the United States.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	i
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=3,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=397719,FOLIO='I',FILE='DISK124:[15ZCT1.15ZCT79601]BG79601A.;21',USER='CHE105536',CD='16-JUN-2016;03:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_1">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_TABLE_OF_CONTENTS>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<EFX_PROSPECTUS_SUMMARY>
<A NAME="FIS_PROSPECTUS_SUMMARY"></A>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_CA79601_SUMMARY">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_CA79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	SUMMARY
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	This summary highlights, and is qualified in its entirety by, the more detailed information and consolidated
	financial statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire
	prospectus, especially our consolidated financial statements and the related notes thereto included elsewhere in this prospectus and the "Risk Factors" section of this prospectus, before deciding to
	invest in our common stock.
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Overview
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company pioneering an understanding of the region of the genome controlling the activation and repression of
	genes. Our goal is to advance a new wave of medicines to control the expression of disease-driving genes. We have built a proprietary gene control platform designed to systematically and efficiently
	analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the
	function of all cells, we believe that our gene control platform has broad potential to create medicines that achieve profound and durable benefit across therapeutic areas and a range of diseases. By
	focusing on genomically defined subsets of patients, we believe we can conduct efficient clinical trials with a higher likelihood of success. We are currently focused on developing treatments for
	cancer and immune-mediated diseases and are building a pipeline of gene control medicines. We plan to begin a Phase&nbsp;2 clinical trial for our lead product candidate, SY-1425 (tamibarotene), in
	mid-2016. This trial will enroll genomically defined subsets of patients with relapsed or refractory acute myelogenous leukemia, or AML, and relapsed high-risk myelodysplastic syndrome, or MDS. We
	plan to initiate a Phase 1/2 clinical trial for our development candidate SY-1365, initially for the treatment of acute leukemia, in the first half of 2017. Both of these programs may have potential
	in additional indications. Using our platform, we are also generating a pipeline of novel preclinical drug candidates for genomically defined subsets of currently underserved patients. Our goal is to
	build a fully integrated biopharmaceutical company based on our leadership position in gene control.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Focus&#151;Gene Control Medicines
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are approximately 200 different cell types in the human body. Despite having identical genomes, each of these cell types has a
	different function. For example, a skin cell functions differently from a muscle cell despite sharing the exact same DNA. What determines a
	cell's type and function is the specific set of genes that is expressed, or turned "on" or "off," in that particular cell. This coordinated activation and repression of genes, known as the cell's gene
	expression program, is controlled by non-coding regions of the genome. Alterations in these non-coding regions change a cell's gene expression program, altering its normal function and leading to
	disease. Because this biology is fundamental to the function of all cells, it applies across diseases, whether the cause is genetic, environmental, bacterial, viral or multi-factorial.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
	researchers have long believed that alterations in non-coding regions of DNA, which account for 98% of the genome, play a key role in driving disease, the scientific community
	has lacked the tools to study these regions of the genome, rendering them poorly understood. As a result, the discovery and development of targeted therapies to date has focused almost exclusively on
	abnormal proteins resulting from genetic alterations found in regions of DNA that encode for proteins, which represent less than 2% of the entire genome.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
	targeted therapies, in which the right drug is matched to the right patient, have dramatically improved the ability to treat certain cancers and other serious diseases, the
	identification of new drug targets by sequencing coding regions of DNA has been largely exhausted. Moreover, in cancer,
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=4,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=299860,FOLIO='1',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_2">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	inhibiting
	abnormal proteins resulting from single genetic alterations can often lead to drug resistance and limited durable clinical benefit. Furthermore, many serious diseases continue to go
	unaddressed due to the limitations of current drug discovery approaches. Taken together, these factors underscore the need for fundamentally new approaches to drug discovery and development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
	on the work of our scientific founders, we believe we have developed the first proprietary platform designed to systematically and efficiently analyze non-coding regions of the
	genome in healthy and diseased cells taken from patient tissues to identify alterations in gene expression programs that represent optimal points of therapeutic intervention and develop drugs to
	control the expression of disease-driving genes. By doing so, we believe our gene control platform will allow us to (i)&nbsp;identify a wide array of potential new drug targets across a range of
	diseases, (ii)&nbsp;provide a new lens for diagnosing and segmenting patients, including those with complex, multi-factorial diseases that have eluded segmentation with other genomic-based
	approaches, and (iii)&nbsp;advance a new wave of medicines
	that have the potential to influence multiple drivers of disease through a single target, making them less susceptible to drug resistance and providing patients with a more profound and durable
	benefit than many of today's targeted therapies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	contrast to therapies that target a single abnormal protein, gene control medicines target alterations in the cell's underlying gene expression program, modulating the coordinated
	expression of the crucial set of genes that contribute to disease. The relatively few gene control medicines available today are among the most important targeted therapies and are widely used for
	their approved indications. These drugs, including estrogen receptor inhibitors for breast cancer, androgen receptor inhibitors for prostate cancer and glucocorticoids for inflammatory diseases,
	illustrate the significant therapeutic potential of gene control medicines. However, the poor understanding of non-coding regions of DNA has historically prevented a systematic approach to identifying
	these critical points of therapeutic intervention, making gene control a largely untapped field for targeted drug discovery and development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Gene Control Platform
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that we have created a systematic and efficient approach to analyzing non-coding regions of the genome in human disease
	tissue to identify and drug novel targets linked to genomically defined patient populations. Our proprietary gene control platform consists of two fundamental pillars: identifying novel gene control
	targets linked to genomically defined patient populations, and drugging gene control targets.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Identifying Novel Gene Control Targets
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Starting from human tissue samples, we compare diseased cells to normal cells and analyze the cells of different patient subsets within
	a disease to systematically and efficiently identify alterations in gene expression programs that represent optimal points of therapeutic intervention and associated biomarkers for patient selection.
	We home in on a cell's gene expression program by using genomic tools to locate super-enhancers, which are highly specialized regions of non-coding DNA that are central to orchestrating gene
	expression programs and drive the increased expression of the genes crucial to the function of a given cell. Analysis of super-enhancers and their associated genes provides critical insights into
	changes in gene expression programs that contribute to disease. We have invested significant resources in our tissue processing, genomics and computational biology capabilities to industrialize the
	analysis of gene expression programs to reveal the genes crucial to cell type and function in diseased cells. We have amassed one of the largest known datasets of gene expression programs across a
	wide range of human diseases and cell types and have validated multiple novel disease targets and biomarkers. To date, we have analyzed or are in the process of analyzing gene
	expression programs in AML, breast cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, non-disease and lupus immune cells, polycystic kidney disease, spinal
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=5,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=663788,FOLIO='2',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_3">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	muscular
	atrophy and Alzheimer's disease. Through those efforts, we have identified approximately 50 novel drug targets in oncology, immuno-oncology and autoimmune diseases and validated seven of
	those targets using biological methods to knock out the target gene or chemical methods to modulate the target's activity. The discovery and validation of these targets has led to the identification
	of our product candidate SY-1425 as well as additional novel preclinical drug candidates in earlier stages of research and development. We plan to analyze gene expression programs in several other
	cancers, including colorectal, lung and melanoma, as well as several other diseases and cell types including additional inflammatory disorders and immune cells from tumors. Our long-term goal is to
	analyze gene expression programs in serious diseases where we believe currently underserved patients can benefit from gene control medicines.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Drugging Gene Control Targets
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our platform is designed to identify drug targets across a broad range of therapeutic areas and therapeutic modalities. We focus our
	internal drug discovery efforts on small molecule chemistry to target specialized proteins responsible for gene expression, including transcription factors, transcriptional kinases and other
	transcriptional and regulatory proteins, for several reasons. First, because these specialized proteins play a central role in implementing gene expression programs, they are among the most promising
	and high-potential gene control targets for therapeutic intervention. Transcription factors bind directly to DNA sequences to control the transcription of genetic information from DNA. Transcription
	factors perform this function with other transcriptional and regulatory proteins, including transcriptional kinases. Second, transcriptional and regulatory proteins have historically been difficult to
	drug and represent an opportunity to bring novel and differentiated therapies to patients. Third, we have built a differentiated combination of expertise, tools and capabilities that we believe will
	give us cutting-edge insights into drugging transcriptional and regulatory proteins. Through significant investments in developing our capabilities in biochemistry, structural biology and medicinal
	chemistry and in developing a sophisticated suite of proprietary assays,
	which are internally developed tests that we use to measure the biochemical, biophysical, cellular and genomic activity of known and novel compounds against gene control targets, we believe we will be
	able to overcome challenges that have prevented others from systematically and successfully developing gene control medicines. We are building a pipeline of product candidates to modulate gene
	expression programs through two distinct approaches: internal efforts to discover novel drugs against our validated gene control targets, and externally focused efforts to link existing drugs to novel
	genomically defined patient populations identified through our platform. These externally focused efforts could enable us to identify drugs that we may seek to in-license or acquire or use as starting
	points for our own drug discovery and development programs to accelerate our development path.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Clinical Programs
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are leveraging our platform to develop a pipeline of gene control product candidates. By focusing on genomically defined subsets of
	patients who are most likely to respond, we believe we will conduct efficient clinical trials and rapidly achieve clinical proof-of-concept. With positive clinical results in areas of unmet medical
	need, we intend to apply for Breakthrough Therapy designation and
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=6,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=237402,FOLIO='3',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_4">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Fast
	Track designation which, if granted, could accelerate our clinical development path. Our most advanced drug programs are summarized in the table below:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:54%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="150%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="103PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="111PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="111PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="103PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Program
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Initial
<BR>
	Indications
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Planned
<BR>
	Milestones
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Potential
<BR>
	Indications
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Syros
<BR>
	Commercial
<BR>
	Rights
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	SY-1425 (RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	AML and MDS
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Initiate Phase&nbsp;2 clinical trial in
<BR>
	mid-2016
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Expect initial data readout in mid-2017
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Breast cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Acute promyelocytic leukemia (APL)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	North America, Europe
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	SY-1365 (CDK7 inhibitor)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Acute leukemia
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Initiate Phase&nbsp;1/2 clinical trial in
<BR>
	1H 2017
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Expect initial data readout in
<BR>
	1H&nbsp;2018
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Small cell lung cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Triple negative breast cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:11PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Worldwide
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	. We leveraged our platform to analyze gene expression programs in primary AML and breast cancer patient tumor cells and discovered that
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	, the gene that codes for
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	, was associated with a super-enhancer in some patients' tumors but not in
	others. We also identified a proprietary biomarker, which we refer to as the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, related to the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	. The
	super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	is believed to lock cells in an immature, proliferative
	and undifferentiated state. Treatment with SY-1425 in cancer cells with the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	appears to promote differentiation of
	these cells.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are initially advancing SY-1425 into novel genomically defined patient populations with AML and MDS. We chose these initial indications due to high levels of observed efficacy of
	SY-1425 in our preclinical models, the significant unmet medical need of these patients and the potential for accelerated development. We intend to pursue additional indications, including breast
	cancer, in the near future. We plan to use our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker for patient selection.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have the exclusive North American and European commercial rights to the existing preclinical data for SY-1425 in all human cancers under our license agreement with
	TMRC&nbsp;Co.,&nbsp;Ltd. SY-1425 is approved as tamibarotene in Japan for the treatment of APL, a form of AML, for which the drug has a well-characterized efficacy and safety profile. We intend to
	explore the development of SY-1425 for the treatment of APL in North America and Europe.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Preclinical Data
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have conducted multiple preclinical studies of SY-1425 in AML and breast cancer. In a mouse model implanted with human AML cells
	with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, known as a
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker-positive patient-derived xenograft, or PDX, model,
	SY-1425 was observed to
	have significant anti-tumor activity and prolonged survival in treated animals relative to untreated animals. In contrast, in a PDX model with human AML cells without the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, SY-1425 was not
	observed to have an effect on tumor control or survival. These data demonstrate a strong link between the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=7,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=705413,FOLIO='4',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_5">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	and
	response to treatment with SY-1425, and provide meaningful evidence that patients with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker will be promising candidates for treatment
	with SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425 Clinical Development Plan
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to initiate a Phase&nbsp;2 clinical trial in mid-2016 that will enroll genomically defined subsets of patients with relapsed
	or refractory AML or relapsed high-risk MDS. In May&nbsp;2016, the U.S. Food and Drug Administration, or FDA, accepted our Investigational New Drug, or IND, application for this trial. We plan to
	select patients for this trial using the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker. We believe patients whose tumors have this biomarker will be more likely to experience a
	profound and durable clinical benefit from treatment with SY-1425. We expect to have initial data from this study in mid-2017, or 12 months after the first patient is enrolled. We also plan to
	evaluate SY-1425 in newly diagnosed AML patients 60 years of age or older who are not suitable candidates for standard chemotherapy and low-risk transfusion-dependent MDS patients. In order to
	prospectively select patients in these populations using our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, we will seek clearance for the use of the biomarker test from the FDA
	through the Investigational Device Exemption process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1365 is a highly potent and selective small molecule inhibitor of the transcriptional kinase known as cyclin-dependent
	kinase&nbsp;7, or CDK7. We are investigating SY-1365 for the treatment of cancers that are dependent on a high and constant expression of certain transcription factors for their growth and survival,
	a phenomenon known as transcriptional addiction. CDK7 is a transcriptional kinase that is associated with super-enhancers controlling the expression of the transcription factors driving these cancers'
	growth and survival.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inhibiting
	CDK7 preferentially lowers the expression of disease-driving genes controlled by super-enhancers, including oncogenic transcription factors
</FONT>
<FONT SIZE=2>
<I>
	MYB
</I>
</FONT>
<FONT SIZE=2>
	and
</FONT>
<FONT SIZE=2>
<I>
	MYC,
</I>
</FONT>
<FONT SIZE=2>
	and results in the selective killing of cancer cells over non-cancerous cells. Preclinical
	studies of our CDK7 inhibitors demonstrated that transcriptionally addicted cancers are particularly sensitive to selective inhibition of CDK7, including AML, T-ALL, a form of acute lymphoblastic
	leukemia, or ALL,
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma, small cell lung cancer and triple negative breast cancer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Preclinical Data
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1365 has shown promising efficacy and safety in our
</FONT>
<FONT SIZE=2>
<I>
	in vivo
</I>
</FONT>
<FONT SIZE=2>
	and
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	preclinical
	studies. In terms of efficacy, SY-1365 was observed to have complete responses and survival benefit in cell-derived xenograft, or
	CDX, and PDX models of AML. In one such study, mice treated with SY-1365 experienced initial clearance of the disease and maintained residual low levels of human leukemia cells. In fact, 80% of
	treated mice remained alive and levels of human leukemia cells in the blood remained at less than 5% beyond the dosing period. By contrast, in untreated mice, the cancer progressed, reaching levels of
	human leukemia cells of greater than 50% in blood and greater than 90% in tissues.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	terms of selectivity and safety, in cell lines, SY-1365 was observed to preferentially kill cancer cells by inducing robust, sustained and dose-dependent apoptosis of AML cells with
	minimal impact on non-cancerous cells. In addition, SY-1365 was observed to have markedly fewer negative effects on healthy cells than a pan-CDK inhibitor. Pan-CDK inhibitors have been observed to
	result in blood cell death, or myelosuppression.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365 Clinical Development Plan
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have begun IND-enabling activities for SY-1365, and our goal is to initiate a Phase&nbsp;1/2 clinical trial in patients with acute
	leukemia, including AML and ALL, in the first half of 2017. We expect to have initial data from this study in the first half of 2018. We believe there is a well-defined path to
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=8,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=370109,FOLIO='5',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_6">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	clinical proof-of-concept in acute leukemia. We then plan to expand into a broader set of cancers using our platform to identify patient subsets with transcriptionally addicted cancers, such as small
	cell lung cancer, triple negative breast cancer and
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma. We continue to explore the potential of CDK7 inhibition in additional
	cancers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Programs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are using our platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to
	identify optimal points of therapeutic intervention in specific subsets of patients and to create a pipeline of novel preclinical drug candidates targeting transcriptional and regulatory proteins, as
	well as to link existing drugs to novel genomically defined patient populations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Team
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were founded by leaders in the field of gene control from the Whitehead Institute for Biomedical Research at the Massachusetts
	Institute of Technology, or Whitehead, and the Dana-Farber Cancer Institute, or Dana-Farber, an affiliate of Harvard Medical School. Our management team consists of drug discovery, development and
	commercialization experts with experience in translating scientific discoveries into innovative treatments, including Avonex and Tysabri for multiple sclerosis, Velcade and Ninlaro for hematological
	malignancies, Ibrance for breast cancer, Entyvio for&nbsp;ulcerative colitis and Kalydeco and Orkambi for cystic fibrosis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Financial Position
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March 31, 2016, we had cash and cash equivalents of $62.1 million. We believe our current cash position is sufficient to enable
	us to reach an initial clinical data readout for SY-1425 in AML and MDS and to fund our operating expenses and capital expenditure requirements at least through mid-2017. To date, our investors
	include Flagship Ventures, ARCH Venture Partners, Fidelity Management and Research Company, Deerfield Management Company, Polaris Partners, WuXi PharmaTech, Redmile Group, Aisling Capital, Alexandria
	Venture Investments and Casdin Capital.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Strategy
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated,
	leading biopharmaceutical company. To achieve this mission, we are executing on the following strategy:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Rapidly and efficiently advance our lead programs through clinical
	development.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We intend to enrich our trials with patients most likely to respond, which we believe will enable us to rapidly establish
	clinical proof-of-concept.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Develop a robust pipeline of gene control product
	candidates.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We plan to continue to leverage our gene control platform to systematically and efficiently identify optimal points of
	therapeutic intervention and associated biomarkers in specific patient populations. We intend to continue to generate a pipeline of gene control product candidates either through our internal drug
	discovery efforts or by linking existing drugs to novel patient populations.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Maintain our leadership position in the field of gene
	control.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Our long-term goal is to analyze gene expression programs in serious diseases where we believe currently underserved patients
	can benefit from gene control medicines. We intend to use these analyses of gene expression programs to pinpoint crucial genes driving disease and to validate the associated targets for therapeutic
	intervention.
</FONT>
</DD>
</DL>
</UL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=9,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=561795,FOLIO='6',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_7">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Continue to foster a culture of
	innovation.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We are committed to pioneering science and leadership in gene control medicines. We will continue to foster an environment
	that encourages innovation, excellence and productivity and develops our team as leaders in the field of gene control.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Execute strategic collaborations to maximize value and extend the potential of our gene control platform
	across multiple disease areas.
</B>
</FONT>
<FONT SIZE=2>
	We intend to engage in strategic collaborations for both our programs and our platform. For our programs, we are focused on partnerships that
	could expand our geographic reach and allow us to expand into additional indications. For our platform, we are seeking target and drug discovery collaborations that allow us to leverage the potential
	of our platform in cancers and other serious diseases beyond those that we can address on our own. We believe that our platform provides significant optionality for collaborations around therapeutic
	modalities and target classes that fall outside of our current focus on small molecule drugs targeting transcriptional and regulatory proteins.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Associated with Our Business
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are
	discussed more fully in the "Risk Factors" section of this prospectus immediately following this prospectus summary. These risks include the
	following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We have incurred significant losses since inception, expect to incur significant and increasing losses for at least the next several
	years and may never achieve or maintain profitability.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We have a limited operating history, no products approved for sale and no history of commercializing pharmaceutical products, which
	may make it difficult to evaluate the prospects for our future viability.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or
	eliminate our product development programs or commercialization efforts.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Our approach to the discovery and development of product candidates based on our gene control platform is unproven, and we do not know
	whether or when we will be able to develop any products of commercial value.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	In the near term, we are dependent on the successful development and commercialization of our lead product candidate, SY-1425, and our
	development candidate SY-1365.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Our gene control platform may fail to help us discover and develop additional potential product candidates.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Clinical drug development involves a lengthy and expensive process and has an uncertain outcome.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	If clinical trials of any product candidates that we develop fail to demonstrate safety and efficacy, we may incur additional costs or
	experience delays in completing, or be unable to complete, the development and commercialization of these product candidates. A clinical trial of tamibarotene for the treatment of lung cancer
	conducted by a third party was terminated when data suggested the endpoint of progression-free survival for 18&nbsp;months would not be reached.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Adverse events or undesirable side effects caused by product candidates that we develop may be identified during development and could
	delay or prevent their marketing approval or limit their use. For example, SY-1425 is a retinoid, a class of compounds related to vitamin&nbsp;A that have been observed in certain circumstances to
	cause birth defects.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We expect to rely on third parties to conduct clinical trials and certain aspects of our research and preclinical testing, to
	manufacture preclinical, clinical and commercial supplies of our product candidates and to develop our companion diagnostics.
</FONT>
</DD>
</DL>
</UL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=10,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=353457,FOLIO='7',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CA79601_1_8">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We are dependent on licenses with third parties for important intellectual property related to our business.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	If we are unable to obtain and maintain sufficient patent protection for our product candidates and gene control platform, including
	through existing and future licenses, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our
	ability to commercialize our product candidates successfully may be adversely affected. We do not have composition of matter patent protection with respect to SY-1425.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Corporate Information
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated under the laws of the State of Delaware on November&nbsp;9, 2011 under the name LS22,&nbsp;Inc. Our executive
	offices are located at 620 Memorial Drive, Suite&nbsp;300, Cambridge, Massachusetts 02139, and our telephone number is (617)&nbsp;744-1340. Our website address is www.syros.com. The information
	contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
	as otherwise indicated herein or as the context otherwise requires, references in this prospectus to "Syros," "the company," "we," "us" and "our" refer to Syros
	Pharmaceuticals,&nbsp;Inc. and our wholly owned subsidiary Syros Securities Corporation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Syros logo, "Syros" and "Syros Pharmaceuticals" are our trademarks. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the
	&reg; and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
	rights thereto. The trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Implications of Being an Emerging Growth Company
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a company with less than $1.0&nbsp;billion of revenue during our last fiscal year, we qualify as an "emerging growth company" as
	defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain
	disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. In particular, in this prospectus, we have provided only two years of audited
	consolidated financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. The JOBS Act also
	provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves
	of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Because we intend to rely on
	certain disclosure and other requirements of the JOBS Act, the information contained herein may be different than the information you receive from other public companies in which you hold stock. In
	addition, it is possible that some investors will find our common stock less attractive as a result of our determination to avail ourselves of exemptions under the JOBS Act, which may result in a less
	active trading market for our common stock and higher volatility in our stock price. We will remain an emerging growth company until the earlier to occur of: (1)&nbsp;the last day of the fiscal year
	in which we have total annual gross revenues of $1.0&nbsp;billion or more; (2)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the closing of this offering;
	(3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (4)&nbsp;the date on which we are deemed to be a large
	accelerated filer under the rules of the Securities and Exchange Commission.
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=11,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=408183,FOLIO='8',FILE='DISK124:[15ZCT1.15ZCT79601]CA79601A.;111',USER='CHE105948',CD='18-JUN-2016;12:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_CC79601_1_9">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_PROSPECTUS_SUMMARY>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<EFX_THE_OFFERING>
<A NAME="FIS_THE_OFFERING"></A>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_CC79601_THE_OFFERING">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_CC79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	THE OFFERING
<BR>
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Common stock offered by us
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,000,000 shares
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Common stock to be outstanding immediately after this offering
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	22,760,161&nbsp;shares, or 23,360,161&nbsp;shares if the underwriters exercise their option to purchase additional shares in
	full
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Underwriters' option to purchase additional shares
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	600,000 shares
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Use of proceeds
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	We estimate that we will receive net proceeds from this offering of approximately $52.8&nbsp;million, assuming an initial
	public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We intend to
	use the net proceeds from this offering together with our existing cash and cash equivalents, to fund clinical activity readouts for our product and development candidates. In particular, we intend to use the net proceeds from this offering to fund a
	Phase&nbsp;2 clinical trial of SY-1425 and to complete IND-enabling activities and the Phase&nbsp;1 portion of our planned Phase&nbsp;1/2 clinical trial of SY-1365; in each case, clinical trial expenses may include clinical research outsourcing, drug
	manufacturing, companion diagnostic development and internal personnel costs. We also intend to use a portion of the proceeds for new and ongoing research activities including our preclinical programs and our platform. The balance will be used for
	working capital and other general corporate purposes. See the "Use of Proceeds" section in this prospectus for a more complete description of the intended use of proceeds from this offering.
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Risk factors
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	You should read the "Risk Factors" section of this prospectus for a discussion of factors to consider carefully before
	deciding to invest in shares of our common stock.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proposed NASDAQ Global Market symbol
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	"SYRS"
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</FONT>
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of our common stock to be outstanding after this offering is based on 2,771,361&nbsp;shares of our common stock outstanding as of June&nbsp;15, 2016 and
	15,988,800 additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	number of shares of our common stock to be outstanding after this offering excludes:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,043,612&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;15, 2016, at a
	weighted-average exercise price of $4.67 per share;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	98,742 shares of our common stock available for future issuance as of June&nbsp;15, 2016 under our 2012 equity incentive plan; and
</FONT>
</DD>
</DL>
</UL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=12,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=158635,FOLIO='9',FILE='DISK124:[15ZCT1.15ZCT79601]CC79601A.;41',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CC79601_1_10">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,120,000 and 586,666 additional shares of our common stock that will become available for future issuance under our 2016 stock
	incentive plan and our 2016 employee stock purchase plan, respectively, each of which will become effective immediately prior to the closing of this offering, as well as any automatic annual increases
	in the number of shares of common stock reserved for future issuance under these plans.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
	otherwise indicated, all information in this prospectus assumes:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the filing and effectiveness of our restated certificate of incorporation and the adoption of our amended and restated bylaws, which
	will occur immediately prior to the closing of this offering;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	no exercise of the outstanding stock options described above;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	no exercise by the underwriters of their option to purchase up to 600,000 additional shares of our common stock to cover
	overallotments, if any; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,988,800 shares of our common stock
	upon the closing of this offering.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, all information in this prospectus gives effect to a one-for-3.75 reverse stock split of our common stock and a corresponding adjustment in the ratio at which our preferred
	stock will convert into common stock, which became effective on June&nbsp;17, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our existing principal stockholders have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million in shares of our common stock in this offering
	at the initial public offering price. Assuming an initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
	these stockholders would purchase an aggregate of approximately 2,333,333 of the 4,000,000&nbsp;shares offered in this offering based on these indications of interest. However, because indications
	of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares to any of these potential purchasers and any of these potential
	purchasers could determine to purchase more, less or no shares in this offering.
</FONT>
</P>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=13,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=677719,FOLIO='10',FILE='DISK124:[15ZCT1.15ZCT79601]CC79601A.;41',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_CE79601_1_11">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_THE_OFFERING>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_CE79601_SUMMARY_CONSOLIDATED_FINANCIAL_INFORMATION">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_CE79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	SUMMARY CONSOLIDATED FINANCIAL INFORMATION
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	You should read the following summary consolidated financial data together with our consolidated financial
	statements and the related notes included elsewhere in this prospectus and the "Selected Consolidated Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of
	Operations" sections of this prospectus. We have derived the statement of operations data for the years ended December&nbsp;31, 2014 and 2015 from our audited consolidated financial statements
	included elsewhere in this prospectus. We have derived the statement of operations data for the three months ended March&nbsp;31, 2015 and 2016 and the balance sheet data as of March&nbsp;31, 2016
	from our unaudited consolidated financial statements included elsewhere in this prospectus, which have been prepared on the same basis as the audited consolidated financial statements. In the opinion
	of management, the unaudited consolidated financial data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information as of
	and for the periods presented. Our historical results are not necessarily indicative of results that should be expected in any future period, and our results for any interim period are not necessarily
	indicative of results that should be expected for any full year.
</I>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(in thousands, except share and per share data)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Statements of Operations Data:
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	317
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating expenses:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,923
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,408
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,736
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,265
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,512
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,729
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	836
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,371
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,137
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,820
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss and comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,431
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,568
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss per share applicable to common stockholders&#151;basic and diluted(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10.26
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(17.55
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3.44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5.15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in net loss per share applicable to common stockholders&#151;basic and diluted(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,525,018
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,980,286
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,682,690
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,394,470
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma net loss per share&#151;basic and diluted (unaudited)(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2.09
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.59
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in pro forma net loss per share&#151;basic and diluted (unaudited)(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,593,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17,947,602
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	See
	Note&nbsp;2 to our consolidated financial statements included elsewhere in this prospectus for a description of the method used to calculate basic and
	diluted net loss per share and unaudited pro forma basic and diluted net loss per share as well as the weighted-average number of common shares used in the calculation of the per share amounts.
</FONT>
</DD>
</DL>
</DIV>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=14,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=576205,FOLIO='11',FILE='DISK124:[15ZCT1.15ZCT79601]CE79601A.;36',USER='CHE105231',CD='18-JUN-2016;12:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_CE79601_1_12">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
</I>
</FONT>
</P>
<DIV STYLE="WIDTH:100%;BOX-SIZING:BORDER-BOX;BORDER:#000000 SOLID 1.0PT;PADDING-TOP:12.0PT;PADDING-RIGHT:12.0PT;PADDING-BOTTOM:12.0PT;PADDING-LEFT:12.0PT;">
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	following table sets forth our summary consolidated balance sheet data as of March&nbsp;31, 2016:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	on an actual basis;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	on a pro forma basis to give effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into an aggregate of
	15,988,800 shares of common stock and (ii)&nbsp;the change in our total stockholders' (deficit) equity resulting from the stock-based compensation expense associated with the vesting of 53,334
	shares of restricted common stock and the vesting of performance-based option awards to purchase up to 59,387 shares of our common stock, each upon the closing of this offering; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	on a pro forma as adjusted basis to give further effect to the issuance and sale of 4,000,000 shares of our common stock in this
	offering at an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting
	discounts and commissions and estimated offering expenses payable by us.
</FONT>
</DD>
</DL>
</UL>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="70PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31, 2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Actual
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Pro Forma
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Pro Forma
<BR>
	As Adjusted(2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(in thousands)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Balance Sheet Data:
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	114,933
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Working capital(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	57,824
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	57,824
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	110,624
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total assets
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	123,625
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Convertible preferred stock
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	121,807
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total stockholders' (deficit) equity
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(57,890
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,917
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	116,717
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_UNIDENTIFIED_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We
	define working capital as current assets less current liabilities. See our consolidated financial statements for further details regarding our current
	assets and current liabilities.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	pro forma as adjusted information presented in the summary consolidated balance sheet data is illustrative only and will change based on the actual
	initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the
	midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total
	assets and total stockholders' equity by $3.7&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
	underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page
	of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders' equity by
	$14.0&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts and commissions and estimated offering expenses payable by
	us.
</FONT>
</DD>
</DL>
</DIV>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=15,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=395442,FOLIO='12',FILE='DISK124:[15ZCT1.15ZCT79601]CE79601A.;36',USER='CHE105231',CD='18-JUN-2016;12:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_13">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_FINANCIAL_DATA>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DA79601_RISK_FACTORS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DA79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	RISK FACTORS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock,
	you should carefully consider the risks described below, together with the other information contained in this prospectus, including our consolidated financial statements and the related notes
	included elsewhere in this prospectus. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects could be harmed. In these
	circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to Our Financial Position and Need for Additional Capital
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We have incurred significant losses since inception, expect to incur significant and increasing
	losses for at least the next several years, and may never achieve or maintain profitability.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred significant annual net operating losses in every year since our inception. We expect to continue to incur significant
	and increasing net operating losses for at least the next several years. Our net losses were $13.4&nbsp;million and $29.8&nbsp;million for the years ended December&nbsp;31, 2014 and 2015,
	respectively, and $10.6&nbsp;million for the three months ended March&nbsp;31, 2016. As of March&nbsp;31, 2016, we had an accumulated deficit of $64.1&nbsp;million. We have not generated any
	revenues from product sales, have not completed the development of any product candidate and may never have a product candidate approved for commercialization. We have financed our operations to date
	primarily through private placements of our preferred stock. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense
	to support such research and development. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have,
	an adverse effect on our stockholders' (deficit) equity and working capital.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	anticipate that our expenses will increase substantially if and as we:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	continue to develop and begin clinical trials with respect to SY-1425, including a Phase&nbsp;2 clinical trial we expect to initiate
	in mid-2016;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	continue to develop SY-1365, including initiating a Phase 1/2 clinical trial in the first half of 2017;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	initiate and continue research, preclinical and clinical development efforts for our preclinical programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	further develop our gene control platform;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	seek to identify and develop additional product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	acquire or in-license other product candidates or technologies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which
	we may obtain marketing approval, if any;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	maintain, expand and protect our intellectual property portfolio;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	hire and retain additional personnel, such as clinical, quality control and scientific personnel;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=16,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=268874,FOLIO='13',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_14">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	add operational, financial and management information systems and personnel, including personnel to support our product development
	and help us comply with our obligations as a public company; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	add equipment and physical infrastructure to support our research and development programs.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or any future
	collaborator is, able to obtain marketing approval for, and successfully commercialize, one or more of our product candidates. Successful commercialization will require achievement of key milestones,
	including initiating and successfully completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those
	products for which we, or any of our future collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance
	or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of revenues, and if or when we might achieve
	profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenues that are large enough for us to
	achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
	decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or
	continue our operations and cause a decline in the value of our common stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We have a limited operating history, no products approved for sale and no history of commercializing
	pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We commenced operations in 2011. Our operations to date have been limited to financing and staffing our company, developing our gene
	control platform and conducting preclinical research. We have not yet demonstrated an ability to successfully conduct clinical trials, obtain marketing approvals, manufacture a commercial-scale
	product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, you should consider our
	prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development, especially clinical stage biopharmaceutical companies
	such as ours. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and
	commercializing pharmaceutical products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will eventually need to transition
	from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are
	beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We will need substantial additional funding, and if we are unable to raise capital when needed, we
	could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time consuming, expensive
	and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate clinical trials of SY-1425, advance the
	development of SY-1365, initiate new research and preclinical development
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=17,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=867732,FOLIO='14',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_15">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	efforts
	and seek marketing approval for any product candidates that we successfully develop. Moreover, under license agreements with various licensors, we are obligated to make milestone payments upon
	the successful completion of specified development and commercialization activities. In addition, if we obtain marketing approval for any product candidate that we may successfully develop, we may
	incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the
	responsibility of a future collaborator. Furthermore, following the closing of this offering, we expect to incur significant additional costs associated with operating as a public company.
	Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced
	to delay, reduce or eliminate our research and development programs or any future commercialization efforts.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	plan to use the net proceeds of this offering primarily to fund our ongoing research and development efforts. We will be required to expend significant funds in order to advance the
	development of SY-1425 and SY-1365, as well as our other preclinical programs. In addition, while we may seek one or more collaborators for future development of our current product candidate or any
	future product candidates that we may develop for one or more indications, we may not be able to enter into a collaboration for any of our product candidates for such indications on suitable terms, on
	a timely basis or at all. In any event, the net proceeds of this offering and our existing cash and cash equivalents will not be sufficient to fund all of the efforts that we plan to undertake or to
	fund the completion of development of our product candidates or our other preclinical programs. Accordingly, we will be required to obtain further funding through public or private equity offerings,
	debt financings, collaborations and licensing arrangements or other sources. We do not have any committed external source of funds. Adequate additional financing may not be available to us on
	acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the net proceeds from this offering, together with our existing cash and cash equivalents as of March&nbsp;31, 2016, will enable us to fund our operating expenses and
	capital expenditure requirements at least through mid-2018. Our estimate as to how long we expect the net proceeds from this offering, together with our existing cash and cash equivalents, to be able
	to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing
	circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than
	planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the scope, progress, timing, costs and results of clinical trials of SY-1425 and SY-1365;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	research and preclinical development efforts for any future product candidates that we may develop;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of future product candidates that we pursue and their development requirements;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the outcome, timing and costs of seeking regulatory approvals;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs
	are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of acquiring potential new product candidates or technology;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=18,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=941341,FOLIO='15',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_16">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of any physician education programs relating to selecting and treating genomically defined patient populations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the timing and amount of milestone and other payments due to licensors for patent and technology rights used in our development
	platform;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	revenue received from commercial sales, if any, of our current and future product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and
	defending against intellectual property related claims; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of operating as a public company.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Raising additional capital may cause dilution to our stockholders, including purchasers of common
	stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our expenses to increase in connection with our planned operations. To the extent that we raise additional capital through
	the sale of common stock, convertible securities or other equity securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences
	and anti-dilution protections that could adversely affect your rights as a common stockholder. In addition, debt financing, if available, would
	result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital
	expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial
	amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management's ability to
	oversee the development of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our
	technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to
	delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and
	market ourselves.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to the Discovery, Development and Commercialization of Product Candidates
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our approach to the discovery and development of product candidates based on our gene control
	platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are focused on discovering and developing medicines for the treatment of cancer and other diseases based upon our gene control
	platform. We are leveraging our platform to create a pipeline of gene control drug candidates for genomically defined patients whose diseases have not been adequately addressed to date by other
	genomics approaches and to design and conduct efficient clinical trials with a higher likelihood of success. While we believe that applying our gene control platform to create medicines for
	genomically defined patient populations may potentially enable drug research and clinical development that is more efficient than conventional small molecule drug research and development, our
	approach is both novel and unproven. Because our approach is both novel and unproven, the cost and time needed to develop our product candidates is difficult to predict, and our efforts may not result
	in the discovery and development of commercially viable medicines. We may also be incorrect about the effects of our product candidates on the diseases of genomically defined patient populations,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=19,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=868455,FOLIO='16',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_17">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	which
	may limit the utility of our approach or the perception of the utility of our approach. Furthermore, our estimates of genomically defined patient populations available for study and treatment
	may be lower than expected, which could adversely affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully commercialize.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have not yet succeeded and may never succeed in demonstrating efficacy and safety for our current or any future product candidates in clinical trials or in obtaining marketing
	approval thereafter. For example, although we have discovered and evaluated compounds using our novel gene control platform, we have not yet advanced a compound into any phase of clinical development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our gene control platform may fail to help us discover and develop additional potential product
	candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of the research that we are conducting involves identifying novel targets and points of intervention and
	developing new compounds using our gene control platform. The drug discovery that we are conducting using our gene control platform may not be successful in identifying compounds that have commercial
	value or therapeutic utility. Our gene control platform may initially show promise in identifying potential product candidates, yet fail to yield viable product candidates for clinical development or
	commercialization for a number of reasons, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	compounds created through our gene control platform may not demonstrate efficacy, safety or tolerability;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that
	they are unlikely to receive marketing approval and achieve market acceptance;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a potential product candidate may not be capable of being produced at an acceptable cost.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new
	product candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future
	periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	In the near term, we are dependent on the success of SY-1425 and SY-1365. If we are unable to
	initiate or complete the clinical development of, obtain marketing approval for or successfully commercialize SY-1425 or SY-1365, either alone or with a collaborator, or if we experience significant
	delays in doing so, our business could be substantially harmed.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no products approved for sale and are investing a significant portion of our efforts and financial resources in the
	development of SY-1425 and SY-1365. Our prospects are substantially dependent on our ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully
	commercialize product candidates in one or more disease indications.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	success of SY-1425 and SY-1365 will depend on several factors, including the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	initiation and successful enrollment and completion of clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a safety, tolerability and efficacy profile that is satisfactory to the U.S. Food and Drug Administration, or FDA, or any comparable
	foreign regulatory authority for marketing approval;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=20,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=676063,FOLIO='17',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_18">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	timely receipt of marketing approvals from applicable regulatory authorities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the performance of our future collaborators, if any;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the extent of any required post-marketing approval commitments to applicable regulatory authorities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishment of supply arrangements with third-party raw materials suppliers and manufacturers including with respect to the supply
	of active pharmaceutical ingredient for SY-1425;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishment of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally,
	including our ability to maintain our license agreement with TMRC, which we refer to as the TMRC license agreement;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	protection of our rights in our intellectual property portfolio;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successful launch of commercial sales following any marketing approval;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a continued acceptable safety profile following any marketing approval;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	commercial acceptance by patients, the medical community and third-party payors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successful identification of biomarkers for patient selection;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	continued availability of appropriate tissue samples to enable the identification of novel targets in genomically defined subsets of
	patients; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our ability to compete with other therapies.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
	of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the
	manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for and successfully commercialize SY-1425 or SY-1365, on our own or with
	any future collaborator, or experience delays as a result of any of these factors or otherwise, our business could be substantially harmed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If clinical trials of any future product candidates that we, or any future collaborators, may
	develop fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we, or any future collaborators, may incur additional costs or experience delays in completing, or
	ultimately be unable to complete, the development and commercialization of these product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United
	States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the European Medicines Agency, or the EMA, impose similar requirements. We, and any future
	collaborators, must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these
	approvals.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
	testing is expensive, is difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical
	trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product
	development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially
	unacceptable, failure to
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=21,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=838689,FOLIO='18',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_19">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	comply
	with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not
	approvable. For example, a Phase&nbsp;2 clinical trial of tamibarotene (SY-1425) for the treatment of
	late-stage non-small cell lung cancer, or NSCLC, under a previous license between TMRC and a third party was terminated when interim data suggested that the primary endpoint of progression-free
	survival for 18&nbsp;months after starting therapy would not be reached. Interim data also showed that tamibarotene combined with paclitaxel and carboplatin chemotherapy was associated with
	increased toxicity in this non-selected NSCLC patient population. Although we have no current plans to conduct studies of SY-1425 in NSCLC or combine tamibarotene with paclitaxel and carboplatin in
	late-stage NSCLC patients, we face a similar risk of failure in our planned clinical trials of SY-1425. It is possible that even if one or more of our product candidates has a beneficial effect, that
	effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical
	trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any.
	Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well
	tolerated when that is not in fact the case.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	inability to successfully complete preclinical and clinical development could result in additional costs to us, or any future collaborators, and impair our ability to generate
	revenues from product sales, regulatory and commercialization milestones and royalties. Moreover, if we, or any future collaborators, are required to conduct additional clinical trials or other
	testing of our product candidates beyond the trials and testing that we or they contemplate, if we, or they, are unable to successfully complete clinical trials of our product candidates or other
	testing, or the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or there are unacceptable safety concerns associated with our product candidates, we, or any
	future collaborators, may:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	incur additional unplanned costs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	be delayed in obtaining marketing approval for our product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	not obtain marketing approval at all;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	obtain approval for indications or patient populations that are not as broad as intended or desired;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including
	boxed warnings;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	be subject to additional post-marketing testing or other requirements; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	be required to remove the product from the market after obtaining marketing approval.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	failure to successfully initiate and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market
	any of our product candidates would significantly harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Adverse events or undesirable side effects caused by, or other unexpected properties of, product
	candidates that we develop may be identified during development and could delay or prevent their marketing approval or limit their use.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse events or undesirable side effects caused by, or other unexpected properties of, SY-1425, SY-1365 or any future product
	candidates that we may develop could cause us, any future collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our
	product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Because gene control techniques
	are relatively new, side effects from gene control approaches may be
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=22,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=777345,FOLIO='19',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DA79601_1_20">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	unpredictable.
	Tamibarotene has been observed to be associated with adverse events, such as mild or moderate dry skin, skin rash, headache and bone pain, as well as retinoic acid syndrome and elevated
	levels of cholesterol, lipids, liver function enzymes and white blood cells, which were severe in certain cases. Furthermore, retinoids such as SY-1425 may cause birth defects and therefore may carry
	a warning on their label. Other examples of retinoids, a class of chemical compounds that are related to vitamin A, include all trans retinoic acid or ATRA, Retin-A, retinol (found in over-the-counter
	skin creams), isotretinoin and bexarotene. We have not yet tested SY-1365 in humans so the safety profile that SY-1365 will demonstrate in human clinical trials is unknown. If any of our product
	candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we, or any future collaborators, may need to abandon development or limit development of
	that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit
	perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development
	of the compound.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we, or any future collaborators, experience any of a number of possible unforeseen events in
	connection with clinical trials of our current product candidate or any future product candidates that we, or any future collaborators, may develop, potential clinical development, marketing approval
	or commercialization of our product candidates could be delayed or prevented.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, or any future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay
	or prevent clinical development, marketing approval or commercialization of our current product candidate or any future product candidates that we, or any future collaborators, may develop,
	including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulators or institutional review boards may not authorize us, any future collaborators or our or their investigators to commence a
	clinical trial or conduct a clinical trial at a prospective trial site;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we, or any future collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or
	clinical trial protocols with prospective trial sites;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	clinical trials of our product candidates may produce unfavorable or inconclusive results;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we, or any future collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials or abandon
	product development programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of patients required for clinical trials of our product candidates may be larger than we, or any future collaborators,
	anticipate, patient enrollment in these clinical trials may be slower than we, or any future collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we,
	or any future collaborators, anticipate;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our estimates of the genomically defined patient populations available for study may be higher than actual patient numbers and result
	in our inability to sufficiently enroll our trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the cost of planned clinical trials of our product candidates may be greater than we anticipate;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our third-party contractors or those of any future collaborators, including those manufacturing our product candidates or components
	or ingredients thereof or conducting clinical trials on our behalf or on behalf of any future collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us
	or any future collaborators in a timely manner or at all;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical
	trial protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial's duration;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	20
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=23,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=381963,FOLIO='20',FILE='DISK124:[15ZCT1.15ZCT79601]DA79601A.;46',USER='NDEWIND',CD='16-JUN-2016;20:15' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_21">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we, or any future collaborators, may have to delay, suspend or terminate clinical trials of our product candidates for various
	reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulators or institutional review boards may require that we, or any future collaborators, or our or their investigators suspend or
	terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable
	health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar product or
	product candidate;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the FDA or comparable foreign regulatory authorities may disagree with our, or any future collaborators', clinical trial designs or
	our or their interpretation of data from preclinical studies and clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes
	or facilities of third-party manufacturers with which we, or any future collaborators, enter into agreements for clinical and commercial supplies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of
	our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
	rendering our clinical data insufficient to obtain marketing approval.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
	development costs for us, or any future collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required
	to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin
	as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we, or any
	future collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any future collaborators, to bring products to market before
	we, or any future collaborators, do and impair our ability, or the ability of any future collaborators, to successfully commercialize our product candidates and may harm our business and results of
	operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics
	could harm our drug development strategy.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As one of the key elements of our development strategy, we seek to identify genomically defined subsets of patients within a disease
	category who may derive benefit from the product candidates we are developing. In collaboration with partners, we plan to develop companion diagnostics to help us to more accurately identify patients
	within a particular subset, both during our clinical trials and in connection with the commercialization of our product candidates that we are developing or may in the future develop. Companion
	diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. We do not develop
	companion diagnostics internally and thus we will be dependent on the sustained cooperation and effort of our third-party collaborators in developing and obtaining approval for these companion
	diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical
	validation, reproducibility, or clinical validation. Any delay or failure by our
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=24,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=852308,FOLIO='21',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_22">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators
	to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, our collaborators may encounter production
	difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical
	community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales, if any, of our products. In addition, the
	diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of
	our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an
	alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or
	delay the development or commercialization of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we, or any future collaborators, experience delays or difficulties in the enrollment of patients
	in clinical trials, our or their receipt of necessary regulatory approvals could be delayed or prevented.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, or any future collaborators, may not be able to initiate or continue clinical trials for our current product candidate or any
	future product candidates that we, or any future
	collaborators, may develop if we, or they, are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials. Patient enrollment is a significant factor in the
	timing of clinical trials, and is affected by many factors, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the size and nature of the patient population;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the severity of the disease under investigation;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the availability of approved therapeutics for the relevant disease;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the proximity of patients to clinical sites;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the eligibility criteria for the trial;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the design of the clinical trial;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	efforts to facilitate timely enrollment;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	competing clinical trials; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	clinicians' and patients' perceptions as to the potential advantages and risks of the drug being studied in relation to other
	available therapies, including any new drugs that may be approved for the indications we are investigating.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	particular, we intend to enrich our clinical trials with patients most likely to respond to our gene control therapies. However, genomically defined diseases may have relatively low
	prevalence and it may be difficult for us or third parties with whom we collaborate to identify patients for our trials, which may lead to delays in enrollment for our trials. We intend to develop, or
	engage third parties to develop, companion diagnostics for use in our clinical trials, but we or such third parties may not be successful in developing such companion diagnostics, furthering the
	difficulty in identifying genomically defined subsets of patients for our clinical trials. Our inability to enroll a sufficient number of genomically defined patients for our clinical trials would
	result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product
	candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Further, if we are unable to include a sufficient number of genomically defined
	patients in our trials, this could compromise our ability to seek participation in FDA's expedited review and approval programs, including Breakthrough Therapy designation and Fast Track designation,
	or otherwise to seek to accelerate clinical development and regulatory timelines.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=25,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=859857,FOLIO='22',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_23">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	inability, or the inability of any future collaborators, to enroll a sufficient number of patients for our, or their, clinical trials could result in significant delays or may
	require us or them to abandon one or more clinical trials altogether. Enrollment delays in our, or their, clinical trials may result in increased development costs for our product candidates, delay or
	halt the development of and approval processes for our product candidates and jeopardize our, or any future collaborators', ability to commence sales of and generate revenues from our product
	candidates, which could cause the value of our company to decline and limit our ability to obtain additional financing, if needed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Results of preclinical studies and early clinical trials may not be predictive of results of future
	late-stage clinical trials.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not conducted any clinical trials, and all our data results from preclinical studies. We cannot assure you that we will be able
	to replicate in human clinical trials the results we observed in animal models. Moreover, the outcome of preclinical studies and early clinical trials may not be predictive of the success of later
	clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered
	significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its
	results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing
	clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and
	analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product
	candidates. Even if we, or any future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory
	authorities may disagree and may not grant marketing approval of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including
	changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and
	the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and
	commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We have never obtained marketing approval for a product candidate and we may be unable to obtain, or
	may be delayed in obtaining, marketing approval for our current product candidates or any future product candidates that we, or any future collaborators, may develop.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive
	review any new drug applications, or NDAs, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our
	product candidates. If the FDA does not accept or approve our NDAs for any of our product candidates, it may require that we conduct additional clinical trials, preclinical studies or manufacturing
	validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required trials or studies, approval of any NDA or application
	that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional trials or studies, if performed and completed,
	may not be considered sufficient by the FDA to approve
	our NDAs. In addition, our development programs contemplate the development of companion diagnostics by our third-party collaborators. Companion diagnostics are subject to regulation as medical
	devices and must themselves
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=26,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=789410,FOLIO='23',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_24">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	be
	approved for marketing by the FDA or certain other foreign regulatory agencies before we may commercialize our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates or any companion diagnostics, generating revenues and
	achieving and sustaining profitability. If any of these outcomes occurs, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Even if any product candidates that we, or any future collaborators, may develop receive marketing
	approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our
	ability, or that of any future collaborators, to market the product.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials of SY-1425, SY-1365 or any future product candidates that we, or any future collaborators, may develop will be
	conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may
	indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval
	of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following
	adverse events could occur:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulatory authorities may withdraw their approval of the product or seize the product;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we, or any future collaborators, may be required to recall the product, change the way the product is administered or conduct
	additional clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we may be subject to fines, injunctions or the imposition of civil or criminal penalties;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulatory authorities may require the addition of labeling statements, such as a "black box" warning or a contraindication;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side
	effects for distribution to patients;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we, or any future collaborators, could be sued and held liable for harm caused to patients;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the product may become less competitive; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our reputation may suffer.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	of these events could harm our business and operations, and could negatively impact our stock price.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Even if our current product candidates, or any future product candidate that we, or any future
	collaborators, may develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary
	for commercial success, in which case we may not generate significant revenues or become profitable.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never commercialized a product, and even if one of our product candidates is approved by the appropriate regulatory authorities
	for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Physicians are often reluctant to
	switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are
	currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=27,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=579542,FOLIO='24',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_25">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efforts
	to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our
	product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance
	of our product candidates, if approved for commercial sale, will depend on a number of factors, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the efficacy and safety of the product;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the potential advantages of the product compared to competitive therapies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the prevalence and severity of any side effects;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the product's convenience and ease of administration compared to alternative treatments;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the willingness of the target patient population to try, and of physicians to prescribe, the product;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	limitations or warnings, including distribution or use restrictions, contained in the product's approved labeling;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the strength of sales, marketing and distribution support;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	changes in the standard of care for the targeted indications for the product; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	availability and amount of coverage and reimbursement from government payors, managed care plans and other third-party payors.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may expend our limited resources to pursue a particular product candidate or indication and fail
	to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific
	indications that we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with
	other product candidates or for other indications that may prove to have greater commercial potential.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and
	development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target
	market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
	been more advantageous for us to retain sole development and commercialization rights to the product candidate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we are unable to establish sales, marketing and distribution capabilities or enter into sales,
	marketing and distribution arrangements with third parties, we may not be successful in commercializing any product candidates if approved.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have a sales, marketing or distribution infrastructure and have no experience in the sale, marketing or distribution of
	pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. We plan to
	build focused capabilities to commercialize development programs for certain indications where we believe that the medical specialists for the indications are sufficiently concentrated to allow us to
	effectively promote the product with a targeted sales team. The
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	25
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=28,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=664353,FOLIO='25',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_26">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	development
	of sales, marketing and distribution capabilities will require substantial resources, will be time consuming and could delay any product launch. If the commercial launch of a product
	candidate for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we could have prematurely or unnecessarily incurred
	these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire or
	retain a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and
	marketing and distribution capabilities, our operating results may be adversely affected. If a potential partner has development or commercialization expertise that we believe is particularly relevant
	to one of our products, then we may seek to collaborate with that potential partner even if we believe we could otherwise develop and commercialize the product independently.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	certain indications, we plan to seek to enter into collaborations that we believe may contribute to our ability to advance development and ultimately commercialize our product
	candidates. We also intend to seek to enter into collaborations where we believe that realizing the full commercial value of our development programs will require access to broader geographic markets
	or the pursuit of broader patient populations or indications. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues
	or the profitability of these product revenues may be lower, perhaps substantially lower, than if we were to directly market and sell products in those markets. Furthermore, we may be unsuccessful in
	entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we may have little or no control over such third parties, and any
	of them may fail to devote the necessary resources and attention to sell and market our products effectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we do not establish sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our
	product candidates that receive marketing approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We face substantial competition, which may result in others discovering, developing or
	commercializing products before or more successfully than we do.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development and commercialization of new products is highly competitive. We expect that we, and any future collaborators, will face
	significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to any of our product candidates that we, or any
	future collaborators, may seek to develop or commercialize in the future. Specifically, there are a number of large pharmaceutical and biotechnology companies that currently market and sell products
	or are pursuing the development of product candidates for the treatment of the key indications of our most advanced programs, such as the
	use of chemotherapy followed by stem cell transplantation in the case of AML, MDS and ALL. SY-1425 may also face competition from other drug candidates currently in clinical development for relapsed
	or refractory AML and MDS, including drug candidates in development from Daiichi Sankyo Company, Limited, Boehringer Ingelheim GmbH, Agios Pharmaceuticals,&nbsp;Inc., Novartis AG, Astellas
	Pharma&nbsp;Inc. and Karyopharm Therapeutics&nbsp;Inc. We are aware of only one other selective RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	&nbsp;program, which is being undertaken by IO
	Therapeutics,&nbsp;Inc. and which appears to be in early preclinical development. SY-1365 may face competition from other drug candidates currently in clinical development for relapsed or refractory
	AML and MDS or from other drug candidates currently in development for relapsed and refractory ALL, including drug candidates in development from Amgen&nbsp;Inc., Novartis AG, F.&nbsp;Hoffman-La
	Roche&nbsp;AG and Juno Therapeutics,&nbsp;Inc. We are aware of two other selective cyclin-dependent kinase 7, or CDK7, inhibitor programs, both of which appear to be in early preclinical
	development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	competitors may succeed in developing, acquiring or licensing technologies and products that are more effective, have fewer side effects or more tolerable side effects or are less
	costly than any
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=29,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=908022,FOLIO='26',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_27">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	product
	candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer or more effective, have fewer or less severe side effects,
	are more convenient or are less expensive than any products that we, or any future collaborators, may develop. Our competitors also may obtain FDA or other marketing approval for their products before
	we, or any future collaborators, are able to obtain approval for ours, which could result in our competitors establishing a strong market position before we, or any future collaborators, are able to
	enter the market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
	of our existing and potential future competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing,
	conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even
	more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative
	arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial
	sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, the development of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Even if we, or any future collaborators, are able to commercialize any product candidate that we, or
	they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives, any of which could harm our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the
	costs of our product candidates will be paid by third-party payors, including government health care programs and private health insurers. If coverage is not available, or reimbursement is limited,
	we, or any future collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow
	us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and
	reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination
	process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
	coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products
	vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or
	product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a
	result, we, or any future collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product,
	possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or
	the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=30,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=998428,FOLIO='27',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_28">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patients
	who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore,
	our ability, and the ability of any future collaborators, to commercialize successfully any of our product candidates will depend in part on the extent to which coverage and adequate reimbursement for
	these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry
	is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount
	of reimbursement for
	particular medications, which could affect our ability or that of any future collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective,
	and coverage and reimbursement may not be available to our customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive
	basis. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product
	revenues. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and
	profitability will suffer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA
	or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
	development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates
	may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged.
	Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at
	lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which
	we, or any future collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial
	condition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Product liability lawsuits against us could divert our resources, cause us to incur substantial
	liabilities and limit commercialization of any products that we may develop.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will face an inherent risk of product liability claims as a result of the clinical testing of our product candidates despite
	obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we or any future collaborators commercially sell any product that we may or they may
	develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such
	product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of
	warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
	required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	decreased demand for our product candidates or products that we may develop;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	injury to our reputation and significant negative media attention;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	28
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=31,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=265487,FOLIO='28',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DC79601_1_29">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	withdrawal of clinical trial participants;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	significant costs to defend resulting litigation;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	substantial monetary awards to trial participants or patients;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	loss of revenue;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reduced resources of our management to pursue our business strategy; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the inability to commercialize any products that we may develop.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
	we intend to maintain clinical trial liability insurance coverage in the amount of up to $5.0&nbsp;million in the aggregate, this insurance may not fully cover potential
	liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if
	and when we commercialize any product that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance
	coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product
	candidates, which could harm our business, financial condition, results of operations and prospects.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If the FDA or comparable foreign regulatory authorities approve generic versions of any of our
	products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our
	products could be adversely affected.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an NDA is approved, the product covered thereby becomes a "reference-listed drug" in the FDA's publication, "Approved Drug
	Products with Therapeutic Equivalence Evaluations," or the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug
	applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same
	active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the
	reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug
	and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded
	product or reference-listed drug may be typically lost to the generic product.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and
	Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. Specifically, in cases where such exclusivity has been
	granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent covering the
	reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed
	drug. Because the composition of matter patent for SY-1425
	has expired, it is possible that another applicant could obtain approval of tamibarotene from the FDA before us, in which case our NDA would not be eligible for NCE exclusivity. See
	"&#151;Risks Related to Our Intellectual Property&#151;We do not have composition of matter patent protection with respect to SY-1425." If any product we develop does not receive five
	years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of approval, subject to the requirement that the ANDA applicant certifies to any patents
	listed for our products in the Orange Book. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have
	patent protection for our product.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=32,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=993230,FOLIO='29',FILE='DISK124:[15ZCT1.15ZCT79601]DC79601A.;34',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DE79601_1_30">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition that our products may face from generic versions of our products could negatively impact our future revenue, profitability and cash flows and
	substantially limit our ability to obtain a return on our investments in those product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to Our Dependence on Third Parties
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We expect to rely on third parties to conduct our clinical trials and certain aspects of our
	research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to rely on third parties, such as contract research organizations, clinical data management organizations, medical
	institutions and clinical investigators, to conduct our clinical trials. We currently rely and expect to continue to rely on third parties to conduct certain aspects of our research and preclinical
	testing. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	reliance on these third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. For example,
	we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to
	comply with standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and
	accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical
	trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
	these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their
	contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in
	obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical
	development or marketing approval of our product candidates or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We currently depend on third-party manufacturers to produce our preclinical and clinical drug
	supplies and we intend to rely upon third-party manufacturers to produce commercial supplies of any approved product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the
	manufacture of our product candidates for preclinical and clinical testing and for commercial supply of any of these product candidates for which we or our collaborators obtain marketing approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	do not currently have a long term supply agreement with any third-party manufacturers. We may be unable to establish any agreements with third-party manufacturers or to do so on
	acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks,
	including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reliance on the third party for regulatory compliance and quality assurance;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=33,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=375406,FOLIO='30',FILE='DISK124:[15ZCT1.15ZCT79601]DE79601A.;27',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DE79601_1_31">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the possible breach of the manufacturing agreement by the third party;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reliance on the third party for regulatory compliance, quality assurance, and safety and pharmacovigilance reporting.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-party
	manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside the United States. Our
	failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays,
	suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly
	and adversely affect supplies of our medicines and harm our business and results of operations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate
	under cGMP regulations and that might be capable of manufacturing for us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for
	redundant supply for bulk drug substances. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there
	are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to
	commercialize any medicines that receive marketing approval on a timely and competitive basis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We expect to seek to establish collaborations and, if we are not able to establish them on
	commercially reasonable terms, we may have to alter our development and commercialization plans.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to seek one or more collaborators for the development and commercialization of one or more of our product candidates. Likely
	collaborators may include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In addition, if we are able to obtain marketing
	approval for product candidates from foreign regulatory authorities, we intend to enter into strategic relationships with international biotechnology or pharmaceutical companies for the
	commercialization of such product candidates outside of the United States.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of
	the collaborator's resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator's evaluation of a number of factors. Those factors may include the
	potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory
	authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the
	potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a
	collaboration could be more attractive than the one with us for our product candidate. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may
	need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=34,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=957438,FOLIO='31',FILE='DISK124:[15ZCT1.15ZCT79601]DE79601A.;27',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DE79601_1_32">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	may
	not be able to further develop our product candidates or bring them to market and generate product revenue.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Collaborations are complex and time consuming to negotiate and document.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any collaboration agreements that we enter into in the future may contain, restrictions on our ability to enter into potential
	collaborations or to otherwise develop specified product candidates. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have
	resulted in a reduced number of potential future collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have
	to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its
	potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we enter into collaborations with third parties for the development and commercialization of any
	product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to enter into collaborations for the development and commercialization of one or more product candidates we may develop. We
	have not entered into any collaborations to date. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the
	development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators' abilities to successfully perform the
	functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including
	funding obligations, prior to or upon the expiration of the agreed upon terms.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborations
	involving our product candidates pose a number of risks, including the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators may not perform their obligations as expected;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew
	development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding or external factors, such as an acquisition, that divert
	resources or create competing priorities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a
	product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our
	product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and
	distribution of such product or products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of
	development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product
	candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	32
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=35,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=461473,FOLIO='32',FILE='DISK124:[15ZCT1.15ZCT79601]DE79601A.;27',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DE79601_1_33">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a
	way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential
	liability; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or
	commercialization of the applicable product candidates.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
	agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in
	a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to Our Intellectual Property
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we fail to comply with our obligations under our existing and any future intellectual property
	licenses with third parties, we could lose license rights that are important to our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are party to several license agreements under which we license patent rights and other intellectual property related to or business,
	including: a license agreement with Dana-Farber under which we were granted an exclusive worldwide license under specified patents relating to CDK7 inhibitors and JNK inhibitors; a license agreement
	with the Whitehead Institute for Biomedical Research, or Whitehead, and the Dana-Farber Cancer Institute, or Dana-Farber, pursuant to which we were granted a predominantly exclusive, with certain
	non-exclusive exceptions (see corresponding agreement summary in "Business&#151;License Agreements&#151;Whitehead Institute for Biomedical Research and Dana-Farber Cancer
	Institute,&nbsp;Inc.") worldwide license under specified patents relating to modulators of Myc/Max Screen and relating to Chem-Seq; a license agreement with Whitehead pursuant to which we were
	granted an exclusive worldwide license under specified patents relating to super-enhancers until April&nbsp;2016, which license can remain exclusive thereafter, on a field-by-field basis, as long as
	we can demonstrate that we are using commercially reasonable efforts in the applicable field; and the TMRC license agreement, pursuant to which we were granted a license under specified patent rights,
	data, regulatory filings and other intellectual property for the North American and European development and commercialization
	of SY-1425 for the treatment of human cancer indications. We may enter into additional license agreements in the future. Our license agreements impose, and we expect that future license agreements
	will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under these licenses, our licensors may have the right to
	terminate these license agreements, in which event we might not be able to market any product that is covered by these agreements, or our licensors may convert the license to a non-exclusive license,
	which could adversely affect the value of the product candidate being developed under the license agreement. Termination of these license agreements or reduction or elimination of our licensed rights
	may also result in our having to negotiate new or reinstated licenses with less favorable terms.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We do not have composition of matter patent protection with respect to SY-1425.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We own certain patents and patent applications with claims directed to specific methods of using SY-1425 and we expect to have
	marketing exclusivity from the FDA and EMA for a period of seven and ten years, respectively because SY-1425 has not been approved in these markets. However, composition of matter protection in the
	United States and elsewhere covering SY-1425 has expired. We may be limited in our ability to list our patents in the FDA's Orange Book if the use of our product, consistent with its FDA-approved
	label, would not fall within the scope of our patent claims. Also, our
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	33
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=36,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=22976,FOLIO='33',FILE='DISK124:[15ZCT1.15ZCT79601]DE79601A.;27',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DE79601_1_34">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	competitors
	may be able to offer and sell products so long as these competitors do not infringe any other patents that we (or third parties) hold, including patents with claims directed to the
	manufacture of SY-1425 and/or method of use patents. In general, method of use patents are more difficult to enforce than composition of matter patents because, for example, of the risks that the FDA
	may approve alternative uses of the subject compounds not covered by the method of use patents, and others may engage in off-label sale or use of the subject compounds. Physicians are permitted to
	prescribe an approved product for uses that are not described in the product's labeling. Although off-label prescriptions may infringe our method of use patents, the practice is common across medical
	specialties and such infringement is difficult to prevent or prosecute. FDA approval of uses that are not covered by our patents would limit our ability to generate revenue from the sale of SY-1425,
	if approved for commercial sale. Off-label sales would limit our ability to generate revenue from the sale of SY-1425, if approved for commercial sale.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our intellectual property licenses with third parties may be subject to disagreements over contract
	interpretations, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The agreements under which we currently license intellectual property or technology from third parties are complex, and certain
	provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of
	our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could harm our
	business, financial condition, results of operations and prospects.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may not be successful in obtaining or maintaining necessary rights to current or future product
	candidates through acquisitions and in-licenses.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have rights to certain intellectual property, through licenses from third parties, to develop SY-1425 and SY-1365. Because
	our programs may require the use of proprietary rights by third parties, the growth of our business likely will depend, in part, on our ability to acquire, in-license or use these proprietary rights.
	We may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for any product candidates.
	The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party
	intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
	and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire
	third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	sometimes collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically,
	these institutions provide us with an option to negotiate a license to any of the institution's rights in technology resulting from the collaboration. Regardless of such option, we may be unable to
	negotiate a license within the specified timeframe or under terms that are acceptable to us or we may decide not to execute such option if we believe such license is not necessary to pursue our
	program. If we are unable or opt not to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to
	expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	34
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=37,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=310612,FOLIO='34',FILE='DISK124:[15ZCT1.15ZCT79601]DE79601A.;27',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DE79601_1_35">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	develop
	or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected
	product candidate, which could harm our business significantly.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We depend upon our license with TMRC, and we may not be able to maintain that license.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a standby license with TMRC and Toko providing that if at any time the license agreement between Toko and TMRC
	relating to the SY-1425 rights, that TMRC has licensed to us terminates or otherwise ceases to be in effect for any reason, Toko will grant directly to us such rights and licenses with respect to
	SY-1425 as are necessary for us to continue to develop SY-1425. If the TMRC license agreement terminates and this standby license terminates, then we may lose rights to SY-1425 that may be necessary
	to the development and commercialization of SY-1425, which could have a material adverse impact on our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we are unable to obtain and maintain sufficient patent protection for any product candidates, or
	if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize
	our product candidates may be adversely affected.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with
	respect to our proprietary product candidates. If we do not adequately protect our intellectual property, our competitors may be able to erode or negate any competitive advantage we may have, which
	could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our novel product candidates
	that are important to our business. We also license or purchase patent applications filed by others. The patent application and approval process is expensive and time consuming. We may not be able to
	file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agreements
	through which we license patent rights may not give us control over patent prosecution or maintenance, so that we may not be able to control which claims or arguments are
	presented and may not be able to secure, maintain, or successfully enforce necessary or desirable patent protection from those patent rights. We have not had and do not have primary control over
	patent prosecution and maintenance for certain of the patents and patent applications we license, and therefore cannot guarantee that these patents and applications will be prosecuted in a manner
	consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with
	applicable laws and regulations or will result in valid and enforceable patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We,
	or any future partners, collaborators or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it
	is too late to obtain patent protection for them. Therefore, we may miss potential opportunities to strengthen our patent position.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
	is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority
	claims, inventorship, claim scope or patent term adjustments. If we or our partners, collaborators, licensees, or licensors, whether current or future, fail to establish, maintain or protect such
	patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to
	the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our
	patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability
	to prevent competition from third parties, which may have an adverse impact on our business.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=38,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=668367,FOLIO='35',FILE='DISK124:[15ZCT1.15ZCT79601]DE79601A.;27',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_36">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in
	biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical
	compounds commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and
	commercial value of our patent rights are highly uncertain.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
	patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications.
	Assuming the other requirements for patentability are met, currently, the first to file&nbsp;a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the
	United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United
	States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases, not at all. Therefore, we cannot be certain that we were the first to make the
	inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, we cannot be certain that parties from whom we
	do or may license or purchase patent rights were the first to make relevant claimed inventions, or were the first to file for patent protection for them. If third parties have filed
	patent applications on inventions claimed in our patents or applications on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to
	determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&nbsp;15, 2013, a
	derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
	because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in
	the courts or patent offices in the United States and abroad. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found. If
	such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party
	preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, to other patent offices around the world. Alternately or additionally, we may become involved in post-grant
	review procedures, oppositions, derivations, proceedings, reexaminations,
</FONT>
<FONT SIZE=2>
<I>
	inter partes
</I>
</FONT>
<FONT SIZE=2>
	review or interference proceedings, in the United States or
	elsewhere, challenging patents or patent applications in which we have rights, including patents on which we rely to protect our business. An adverse determination in any such challenges may result in
	loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or
	identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and
	regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
	and future patent applications may not result in patents being issued which protect our business, in whole or in part, or which effectively prevent others from commercializing
	competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our
	patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issued
	patents that we have or may obtain or license may not provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any
	competitive
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	36
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=39,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=178547,FOLIO='36',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_37">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	advantage.
	Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to
	market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the
	FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not
	infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or
	other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents,
	these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. We are aware of a third party that is offering super-enhancer
	identification and analysis services, which we believe infringe our recently issued in-licensed United States patent relating to this subject matter. We are in communication with that third party and
	are seeking to have them cease offering those services in light of our issued patent. If we are unsuccessful we may be required to file infringement claims against that party with all of the
	associated risks of patent infringement litigation set forth herein. If that party continues to offer these services, it may affect our ability to attract corporate partners who are interested in
	super-enhancer identification and analysis and may negatively affect the value of our technology platform and therefore harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the terms of some of our license agreements with third parties, some of our third party licensors have the right, but not the obligation in certain circumstances to control
	enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents. Even if we are permitted to pursue such enforcement or defense, we will require the cooperation
	of our licensors, and cannot guarantee that we would receive it and on what terms. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of
	such patents or defense of such claims to protect our interests in the licensed patents. If we cannot obtain patent protection, or enforce existing or future patents against third parties, our
	competitive position and our financial condition could suffer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we are unable to protect the confidentiality of our trade secrets, the value of our technology
	could be materially adversely affected and our business would be harmed.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the protection afforded by patents, we also rely on trade secret protection for certain aspects of our technology
	platform, including certain aspects of our gene control platform. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have
	access to them, such as our employees, consultants, independent contractors, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or
	patent assignment agreements with employees and certain consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information,
	including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult,
	expensive and time consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third
	parties for misappropriating the trade secret. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such
	third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or
	independently developed by a competitor, our business and competitive position could be harmed.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	37
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=40,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=518408,FOLIO='37',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_38">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may become involved in lawsuits to protect or enforce our patents or other intellectual property,
	which could be expensive, time consuming and unsuccessful.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized
	use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert
	against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid
	or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not
	have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent's claims
	narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a
	litigation or proceeding involving one or more of our patents could limit our ability to assert those patents against those parties or other competitors, and may curtail or preclude our ability to
	exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid
	or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such
	trademarks.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
	if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an
	adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
	could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
	or investors perceive these results to be negative, it could adversely affect the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or
	other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such
	litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we are sued for infringing intellectual property rights of third parties, such litigation could
	be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates and use our
	gene control technology without infringing the intellectual property and other proprietary rights of third parties. Third parties may have U.S. and non-U.S. issued patents and pending patent
	applications relating to compounds and methods of use for the treatment of the disease indications for which we are developing our product candidates. If any third-party patents or patent applications
	are found to cover our product candidates or their methods of use, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available
	on commercially reasonable terms, or at all.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other
	adversarial proceedings regarding intellectual property rights with respect to our product candidates, including interference proceedings before the USPTO. There may be third-party patents or patent
	applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=41,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=926928,FOLIO='38',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_39">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	many
	years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be accused of infringing. In addition, third parties
	may obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on existing or future
	intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology
	industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The
	coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product
	candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving
	invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.
	Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings,
	which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we are found to infringe a third party's intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the
	infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or
	marketing the infringing product candidate or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license,
	it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Alternatively or additionally, it could include terms that impede or destroy our ability to
	compete successfully in the commercial marketplace. In addition, we could be found liable for monetary damages, including treble damages and attorneys' fees if we are found to have willfully infringed
	a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we
	have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Changes to the patent law in the United States and other jurisdictions could diminish the value of
	patents in general, thereby impairing our ability to protect our products.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
	Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent
	reform legislation in the United States, including the Leahy-Smith America Invents Act, or the America Invents Act, could increase those uncertainties and costs. The America Invents Act was signed
	into law on September&nbsp;16, 2011, and many of the substantive changes became effective on March&nbsp;16, 2013. The America Invents Act reforms United States patent law in part by changing the
	U.S. patent system from a "first to invent" system to a "first inventor to file" system, expanding the definition of prior art, and developing a post-grant review system. This legislation changes
	United States patent law in a way that may weaken our ability to obtain patent protection in the United States for those applications filed after March&nbsp;16, 2013.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
	the America Invents Act created new procedures to challenge the validity of issued patents in the United States, including post-grant review and
</FONT>
<FONT SIZE=2>
<I>
	inter
	partes
</I>
</FONT>
<FONT SIZE=2>
	review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent with an
	effective filing date of March&nbsp;16, 2013 or later, a petition for
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=42,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=941772,FOLIO='39',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_40">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	post-grant
	review can be filed by a third party in a nine month window from issuance of the patent. A petition for
</FONT>
<FONT SIZE=2>
<I>
	inter partes
</I>
</FONT>
<FONT SIZE=2>
	review can be filed
	immediately following the issuance of a patent if the patent has an effective filing date prior to March&nbsp;16, 2013. A petition for
</FONT>
<FONT SIZE=2>
<I>
	inter partes
</I>
</FONT>
<FONT SIZE=2>
	review can be filed after the nine month period for filing a post-grant review petition has expired for a patent with an effective
	filing date of March&nbsp;16, 2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas
</FONT>
<FONT SIZE=2>
<I>
	inter partes
</I>
</FONT>
<FONT SIZE=2>
	review
	proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to
	U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third
	party to have a U.S. patent invalidated in a USPTO post-grant review or
</FONT>
<FONT SIZE=2>
<I>
	inter partes
</I>
</FONT>
<FONT SIZE=2>
	review proceeding than invalidated in a litigation in a U.S.
	federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we or our licensors or collaborators will be successful in defending the
	patent, which would result in a loss of the challenged patent right to us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, recent court rulings in cases such as Association for Molecular Pathology v. Myriad Genetics,&nbsp;Inc.; BRCA1-&nbsp;&amp; BRCA2-Based Hereditary Cancer Test Patent
	Litigation; and Promega Corp.&nbsp;v. Life Technologies Corp. have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
	situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents
	once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could
	change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may not be able to enforce our intellectual property rights throughout the world.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively
	expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in
	certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our
	products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
	our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of
	some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered
	significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing
	countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our
	other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able
	to prevent third parties from practicing our inventions in certain countries outside the United States and Europe. Competitors may use our technologies in jurisdictions where we have not obtained
	patent protection to develop and market their own products and, further, may export otherwise infringing products to territories where
	we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual
	property rights may not be effective or sufficient to prevent them from competing.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	40
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=43,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=352250,FOLIO='40',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_41">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agreements
	through which we license patent rights may not give us sufficient rights to permit us to pursue enforcement of our licensed patents or defense of any claims asserting the
	invalidity of these patents (or control of enforcement or defense) of such patent rights in all relevant jurisdictions as requirements may vary.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceedings
	to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of
	our business. Moreover, such proceedings could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties
	to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend to
	protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to
	market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Patent terms may be inadequate to protect our competitive position on our products for an adequate
	amount of time.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
	candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are
	prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the
	patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the
	United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our
	patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our
	clinical and preclinical data and launch their product earlier than might otherwise be the case.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may be subject to claims by third parties asserting that our employees or we have misappropriated
	their intellectual property, or claiming ownership of what we regard as our own intellectual property.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our employees and our licensors' employees, including our senior management, were previously employed at universities or at
	other biotechnology or pharmaceutical companies, some of which may be competitors or potential competitors. Some of these employees, including each member of our senior management, executed
	proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the
	proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or
	other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we
	may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from
	such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such
	claims, litigation could result in substantial costs and be a distraction to management.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such
	intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	41
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=44,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=792492,FOLIO='41',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_42">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	develops
	intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any
	such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could
	result in substantial costs and be a distraction to our senior management and scientific personnel.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Obtaining and maintaining patent protection depends on compliance with various procedural, document
	submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to
	be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S.
	governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued.
	There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
	jurisdiction.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal
	Compliance Matters
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Even if we complete the necessary preclinical studies and clinical trials, the marketing approval
	process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a
	result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to
	extensive regulation by the FDA and comparable foreign regulatory authorities. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other
	countries until we, or they, receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various
	stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in
	the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can
	vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive
	preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. Securing marketing approval
	also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other regulatory
	authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that
	preclude our obtaining marketing approval or prevent or limit commercial use. Moreover, the FDA or other regulatory authorities may fail to approve the companion diagnostics we contemplate developing
	with partners. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	42
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=45,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=42556,FOLIO='42',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_43">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes
	in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process
	and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations
	of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately
	obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	delay in obtaining or failure to obtain required approvals could negatively affect our ability or that of any future collaborators to generate revenue from the particular product
	candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we are required by the FDA to obtain approval of a companion diagnostic in connection with
	approval of a candidate therapeutic product, and we do not obtain or there are delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize the product candidate and
	our ability to generate revenue will be materially impaired.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective
	use of a novel therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or
	cleared for that indication. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, companion diagnostics are regulated as medical devices and the FDA has generally required companion diagnostics
	intended to select the patients who will respond to cancer treatment to obtain premarket approval, or a PMA. Consequently, we anticipate that certain of our companion diagnostics may require us or our
	collaborators to obtain a PMA. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, involves a rigorous premarket review during which
	the applicant must prepare and provide the FDA with reasonable assurance of the device's safety and effectiveness and information about the device and its components regarding, among other things,
	device design, manufacturing and labeling. PMA approval is not guaranteed and may take considerable time, and the FDA may ultimately respond to a PMA submission with a not approvable determination
	based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. As a
	result, if we or our collaborators are required by the FDA to obtain approval of a companion diagnostic for a candidate therapeutic product, and we or our collaborators do not obtain or there are
	delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize the product candidate and our ability to generate revenue will be materially impaired.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	its August 2014 guidance, FDA also indicated that companion diagnostics used to make treatment decisions in clinical trials of a therapeutic product generally will be considered
	investigational devices. When a companion diagnostic is used to make critical treatment decisions, such as patient selection, the FDA stated that the diagnostic will be considered a significant risk
	device requiring an IDE. We plan to use our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker to prospectively select patients in our evaluation of SY-1425 for newly diagnosed AML
	patients 60 years of age or older who are not suitable candidates for standard chemotherapy and low-risk transfusion-dependent MDS patients. Accordingly, these studies will need to meet the
	requirements of FDA's IDE regulations. There is a risk that FDA may find that we do not comply with those requirements and, if this were to occur, we would not be able to proceed with our planned
	trial of SY-1425 in these patient populations.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=46,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=351315,FOLIO='43',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_44">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates
	from being marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market and sell our products in the European Union and other foreign jurisdictions, we, and any future collaborators, must
	obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to
	obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the
	United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, a product must be approved for reimbursement before
	the product can be approved for sale in that country. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all.
	Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval
	by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our products in any market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug
	exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing products.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient
	populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a
	patient population of fewer than 200,000 individuals annually in the United States. We, or any future collaborators, may seek orphan drug designations for product candidates and may be unable to
	obtain such designations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
	if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product
	candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such
	designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable
	exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug
	designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for
	designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
	if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs
	can be approved for the same condition and the same drug can be approved for different conditions. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same
	condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Even if we, or any future collaborators, obtain marketing approvals for our product candidates, the
	terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could impair our ability to generate revenue.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and
	extensive regulation. We, and any future collaborators,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	44
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=47,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=669487,FOLIO='44',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DG79601_1_45">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	must
	therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect
	to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product's approved labeling. Thus, we and any future
	collaborators will not be able to promote any products we develop for indications or uses for which they are not approved.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, manufacturers of approved products and those manufacturers' facilities are required to comply with extensive FDA requirements, including ensuring that quality control and
	manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and
	reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure
	compliance with cGMPs.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
	assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators, and our and their contract
	manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the marketing approvals for our
	products withdrawn by regulatory authorities and our, or any future collaborators', ability to market any future products could be limited, which could adversely affect our ability to achieve or
	sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Any of our product candidates for which we, or any future collaborators, obtain marketing approval
	in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply
	with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any of our product candidates for which we, or any future collaborators, obtain marketing approval, as well as the manufacturing
	processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA
	and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to
	manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if
	marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including
	the requirement to implement a Risk Evaluation and Mitigation Strategy.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies,
	including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the
	approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers' communications regarding off-label use and if we, or any
	future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or
	enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to
	investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	45
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=48,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=23094,FOLIO='45',FILE='DISK124:[15ZCT1.15ZCT79601]DG79601A.;22',USER='CHE105536',CD='16-JUN-2016;03:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_46">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or
	failure to comply with regulatory requirements, may yield various results, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	restrictions on such products, manufacturers or manufacturing processes;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	restrictions on the labeling or marketing of a product;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	restrictions on product distribution or use;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	requirements to conduct post-marketing studies or clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	warning letters or untitled letters;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	withdrawal of the products from the market;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	refusal to approve pending applications or supplements to approved applications that we submit;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	recall of products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	restrictions on coverage by third-party payors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	fines, restitution or disgorgement of profits or revenues;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	suspension or withdrawal of marketing approvals;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	refusal to permit the import or export of products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	product seizure; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	injunctions or the imposition of civil or criminal penalties.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may seek a Breakthrough Therapy designation for one or more of our product candidates, but we
	might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may seek a Breakthrough Therapy designation for one or more of our product candidates. A Breakthrough Therapy is defined as a
	product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate
	substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For biologics that have
	been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while
	minimizing the number of patients placed in ineffective control regimens. Products designated as Breakthrough Therapies by the FDA may also be eligible for priority review if supported by clinical
	data at the time the NDA is submitted to FDA.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designation
	as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a
	Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product
	candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate
	approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough
	Therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	46
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=49,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=698516,FOLIO='46',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_47">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may seek Fast Track designation for one or more of our product candidates, but we might not
	receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a product is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address
	unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a product candidate, we may not receive it from the FDA.
	However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We
	may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track
	designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA's
	priority review procedures.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Current and future legislation may increase the difficulty and cost for us and any future
	collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed
	changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our
	ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform
	measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any
	approved products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	March 2010 for example, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act,
	or
	collectively the PPACA. Among the provisions of the PPACA of potential importance to our business and our product candidates are the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new
	government investigative powers and enhanced penalties for noncompliance;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off
	negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer's outpatient drugs to be covered under Medicare Part&nbsp;D;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	extension of manufacturers' Medicaid rebate liability;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expansion of eligibility criteria for Medicaid programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	new requirements to report certain financial arrangements with physicians and teaching hospitals;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=50,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=534905,FOLIO='47',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_48">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
	research, along with funding for such research.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to
	aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2025
	unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the
	statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare
	funding. Further, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship
	between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative
	and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure
	whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of
	our
	product candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as
	subject us and any future collaborators to more stringent product labeling and post-marketing testing and other requirements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Governments outside the United States tend to impose strict price controls, which may adversely
	affect our revenues, if any.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In some countries, such as the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental
	control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing
	approval in some countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If
	reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may be subject to certain healthcare laws and regulations, which could expose us to criminal
	sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations,
	and diminished profits and future earnings.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers, third-party payors and others will play a primary role in the recommendation and prescription of any products for
	which we obtain marketing approval. Our future arrangements with healthcare providers and third-party payors will expose us to broadly applicable fraud and abuse and other healthcare laws and
	regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Potentially
	applicable U.S. federal and state healthcare laws and regulations include the following:
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Kickback Statute.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and
	willfully soliciting,
	offering, receiving or providing remuneration,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=51,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=773436,FOLIO='48',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_49">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	directly
	or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be
	made under federal healthcare programs such as Medicare and Medicaid;
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;False Claims Laws.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including
	those from
	civil whistleblower or
</FONT>
<FONT SIZE=2>
<I>
	qui tam
</I>
</FONT>
<FONT SIZE=2>
	actions against individuals or entities for knowingly presenting, or causing to be presented to the federal government
	claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HIPAA.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for
	executing or
	attempting to execute a scheme to defraud any healthcare benefit program;
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HIPAA and HITECH.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, also
	imposes
	obligations on certain types of individuals and entities, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
	information;
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;False Statements Statute.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up
	a material
	fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transparency Requirements.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and
	medical
	supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program, with specific exceptions, to report annually to the U.S. Department of Health and Human
	Services information related to physician payments and other transfers of value and physician ownership and investment interests; and
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Analogous State and Foreign Laws.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;Analogous state laws and regulations, such as state anti-kickback and false claims laws, and
	transparency laws, may
	apply to sales or marketing arrangements, and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers, and some state laws require
	pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to
	requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Many state laws also govern the privacy and security of
	health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Foreign laws also govern
	the privacy and security of health information in many circumstances.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efforts
	to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial
	costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and
	abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to
	significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement,
	contractual damages, and reputational harm, any of which could substantially disrupt our operations. If any of the physicians or other providers or entities with whom we expect to do business is found
	not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	49
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=52,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=420358,FOLIO='49',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_50">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to
	our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained
	in 18 U.S.C. &sect;&nbsp;201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct
	activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing,
	promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and
	employees of government agencies or
	government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain
	necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives,
	contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
	to the completion of this offering, we will adopt a Code of Business Conduct and Ethics, which will be effective upon the completion of this offering, and expect to prepare and
	implement policies and procedures to ensure compliance with such code. The Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our
	business throughout the world. However, we cannot assure you that our employees and third party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with
	anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits,
	significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm,
	adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not
	prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result
	in a materially significant diversion of management's attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may
	even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We are subject to governmental export and import controls that could impair our ability to compete
	in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our products and solutions are subject to export control and import laws and regulations, including the U.S. Export Administration
	Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign Assets Controls. Exports of our products
	and solutions outside of the United States must be made in compliance with these laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be
	subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme
	cases, the incarceration of responsible employees or managers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, changes in our products or solutions or changes in applicable export or import laws and regulations may create delays in the introduction, provision, or sale of our products
	and solutions in international markets, prevent customers from using our products and solutions or, in some cases,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	50
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=53,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=951134,FOLIO='50',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_51">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	prevent
	the export or import of our products and solutions to certain countries, governments or persons altogether. Any limitation on our ability to export, provide, or sell our products and solutions
	could adversely affect our business, financial condition and results of operations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If we fail to comply with environmental, health and safety laws and regulations, we could become
	subject to fines or penalties or incur costs that could harm our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and
	the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials,
	including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot
	completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could
	be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to
	comply with such laws and regulations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this
	insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and
	regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Unfavorable global economic conditions could adversely affect our business, financial condition or
	results of operations.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets.
	The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the most recent global financial
	crisis, could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all.
	This is particularly true in the European Union, which is undergoing a continued severe economic crisis. A weak or declining economy could strain our suppliers, possibly resulting in supply
	disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the
	current economic climate and financial market conditions could adversely impact our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our internal computer systems, or those of our collaborators or other contractors or consultants,
	may fail or suffer security breaches, which could result in a material disruption of our product development programs.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable
	to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure,
	accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations,
	whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	51
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=54,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=102377,FOLIO='51',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_52">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	future
	clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
	breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position
	could be harmed and the further development and commercialization of our product candidates could be delayed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our employees may engage in misconduct or other improper activities, including non-compliance with
	regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or
	similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have
	established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities,
	report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical
	trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and
	prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure
	to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions
	could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to Employee Matters and Managing Growth
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our future success depends on our ability to retain our executive officers and to attract, retain
	and motivate qualified personnel.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on the pharmaceutical research and development and business development expertise of Nancy Simonian, M.D., our
	president and chief executive officer; Kyle D. Kuvalanka, our chief operating officer; Eric R. Olson, Ph.D., our chief scientific officer; David&nbsp;A. Roth,&nbsp;M.D., our chief medical officer;
	and Jorge Conde, our chief strategy officer. Each of these executive officers is employed "at will," meaning any of them may terminate his or her employment with us at any time with or without notice
	and for any reason or no reason. In the future, we may be dependent on other members of our management, scientific and development team.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.
	Our industry has
	experienced a high rate of turnover of management personnel in recent years. If we lose one or more of our executive officers or other key employees, our ability to implement our business strategy
	successfully could be seriously harmed. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of
	individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully. Competition to hire from this limited
	pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology
	companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants
	and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	52
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=55,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=886769,FOLIO='52',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_53">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	advisors
	may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to
	attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We expect to expand our organization, and as a result, we may encounter difficulties in managing our
	growth, which could disrupt our operations.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, we had 49 full-time employees. We expect to experience significant growth in the number of our employees
	and the scope of our operations, particularly in the areas of drug manufacturing, regulatory affairs and sales, marketing and distribution. To manage these growth activities, we must continue to
	implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a
	significant amount of its attention to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such
	anticipated growth, we may not be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit and train additional qualified personnel. Our
	inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of
	employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as
	the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected,
	our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or
	reduce our financial resources.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the future, we may enter into transactions to acquire other businesses, products or technologies. Because we have not made any
	acquisitions to date, our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions
	we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue
	our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from
	undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired
	personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities,
	increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might
	have on our operating results.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Risks Related to Our Common Stock and This Offering
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	No public market for our common stock currently exists, and an active trading market for our common
	stock may not develop.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock
	will be determined through negotiations with the underwriters. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following
	this offering. Although we have applied to list our common stock on The
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	53
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=56,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=19957,FOLIO='53',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DI79601_1_54">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	NASDAQ
	Global Market, an active trading market for our shares may never develop or, if developed, be maintained following this offering. If an active market for our common stock does not develop or is
	not maintained, it may be difficult for you to sell shares you purchase in this offering without depressing the market price for the shares or at all. An inactive trading market may also impair our
	ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If you purchase shares of common stock in this offering, you will suffer immediate dilution in the
	book value of your investment.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial public offering price of our common stock is substantially higher than the net tangible book value per share of our common
	stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering.
	Based on the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution
	of $9.82 per share, representing the difference between our pro forma as adjusted, net tangible book value per share after giving effect to this offering and the assumed initial public offering price.
	Purchasers of common stock in this offering will have contributed approximately 32.8% of the aggregate price paid by all purchasers of our stock and will own approximately 17.7% of our common stock
	outstanding after this offering, excluding any shares of our common stock that they may have acquired prior to this offering. Furthermore, if the underwriters exercise their overallotment option or
	our previously issued options to acquire common stock at prices below the assumed initial public offering price are exercised, you will experience further dilution. For additional information on the
	dilution that you will experience immediately after this offering, see the section titled "Dilution."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	The price of our common stock is likely to be highly volatile, which could result in substantial
	losses for purchasers of our common stock in this offering.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price is likely to be highly volatile. The stock market in general and the market for smaller pharmaceutical and
	biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may
	not be able to sell your common stock at or above the initial public offering price and you may lose some or all of your investment. The market price for our common stock may be influenced by many
	factors, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the timing and results of clinical trials of SY-1425 and SY-1365;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the success of existing or new competitive products or technologies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulatory actions with respect to our product candidates or our competitors' products and product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital
	commitments;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	commencement or termination of collaborations for our development programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	failure or discontinuation of any of our development programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	results of clinical trials of product candidates of our competitors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulatory or legal developments in the United States and other countries;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	developments or disputes concerning patent applications, issued patents or other proprietary rights;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	54
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=57,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=465318,FOLIO='54',FILE='DISK124:[15ZCT1.15ZCT79601]DI79601A.;42',USER='CHE106781',CD='18-JUN-2016;12:42' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_55">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the recruitment or departure of key personnel;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the level of expenses related to any of our product candidates or clinical development programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the results of our efforts to develop additional product candidates or products;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	actual or anticipated changes in estimates as to financial results or development timelines or recommendations by securities analysts;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	announcement or expectation of additional financing efforts;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	sales of our common stock by us, our insiders or other stockholders;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	variations in our financial results or those of companies that are perceived to be similar to us;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	changes in estimates or recommendations by securities analysts, if any, that cover our stock;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	changes in the structure of healthcare payment systems;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	market conditions in the pharmaceutical and biotechnology sectors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	general economic, industry and market conditions; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the other factors described in this "Risk Factors" section.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
	our stock price is likely to be volatile, and in the past companies that have experienced volatility in the market price of their stock have been subject to an increased
	incidence of securities class action litigation. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we
	face such litigation, it could result in substantial costs and a diversion of management's attention and resources, which could harm our business.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We have broad discretion in the use of the net proceeds from this offering and may not use them
	effectively or in ways with which you agree.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we currently intend to use the net proceeds from this offering in the manner described in the section titled "Use of Proceeds"
	in this prospectus, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of
	operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering. The failure by our management to
	apply these funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending
	their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We are an "emerging growth company," and the reduced disclosure requirements applicable to emerging
	growth companies may make our common stock less attractive to investors.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an
	emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are
	applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
	the Sarbanes-Oxley Act of 2002, or SOX
	Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to
	the auditor's report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements
	of holding a
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=58,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=216568,FOLIO='55',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_56">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	nonbinding
	advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In this prospectus, we have provided only two years of audited
	financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors
	will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
	stock and our stock price may be more volatile.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows
	an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
	this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth
	companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We will incur increased costs as a result of operating as a public company, and our management will
	be required to devote substantial time to new compliance initiatives and corporate governance practices.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a public company, and particularly after we are no longer an "emerging growth company," we will incur significant legal, accounting
	and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ
	Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial
	controls and corporate governance practices. We expect that we will need to hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the
	requirements of being, a public company and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These
	requirements will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that the rules and regulations applicable to us
	as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified
	members of our board of directors. We are
	currently evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject
	to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing
	bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We have identified material weaknesses in our internal control over financial reporting. If we are
	unable to remedy our material weaknesses, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude
	that our internal control over financial reporting is not effective, which could adversely impact our investors' confidence and our stock price.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, we were a private company and had limited accounting and financial reporting personnel and other resources with
	which to address our internal controls and related procedures. In connection with the audit of our consolidated financial statements for the years ended December&nbsp;31, 2013 and 2014, we and our
	independent registered public accounting firm identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in
	internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	56
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=59,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=444883,FOLIO='56',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_57">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	will
	not be prevented or detected on a timely basis. The material weaknesses related to our controls over the classification of certain indirect and other expenses between general and administrative
	and research and development, and to the accounting for stock-based compensation. We also identified deficiencies related to our controls over our accounting for income taxes. The material weaknesses
	that we identified were due to the lack of appropriate oversight and review procedures by accounting personnel to properly identify and evaluate certain accounting matters that resulted in errors in
	our financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are implementing measures designed to improve our internal control over financial reporting to remediate these material weaknesses, including the
	following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we are formalizing our processes and internal control documentation and strengthening supervisory reviews by our management;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we have hired additional qualified accounting personnel and engaged financial consultants, both of whom have significant accounting
	and financial reporting experience, which will enable the implementation of internal controls over financial reporting and segregating duties amongst accounting personnel;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we expect to hire additional senior accounting and finance staff to complete this remediation; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we intend to implement certain accounting systems to automate manual processes, such as tracking and accounting for stock-based
	awards.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	expect to incur additional costs to remediate these weaknesses, primarily personnel costs and external consulting fees. We cannot assure you that the measures we have taken to date,
	together with any measures we may take in the future, will be sufficient to remediate the control deficiencies that led to the material weaknesses in our internal control over financial reporting or
	to avoid potential future material weaknesses. In addition, neither our management nor an independent registered public accounting firm has ever performed an evaluation of our internal control over
	financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required. Had we or our independent registered public accounting firm performed an
	evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. If we are unable to
	successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of
	our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock
	exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by NASDAQ, the
	Securities and Exchange Commission, or SEC, or other regulatory authorities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	As a result of becoming a public company, we will be obligated to develop and maintain proper and
	effective internal controls over financial reporting. Any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the
	value of our common shares.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to SOX Section&nbsp;404 we will be required to furnish a report by our management on our internal control over financial
	reporting beginning with our second filing of an Annual Report on Form&nbsp;10-K with the Securities and Exchange Commission, or SEC, after we become a public company. However, while we remain an
	emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. This
	assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Our independent
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	57
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=60,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=994447,FOLIO='57',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_58">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	registered
	public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the SEC
	following the date we are no longer an "emerging growth company," as defined in the JOBS Act. At such time as we are required to obtain auditor attestation, if we then have a material weakness, we
	would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting,
	which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and
	document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and
	implement a continuous reporting and improvement process for internal control over financial reporting. During our evaluation of our internal control, if we identify one or more material weaknesses in
	our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material
	weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our
	ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent
	registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy
	and completeness of our financial reports, the market price of our ordinary shares could decline, and we could be subject to sanctions or investigations by NASDAQ, the SEC or other regulatory
	authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could
	also restrict our future access to the capital markets.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	A significant portion of our total outstanding shares is restricted from immediate resale but may be
	sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the
	perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Following this offering, we will have
	22,760,161 shares of common stock outstanding based on the 18,760,161 shares of our common stock outstanding as of June&nbsp;15, 2016 after giving effect to the conversion of all outstanding shares
	of our preferred stock into 15,988,800 shares of our common stock upon the closing of this offering. Of these shares, the 4,000,000 shares sold by us in this offering may be resold in the public
	market immediately, unless purchased by our affiliates. The remaining 18,760,161 shares are currently restricted under securities laws or as a result of lock-up or other agreements, but will be able
	to be sold after this offering as described in the "Shares Eligible for Future Sale" section of this prospectus. The representatives of the underwriters may release these stockholders from their
	lock-up agreements with the underwriters at any time and without notice, which would allow for earlier sales of shares in the public market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover, after this offering, holders of an aggregate of 16,774,912 shares of our common stock will have rights, subject to conditions, to require us to file registration statements
	covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all 5,818,869&nbsp;shares of common stock
	that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations
	applicable to affiliates and the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	58
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=61,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=267996,FOLIO='58',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_59">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	lock-up
	agreements described in the "Underwriting" section of this prospectus. If additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of
	our common stock could decline.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We might not be able to utilize a significant portion of our net operating loss carryforwards and
	research and development tax credit carryforwards.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2015, we had federal and state net operating loss carryforwards of $44.8&nbsp;million and
	$44.3&nbsp;million, respectively, and federal and state research and development tax credit carryforwards of $1.4&nbsp;million and $0.9&nbsp;million, respectively, each of which if not utilized
	will expire at various dates through 2035. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, under
	Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an "ownership change," which is generally defined as a
	greater than 50% change, by value, in its equity ownership over a three-year period, the corporation's ability to use its pre-change net operating loss carryforwards and other pre-change tax
	attributes to offset its post-change income may be limited. We have not determined if we have experienced Section&nbsp;382 ownership changes in the past and if a portion of our net operating loss
	and tax credit carryforwards are subject to an annual limitation under Section&nbsp;382. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock
	ownership, including this offering, some of which may be outside of our control. We have not conducted a detailed study to document whether our historical activities qualify to support the research
	and development credit carryforwards. A detailed study could result in adjustment to our research and development credit carryforwards. If we determine that an ownership change has occurred and our
	ability to use our historical net operating loss and tax credit carryforwards is materially limited, or if our research and development carryforwards are adjusted, it would harm our future operating
	results by effectively increasing our future tax obligations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	We do not anticipate paying any cash dividends on our capital stock in the foreseeable future.
	Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to
	finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital appreciation,
	if any, of our common stock will be your sole source of gain for the foreseeable future.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Concentration of ownership of our common stock among our existing executive officers, directors and
	principal stockholders may prevent new investors from influencing significant corporate decisions.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon shares outstanding as of June&nbsp;15, 2016, upon the closing of this offering, our executive officers and directors,
	combined with our stockholders who owned more
	than 5% of our outstanding common stock before this offering and their affiliates, will, in the aggregate, beneficially own shares representing approximately 71.8% of our common stock. As a result, if
	these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these
	persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of
	ownership control may:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	delay, defer or prevent a change in control;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	entrench our management or the board of directors; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=62,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=64572,FOLIO='59',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_60">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
	of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the price
	at which shares are being sold in this offering and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or they may want
	us to pursue strategies that deviate from the interests of other stockholders.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our existing principal stockholders have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million in shares of our common stock in this offering
	at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares
	to any of these potential purchasers and any of these potential purchasers could determine to purchase more, less or no shares in this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Provisions in our certificate of incorporation and bylaws and under Delaware law may prevent or
	frustrate attempts by our stockholders to change our management or hinder efforts to acquire a controlling interest in us.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our certificate of incorporation and our bylaws that will become effective upon the closing of this offering may
	discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for
	your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.
	In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or
	remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these
	provisions:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establish a classified board of directors such that all members of the board are not elected at one time;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	allow the authorized number of our directors to be changed only by resolution of our board of directors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	limit the manner in which stockholders can remove directors from the board;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be
	acted on at stockholder meetings;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by
	written consent;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	limit who may call a special meeting of stockholders;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a "poison
	pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or
	repeal certain provisions of our certificate of incorporation or bylaws.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
	because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits a
	person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess
	of 15% of our
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=63,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=332954,FOLIO='60',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DK79601_1_61">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	outstanding
	voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it
	is desired by, or beneficial to, our stockholders. This could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your
	best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	If securities or industry analysts do not publish research or publish inaccurate or unfavorable
	research about our business, our share price and trading volume could decline.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock will likely depend in part on the research and reports that securities or industry analysts
	publish about us or our business. We do not have any control over these analysts. We do not currently have research coverage, and there can be no assurance that analysts will cover us, or provide
	favorable coverage. Securities or industry analysts may elect not to provide research coverage of our common stock after this offering, and such lack of research coverage may negatively impact the
	market price of our common stock. In the event we do have analyst coverage, if one or more analysts downgrade our stock or change their opinion of our stock, our share price would likely decline. In
	addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or
	trading volume to decline.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	Our certificate of incorporation that will become effective upon the closing of this offering
	designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and
	exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against our company and our directors and officers.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation that will become effective upon the closing of this offering provides that, unless we consent in
	writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District
	of Delaware) will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our
	directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware
	or our certificate of incorporation or bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision may limit the ability of our
	stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against us and our
	directors and officers.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	61
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=64,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=150217,FOLIO='61',FILE='DISK124:[15ZCT1.15ZCT79601]DK79601A.;43',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_62">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_RISK_FACTORS>
<EFX_FORWARD_LOOK>
<A NAME="FIS_FORWARD_LOOK"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DM79601_SPECIAL_NOTE_REGARDING_FORWARD__SPE02700">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DM79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements
	are contained principally in the sections of this prospectus entitled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and
	"Business," but are also contained elsewhere in this prospectus. All statements, other than statements of historical facts, contained in this prospectus, including statements regarding our strategy,
	future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words
	"anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to
	identify forward-looking statements, although not all forward-looking statements contain these identifying words. In addition, statements that "we believe" and similar statements reflect our beliefs
	and opinions on the relevant subject. The forward-looking statements and opinions contained in this prospectus are based upon information available to us as of the date of this prospectus and, while
	we believe such information forms&nbsp;a reasonable basis for such
	statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available
	relevant information.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
	forward-looking statements include, among other things, statements about:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our plans to initiate clinical trials for SY-1425 and SY-1365;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	planned clinical trials for our product candidates, whether conducted by us or by any future collaborators, including the timing of
	these trials and of the anticipated results;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our plans to research, develop and commercialize our current and future product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our expectations regarding the potential benefits of our gene control platform and our approach;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our plans to seek to enter into collaborations for the development and commercialization of certain product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the potential benefits of any future collaboration;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our commercialization, marketing and manufacturing capabilities and strategy;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our intellectual property position and strategy;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our ability to identify additional products or product candidates with significant commercial potential;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our expectations related to the use of proceeds from this offering;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our estimates regarding expenses, future revenue, capital requirements and need for additional financing;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	developments relating to our competitors and our industry; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the impact of government laws and regulations.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
	Actual results or events could differ materially from the plans, intentions and expectations disclosed in the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=65,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=852907,FOLIO='62',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_63">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	forward-looking
	statements we make. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the
	forward-looking statements contained in this prospectus. We have included important factors in the cautionary statements included in this prospectus, particularly in the "Risk Factors" section, that
	could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future
	acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
	should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding
	that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future
	events or otherwise, except as required by law. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act of 1933, as amended, do not protect any
	forward-looking statements that we make in connection with this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. All of
	the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. We believe that the information from these
	industry publications, surveys and studies is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those
	described in the section titled "Risk Factors." These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=66,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=5777,FOLIO='63',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_64">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_FORWARD_LOOK>
<EFX_PROCEED_USE>
<A NAME="FIS_PROCEED_USE"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DM79601_USE_OF_PROCEEDS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DM79601_2">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	USE OF PROCEEDS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds from our issuance and sale of 4,000,000&nbsp;shares of our common stock in this offering will be
	$52.8&nbsp;million, or $61.2&nbsp;million if the underwriters exercise their overallotment option in full, assuming an initial public offering price of $15.00&nbsp;per share, which is the
	midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this
	prospectus, would increase (decrease) our net proceeds from this offering by $3.7&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
	remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000&nbsp;shares in the number of shares
	offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from this offering by $14.0&nbsp;million, assuming no change in the assumed initial
	public offering price per share and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of March&nbsp;31, 2016, we had cash and cash equivalents of $62.1&nbsp;million. We currently estimate that we will use the net proceeds from this offering, together with our
	existing cash and cash equivalents, as follows:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $25.0&nbsp;million to fund our proof-of-concept Phase&nbsp;2 clinical trial of SY-1425 in AML and MDS, including
	clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs, with costs to be approximately allocated based on the number of AML and MDS patients
	enrolled in this trial, respectively;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $20.0&nbsp;million to complete our IND-enabling activities and the Phase&nbsp;1 portion of our planned
	Phase&nbsp;1/2 clinical trial for SY-1365, including clinical research outsourcing, drug manufacturing and internal personnel costs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $40.0&nbsp;million for new and ongoing research activities, including for our preclinical programs and our platform
	with a goal of systematically delivering additional INDs; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the remainder for working capital and other general corporate purposes.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	expected use of the net proceeds from this offering and our existing cash and cash equivalents represents our intentions based upon our current plans and business conditions. The
	amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and commercialization efforts, the status of and results
	from clinical trials, any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will retain broad discretion
	over the allocation of the net proceeds from this offering and our existing cash and cash equivalents. We have no current agreements, commitments or understandings for any material acquisitions or
	licenses of any products, businesses or technologies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on our planned use of the net proceeds from this offering, we estimate that such funds will be sufficient to enable us to reach clinical activity data readouts for SY-1425 in AML
	and MDS and SY-1365 in acute leukemias and to fund our operating expenses and capital expenditure requirements at least through mid-2018. We have based this estimate on assumptions that may prove to
	be wrong, and we could use our available capital resources sooner than we currently expect. We do not expect that the net proceeds from this offering and our existing cash and cash equivalents will be
	sufficient to enable us to fund the completion of development of any of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
	our use of the net proceeds from this offering, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing instruments and U.S. government securities.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	64
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=67,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=93020,FOLIO='64',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_65">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_PROCEED_USE>
<EFX_DIVIDEND_POLICY>
<A NAME="FIS_DIVIDEND_POLICY"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DM79601_DIVIDEND_POLICY">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DM79601_3">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	DIVIDEND POLICY
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any,
	to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay cash dividends
	will be made at the discretion of our board of directors and will depend on restrictions and other factors our board of directors may deem relevant. Investors should not purchase our common stock with
	the expectation of receiving cash dividends.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	65
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=68,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=660620,FOLIO='65',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_66">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_DIVIDEND_POLICY>
<EFX_CAPITALIZATION>
<A NAME="FIS_CAPITALIZATION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DM79601_CAPITALIZATION">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DM79601_4">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	CAPITALIZATION
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our cash and cash equivalents and our capitalization as of March&nbsp;31, 2016
	on:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an actual basis excluding 142,215 shares of our common stock that are subject to repurchase by&nbsp;us;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a pro forma basis to give effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into an aggregate of
	15,988,800&nbsp;shares of common stock, (ii)&nbsp;the vesting of 53,334&nbsp;shares of restricted common stock, (iii)&nbsp;the change in our total stockholders' (deficit) equity resulting from
	the stock-based compensation expense associated with the vesting of 53,334 shares of restricted common stock and the vesting of performance-based option awards to purchase up to 59,387&nbsp;shares
	of our common stock and (iv)&nbsp;the filing and effectiveness of our restated certificate of incorporation, each upon the closing of this offering;
	and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a pro forma as adjusted basis to give further effect to the issuance and sale of 4,000,000&nbsp;shares of our common stock in this
	offering at an assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting
	discounts and commissions and estimated offering expenses payable by us.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
	should read this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and the sections of this prospectus titled
	"Selected Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Description of Capital Stock."
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="47PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="58PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31, 2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Actual
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Pro Forma
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Pro Forma
<BR>
	As Adjusted
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)(in thousands, except share and per share data)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:9PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	114,933
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:9PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Series&nbsp;A convertible preferred stock, $0.001 par value; 30,350,000 shares authorized, issued and outstanding, actual; no shares
	authorized, issued and outstanding, pro forma and pro forma as adjusted
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:9PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Series&nbsp;B convertible preferred stock, $0.001 par value; 29,608,081 shares authorized, issued and outstanding, actual; no shares
	authorized, issued and outstanding pro forma and pro forma as adjusted
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	92,792
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:9PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stockholders' (deficit) equity:
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:18PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Preferred stock, $0.001 par value: no shares authorized, issued and outstanding actual; 10,000,000 shares authorized, no shares issued and
	outstanding pro forma and pro forma as adjusted
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:18PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Common stock, $0.001 par value; 78,886,062 shares authorized, 2,404,350&nbsp;shares issued and outstanding, actual; 200,000,000 shares
	authorized, 18,446,484&nbsp;shares issued and outstanding, pro forma; 200,000,000 shares authorized, 22,446,484 shares issued and outstanding, pro forma as adjusted
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:18PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Additional paid-in capital
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,209
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	128,725
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	181,521
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:18PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accumulated deficit
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(64,101
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(64,826
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(64,826
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:28PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total stockholders' (deficit) equity
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(57,890
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,917
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	116,717
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:9PT;TEXT-INDENT:-9PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total capitalization
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,917
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,917
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	116,717
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	capitalization following the closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00
	increase (decrease) in
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	66
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=69,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=206278,FOLIO='66',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_67">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma
	as adjusted amount of each additional paid-in-capital, total stockholders' equity and total capitalization by $3.7&nbsp;million, assuming that the number of shares offered by us, as set forth on the
	cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated expenses payable by us. Each increase (decrease) of 1,000,000&nbsp;shares in
	the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of additional paid-in-capital, total
	stockholders' equity and total capitalization by $14.0&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts and
	commissions and estimated expenses payable by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	number of shares of our common stock shown as outstanding on an actual, pro forma and pro forma as adjusted basis in the table above does not
	include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,217,953&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2016, at a
	weighted-average exercise price of $4.14&nbsp;per share;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	149,197&nbsp;shares of our common stock available for future issuance as of March&nbsp;31, 2016 under our 2012 equity incentive
	plan; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,120,000 and 586,666&nbsp;additional shares of our common stock that will become available for future issuance under our 2016 stock
	incentive plan and our 2016 employee stock purchase plan, respectively, each of which will become effective immediately prior to the closing of this offering, as well as any automatic annual increases
	in the number of shares of common stock reserved for future issuance under these plans.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	67
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=70,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=898143,FOLIO='67',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_68">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_CAPITALIZATION>
<EFX_DILUTION>
<A NAME="FIS_DILUTION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DM79601_DILUTION">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DM79601_5">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	DILUTION
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
	between the public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our historical net tangible book deficit as of March&nbsp;31, 2016 was $57.9&nbsp;million, or $22.73&nbsp;per share of our common stock. Our historical net tangible book deficit is
	the amount of our total tangible assets less
	our total liabilities. Historical net tangible book deficit per share represents historical net tangible book deficit, divided by the 2,546,565 shares of our common stock outstanding as of
	March&nbsp;31, 2016, including 142,215 shares of unvested restricted stock subject to repurchase by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our pro forma net tangible book value as of March&nbsp;31, 2016 was $63.9&nbsp;million, or $3.45&nbsp;per share of our common stock. Pro forma net tangible book value represents
	the amount of our total tangible assets less our total liabilities. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the 18,535,365 shares of our
	common stock, including the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,988,800&nbsp;shares of our common stock upon the closing of this offering,
	outstanding as of March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After giving effect to our issuance and sale of 4,000,000&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $15.00&nbsp;per share, which
	is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro
	forma as adjusted net tangible book value as of March&nbsp;31, 2016 would have been $116.7&nbsp;million, or $5.18&nbsp;per share. This represents an immediate increase in pro forma as adjusted
	net tangible book value per share of $1.73 to existing stockholders and immediate dilution of $9.82 in pro forma as adjusted net tangible book value per share to new investors purchasing common stock
	in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price
	per share paid by new investors. The following table illustrates this dilution on a per share basis:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Assumed initial public offering price per share
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15.00
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Historical net tangible book value (deficit) per share as of March&nbsp;31, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(22.73
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Increase per share attributable to pro forma adjustments
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26.18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma net tangible book value per share as of March&nbsp;31, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.45
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Increase in net tangible book value per share attributable to new investors
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.73
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma as adjusted net tangible book value per share after this offering
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Dilution per share to new investors
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.82
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing.
	Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase
	(decrease) the pro forma as adjusted net tangible book value per share by $0.17 and dilution per share to new investors purchasing shares in this offering by $0.83, assuming that the number of shares
	offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. An increase
	of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per share after this
	offering by $0.37 and decrease the dilution per share to new investors participating in this offering by $0.37, assuming no change in the assumed initial public offering price and after deducting
	estimated underwriting discounts and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	68
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=71,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=805169,FOLIO='68',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_69">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	commissions and estimated offering expenses payable by us. A decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the
	pro forma as adjusted net tangible book value per share after this offering by $0.41 and increase the dilution per share to new investors participating in this offering by $0.41, assuming no change in
	the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the underwriters exercise their overallotment option in full, the pro forma as adjusted net tangible book value will increase to $5.41&nbsp;per share, representing an immediate
	increase to existing stockholders of $1.96&nbsp;per share and an immediate dilution of $9.59&nbsp;per share to new investors. If any shares are issued upon exercise of outstanding options, you
	will experience further dilution.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes, on a pro forma as adjusted basis as of March&nbsp;31, 2016, the number of shares of common stock purchased from us, the total consideration paid to us
	and the average price per share paid by existing stockholders and by new investors purchasing shares of common stock in this offering. The calculation below is based on an assumed initial public
	offering price of $15.00&nbsp;per share,
	which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT>
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="37PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="69PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="37PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
<BR>
	Consideration
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares Purchased
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Average Price
<BR>
	Per Share
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Percent
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amount
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Percent
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(in thousands)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Existing stockholders
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	18,535,365
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	82.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	122,685
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	67.2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.62
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	New investors
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17.7
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	32.8
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22,535,365
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	182,685
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.11
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this
	prospectus, would increase
	(decrease) the total consideration paid by new investors by $4.0&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by
	1.4&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by 1.5&nbsp;percentage points, assuming that the number of
	shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase (decrease) of 1,000,000&nbsp;shares in the number of shares offered by us, as set forth on the
	cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by $15.0&nbsp;million and, in the case of an increase, would increase the percentage of total
	consideration paid by new investors by 5.1&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by 6.0&nbsp;percentage
	points, assuming no change in the assumed initial public offering price.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares purchased from us by existing stockholders is based on 18,535,365 shares of our common stock outstanding as of March&nbsp;31, 2016, after giving effect to the
	automatic conversion of all of our outstanding shares of preferred stock into 15,988,800 shares of common stock upon the closing of this offering, and
	excludes:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,217,953&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2016, at a
	weighted-average exercise price of $4.14&nbsp;per share;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	149,197&nbsp;additional shares of our common stock available for future issuance as of March&nbsp;31, 2016 under our 2012 equity
	incentive plan; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,120,000 and 586,666&nbsp;additional shares of our common stock that will become available for future issuance under our 2016 stock
	incentive plan and our 2016 employee stock purchase plan,
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=72,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=572410,FOLIO='69',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DM79601_1_70">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	respectively,
	each of which will become effective immediately prior to the closing of this offering, as well as any automatic annual increases in the number of shares of common stock reserved for
	future issuance under these plans.
</FONT>
</P>
</UL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	the extent that stock options are exercised, new stock options are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be
	further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that
	we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could
	result in further dilution to our stockholders.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	the underwriters exercise their overallotment option in full, the following will occur:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the percentage of shares of our common stock held by existing stockholders will decrease to 80.1% of the total number of shares of our
	common stock outstanding after this offering; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares of our common stock held by new investors will increase to 4,600,000, or 19.9% of the total number of shares of
	our common stock outstanding after this offering.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our existing principal stockholders have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million in shares of our common stock in this offering
	at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares
	to any of these existing stockholders and any of these existing stockholders could determine to purchase more, less or no shares in this offering. The foregoing discussion and tables do not reflect
	any potential purchases by these existing stockholders or their affiliated entities. If these existing stockholders are allocated and purchase the shares in which they have indicated an interest in
	purchasing, our existing stockholders would hold
	92.6% (90.2% if the underwriters exercise their over-allotment option in full) of the total number of shares of our common stock outstanding after this offering and our new investors would hold 7.4%
	(9.8% if the underwriters exercise their over-allotment option in full) of the total number of shares of our common stock outstanding after this offering.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=73,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=306807,FOLIO='70',FILE='DISK124:[15ZCT1.15ZCT79601]DM79601A.;87',USER='KSEAMON',CD='19-JUN-2016;10:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_71">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_DILUTION>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA_2"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DO79601_SELECTED_CONSOLIDATED_FINANCIAL_DATA">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DO79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	SELECTED CONSOLIDATED FINANCIAL DATA
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	You should read the following selected consolidated financial data together with our consolidated financial
	statements and the related notes included elsewhere in this prospectus and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of this prospectus. We
	have derived the statement of operations data for the years ended December&nbsp;31, 2014 and 2015 and the balance sheet data as of December&nbsp;31, 2014 and 2015 from our audited consolidated
	financial statements included elsewhere in this prospectus. We have derived the statement of operations data for the three months ended March&nbsp;31, 2015 and 2016 and the balance sheet data as of
	March&nbsp;31, 2016 from our unaudited consolidated financial statements included elsewhere in this prospectus, which have been prepared on the same basis as the audited consolidated financial
	statements. In the opinion of management, the unaudited consolidated financial data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the
	financial information as of and for the periods presented. Our historical results are not necessarily indicative of results that should be expected in any future period, and our results for any
	interim period are not necessarily indicative of results that should be expected for any full year.
</I>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=11 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(in thousands, except share and per share data)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Statements of Operations Data:
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	317
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating expenses:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,923
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,408
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,736
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,265
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,512
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,729
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	836
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,371
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,137
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,820
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss and comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,431
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,568
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss per share applicable to common stockholders&#151;basic and diluted(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10.26
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(17.55
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3.44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5.15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in net loss per share applicable to common stockholders&#151;basic and diluted(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,525,018
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,980,286
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,682,690
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,394,470
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma net loss per share&#151;basic and diluted (unaudited)(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2.09
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.59
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in pro forma net loss per share&#151;basic and diluted (unaudited)(1)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,593,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17,947,602
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	See
	Note&nbsp;2 to our consolidated financial statements included elsewhere in this prospectus for a description of the method used to calculate basic and
	diluted net loss per share and unaudited pro forma basic and diluted net loss per share as well as the weighted-average number of common shares used in the calculation of the per share amounts.
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=74,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=775467,FOLIO='71',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_72">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="56PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31,
<BR>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(in thousands)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Balance Sheet Data:
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,393
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,909
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Working capital(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	59,291
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	28,493
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	57,824
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total assets
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	61,494
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43,631
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Convertible preferred stock
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	82,013
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	82,013
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	121,807
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total stockholders' deficit
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(21,772
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(47,964
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(57,890
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_UNIDENTIFIED_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We
	define working capital as current assets less current liabilities. See our consolidated financial statements for further details regarding our current
	assets and current liabilities.
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	72
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=75,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=454923,FOLIO='72',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_73">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_FINANCIAL_DATA>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DO79601_MANAGEMENT_S_DISCUSSION_AND_AN__MAN03466">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DO79601_2">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
<BR>
	RESULTS OF OPERATIONS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	You should read the following discussion and analysis of our financial condition and results of operations
	together with the section of this prospectus titled "Selected Consolidated Financial Data" and our consolidated financial statements and related notes included elsewhere in this prospectus. This
	discussion and other parts of this prospectus contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a
	result of many factors, including those factors set forth in the "Risk Factors" section of this prospectus, our actual results could differ materially from the results described in or implied by the
	forward-looking statements contained in the following discussion and analysis.
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Overview
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company pioneering an understanding of the region of the genome controlling the activation and repression of
	genes. Our goal is to advance a new wave of medicines to control the expression of disease-driving genes. We have built a proprietary gene control platform designed to systematically and efficiently
	analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the
	function of all cells, we believe that our gene control platform has broad potential to create medicines that achieve profound and durable benefit across therapeutic areas and a range of diseases. By
	focusing on genomically defined subsets of patients, we believe we can conduct efficient clinical trials with a higher likelihood of success. We are currently focused on developing treatments for
	cancer and immune-mediated diseases and are building a pipeline of gene control medicines. We plan to begin a Phase&nbsp;2 clinical trial for our lead product
	candidate, SY-1425 (tamibarotene), in mid-2016. This trial will enroll genomically defined subsets of patients with relapsed or refractory acute myelogenous leukemia, or AML, and relapsed high-risk
	myelodysplastic syndrome, or MDS. We plan to initiate a Phase 1/2 clinical trial for our development candidate SY-1365, initially for the treatment of acute leukemia, in the first half of 2017. Both
	of these programs may have potential in additional indications. Using our platform, we are also generating a pipeline of novel preclinical drug candidates for genomically defined subsets of currently
	underserved patients. Our goal is to build a fully integrated biopharmaceutical company based on our leadership position in gene control.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
	our inception in November 2011, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, developing our
	technology platform and conducting preclinical research for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. We have
	financed our operations to date primarily through private placements of preferred stock. From inception through March&nbsp;31, 2016, we have raised an aggregate of $122.2&nbsp;million of gross
	proceeds from sales of our preferred stock and the issuance of convertible notes that subsequently converted to preferred stock to fund operations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
	inception, we have incurred significant operating losses. Our net losses were $13.4&nbsp;million and $29.8&nbsp;million for the years ended December&nbsp;31, 2014 and 2015,
	respectively, and $4.6&nbsp;million and $10.6&nbsp;million for the three months ended March&nbsp;31, 2015 and 2016, respectively. As of March&nbsp;31, 2016, we had an accumulated deficit of
	$64.1&nbsp;million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection
	with our ongoing activities, as we:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	pursue clinical development of SY-1425, including a Phase&nbsp;2 clinical trial we expect to initiate in the middle of 2016;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	continue development efforts for SY-1365, for which we plan to initiate a Phase&nbsp;1/2 clinical trial in the first half of 2017;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	73
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=76,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=366180,FOLIO='73',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_74">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	continue our disease mapping efforts;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	initiate and continue research, preclinical and clinical development efforts for other gene control programs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	continue investment in our proprietary gene control platform;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	develop and scale up our manufacturing processes and capabilities to support our ongoing preclinical activities and clinical trials of
	our product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	maintain, expand and protect our intellectual property portfolio;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	hire and retain key scientific personnel; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expand our operational, financial and management systems and increase personnel, including personnel to support our clinical
	development and manufacturing efforts and our operations as a public company upon closing of this offering.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
	of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to
	achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing
	basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2016, we had cash and cash equivalents of $62.1&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash
	and cash equivalents as of March&nbsp;31, 2016, will enable us to fund our operating expenses and capital expenditure requirements at least through mid-2018. See "&#151;Liquidity and Capital
	Resources."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Financial Operations Overview
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Revenue
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the
	foreseeable future. For additional information about our revenue recognition policy, see the section titled "&#151;Critical Accounting Policies and Estimates&#151;Revenue."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Research and Development Expenses
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of costs incurred for our research activities, including development of our gene
	control platform and gene control product candidates, which initially focus on cancer indications, and which include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	employee-related expenses including salaries and benefits;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	stock-based compensation expense;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	external costs of funding research performed by third parties that conduct research and development and preclinical activities on our
	behalf and of purchasing lab supplies used in designing, developing and manufacturing preclinical study materials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	consulting, licensing and professional fees related to research and development activities; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	facilities costs, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities
	and insurance.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=77,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=300204,FOLIO='74',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_75">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
	and development costs are expensed as incurred. Nonrefundable advance payments made to vendors for goods or services that will be received in the future for use in research and
	development activities are deferred and capitalized, even when there is no alternative future use for the research and development, until related goods or services are provided.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	following summarizes our most advanced current research and development programs:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Our lead product candidate, SY-1425, is an oral, potent and selective RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist. We plan to
	initiate a Phase&nbsp;2 clinical trial in genomically defined subsets of patients with AML and MDS in mid-2016.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Our development candidate SY-1365 is a highly potent and selective small molecule inhibitor of cyclin-dependent kinase 7, or CDK7. We
	expect to initiate a Phase&nbsp;1/2 clinical trial in patients with acute leukemia, including AML and ALL, in the first half of 2017.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program,
	but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have not provided program costs for the year ended December&nbsp;31, 2014 because prior to 2015, we did not track or record our research and development expenses on a
	program-by-program basis. The following table summarizes our research and development expenses by program (in thousands):
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December&nbsp;31,
<BR>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SY-1365 and other CDK7 program external costs
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,998
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,352
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,980
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SY-1425 external costs
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,484
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,397
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other research and platform programs external costs
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,239
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	721
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,701
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Employee-related expenses, including stock-based compensation
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,077
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,417
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,578
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Facilities and other expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,610
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	222
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	609
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total research and development expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,408
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,736
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,265
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	expect our research and development expenses will increase for the foreseeable future as we seek to advance our programs. At this time, we cannot reasonably estimate or know the
	nature, timing and estimated costs of the efforts that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows
	will commence from sales of our product candidates. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty
	of:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successful completion of preclinical studies, including activities related to an investigational new drug application, or IND, and
	minimally efficacious dose studies in animals, where applicable and requested under the good laboratory practice, or GLP, requirements of the U.S. Food and Drug Administration, or FDA;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approval of INDs for our product candidates to commence planned or future clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successful enrollment in, and completion of preclinical studies and clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successful data from our clinical program that supports an acceptable benefit-risk profile of our product candidates in the intended
	populations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successful development, and subsequent clearance or approval, of companion diagnostics for use as screening criteria for potential
	patients;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	receipt of regulatory approvals from applicable regulatory authorities;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	75
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=78,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=394300,FOLIO='75',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_76">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishment of arrangements with third-party manufacturers for clinical supply and commercial manufacturing and, where applicable,
	commercial manufacturing capabilities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishment and maintenance of patent and trade secret protection or regulatory exclusivity for our product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	commercial launch of our product candidates, if and when approved, whether alone or in collaboration with others;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	enforcement and defense of intellectual property rights and claims;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	maintenance of a continued acceptable safety profile of the product candidates following approval; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	retention of key research and development personnel.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in
	the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require
	us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to
	expend significant additional financial resources and time on the completion of clinical development of our product candidates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	General and Administrative Expenses
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for
	personnel in executive, finance and administrative functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related
	to patent and corporate matters and fees for accounting and consulting services.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our
	product candidates and remediate our material weakness in our internal control over financial reporting. We also anticipate that we will incur increased accounting, audit, legal, regulatory,
	compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Income, Net
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net consists of interest income on our cash and cash equivalents and interest expense related to our equipment financing
	arrangement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Critical Accounting Policies and Estimates
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements,
	which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S.&nbsp;GAAP. The preparation of these financial statements requires us to make judgments and
	estimates that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on
	historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different
	assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if
	any, will be reflected in the financial statements prospectively from the date of the change in estimates.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	76
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=79,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=213406,FOLIO='76',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_77">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
	our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this prospectus, we believe the following
	accounting policies used in the preparation of our financial statements require the most significant judgments and estimates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Revenue
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2016, all of our revenue was generated exclusively from our research agreement with a multinational
	pharmaceutical company. We recognize revenue in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&nbsp;605
</FONT>
<FONT SIZE=2>
<I>
	Revenue Recognition
</I>
</FONT>
<FONT SIZE=2>
	, or ASC 605.
	Accordingly, revenue is recognized for each unit of accounting when all of the following criteria are
	met:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	persuasive evidence of an arrangement exists;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	delivery has occurred or services have been rendered;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the seller's price to the buyer is fixed or determinable; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	collectability is reasonably assured.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	analyze multiple element arrangements based on the guidance in ASC Topic 605-25,
</FONT>
<FONT SIZE=2>
<I>
	Revenue Recognition&#151;Multiple Element
	Arrangements
</I>
</FONT>
<FONT SIZE=2>
	, or ASC 605-25. Pursuant to the guidance in ASC 605-25, we evaluate multiple element arrangements to determine (1)&nbsp;the deliverables included in the
	arrangement and (2)&nbsp;whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves
	subjective determinations and we are required to make judgements about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship.
	Deliverables are considered separate units of accounting provided that: (i)&nbsp;the delivered item(s) has value to the customer on a standalone basis and (ii)&nbsp;the arrangement includes a
	general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within our control.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	recognize arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 605 are satisfied for that particular unit of accounting.
	In the event that a deliverable does not represent a separate unit of accounting, we recognize revenue from the combined unit of accounting over the contractual or estimated performance period for the
	undelivered items, which is typically the term of our research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not
	exist, then we recognize revenue under the arrangement on a straight-line basis over the period we are expected to complete our performance obligations or upon completion when the final act is of such
	significance to the overall arrangement that performance has not substantively occurred until the completion of that act. Conversely, if the pattern of performance over which the service is provided
	to the customer can be determined and objectively measurable performance measures exist, then we recognize revenue under the arrangement using the proportional performance method.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	research agreement contains a single unit of accounting and we recognize service revenue based upon the completed performance method of revenue recognition as we are unable to
	reasonably estimate the period of performance of the services and the delivery of the final study report is significant to the arrangement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Research and Development Expenses
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet
	date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of
	service performed and the associated cost incurred for the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	77
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=80,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=565796,FOLIO='77',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_78">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	service
	when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual
	milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our
	estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by
	our service providers in connection with research and development activities for which we have not yet been invoiced.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	record our expenses related to research and development activities based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors
	that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There
	may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we
	estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
	from our estimate, we adjust the accrual or prepaid accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are deferred and
	capitalized, even when there is no alternative future use for the research and development, until related goods or services are provided.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
	we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual
	status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our
	estimates of such expenses and the amounts actually incurred.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have and may in the future in-license the rights to develop and commercialize product candidates. For each in-license transaction we evaluate whether we have acquired processes or
	activities along with inputs that would be sufficient to constitute a "business" as defined under U.S.&nbsp;GAAP. A "business" as defined under U.S.&nbsp;GAAP consists of inputs and processes
	applied to those inputs that have the ability to create outputs. Although businesses usually have outputs, outputs are not required for an integrated set of activities to qualify as a business. When
	we determine that we have not acquired sufficient processes or activities to constitute a business, any up-front payments, as well as milestone payments, are immediately expensed as acquired research
	and development in the period in which they are incurred.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stock-Based Compensation
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We apply the fair value recognition provisions of ASC Topic 718,
</FONT>
<FONT SIZE=2>
<I>
	Compensation&#151;Stock
	Compensation
</I>
</FONT>
<FONT SIZE=2>
	, or ASC 718. Determining the amount of stock-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their
	grant date. Calculating the fair value of stock-based awards requires that we make highly subjective assumptions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	use the Black-Scholes option pricing model to value our stock option awards. Use of this valuation methodology requires that we make assumptions as to the volatility of our common
	stock, the expected term of our stock options, the risk free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. Because we are a
	privately held company with a limited operating history, we utilize data from a representative group of public companies to estimate expected stock price volatility. For purposes of identifying
	representative companies, we considered characteristics such as number of product candidates in early stages of product development, area of therapeutic focus, length of trading history and similar
	vesting provisions. The expected volatility was determined using an average of the historical volatilities of the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	78
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=81,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=955635,FOLIO='78',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DO79601_1_79">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	representative
	group of companies for a period equal to the expected term of the option grant. We intend to consistently apply this process using the same representative companies until a sufficient
	amount of historical information regarding the volatility of our own share price becomes available or until circumstances change, such that the identified entities are no longer representative
	companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	use the "simplified method" to estimate the expected term of stock option grants to employees. Under this approach, the weighted-average expected option term is presumed to be the
	average of the contractual term (ten years) and the vesting term (generally four years) of our stock options. We utilize this method due to lack of historical exercise data and the "plain-vanilla"
	nature of our stock-based awards. For options granted to non-employees, we utilize the contractual term of the arrangement as the basis for the expected option term assumption. The risk-free rate is
	based on the yield curve of U.S. Treasury securities in effect at the time of grant with periods commensurate with the expected term of the options being valued. We have never paid, and do not
	anticipate paying, any cash dividends in the foreseeable future, and therefore use an expected dividend yield of zero in the option-pricing model.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have computed the fair value of each stock option on the date of grant using the following weighted-average assumptions:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="15PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average risk-free interest rate
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.78
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.47
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expected dividend yield
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expected option term
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.03
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.09
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Volatility
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	85.51
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	82.71
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	84.32
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	85.52
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are also required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates. The term "forfeitures"
	is distinct from "cancellations" or "expirations" and represents only the unvested portion of the surrendered option. We use historical data to estimate pre-vesting option forfeitures and record
	stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment
	in the period in which the estimates are revised. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. Through
	March&nbsp;31, 2016, actual forfeitures have not been material.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	expense the fair value of our stock-based awards to employees on a straight-line basis over the associated service period, which is generally the vesting period. For stock-based
	awards granted to consultants and non-employees, we recognize compensation expense over the period during which the services are rendered by such consultants and non-employees. At the end of each
	financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of our common stock for restricted stock and updated
	assumptions in the Black-Scholes option-pricing model for stock options.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	record the expense for stock-based awards that contain performance-based milestones in accordance with the accelerated attribution model. Management evaluates when the achievement of
	a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. For certain of our performance-based awards, notwithstanding any
	vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. Compensation expense for such awards is
	recognized over the six-year vesting period unless management determines that the achievement of any performance-based milestones are probable, in which case expense is accelerated.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	79
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=82,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=211063,FOLIO='79',FILE='DISK124:[15ZCT1.15ZCT79601]DO79601A.;84',USER='GPEARMO',CD='17-JUN-2016;20:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_80">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents the grant dates, number of underlying shares of common stock and the per share exercise prices of stock options granted between
	January&nbsp;1, 2014 and June&nbsp;15, 2016, along with the fair value per share utilized to calculate stock-based compensation expense:
</FONT>
</P>
<EFX_OPTIONS>
<A NAME="FIS_OPTIONS"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:57%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="140%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="47PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="55PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="67PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="55PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="49PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:59PT;">
<FONT SIZE=1>
<B>
	Date of Issuance
<!-- COMMAND=ADD_SCROPPEDRULE,59PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Type of
<BR>
	Award
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of
<BR>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exercise Price
<BR>
	of Award per
<BR>
	Share(1)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Fair Value
<BR>
	of Common
<BR>
	Stock per
<BR>
	Share at
<BR>
	Grant
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Per Share
<BR>
	Estimated
<BR>
	Fair
<BR>
	Value of
<BR>
	Award(2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	1/29/2014
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	1,333
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.01
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.98
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.71
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	6/3/2014
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	180,777
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.01
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	9/4/2014
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	17,689
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.01
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	10/22/2014
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	91,783
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.43
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2/5/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	224,513
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.16
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.16
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	6/9/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	386,102
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.96
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.76
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	9/17/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	64,330
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.90
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	9/21/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	258,071
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.89
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	10/11/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	54,497
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.31
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.23
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	10/21/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	47,332
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.31
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.24
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	12/23/2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	287,036
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.85
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.27
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	3/31/2016
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	125,253
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.51
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.51
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.13
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	6/1/2016
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	64,798
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11.66
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11.66
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.42
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_OPTIONS>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	Exercise Price of Award per Share represents the fair value of our common stock on the date of grant, as determined by our board of directors, taking
	into account our most recently available independent third-party valuation of our common stock as well as additional factors that may have changed since the date of such valuation.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	Per Share Estimated Fair Value of Award reflects the fair value of options as estimated at the date of grant using the Black-Scholes option-pricing
	model.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	At
	the time of the option grants on February&nbsp;5, 2015 and June&nbsp;9, 2015, our board of directors determined the fair value of our common stock
	was $3.04 per share, based on an independent third-party valuation report dated as of October&nbsp;9, 2014. However, as described below, in connection with a retrospective fair value assessment for
	financial reporting purposes we adjusted the fair value of common stock at the date of these grants.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(4)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	At
	the time of the option grants on October&nbsp;11, 2015 and October&nbsp;21, 2015, our board of directors determined the fair value of our common
	stock was $6.94 per share, based on an independent third-party valuation report dated as of September&nbsp;9, 2015. In connection with a retrospective fair value assessment for financial reporting
	purposes performed as of October&nbsp;21, 2015, we adjusted the fair value of common stock at the date of these grants.
</FONT>
</DD>
</DL>
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
	compensation expense totaled approximately $3.2&nbsp;million for the year ended December&nbsp;31, 2015 and $0.7 million for the three months ended March&nbsp;31, 2016.
	As of March&nbsp;31, 2016, we had $7.1&nbsp;million of unrecognized compensation expense related to unvested stock options and unvested restricted stock which we expect to recognize over a
	weighted-average period of 3.1&nbsp;years. We expect the impact of our stock-based compensation expense for restricted stock and stock options granted to employees, directors and other service
	providers to increase in future periods due to potential increases in the value of our common stock and headcount.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Determination of Fair Value of Common Stock on Grant Dates
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are required to estimate the fair value of our common stock underlying our stock-based awards when performing the fair value
	calculations using the Black-Scholes option pricing model. The fair value of our common stock underlying our stock-based awards was determined on each grant date by
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	80
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=83,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=471732,FOLIO='80',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_81">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our
	board of directors, with input from management, considering our most recently available independent third-party valuations of common stock and our board of directors' assessment of additional
	objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. These independent third-party
	valuations of our common stock were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants
</FONT>
<FONT SIZE=2>
<I>
	Audit and Accounting Practice
	Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation
</I>
</FONT>
<FONT SIZE=2>
	, or the Practice Aid. Once a public trading market for our common stock has been
	established in connection with the closing of this offering, it will no longer be necessary for us to estimate the fair value of our common stock in connection with our accounting for stock options
	and restricted stock, as the fair value of our common stock will be its trading price on The NASDAQ Global Market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For financial reporting purposes, we performed common stock valuations, with the assistance of an independent third-party valuation specialist, as of April&nbsp;1, 2014,
	October&nbsp;9, 2014, September&nbsp;9, 2015, December&nbsp;10, 2015, March&nbsp;21, 2016 and May&nbsp;27, 2016, which resulted in valuations of our common stock of $1.39, $3.04, $6.94,
	$8.85, $8.51 and $11.66, respectively, as of those dates. With the assistance of an independent third-party valuation specialist, we performed retrospective common stock valuations for financial
	reporting purposes as of March&nbsp;31, 2015, June&nbsp;30, 2015 and October&nbsp;21, 2015, which resulted in valuations of our common stock of $4.65, $5.96 and $7.31 per share, respectively, as
	of those dates. In conducting these independent third-party valuations, we considered all objective and subjective factors that we believed to be relevant for each valuation conducted, including our
	best estimate of our business condition, prospects and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions and methodologies were used. The
	significant factors included:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the lack of an active public market for our common and preferred stock;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	prices of shares of our preferred stock that we had sold to outside investors in arm's length transactions, and the rights,
	preferences and privileges of that convertible stock relative to our common stock;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our results of operations and financial position and the status of our research and preclinical development efforts;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the material risks related to our business;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our business strategy;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the market performance of publicly traded companies in the life sciences and biotechnology sectors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering, or IPO, given
	prevailing market conditions; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	recent independent third-party valuations of our common stock prepared in accordance with methodologies outlined in the Practice Aid.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future
	operating performance, the time to completing an IPO or other liquidity event, the related company valuations associated with such events and the determinations of the appropriate valuation methods.
	If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share applicable to common stockholders could have been significantly different.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Common Stock Valuations Methodologies
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock valuation methodologies.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The valuations of our common stock were prepared in accordance with the guidelines in the
	Practice Aid, which
	prescribes several valuation approaches for determining the value of an enterprise, such as the cost, market and income approaches, and various
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	81
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=84,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=610608,FOLIO='81',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_82">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	methodologies
	for allocating the value of an enterprise to its capital structure and specifically the common stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	market approach estimates the fair value of a company by applying market multiples of comparable companies in a similar line of business and considers the price that investors have
	paid for the equity of publicly traded companies or venture investments in a private firm. Through the creation of multiples of revenue, operating income, net income and other key metrics for
	comparable assets, a method of obtaining a relative valuation of an asset can be made.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
	our enterprise value was determined using the market approach valuation method.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Methods used to allocate our enterprise value to classes of securities.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the Practice Aid, we considered the
	following methods for
	allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date:
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OPM.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The option pricing method, or OPM, treats common stock and preferred stock as call options on the total equity value of a company,
	with exercise
	prices based on the value thresholds at which the allocation among the various holders of a company's securities changes. Under this method, the common stock has value only if the funds available for
	distribution to stockholders exceed the value of the liquidation preferences at the time of a liquidity event, such as a strategic sale or merger. The common stock is modeled as a call option on the
	underlying equity value at a predetermined exercise price. In the model, the exercise price is based on a comparison with the total equity value rather than, as in the case of a regular call option, a
	comparison with a per share stock price. Thus, common stock is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately after the
	preferred stock liquidation preference is paid.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	OPM uses the Black-Scholes option-pricing model to price the call options. This model defines the securities' fair values as functions of the current fair value of a company and uses
	assumptions, such as the anticipated timing of a potential liquidity event and the estimated volatility of the equity securities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	OPM backsolve approach was used to estimate enterprise value under the OPM. The OPM backsolve approach uses the OPM to derive the implied equity value for one type of equity security
	from a contemporaneous sale transaction involving another type of the company's equity securities. In
	the OPM, the assumed volatility factor was based on the historical trading volatility of our publicly traded peer companies. At each valuation date, a determination was made by us as to the
	appropriate volatility to be used, considering such factors as the expected time to a liquidity event and our stage of development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	derive the fair value of the common stock using the OPM, the proceeds to the common stockholders were calculated based on the preferences and priorities of the preferred stock and
	common stock. We then applied a discount for lack of marketability to the common stock to account for the lack of access to an active public market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PWERM.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;Under a probability-weighted expected return method, or PWERM, the value of the various equity securities are estimated based
	upon an analysis
	of future values for the enterprise, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the
	possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate
	risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hybrid Method.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;The hybrid method is a PWERM where the equity value in one of the scenarios is calculated using an OPM. In the hybrid
	method used by
	us, two types of future-event scenarios were considered: an IPO and an unspecified liquidity event. The enterprise value for the IPO scenario was determined using a market approach. The enterprise
	value for the unspecified liquidity event scenario was determined using the OPM backsolve approach. The relative probability of each type of future-
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	82
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=85,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=209950,FOLIO='82',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_83">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	event
	scenario was determined based on an analysis of market conditions at the time, including then-current IPO valuations of similarly situated companies, and expectations as to the timing and likely
	prospects of the future-event scenarios.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	determine the enterprise value for the IPO scenario, we used the guideline public company method, which includes comparisons to publicly traded companies in the biopharmaceutical
	industry that recently completed IPOs. That enterprise value was then discounted back to the valuation date at an appropriate risk-adjusted discount rate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	derive the fair value of the common stock for each scenario under the hybrid method, the proceeds to the common stockholders were calculated based on the conversion rights and
	preferences of the preferred stock. We then applied a discount for lack of marketability to the common stock to account for the lack of access to an active public market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
	to January&nbsp;1, 2015, our common stock valuations were prepared utilizing OPM. Our common stock valuations in 2015 and 2016 were prepared utilizing the hybrid method.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Results of Operations
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Comparison of Three Months Ended March&nbsp;31, 2015 and 2016
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the three months ended March&nbsp;31, 2015 and 2016, together with the
	changes in those items in dollars (in thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="69PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Dollar Change
</B>
</FONT>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Percentage Change
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Statements of Operations Data:
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenue
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	n/a
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating expenses:
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,736
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,265
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,529
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	121
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	836
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,371
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,535
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	184
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,572
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,636
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,064
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	133
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income, net
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	44
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,100
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss and comprehensive loss
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,568
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,588
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6,020
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	132
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Revenue
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2014, we entered into a research agreement with a multinational pharmaceutical company. We did not earn any revenue under
	this agreement for the three months ended March&nbsp;31, 2015 and 2016. The amount of revenue to be recognized under this agreement in future periods may fluctuate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Research and Development Expense
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense increased by $4.6&nbsp;million from $3.7&nbsp;million for the three months ended March&nbsp;31,
	2015 to $8.3&nbsp;million for the three months ended March&nbsp;31, 2016. The
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	83
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=86,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=693542,FOLIO='83',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_84">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	following
	table summarizes our research and development expenses for the three months ended March&nbsp;31, 2015 and 2016, together with the changes to those items in dollars (in thousands):
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="69PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Dollar Change
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	External research and preclinical development
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,946
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,486
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,540
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Employee-related expenses, excluding stock based-compensation
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	955
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,018
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,063
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock-based compensation
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	462
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	560
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	98
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consulting, licensing and professional fees
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	151
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	592
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	441
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Facilities and other expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	222
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	609
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	387
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total research and development expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,736
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,265
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,529
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	increase in research and development expense was primarily attributable to research and development activities associated with advancing our lead preclinical programs and enhancing
	our internal capabilities and included the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $2.5&nbsp;million for costs from third parties that conduct research and development and preclinical activities on our
	behalf, including approximately $0.9&nbsp;million for in vivo study and toxicology costs and $0.5&nbsp;million in contract manufacturing and clinical development for SY-1425;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $1.1&nbsp;million for increased personnel related expenses, including increased salary and benefits primarily due to
	the hire of research and development personnel;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.4&nbsp;million in consulting, licensing and professional fees, including clinical and regulatory consultants for
	SY-1425; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.4&nbsp;million for increases in facilities costs including rent, depreciation and maintenance expenses.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	General and Administrative Expense
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense increased by $1.5&nbsp;million from $0.8&nbsp;million for the three months ended
	March&nbsp;31, 2015 to $2.3&nbsp;million for the three months ended March&nbsp;31, 2016. The increase in general and administrative expense was primarily attributable to the
	following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.8&nbsp;million for employee-related costs, including salary and benefits as a result of the increase in
	administrative function headcount; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.4&nbsp;million primarily for consulting and professional fees, including increased corporate legal fees and human
	resources costs.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Income, Net
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net increased by $44,000 from $4,000 for the three months ended March&nbsp;31, 2015 to $48,000 for the three months
	ended March&nbsp;31, 2016, primarily due to higher invested cash balances.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	84
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=87,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=568341,FOLIO='84',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_85">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Comparison of Years Ended December&nbsp;31, 2014 and 2015
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the years ended December&nbsp;31, 2014 and 2015, together with the
	changes in those items in dollars (in thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="69PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Dollar Change
</B>
</FONT>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Percentage Change
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenue
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	317
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	317
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	n/a
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating expenses:
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,923
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,408
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,485
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	123
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,512
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,729
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,217
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	128
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,435
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,137
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	16,702
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	124
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income (expense), net
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(50
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss and comprehensive loss
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,431
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,818
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(16,387
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	122
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Revenue
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue was $0.3&nbsp;million for the year ended December&nbsp;31, 2015 and related to the completion of a research project under
	our research agreement with a multinational
	pharmaceutical company. We did not earn any revenue for the year ended December&nbsp;31, 2014. The amount of revenue to be recognized under this agreement in future periods may fluctuate.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Research and Development Expense
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense increased by $13.5&nbsp;million from $10.9&nbsp;million for the year ended December&nbsp;31,
	2014 to $24.4&nbsp;million for the year ended December&nbsp;31, 2015. The following table summarizes our research and development expenses for the years ended December&nbsp;31, 2014 and
	December&nbsp;31, 2015, together with the changes to those items in dollars (in thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="69PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Dollar Change
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	External research and preclinical development
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,520
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,749
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,229
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Employee-related expenses, excluding stock-based compensation
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,984
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,344
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,360
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock-based compensation
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	830
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,733
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,903
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consulting, licensing and professional fees
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	682
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,972
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,290
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Facilities and other expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	907
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,610
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	703
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total research and development expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,923
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,408
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,485
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	increase in research and development expense was primarily attributable to research and develop activities associated with advancing our lead preclinical programs and enhancing our
	internal capabilities and included the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $7.2&nbsp;million for costs from third parties that conduct research and development and preclinical activities on our
	behalf, including approximately $2.6&nbsp;million in chemistry expenses for contract chemistry personnel and increased chemistry analysis and $1.2&nbsp;million for in vivo study costs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $1.9&nbsp;million for increased stock-based compensation expense;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $2.4&nbsp;million for increased personnel related expenses, including increased salary and benefits primarily due to
	the hire of research and development personnel;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	85
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=88,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=888786,FOLIO='85',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_86">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $1.3&nbsp;million in consulting, licensing and professional fees including the $0.5&nbsp;million upfront payment
	made under the TMRC license agreement; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.7&nbsp;million for increases in facilities costs including rent, depreciation and maintenance expenses.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	General and Administrative Expense
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense increased by $3.2&nbsp;million from $2.5&nbsp;million for the year ended December&nbsp;31,
	2014 to $5.7&nbsp;million for year ended December&nbsp;31, 2015. The increase in general and administrative expense was primarily attributable to the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $1.2&nbsp;million for employee-related costs, including salary and benefits as a result of the increase in
	administrative function headcount;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.9&nbsp;million primarily for consulting and professional fees, including increased corporate legal fees in support
	of the negotiations of the TMRC license agreement and the negotiations of our operating lease agreement for office space and increased public relations expenses; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approximately $0.4&nbsp;million for increased stock-based compensation expense.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Income, Net
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net decreased by $2,000 from $4,000 for the year ended December&nbsp;31, 2014 to $2,000 for the year ended
	December&nbsp;31, 2015. Interest income on our invested cash and cash equivalents increased from $4,000 for the year ended December&nbsp;31, 2014 to $20,000 for the year ended December&nbsp;31,
	2015. For the year ended December&nbsp;31, 2015, the interest income was offset by interest expense of $18,000 related to our equipment financing arrangement.
</FONT>
</P>
<EFX_LIQUIDITY>
<A NAME="FIS_LIQUIDITY"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Liquidity and Capital Resources
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Sources of Liquidity
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have funded our operations from inception through March&nbsp;31, 2016 primarily through gross proceeds of $122.2&nbsp;million
	from sales of our preferred stock and the issuance of convertible notes that subsequently coverted into preferred stock. As of March&nbsp;31, 2016, we had cash and cash equivalents of
	$62.1&nbsp;million.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Cash Flows
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding our cash flows for the years ended December&nbsp;31, 2014 and 2015 and the three
	months ended March&nbsp;31, 2015 and March&nbsp;31, 2016 (in&nbsp;thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash provided by (used in):
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating activities
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11,969
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(23,030
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3,269
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,618
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Investing activities
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(201
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,176
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(108
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,525
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Financing activities
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	68,762
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(278
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38,367
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net increase (decrease) in cash and cash equivalents
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	56,592
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(24,484
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3,377
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26,224
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Net Cash Used in Operating Activities
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of
	working capital.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	86
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=89,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=53172,FOLIO='86',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_87">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
	cash used in operating activities was $10.6&nbsp;million during the three months ended March&nbsp;31, 2016 compared to $3.2&nbsp;million during the three months ended
	March&nbsp;31, 2015. The increase in cash used in operating activities was primarily due to an increase in our net loss of $6.0&nbsp;million for the three months ended March&nbsp;31, 2016 as
	compared to the three months ended March&nbsp;31, 2015.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
	cash used in operating activities was $23.0&nbsp;million during the year ended December&nbsp;31, 2015 compared to $12.0&nbsp;million during the year ended December&nbsp;31,
	2014. The increase in cash used in operating activities was primarily due to an increase in net loss of $16.4&nbsp;million for the year ended December&nbsp;31, 2015 as compared to the year ended
	December&nbsp;31, 2014.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Net Cash Used in Investing Activities
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities was $1.5&nbsp;million during the three months ended March&nbsp;31, 2016 compared to $0.1
	million during the three months ended March&nbsp;31, 2015. The increase in cash used in investing activities was due to increased purchases of property and equipment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
	cash used in investing activities was $1.2&nbsp;million during the year ended December&nbsp;31, 2015 compared to $0.2&nbsp;million during the year ended December&nbsp;31,
	2014. The increase in cash used in investing activities was due to increased purchases of property and equipment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Net Cash Provided by (Used in) Financing Activities
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities was $38.4&nbsp;million during the three months ended March&nbsp;31, 2016 and there was $0
	provided by financing activities during the three months ended March&nbsp;31, 2015. The increase in cash provided by financing activities was primarily due to the issuance of $39.8&nbsp;million of
	Series&nbsp;B preferred stock during the three months ended March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
	cash used in financing activities was $0.3&nbsp;million during the year ended December&nbsp;31, 2015 compared to net cash provided by financing activities of $68.8&nbsp;million
	during the year ended December&nbsp;31, 2014. The decrease in cash provided by financing activities was primarily due to the issuance of $15.8&nbsp;million of Series&nbsp;A-3 preferred stock and
	$53.1&nbsp;million of Series&nbsp;B preferred stock during the year ended December&nbsp;31, 2014, with no preferred stock issuance occurring during the year ended December&nbsp;31, 2015.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Funding Requirements
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate clinical trials of SY-1425,
	advance the development of SY-1365, initiate new research and preclinical development efforts and seek marketing approval for any product candidates that we successfully develop. In addition, if we
	obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing sales, marketing, distribution and other commercial
	infrastructure to commercialize such products. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will
	need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or
	eliminate our research and development programs or future commercialization efforts.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents as of March&nbsp;31, 2016, will enable us to fund our operating
	expenses and capital expenditure requirements at least through mid-2018. Our future capital requirements will depend on many factors, including:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the scope, progress, timing, costs and results of clinical trials of SY-1425 and SY-1365;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	research and preclinical development efforts for any future product candidates that we may develop;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	87
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=90,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1024517,FOLIO='87',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_88">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of future product candidates that we pursue and their development requirements;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the outcome, timing and costs of seeking regulatory approvals;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs
	are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of acquiring potential new product candidates or technology;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of any physician education programs relating to selecting and treating genomically defined patient populations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the timing and amount of milestone and other payments due to licensors for patent and technology rights used in our development
	platform;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	revenue received from commercial sales, if any, of our current and future product candidates;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and
	defending against intellectual property related claims; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the costs of operating as a public company.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identifying
	potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete,
	and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial
	success. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at
	all.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
	such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations,
	strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and
	the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include
	covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
	future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt
	financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates
	that we would otherwise prefer to develop and market ourselves.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	88
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=91,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=274363,FOLIO='88',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_89">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Contractual Obligations
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our significant contractual obligations as of payment due date by period at December&nbsp;31, 2015 (in
	thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="56PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="56PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Less Than
<BR>
	1 Year
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	1 to 3 Years
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	3 to 5 Years
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	More than
<BR>
	5 Years
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating lease commitments(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,212
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,217
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,540
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,455
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Capital lease(2)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	367
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	152
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	215
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_UNIDENTIFIED_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We
	lease office space at 620 Memorial Drive in Cambridge, Massachusetts under a non-cancelable operating lease that expires in October 2020.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We
	have a capital lease for laboratory equipment that expires in March 2018.
</FONT>
</DD>
</DL>
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	enter into agreements in the normal course of business with our contract research organizations and institutions to license intellectual property. We have not included these future
	payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon 30 to 90&nbsp;days prior written notice.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	license agreements include potential milestone payments that are contingent upon the successful development and commercialization of products using the intellectual property licensed
	under such agreements. Under our agreements with Dana-Farber and Whitehead, the maximum aggregate potential milestone payments payable by us total approximately $6.9&nbsp;million. Under the
	applicable agreement, we are also required to pay annual maintenance fees, as well as tiered, single-digit percentage royalties, on a country-by-country, product-by-product basis, on net product
	sales.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	the amended and restated TMRC license agreement, we may make additional payments upon the successful achievement of pre-specified clinical and regulatory milestones in an aggregate
	amount of approximately $13.0&nbsp;million per indication. We paid the balance of the upfront license fee of $0.5 million under this agreement in May 2016. Upon the successful dosing of the first
	patient in our Phase&nbsp;2 clinical trial of SY-1425, which we expect to occur in mid-2016, we are obligated to make a $1.0 million milestone payment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
	that are contingent upon achievement of developmental and commercial milestones, the likelihood of which cannot be reasonably estimated at this time, are not reflected in the
	table above.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Off-Balance Sheet Arrangements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under
	applicable Securities and Exchange Commission rules.
</FONT>
</P>
</EFX_LIQUIDITY>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Quantitative and Qualitative Disclosures About Market Risk
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity,
	which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form of a money market fund and marketable
	securities and are invested in U.S. Treasury obligations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are also exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located in Asia and Europe and certain invoices are
	denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. As
	of December&nbsp;31, 2015, we had minimal or no liabilities denominated in foreign currencies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inflation
	generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or
	results of operations during the years ended December&nbsp;31, 2014 and 2015 and the three months ended March&nbsp;31, 2015 and 2016, respectively.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	89
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=92,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=663187,FOLIO='89',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_90">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Internal Control over Financial Reporting
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the audit of our financial statements as of and for the years ended December&nbsp;31, 2014 and 2013, we identified
	material weaknesses in our internal control over financial reporting. The material weaknesses related to our controls over the classification of certain indirect and other expenses between general and
	administrative and research and development, and to the accounting for stock-based compensation. We also identified deficiencies related to our controls over our accounting for income taxes. The
	material weaknesses were due to the lack of appropriate oversight and review procedures by accounting personnel to properly identify and evaluate certain accounting matters that resulted in errors in
	our financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are implementing measures designed to improve our internal control over financial reporting to remediate these material weaknesses, including the
	following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we are formalizing our processes and internal control documentation and strengthening supervisory reviews by our management;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we have hired additional qualified accounting personnel and engaged financial consultants, all of whom have significant accounting and
	financial reporting experience, which will enable the implementation of internal controls over financial reporting and segregating duties among accounting personnel;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we expect to hire additional senior accounting and finance staff to complete this remediation; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we intend to implement certain accounting systems to automate manual processes, such as tracking and accounting for stock-based
	awards.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
	additional resources and procedures are designed to enable us to broaden the scope and quality of our internal review of underlying information related to financial reporting and
	to formalize and enhance our internal control procedures. With the oversight of senior management, we have begun taking steps and plan to take additional measures to remediate the underlying causes of
	the material weaknesses.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We,
	and our independent registered public accounting firm, were not required to perform an evaluation of our internal control over financial reporting as of December&nbsp;31, 2015 in
	accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot provide assurance that we have identified all, or that we will not in the future have additional, material weaknesses.
	Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section&nbsp;404 of the
	Sarbanes-Oxley Act after the closing of this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	JOBS Act
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107 of the JOBS Act
	provides that an emerging growth company, or EGC, can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the
	Securities Act, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private
	companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which
	adoption of such standards is required for other public companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC, we intend
	to rely on certain of these exemptions, including the exemption from the requirement to provide an auditor's attestation report on our system of internal controls over financial reporting pursuant to
	Section&nbsp;404(b) of the Sarbanes-Oxley Act and with the exemption from any requirement that may be
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	90
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=93,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=677480,FOLIO='90',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DQ79601_1_91">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	adopted
	by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and
	the financial statements, known as the auditor discussion and analysis. We will remain an EGC until the earlier of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
	revenues of $1.0&nbsp;billion or more; (ii)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the closing of this offering; (iii)&nbsp;the date on which we have
	issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the
	Securities and Exchange Commission.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	91
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=94,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=923616,FOLIO='91',FILE='DISK124:[15ZCT1.15ZCT79601]DQ79601A.;80',USER='GPEARMO',CD='17-JUN-2016;20:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_92">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_MARKET_RISK>
</EFX_MANAGEMENTS_DISCUSSION>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_DS79601_BUSINESS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_DS79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	BUSINESS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Overview
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company pioneering the understanding of the region of the genome controlling the activation and repression
	of genes. Our goal is to advance a new wave of medicines to control the expression of disease-driving genes. We have built a proprietary gene control platform designed to systematically and
	efficiently analyze this unexploited region of DNA in
	human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, we believe that our gene
	control platform has broad potential to create medicines that achieve profound and durable benefit across therapeutic areas and a range of diseases. By focusing on genomically defined subsets of
	patients, we believe we can conduct efficient clinical trials with a higher likelihood of success. We are currently focused on developing treatments for cancer and immune-mediated diseases and are
	building a pipeline of gene control medicines. We plan to begin a Phase&nbsp;2 clinical trial for our lead product candidate, SY-1425 (tamibarotene), in mid-2016. This trial will enroll genomically
	defined subsets of patients with relapsed or refractory acute myelogenous leukemia, or AML, and relapsed high-risk myelodysplastic syndrome, or MDS. We plan to initiate a Phase&nbsp;1/2 clinical
	trial for our development candidate SY-1365, initially for the treatment of acute leukemia, in the first half of 2017. Both of these programs may have potential in additional indications. Leveraging
	our platform, we are also generating a pipeline of novel preclinical drug candidates for genomically defined subsets of currently underserved patients. Our goal is to build a fully integrated
	biopharmaceutical company based on our leadership position in gene control.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	discovery and development of targeted therapies, in which the right drug is matched to the right patient, has dramatically improved the ability to treat certain cancers and other
	serious diseases. However, targeted drug discovery and development to date has focused almost exclusively on genetic alterations found in regions of DNA that code for proteins, which represent less
	than 2% of the entire genome, and the identification of new drug targets by sequencing these coding regions has been largely exhausted. Moreover, in cancer, inhibiting abnormal proteins resulting from
	single genetic alterations in coding DNA can often lead to drug resistance and limited durable clinical benefit. Furthermore, many serious diseases continue to go unaddressed due to the limitations of
	current drug discovery approaches. Taken together, these factors underscore the need for fundamentally new approaches to drug discovery and development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Researchers
	have long believed that alterations in non-coding regions of DNA, which account for the other 98% of the genome, play a key role in driving disease. However, the scientific
	community has lacked the tools to study these regions of the genome, rendering them poorly understood and largely unexploited for targeted drug discovery and development. The work of our scientific
	founders, leaders in the field of gene control, as well as other academic researchers is now shedding light on the importance of non-coding regions of the genome in maintaining health and driving
	disease. Rapidly growing scientific evidence points to non-coding regions of DNA as fundamental to determining cell type and function and to alterations in these non-coding regions as involved in the
	development and progression of a broad range of diseases.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
	all cells share the same genome, each of the nearly 200 different cell types in the human body has a different function. For example, a skin cell functions differently from a
	muscle cell despite sharing the exact same DNA. What determines a cell's type and function is the specific set of genes that is expressed, or turned "on" or "off," in that particular cell. This
	coordinated activation and repression of genes, known as the cell's gene expression program, is controlled by non-coding regions of the genome. Alterations in these non-coding regions change a cell's
	gene expression program, altering its normal function and leading to disease. Because this biology is fundamental to the function of all cells, it applies across diseases, whether the cause is
	genetic, environmental, bacterial, viral or multi-factorial.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	92
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=95,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=177933,FOLIO='92',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_93">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	relatively few gene control medicines available today are among the most important targeted therapies and are widely used for their approved indications. Drugs targeting specialized
	proteins known as transcription factors that play a central role in the expression of disease-driving genes, such as estrogen receptors in breast cancer, androgen receptors in prostate cancer and
	glucocorticoid receptors in inflammation, are important examples of gene control medicines that have produced transformative patient benefits. For example, tamoxifen, a gene control medicine that
	targets a transcription factor, revolutionized the treatment of certain breast cancers and is prescribed 1.9&nbsp;million times annually in the United States, illustrating the significant
	therapeutic potential of gene control medicines. However, the difficulty of studying non-coding regions of the genome has historically prevented a systematic approach to identifying these critical
	points of therapeutic intervention.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are solely focused on the discovery and development of gene control medicines. Building on the discoveries of our scientific founders, we believe we have built the first proprietary
	platform designed to systematically and efficiently analyze non-coding regions of the genome in healthy and diseased cells taken from patient tissues to identify optimal points of therapeutic
	intervention and develop drugs to control the expression of disease-driving genes. By doing so, we believe our gene control platform will allow us to (i)&nbsp;identify a wide array of potential new
	drug targets across a range of diseases, (ii)&nbsp;provide a new lens for diagnosing and segmenting patients, including those with complex, multi-factorial diseases that have eluded segmentation
	with other genomic-based approaches, and (iii)&nbsp;advance a new wave of medicines that have the potential to influence multiple drivers of disease through a single target, making them less
	susceptible to drug resistance and providing patients with a more profound and durable benefit than many of today's targeted therapies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	gene control platform consists of two fundamental pillars: identifying novel gene control targets linked to genomically defined patient populations, and drugging gene control
	targets.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	first pillar of our platform is designed to systematically and efficiently home in on the specific set of genes most crucial to determining a cell's type and function. Starting from
	human tissue samples, we compare diseased cells to normal cells and analyze the cells of different patient subsets within a disease to identify alterations in gene expression programs that represent
	optimal points of therapeutic intervention and associated biomarkers for patient selection. We home in on a cell's gene expression program by using genomic tools to locate super-enhancers, which are
	highly specialized regions of non-coding DNA that are central to orchestrating gene expression programs and drive the increased expression of the genes crucial to the function of a given cell.
	Analysis of super-enhancers and their associated genes provides critical insights into changes in gene expression programs that contribute to disease. We have invested significant resources in our
	tissue processing, genomics and computational biology capabilities to industrialize the analysis of gene expression programs to reveal the genes crucial to cell type and function in diseased cells. We
	have amassed one of the largest known datasets of gene expression programs across a wide range of human diseases and cell types and have validated multiple novel disease targets and biomarkers. To
	date, we have analyzed or are in the process of analyzing gene
	expression programs in AML, breast cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, non-disease and lupus immune cells, polycystic kidney disease, spinal
	muscular atrophy and Alzheimer's disease. Through those efforts, we have identified approximately 50 novel drug targets in oncology, immuno-oncology and autoimmune diseases and validated seven of
	those targets using biological methods to knock out the target gene or chemical methods to modulate the target's activity. The discovery and validation of these targets has led to the identification
	of our product candidate SY-1425 as well as additional novel preclinical drug candidates in earlier stages of research and development. We plan to analyze gene expression programs in several other
	cancers, including colorectal, lung and melanoma, as well as several other diseases and cell types including additional inflammatory disorders and immune cells from tumors. Our long-term goal is to
	analyze gene expression programs in all serious diseases where we believe currently underserved patients can benefit from gene control medicines.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	93
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=96,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=597767,FOLIO='93',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_94">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	second pillar of our platform is our small molecule chemistry capabilities to drug gene control targets. While our platform is capable of identifying drug targets across a broad
	range of target classes and therapeutic modalities, our internal drug discovery effort is focused on small molecule chemistry to target specialized proteins responsible for gene expression, including
	transcription factors, transcriptional kinases and other transcriptional and regulatory proteins. We focus on these specialized proteins for several reasons. First, because these specialized proteins
	play a central role in implementing gene expression programs, they are among the most promising and high-potential gene control targets for therapeutic intervention. Transcription factors bind
	directly to DNA sequences to control the transcription of genetic information from DNA. Transcription factors perform this function with other transcriptional and regulatory proteins, including
	transcriptional kinases. Second, transcriptional and regulatory proteins have historically been difficult to drug and represent an opportunity to bring novel and differentiated therapies to patients.
	Third, we have built a differentiated combination of expertise, tools and capabilities that we believe will give us cutting-edge insights into drugging transcriptional and regulatory proteins. Through
	significant investments in developing our capabilities in biochemistry, structural biology and medicinal chemistry and in developing a sophisticated suite of proprietary assays, which are internally
	developed tests that we use to measure the biochemical, biophysical, cellular and genomic activity of known and novel compounds against gene control targets, we believe we will be able to overcome
	challenges that have prevented others from systematically and successfully developing gene control medicines. We are building a pipeline of product candidates to modulate gene expression programs
	through two distinct approaches: internal efforts to discover novel drugs against our validated gene control targets and externally focused efforts to link existing drugs to novel genomically defined
	patient populations identified through our platform. These externally focused efforts could enable to us identify drugs that we may seek to in-license or acquire or use as starting points for our own
	drug discovery and development programs to accelerate our development path. Our CDK7 inhibitor, SY-1365, demonstrates our ability to create proprietary gene control drug candidates targeting
	transcriptional biology. Our SY-1425 program demonstrates our ability to link existing drugs to novel genomically defined subsets of patients, with the aim of accelerating our clinical development
	path.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are leveraging our platform to develop a pipeline of gene control product candidates. Our most advanced drug programs are summarized in the table below:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:67%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="120%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="96PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="16%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="148PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="91PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Program
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Initial
<BR>
	Indications
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Planned&nbsp;Milestones
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Potential&nbsp;Indications
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Syros
<BR>
	Commercial
<BR>
	Rights
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SY-1425 (RAR
<FONT FACE="SYMBOL">
	a
</FONT>
<BR>
	agonist)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	AML and MDS
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Initiate Phase&nbsp;2 clinical trial in
	mid-2016
<BR>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Expect initial data readout in mid-2017
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Breast cancer
<BR>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Acute promyelocytic
<BR>
	leukemia (APL)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	North America,
<BR>
	Europe
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SY-1365 (CDK7 inhibitor)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Acute leukemia
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Initiate Phase&nbsp;1/2 clinical trial in 1H
	2017
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Expect initial data readout in 1H&nbsp;2018
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
</FONT>
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Small cell lung cancer
<BR>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
	Triple negative breast
<BR>
	cancer
<BR>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-BOTTOM:-12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	&#149;
</FONT>
</P>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:0PT;MARGIN-LEFT:10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-
<BR>
	amplified
<BR>
	neuroblastoma
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Worldwide
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	94
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=97,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=863845,FOLIO='94',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_95">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	lead product candidate, SY-1425, is an oral, potent and selective agonist, or activator, of the transcription factor RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	. We plan to initiate a
	Phase&nbsp;2 clinical trial in genomically defined subsets of relapsed or refractory AML and relapsed high-risk MDS patients in mid-2016. We also plan to evaluate SY-1425 in newly diagnosed AML
	patients 60 years of age or older who are not suitable candidates for standard chemotherapy and low-risk transfusion-dependent MDS patients, subject to receipt of FDA clearance to use our biomarker
	test to prospectively select patients in these populations. Using our platform, we identified subsets of AML and breast cancer patients who have a super-enhancer associated with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	gene. We
	identified a proprietary biomarker, which we refer to as the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, related to
	the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	. The super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	is believed to lock
	cells in an immature, proliferative and undifferentiated state. Treatment with SY-1425 in cancer cells with the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	appears to promote differentiation of these cells. In
</FONT>
<FONT SIZE=2>
<I>
	in vivo
</I>
</FONT>
<FONT SIZE=2>
	mouse models implanted with human AML tumors, SY-1425 was observed to be effective in
	stopping the growth of tumors with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker but not in tumors without the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker.
	Importantly, a strong survival benefit was seen in mice with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker-positive tumors that were treated with SY-1425. We observed the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker
	in approximately 25% of AML tissues we analyzed. We believe that a similar percentage of AML and MDS patients will have the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker. Based on our current clinical development plan, we believe
	that the potential market opportunity for SY-1425 is approximately 12,250
	patients diagnosed annually with AML and MDS in the United States, Canada and the five largest European countries by population, Germany, the United Kingdom, France, Spain and Italy. These patient
	populations include relapsed or refractory AML patients, AML patients who are elderly or unfit for standard treatments, relapsed high-risk MDS patients and low-risk transfusion-dependent MDS patients.
	Similarly, we have observed the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker in approximately 35% of breast cancer patient samples we analyzed, leading us to believe that
	approximately 55,000 metastatic breast cancer patients diagnosed annually in the countries listed above could benefit from SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have the exclusive North American and European commercial rights to the existing preclinical data for SY-1425 in human cancer under our license agreement with
	TMRC&nbsp;Co.,&nbsp;Ltd., or TMRC. SY-1425 is approved as tamibarotene in Japan for the treatment of acute promyelocytic leukemia, or APL, a form of AML, for which the drug has a well
	characterized efficacy and safety profile. Given the drug's demonstrated efficacy in APL and the significant unmet medical need, we intend to explore SY-1425
	for treatment of APL in North America and Europe. There are an estimated 2,500 new APL cases diagnosed each year in the United States, Canada and the five largest European countries.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	development candidate SY-1365 is a highly potent and selective small molecule inhibitor of the transcriptional kinase known as cyclin-dependent kinase 7, or CDK7. We are
	investigating SY-1365 for the treatment of cancers that are dependent on a high and constant expression of certain transcription factors for their growth and survival, a phenomenon known as
	transcriptional addiction, and plan to initially develop it in acute leukemia. In preclinical studies, SY-1365 was observed to preferentially kill cancer cells by inducing robust, sustained and
	dose-dependent apoptosis of AML cells with minimal impact on non-cancerous cells. We have begun IND-enabling activities for SY-1365 and plan to initiate a Phase 1/2 clinical trial in patients with
	acute leukemia, including AML and ALL, in the first half of 2017. We selected acute leukemia as our first clinical development indication due to high levels of observed efficacy in our preclinical
	models and because few treatment options exist for these patients. Subject to strong clinical results, there could be an opportunity for accelerated clinical development. We believe that all of the
	approximately 37,000 AML and 12,000 ALL patients diagnosed annually in the United States, Canada, the five largest European countries and Japan could benefit from an effective CDK7 inhibitor.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	were founded by leaders in the field of gene control from the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, or Whitehead, and the
	Dana-Farber Cancer Institute, or Dana-Farber, an affiliate of Harvard Medical School. Many of our employees have
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	95
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=98,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1026394,FOLIO='95',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_96">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	been
	members of teams that uncovered innovative scientific findings and delivered highly impactful drugs to the marketplace. Our management team consists of drug discovery, development and
	commercialization experts with experience in translating scientific discoveries into innovative treatments, including Avonex and Tysabri for multiple sclerosis, Velcade and Ninlaro for hematological
	malignancies, Ibrance for breast cancer, Entyvio for&nbsp;ulcerative colitis and Kalydeco and Orkambi for cystic fibrosis.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Principles
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a culture that embodies the following core principles with the aim to provide long-term benefits to patients and to create
	significant value for our employees, investors and other stakeholders:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We are committed to transforming the lives of patients.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We are pioneering in our science.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We challenge each other to achieve excellence.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We work with passion, integrity and respect.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	We like rigorous work and serious fun.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Strategy
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated,
	leading biopharmaceutical company. To achieve this mission, we are executing on the following strategy:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Rapidly and efficiently advance our lead programs through clinical
	development.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We intend to advance SY-1425 into a Phase&nbsp;2 clinical trial in mid-2016 in genomically defined subsets of relapsed or
	refractory AML and relapsed high-risk MDS patients. For SY-1365, we expect to initiate a Phase 1/2 clinical trial in patients with acute leukemia in the first half of 2017. For both of these programs,
	we intend to enrich our clinical trials with patients most likely to respond, which we believe will enable us to rapidly and efficiently establish clinical proof-of-concept. Because AML, MDS and ALL
	are diseases of significant unmet medical need, we could be eligible, subject to encouraging clinical results, to apply for Breakthrough Therapy designation and Fast Track designation which, if
	granted, could accelerate clinical development and regulatory review.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Develop a robust pipeline of gene control product
	candidates.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We plan to continue leveraging our gene control platform to systematically and efficiently pinpoint genes that cause disease
	and to identify optimal therapeutic points of intervention in genomically defined patient populations. Employing our pioneering drug discovery and development approach, we intend to continue to either
	internally create selective small molecule drugs against these targets or link existing drugs to novel patient populations, enabling us to potentially accelerate our clinical development path. We aim
	to generate at least one investigational new drug application, or IND, submission every other year, on average.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Maintain our leadership position in the field of gene
	control.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We are pioneering a novel approach to discover and develop gene control medicines. To fortify our leadership position, we
	intend to enhance our technologies to create the most extensive dataset of gene expression programs. We also intend to expand our validation technologies to continue to identify and validate novel
	targets and biomarkers across many serious diseases. Our long-term goal is to analyze gene expression programs in serious diseases where gene control is a potential viable therapeutic strategy and to
	identify and drug novel targets based on our understanding of these
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	96
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=99,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=441823,FOLIO='96',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_97">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	gene
	expression programs. We plan to continue investing in building our drugging capabilities, including developing additional proprietary assays and enhancing our biochemistry, structural biology and
	medicinal chemistry expertise to create or acquire gene control medicines targeting disease drivers identified by our platform.
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Continue to foster a culture of
	innovation.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We are committed to pioneering science and to leadership in gene control medicines. Our employees are critical to the
	successful achievement of our leadership vision. We will continue to foster an environment that encourages innovation, excellence and productivity and develops our team as leaders in the field of gene
	control.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Execute strategic collaborations to maximize value and extend the
	potential of our gene control platform across multiple disease areas.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We intend to engage in strategic collaborations around both our
	programs and our platform. With respect to our programs, we currently own the rights to develop and commercialize SY-1425 in North America and Europe for all cancer indications. We currently retain
	full commercial rights to SY-1365 and all our other preclinical programs. We intend to maintain U.S. commercial rights for these programs, while pursuing collaborations that could maximize value for
	these programs by allowing us to expand our geographic reach and expand into additional indications. With respect to our platform, we are seeking target and drug discovery collaborations that allow us
	to expand the potential of our platform in additional cancers and other serious diseases beyond those that we can address on our own. We believe that our platform provides significant optionality for
	collaborations around drug modalities and target classes that fall outside of our current focus on small molecule drugs targeting transcriptional and regulatory proteins.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Focus&#151;Gene Control Medicines
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are approximately 200 different cell types in the human body. Despite having identical genomes, each of these cell types has a
	different function. For example, a skin cell functions differently than a muscle cell despite sharing the exact same DNA. What determines cell type and function is the specific set of genes that is
	expressed, or turned "on" or "off," in that given cell. This coordinated activation and repression of genes, known as the cell's gene expression program, is controlled by non-coding regions of the
	genome. The process of gene expression is carried out by a number of cellular components, key to which are transcription factors, transcriptional kinases and other transcriptional and regulatory
	proteins. These transcriptional and regulatory proteins bind with specific regions of non-coding DNA, called enhancers, to control the rate of transcription of genetic information from DNA into the
	cell.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	disease, alterations in non-coding regions of the genome can change a cell's gene expression program, altering the type and function of that cell. Because the altered gene expression
	program is implemented by transcription factors, transcriptional kinases and other transcriptional and regulatory proteins, these proteins are important points for therapeutic intervention. Because
	this biology is fundamental to the function of all cells, it applies across diseases, whether the cause is genetic, environmental, bacterial, viral or multi-factorial.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
	researchers have long believed that alterations in non-coding regions of DNA, which account for 98% of the genome, play a key role in driving disease, the scientific community
	has lacked the tools to study these regions of the genome, rendering them poorly understood. As a result, the discovery and development of targeted therapies to date has focused almost exclusively on
	abnormal proteins resulting from genetic alterations found in regions of DNA that encode for proteins, which represent less than 2% of the entire genome.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
	targeted therapies, in which the right drug is matched to the right patient, have dramatically improved the ability to treat certain cancers and other serious diseases, the
	identification of new drug targets by sequencing coding regions of DNA has been largely exhausted. Moreover, in cancer,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	97
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=100,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=534200,FOLIO='97',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_98">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	inhibiting
	abnormal proteins resulting from single genetic alterations can often lead to drug resistance and limited durable clinical benefit. Furthermore, many serious diseases continue to go
	unaddressed due to the limitations of current drug discovery approaches. Taken together, these factors underscore the need for fundamentally new approaches to drug discovery and development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	contrast to therapies that target a single abnormal protein, gene control medicines target the cell's underlying gene expression program, influencing the expression of the crucial set
	of genes that contribute to disease. The relatively few gene control medicines available today are among the most important targeted therapies and are widely used for their approved indications. Drugs
	that target transcription factors, such as estrogen receptors in breast cancer, androgen receptors in prostate cancer and glucocorticoid receptors in inflammation, are important examples of gene
	control medicines that have produced transformative patient benefits. For example, tamoxifen, a gene control medicine targeting a transcription factor, revolutionized the treatment of certain breast
	cancers and is prescribed 1.9&nbsp;million times annually in the United States, illustrating the significant therapeutic potential of gene control medicines. However, the difficulty in studying
	non-coding regions of the genome historically prevented a systematic approach to identifying these critical points of intervention, making gene control a largely untapped field for targeted drug
	discovery and development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
	on the work of Syros' scientific founders Richard&nbsp;A. Young, Ph.D., James Bradner, M.D. and Nathanael Gray, Ph.D., and other scientists, there is now a rapidly growing
	scientific understanding of how alterations in non-coding regions of the genome drive disease and how to modulate gene control targets. One of the seminal discoveries that pushed the field forward
	came out of Dr.&nbsp;Young's laboratory at the Whitehead Institute. He discovered that a very small unique subset of enhancers, called super-enhancers, are central to orchestrating gene expression
	programs. These highly specialized regulatory regions of non-coding DNA bring together the cellular components needed for gene expression, assembling large amounts of transcription factors,
	transcriptional kinases and other transcriptional and regulatory proteins to drive increased expression of genes crucial to a given cell's
	type and function. The findings from Young's three original publications on super-enhancers have been cited in approximately 1,000 subsequent publications since they were published in the scientific
	journal
</FONT>
<FONT SIZE=2>
<I>
	Cell
</I>
</FONT>
<FONT SIZE=2>
	in 2013.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	98
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=101,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=24766,FOLIO='98',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DS79601_1_99">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	graphics below illustrate the components and structure of super-enhancers, which drive the expression of genes that are crucial to cell type and function.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G247059.JPG" ALT="GRAPHIC" WIDTH="684" HEIGHT="505">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Super-enhancers
	exist in both normal and diseased cells. In many different diseases, super-enhancers are associated with, and drive the expression of, disease-causing genes. For example,
	multiple well-known genes that are implicated in cancer, such as
</FONT>
<FONT SIZE=2>
<I>
	MYC
</I>
</FONT>
<FONT SIZE=2>
	, are associated with super-enhancers. Notably, analysis of super-enhancers and
	their associated genes allows us to rapidly and systematically elucidate gene expression programs, pinpointing the genes crucial to the function of a given cell and providing critical insights into
	changes in gene expression programs that contribute to disease.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
	and other discoveries from our scientific founders, coupled with technological advancements, have enabled our pioneering approach to therapeutic gene control. We believe we have
	built the first proprietary platform designed to systematically and efficiently analyze non-coding regions of the genome in healthy and diseased cells taken from patient tissues to identify
	alterations in gene expression programs that represent optimal points of therapeutic intervention and develop drugs to control the expression of disease-driving genes. By doing so, we believe our gene
	control platform will allow us to (i)&nbsp;identify a wide array of potential new drug targets across a range of diseases, (ii)&nbsp;provide a new lens for diagnosing and segmenting patients,
	including those with complex, multi-factorial diseases that have eluded segmentation with other genomic-based approaches, and (iii)&nbsp;advance a new wave of medicines that have the potential to
	influence multiple drivers of disease through a single target, making them less susceptible to drug resistance and providing patients with a more profound and durable benefit than many of today's
	targeted therapies.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	99
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=102,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=464507,FOLIO='99',FILE='DISK124:[15ZCT1.15ZCT79601]DS79601A.;122',USER='ALOEW',CD='16-JUN-2016;23:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_100">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Gene Control Platform
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our proprietary gene control platform consists of two fundamental pillars:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Identifying novel gene control targets linked to genomically defined patient
	populations.
</I>
</FONT>
<FONT SIZE=2>
	We analyze gene expression programs in diseased and healthy cells taken from patient tissues to identify disease-causing alterations that represent optimal points
	of therapeutic intervention and associated biomarkers in specific patient populations.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<I>
	Drugging gene control targets.
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We develop product
	candidates to modulate these gene control targets through:
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	internal drug discovery efforts focused on creating small molecule drugs targeting transcription factors, transcriptional
	kinases and other transcriptional and regulatory proteins; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	externally focused efforts to link existing drugs to specific patient populations identified through our platform. These
	externally focused efforts could enable us to identify drugs that we may seek to in-license or acquire or use as starting points for our own drug discovery programs to accelerate our development path.
</FONT>
</DD>
</DL>
</DD>
</DL>
</UL>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;TEXT-ALIGN:CENTER;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G467346.JPG" ALT="GRAPHIC" WIDTH="673" HEIGHT="322">
</B>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Identifying Novel Gene Control Targets
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have invested significant resources in building capabilities to discover novel gene control targets and associated biomarkers. Our
	approach is disease-focused. Our platform consists of technologies and capabilities to analyze gene expression programs directly from patient tissue samples. We do this by employing our expertise and
	technologies in computational, gene control and cellular biologies. We have in-licensed intellectual property from the laboratories of our scientific founders at the Whitehead Institute and
	Dana-Farber. We have significantly improved this licensed technology, including computational algorithms and tissue processing systems, which have produced a highly efficient, scalable approach to
	analyze gene expression programs using small amounts of patient tissue. In addition, we are developing our own intellectual property related to this technology. These advancements have enabled us to
	generate one of the largest known datasets of gene expression programs and identify novel targets across many diseases and cell types. To date, we have analyzed or are in the process of analyzing gene
	expression programs in AML, breast cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, non-disease and lupus immune cells,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=103,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=417145,FOLIO='100',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_101">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	polycystic
	kidney disease, spinal muscular atrophy and Alzheimer's disease. Through those efforts, we have identified approximately 50 novel drug targets in oncology, immuno-oncology and autoimmune
	diseases and validated seven of those targets using biological methods to knock out the target gene or chemical methods to modulate the target's activity. The discovery and validation of these targets
	has led to the identification of our product candidate SY-1425 as well as additional novel preclinical drug candidates in earlier stages of research and development. We plan to analyze gene expression
	programs in several other cancers, including colorectal, lung and melanoma as well as several other diseases and cell types, including additional inflammatory disorders and immune cells from tumors.
	Our long-term goal is to analyze gene expression programs in serious diseases where we believe currently underserved patients can benefit from gene control medicines.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Analyzing Gene Expression Programs in Disease
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Generated and Ongoing
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Planned
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
	AML
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Breast cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Ovarian cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Hepatocellular carcinoma
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Pancreatic cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Renal cell carcinoma
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Normal immune cells
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Systemic lupus erythematosus
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Polycystic kidney disease
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Spinal muscular atrophy
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Alzheimer's disease
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;TEXT-ALIGN:LEFT;">
<FONT SIZE=2>
<!-- COMMAND=ADD_GRID,"TEXT-ALIGN:LEFT;" -->
	Colorectal cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Lung cancer
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Melanoma
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Additional cancers
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Immune cells from tumors
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Other inflammatory disorders, including autoimmune diseases and fibrotic diseases
</FONT>
<P ALIGN=LEFT STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;">
<FONT SIZE=2>
	Other rare genetic disorders
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	use our platform to pinpoint crucial genes in disease. We compare gene expression programs in diseased cells versus healthy cells and analyze the cells of different patient subsets
	within a disease to identify novel drug targets linked to genomically defined subsets of patients. We obtain human disease tissue samples from our network of academic collaborators and commercial
	providers. We then analyze these samples using a variety of genomic tools, including chromatin immunoprecipitation followed by whole genome sequencing, or ChIP-seq, and proprietary computational
	methods. The combination of these tools allows us to identify the location of DNA elements, including super-enhancers and their associated genes, on the genome. We validate this potential pool of
	targets by using biological methods for knocking down or out the target gene in cell lines, or by testing existing drugs against a specific target, to determine if the target represents an attractive
	point of therapeutic intervention.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Validation of Our Approach
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have validated our approach by successfully linking known targets of successful, marketed drugs to super-enhancers in human disease
	tissue. Additionally, using our platform, we have identified super-enhancers associated with genes linked to the hallmarks of cancer, including genes important in proliferation, invasion and
	metastasis and immune avoidance, in cancer cells from patient tissue samples. In breast cancer, we were able to recapitulate current knowledge of disease biology and identify clinically validated
	targets. We analyzed tissue samples from patients with three different types of breast cancer, HER2+, ER+ and triple negative. In HER2+ breast cancer patient samples, we
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	101
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=104,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=820533,FOLIO='101',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_102">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	successfully
	identified a super-enhancer associated with the
</FONT>
<FONT SIZE=2>
<I>
	ERBB2
</I>
</FONT>
<FONT SIZE=2>
	gene, which when overexpressed can lead to HER2+ breast cancer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similarly,
	in ER+, or estrogen receptor-positive, breast cancer patient samples, super-enhancers were associated with the
</FONT>
<FONT SIZE=2>
<I>
	ESR1
</I>
</FONT>
<FONT SIZE=2>
	gene, which
	produces estrogen receptor. Therapies targeting the proteins encoded by the
</FONT>
<FONT SIZE=2>
<I>
	ERBB2
</I>
</FONT>
<FONT SIZE=2>
	and
</FONT>
<FONT SIZE=2>
<I>
	ESR1
</I>
</FONT>
<FONT SIZE=2>
	genes include
	highly successful marketed drugs, such as Herceptin (trastuzumab) for HER2+ breast cancer and tamoxifen for ER+ breast cancer. Using our platform, we also identified novel drug targets in subsets of
	patients with HER2+, ER+ and triple negative breast cancer. Notably, the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	, which we also discovered in subsets of AML
	and MDS patients and is the focus of our SY-1425 program, was found in subsets of patients across all three types of breast cancer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Drugging Gene Control Targets
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We develop product candidates against gene control targets through:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	internal drug discovery efforts focused on creating small molecule drugs targeting transcription factors, transcriptional kinases and
	other transcriptional and regulatory proteins; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	linking existing drugs, which we could in-license, to specific patient populations identified through our platform&#151;a
	strategy designed to accelerate our clinical development path.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have developed significant core internal capabilities in small molecule chemistry, biochemistry and structural biology to characterize the structure and function of transcription
	factors, transcriptional kinases and other transcriptional and regulatory proteins in order to generate novel chemical matter. We have also developed a sophisticated suite of proprietary assays, which
	are internally developed tests to measure the biochemical, biophysical, cellular and genomic activity of known and novel compounds against gene control targets.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
	our platform is designed to identify drug targets across a broad range of therapeutic areas and therapeutic modalities, our drug discovery and development efforts are focused on
	small molecule drugs to target specialized proteins responsible for gene expression, including transcription factors, transcriptional kinases and other transcriptional and regulatory proteins. Because
	these specialized proteins play a central role in implementing gene expression programs, they are among the most promising and high potential gene control targets for therapeutic intervention. The
	graphic below illustrates our areas of focus for development of product candidates.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G482247.JPG" ALT="GRAPHIC" WIDTH="513" HEIGHT="292">
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	102
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=105,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=260390,FOLIO='102',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_103">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Drugging Transcriptional Kinases
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1365 demonstrates our ability to identify tumors with transcriptional dependencies and to selectively drug transcriptional kinases.
	Using our core capabilities in gene control biology and biochemistry, we believe that we created the first selective, small molecule inhibitor of CDK7 with
</FONT>
<FONT SIZE=2>
<I>
	in
	vivo
</I>
</FONT>
<FONT SIZE=2>
	efficacy.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Drugging Transcription Factors
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leveraging our expertise in biology, biochemistry and chemistry, we have developed a suite of proprietary screens and assays to
	demonstrate direct binding of novel transcription factor inhibitors and to directly assess transcription factor inhibition in cells. Using our capabilities and expertise in X-ray crystallography and
	medicinal chemistry, we are developing proprietary atomic-level knowledge of the structural determinants of transcription factor inhibition by small molecules. We have generated novel molecules that
	are in early preclinical development and show biophysical evidence of potent direct transcription factor binding and robust cellular activity.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Linking Existing Drugs to Novel Patient Populations
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1425 demonstrates our ability to link existing drugs to novel genomically defined patient populations identified through our
	platform. We have established a process to systematically screen existing compounds for relationships between drug sensitivity and super-enhancers that we identify in human disease tissue. To date, we
	have identified multiple drug and enhancer relationships, the most advanced leading to the identification of our SY-1425 program. We expect this approach to enable us to more rapidly enter clinical
	development by accessing compounds that serve as accelerated starting points for our own programs.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Advantages of our Platform and Approach
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that there are significant advantages to systematically identifying and drugging gene control targets for specific patient
	populations. Among these advantages are:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Systematic, reproducible and unbiased approach to identifying core
	disease drivers in multiple serious diseases.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We take a disease-centric approach. We start with human tissue and, through our platform,
	systematically identify the core drivers of disease. We identify optimal therapeutic points of intervention in a target- and pathway-agnostic manner, opening up a wide array of potential new drug
	targets.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Highly differentiated and pioneering approach with broad applicability
	across therapeutic areas and diseases.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We are pioneering the understanding of the non-coding, regulatory region of the genome, which has
	been largely unexploited for drug discovery and development, to uncover novel disease drivers in genomically defined patient populations and advance a new wave of medicines that have the potential to
	control the expression of disease-driving genes. We have built a differentiated combination of expertise, capabilities and tools to create medicines targeting transcription factors, transcriptional
	kinases and other transcriptional and regulatory proteins, which have been historically difficult to drug. Because gene expression is fundamental to the function of all cells, we believe that our
	platform has broad applicability across therapeutic areas and diseases.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Ability to discover and develop medicines that address significant
	patient need.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We are initially focused on difficult-to-treat cancers or cancer subtypes for which current therapies are inadequate.
	Because gene control medicines affect multiple disease-driving genes, we believe they will be less susceptible to the development of drug resistance than other types of genomic-based targeted
	medicines, potentially resulting in a more profound and durable benefit for
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	103
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=106,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=336203,FOLIO='103',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_104">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	patients.
	This is evidenced by the proven durable benefits of the gene control medicines available today.
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Potential for efficient clinical
	development.
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;We intend to enrich our clinical trials with genomically defined subsets of patients who are most likely to respond to our
	treatment, which we believe will enable us to determine if there are strong signals of efficacy early in clinical development and well before investments are made in expensive late-stage clinical
	studies. Subject to encouraging clinical results, we could be eligible to apply for Breakthrough Therapy designation and Fast Track designation which, if granted, could accelerate clinical development
	and regulatory review, allowing us to bring our therapies to patients expeditiously.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Clinical Programs
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Overview
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1425 (tamibarotene) is an oral, potent and selective agonist of the transcription factor
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	. In September 2015,
	we in-licensed rights to develop and commercialize SY-1425 for oncology indications in North America and Europe. In mid-2016, we plan to initiate a Phase&nbsp;2 clinical trial that will enroll
	genomically defined subsets of patients with relapsed or refractory AML and relapsed high-risk MDS pursuant to an IND accepted by the U.S. Food and Drug Administration, or FDA, in May 2016. We plan to
	select patients for this trial using the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker we identified. We believe patients whose tumors have this biomarker will be more likely to
	experience a profound and durable clinical benefit from treatment with SY-1425. We also plan to evaluate SY-1425 in newly diagnosed AML patients sixty years of age or older who are not suitable for
	standard chemotherapy and low-risk transfusion-dependent MDS patients. In order to prospectively select patients in these populations using our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, we will seek clearance for the use of the biomarker test from the FDA through the Investigational Device Exemption, or IDE, process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Linking SY-1425 to Novel Patient Populations
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We leveraged our platform to analyze gene expression programs in primary AML and breast cancer patient tissue samples. We discovered
	that
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	, the gene that codes for RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	, was associated with a super-enhancer in some patients' tumors but not in
	others.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G277089.JPG" ALT="GRAPHIC" WIDTH="352" HEIGHT="250">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	function of RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	differs depending on whether it is bound to its ligand. In the absence of a ligand, RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	represses differentiation. We believe that in tumors with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	-associated super-enhancer, there is an abundance of unliganded
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	, resulting in the repression of differentiation, thereby locking the cell in an immature, proliferative and undifferentiated state. Introducing a
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	104
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=107,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=103625,FOLIO='104',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_105">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	agonist,
	such as SY-1425, simulates the activity of a ligand, activating differentiation, as illustrated in the graphic below.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G388.JPG" ALT="GRAPHIC" WIDTH="616" HEIGHT="235">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1425
	is an oral, selective RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist. Based on experiments we conducted, we have concluded that the mechanism of action of SY-1425 on non-APL
	AML cells with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	-associated super-enhancer is very similar to the mechanism of approved retinoic acid agonists in APL, a subset of AML with a
	genetic alteration of the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	gene. This gives us increased confidence that SY-1425 may also work in this new subset of AML and MDS patients identified
	by our platform.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	selected SY-1425 based on its superior potency on RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	, its selectivity for RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	over related proteins
	RAR
</FONT>
<FONT SIZE=2>
<B>
<FONT FACE="SYMBOL">
	b
</FONT>
</B>
</FONT>
<FONT SIZE=2>
	and RAR
</FONT>
<FONT SIZE=2>
<B>
<FONT FACE="SYMBOL">
	g
</FONT>
</B>
</FONT>
<FONT SIZE=2>
	and its
	superior pharmacokinetic profile compared to all trans retinoic acid, or ATRA, a pan-agonist of RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	, RAR
<FONT FACE="SYMBOL">
	b
</FONT>
	, and
	RAR
<FONT FACE="SYMBOL">
	g
</FONT>
	. SY-1425 is approved, as tamibarotene (marketed as Amnolake), in Japan for use in acute recurrent or intractable APL, for which it has demonstrated efficacy
	and a well-established safety profile.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
	our platform, we have identified a biomarker for the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	that we will use for patient selection.
	Our
</FONT>
<FONT SIZE=2>
<I>
	in vivo
</I>
</FONT>
<FONT SIZE=2>
	studies demonstrated that cancer cells with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker showed reduced rates of
	proliferation and differentiated to more mature cells when treated with SY-1425, while cancer cells without the biomarker continued to proliferate. Our studies also demonstrated that cancer cells with
	the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker were up to 1,000 times more sensitive to SY-1425 than cancer cells without the biomarker, as shown below. This sensitivity was
	consistent across multiple cancer cells lines.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G814920.JPG" ALT="GRAPHIC" WIDTH="291" HEIGHT="297">
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	105
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=108,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=375360,FOLIO='105',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_106">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Preclinical Data
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have conducted multiple preclinical studies of SY-1425 in AML, excluding APL, and in breast cancer. In certain studies, we use mouse
	models in which mice are implanted with human tumors, which are referred to as patient-derived xenograft models, or PDX models. In PDX models of AML, SY-1425 was observed to be effective in reducing
	the growth of tumors and prolonging survival in mice with tumors with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, but did not appear to stop tumor growth or prolong survival in
	mice whose tumors did not have the biomarker.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	shown below, in a PDX model derived from AML patient tumor cells with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, referred to as
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker-positive AML, half of the mice were
	treated with SY-1425, and the other half of the mice went untreated. In the untreated group, the
	cancer progressed, as measured by the percentage of human leukemia cells in the blood. Correspondingly, high levels of these cancer cells were measured in the bone marrow and spleen of the untreated
	mice. None of the untreated mice in the study survived beyond 25&nbsp;days. In contrast, the cancer was observed to be controlled in the mice treated with SY-1425, as measured by the levels of human
	leukemia cancer cells detected in the blood. Similarly, low levels of these cancer cells were measured in the bone marrow and spleen. Notably, all of the mice treated with SY-1425 survived until the
	end of the 35-day study.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G829366.JPG" ALT="GRAPHIC" WIDTH="684" HEIGHT="262">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	contrast, as shown below, in a PDX model without the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, SY-1425 was observed to have no effect on tumor control or
	survival. In both the treated and untreated groups, the cancer progressed, as measured by the percentage of human leukemia cells detected in the blood. Correspondingly, high levels of these cancer
	cells were measured in the bone marrow and spleen in both groups of mice. None of the mice in either group survived beyond 20&nbsp;days. These data demonstrate a strong link between the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker
	and response to treatment with SY-1425, and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	106
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=109,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1010300,FOLIO='106',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_107">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide
	meaningful evidence that patients with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker may be promising candidates for a clinical trial of SY-1425.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G134515.JPG" ALT="GRAPHIC" WIDTH="684" HEIGHT="283">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have also compared the activity of SY-1425 to the activity of ATRA in the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker-positive PDX model. We observed superior
	anti-tumor activity and survival with SY-1425 compared to ATRA, with ATRA-treated mice demonstrating similar survival to the untreated mice.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
	in our preclinical studies in breast cancer, we observed a strong link between sensitivity to treatment with SY-1425 and breast cancer tumors with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker. SY-1425 was observed to result in
	significant tumor growth inhibition in PDX models derived from tumors with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker but was observed to have no effect in
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker-negative
	PDX models.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425 Clinical Development Plan
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to develop SY-1425 in North America and Europe for treatment of AML and MDS in genomically defined subsets of patients with the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker. In the United
	States, we expect to initiate a Phase&nbsp;2 clinical trial in relapsed or refractory AML, excluding APL, and relapsed high-risk MDS in mid-2016. This Phase&nbsp;2 clinical trial will be a
	multi-center, open-label trial exploring activity in these patient populations. We anticipate that we will enroll approximately&nbsp;40 patients, who will have been prospectively selected using our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker. The primary endpoint of the trial will be overall response rate. We also plan to measure pharmacodynamic markers, duration of response,
	safety and tolerability, survival and biomarker predictability. We expect to receive initial data from this trial in mid-2017, or 12 months after the first patient is enrolled.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have entered into an agreement with a third party commercial provider to continue developing our novel
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker into a validated
	laboratory test under Clinical Laboratory Improvement Amendment, or CLIA, guidelines using a well-established diagnostic platform and approach that may be used to prospectively enroll
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker-positive patients in our clinical trial. This CLIA laboratory test could become the basis for a commercial companion diagnostic. We are
	evaluating commercial providers to lead the development of a potential commercial companion diagnostic for the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker but have not yet entered
	in to an agreement with a third party for this work. We expect to do so in 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamibarotene
	(SY-1425) has been extensively studied and has a well-established safety profile. We expect to use the same dosage used in the treatment of APL in Japan in our
	Phase&nbsp;2 clinical trial. This same dosage for SY-1425 was previously used in a U.S. trial in relapsed and refractory APL, for which an IND was opened. We have in-licensed the preclinical data
	package that was used for approval in Japan and the IND filing in the United States.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	107
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=110,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1010699,FOLIO='107',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_108">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also plan to evaluate SY-1425 in newly diagnosed AML patients 60 years of age or older who are not suitable candidates for standard chemotherapy as well as low-risk
	transfusion-dependent MDS patients. We believe SY-1425 is ideally suited for these patient groups because, in contrast to cytotoxic chemotherapy, it has been generally well tolerated in a related
	patient population with APL, and because SY-1425 is orally administered and has the potential to be used chronically. In order to prospectively select patients in these populations using our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker, we will seek clearance for the use of the biomarker test from the FDA through the IDE process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	chose AML and MDS for our initial indications due to high levels of observed efficacy of SY-1425 in our preclinical models, the significant unmet medical need of these patients and
	the potential for accelerated development. We intend to pursue additional indications, including breast cancer. Our preclinical data in breast cancer supports the development of SY-1425 in genomically
	defined subsets of patients with breast cancers with our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker. We plan to initiate clinical trials in these patients upon establishing
	proof-of-concept in AML and MDS. We also believe there are subsets of patients with other tumor types with our
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker and continue to research
	the role of the super-enhancer associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	in additional cancers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Existing Clinical Data
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamibarotene (SY-1425) is approved and marketed as Amnolake in Japan for treatment of acute recurrent or intractable APL. Given the
	demonstrated efficacy of the drug in acute recurrent or intractable APL, we intend to evaluate SY-1425 for treatment of APL in North America and Europe. Extensive clinical work had been conducted on
	tamibarotene prior to our in-licensing it from TMRC. The effectiveness of tamibarotene has been evaluated in patients with APL, including for relapsed patients and as maintenance therapy for newly
	diagnosed patients.
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	In a Phase&nbsp;2 clinical trial of tamibarotene as a single agent in patients who relapsed following treatment with ATRA, 58%
	achieved a complete response. The majority of these patients went on to receive a bone marrow transplant or chemotherapy after treatment with tamibarotene and maintained a complete response for at
	least 14&nbsp;months.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	In a Phase&nbsp;3 clinical trial comparing tamibarotene as an add-on therapy to arsenic trioxide, or ATO, a standard of care for
	APL, versus ATRA as an add-on therapy to ATO in relapsed patients, patients in the tamibarotene-treated group demonstrated:
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	An overall complete response rate of 80%, compared to 54% in the ATRA-treated group&nbsp;(p=0.022); and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	A complete molecular remission rate of 23%, compared to 3% in the ATRA-treated group&nbsp;(p=0.0275). Complete
	molecular remission is achieved when there is no evidence of disease in the patient's blood cells as detected by DNA-based tests.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
</DL>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	In a different Phase&nbsp;3 clinical trial comparing tamibarotene to ATRA as maintenance therapy in newly diagnosed APL patients,
	the four-year relapse-free survival rate in high-risk patients treated with tamibarotene was 87%, compared to 58% in high-risk patients treated with ATRA&nbsp;(p=0.028).
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	all these studies, tamibarotene was generally well tolerated. Adverse effects included mild or moderate dry skin, skin rash, headache and bone pain, as well as retinoic acid syndrome
	and elevated levels of cholesterol, lipids, liver function enzymes and white blood cells, which were severe in certain cases. One such adverse effect, retinoic acid syndrome, is referenced on the
	drug's label and was infrequently observed clinically. Retinoic acid syndrome is a side effect associated with retinoids and arsenic trioxide and can be mitigated by regular monitoring of clinical
	parameters, including white
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	108
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=111,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=213236,FOLIO='108',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_109">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	blood
	cell counts. A summary of four published clinical studies of tamibarotene use in APL is provided below.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:100%;MARGIN-LEFT:0%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="55PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="135PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="126PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="27PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Design
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of
<BR>
	Patients
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Patient Population
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Tamibarotene Treatment
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Efficacy / Duration
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Phase&nbsp;2 in relapsed APL
<SUP>
	1
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	25
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Relapse after ATRA-induced CR
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	6 mg/m
<SUP>
	2
</SUP>
	daily, discontinued at CR
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=5 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	CR&nbsp;= 58%
<BR>
	(14/24&nbsp;evaluable)
<BR>
	(
<FONT FACE="SYMBOL">
	&#179;
</FONT>
	14 months duration in 5 patients in conjunction with BMT, 7 patients in conjunction with CT)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Phase&nbsp;3 tamibarotene vs. ATRA as APL maintenance
<SUP>
	2
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	269
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Front-line following ATRA-induced CR and consolidation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Tamibarotene 6 mg/m
<SUP>
	2
</SUP>
	vs. ATRA 45 mg/m
<SUP>
	2
</SUP>
	14&nbsp;days every 3 months for 2 years
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=5 STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Overall 4-year RFS: 91% vs. 84%;
<BR>
	4-year RFS in high risk: 87% vs. 58% (tamibarotene vs. ATRA)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Phase 2 in relapsed/refractory APL after ATRA&nbsp;and ATO
<SUP>
	3
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Patients with prior lines of treatment (9 with 2 prior lines, 3 with 3 prior lines and 2 with 5 prior lines)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	6 mg/m
<SUP>
	2
</SUP>
	daily for 56&nbsp;day induction period then every other month as consolidation for up to one year
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=5 STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	CR&nbsp;= 36%
<BR>
	CRi&nbsp;= 29%
<BR>
	mEFS&nbsp;= 3.5 months
<BR>
	mOS&nbsp;= 9.5 months
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	Phase&nbsp;3,
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	71
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	6 mg/m
<SUP>
	2
</SUP>
	/day
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
<B>
	Tamibarotene
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
<BR>
	&nbsp;
</B>
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=1>
<B>
	ATRA
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	tamibarotene
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	tamibarotene, 25 mg/
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	+ATO
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	+ATO
</B>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	vs. ATRA as add-on to ATO in relapsed APL
<SUP>
	4
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	m
<SUP>
	2
</SUP>
	/day ATRA add-on to 0.15 mg/kg/day ATO for 56&nbsp;days
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	CR
<BR>
	CRm
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	80%
<BR>
	23%
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	54%
<BR>
	&nbsp;&nbsp;3%
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Table legend:
</I>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:100%;MARGIN-LEFT:0%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="152PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="172PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	CR&nbsp;= complete remission
</I>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	CRm&nbsp;= complete molecular remission
</I>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	CRi&nbsp;= complete remission with incomplete blood count recovery
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	RFS&nbsp;= relapse-free survival
</I>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	mEFS&nbsp;= median event-free survival
</I>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	mOS&nbsp;= median overall survival
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	BMT&nbsp;= bone marrow transplant
</I>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<I>
	CT&nbsp;= chemotherapy
</I>
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	1.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Tobita, et al.
</FONT>
<FONT SIZE=1>
<I>
	Blood
</I>
</FONT>
<FONT SIZE=1>
	, August 1997.
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	2.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Shinagawa,
	et al.
</FONT>
<FONT SIZE=1>
<I>
	Journal of Clinical Oncology
</I>
</FONT>
<FONT SIZE=1>
	, November 2014.
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	3.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Sanford
	D, et al.
</FONT>
<FONT SIZE=1>
<I>
	British Journal of Haematology
</I>
</FONT>
<FONT SIZE=1>
	, July 2015.
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-9PT;'>
<FONT SIZE=1>
	4.
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	Wang
	et al, ASH presentation, December 2015.
</FONT>
</DD>
</DL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamibarotene was also studied in a Phase&nbsp;2 clinical trial for the treatment of unselected late-stage non-small cell lung cancer under a
	previous license between TMRC and a third party. The trial evaluated the efficacy and safety of adding tamibarotene or placebo to paclitaxel and carboplatin in patients with stage&nbsp;IIIb (plus
	pleural effusion) or IV non-small cell lung cancer. This trial was terminated when interim data suggested that a primary endpoint of progression-free survival for 18&nbsp;months after starting
	therapy would not be reached. Interim data also showed that tamibarotene combined with paclitaxel and carboplatin chemotherapy was associated with increased toxicity in this non-selected non-small
	cell lung cancer patient population (Levitt DJ et al J&nbsp;Clin Oncol 34, 2006 (suppl; abstr&nbsp;e20560)).
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425&nbsp;Market Opportunity
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that SY-1425 has the potential to address significant unmet medical need across a range of blood cancers and solid tumors.
	Based on our analysis of super-enhancers associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	in patient samples, and on
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker
	data in publicly available databases, we estimate that approximately 25% of AML and MDS patients and approximately 35% of breast cancer patients may benefit from
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist therapy like SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	are an estimated 33,000 new AML diagnoses in the United States, Canada and the five largest European countries each year. AML remains an area of significant unmet medical need. In
	the United
	States, newly diagnosed patients have a 25% five-year survival rate. There has been little improvement in treatment options for AML in the past 20 years, with typical treatment including older
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	109
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=112,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=177466,FOLIO='109',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_110">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	chemotherapeutics
	and stem cell transplantation. Nearly half of newly diagnosed patients, or approximately 16,000&nbsp;patients, are elderly or unfit for treatment with standard therapies, leaving
	this group with very few to no treatment options.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
	the estimated 33,000 newly diagnosed patients each year in the countries listed above, approximately 30% or 10,000 AML patients eventually relapse or are refractory to current
	treatment options. In the absence of adequate therapies, these relapsed or refractory patients may be put into clinical trials for new and emerging therapies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
	on our analysis of super-enhancers associated with
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	in patient samples and on
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker data in publicly available databases, we believe that
	approximately 25% of AML patients could benefit from treatment with a
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist such as SY-1425. Thus we estimate that in the countries listed above, approximately 2,500 patients who eventually relapse or are refractory to
	current treatment options and 4,000 patients who are elderly or unfit for standard treatments could benefit from treatment with a RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist such as SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	are approximately 32,000 new MDS diagnoses in the countries listed above each year, with up to one-third of these newly diagnosed patients estimated to be likely to progress to
	AML. In the United States, high-risk patients have a median survival of only approximately two years, while the low-risk patient population has a median survival of approximately six years. As with
	AML, treatment options are limited. More than half of the newly diagnosed patients, or approximately 17,000&nbsp;patients, have low-risk transfusion-dependent MDS.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
	the estimated 32,000 newly diagnosed patients in the countries listed above each year, approximately 19% or 6,000 MDS patients have relapsed high-risk MDS.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
	on
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker data in publicly available databases, we believe that approximately 25% of MDS patients could benefit from
	treatment with a RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist such as SY-1425. Thus we estimate that in the countries listed above, approximately 1,500 patients diagnosed with relapsed high-risk
	MDS each year and 4,250 patients diagnosed with low-risk transfusion-dependent MDS each
	year could benefit from treatment with a RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist such as SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approximately
	485,000 women in the countries listed above are diagnosed with breast cancer annually, with 158,000 of these women categorized as metastatic and eligible for systemic
	therapies. Breast cancer is categorized and treated by the stage for risk of metastatic recurrence and by whether it is driven by estrogen receptor and progesterone receptor signaling, referred to as
	being hormone positive, driven by HER2 receptor signaling, referred to as being HER2+, or neither, which is referred to as being triple negative. Despite advances in treatments for hormone-positive
	and receptor-positive patients, the lack of similar advances in treatment options for triple negative breast cancer patients, which represent approximately 15 to 20% of all newly diagnosed breast
	cancer patients each year in the countries listed above, represents a significant unmet medical need. In the United States, the five-year survival rate of newly diagnosed metastatic breast cancer is
	approximately 26%. In the United States, 40,000 women die annually from breast cancer, making breast cancer one of the largest causes of cancer-related deaths. Based on our analysis of patient
	samples, we believe that approximately 35% of metastatic patients, or 55,000 patients in the countries listed above, have the
</FONT>
<FONT SIZE=2>
<I>
	RARA
</I>
</FONT>
<FONT SIZE=2>
	biomarker and would
	benefit from a product candidate like SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	are an estimated 2,500 new APL cases diagnosed in the United States, Canada and the five largest European countries each year. Despite advances in treating APL, the disease remains
	associated with a significant incidence of early death due to disease-related susceptibility to bleeding or hemorrhage.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Overview
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1365 is a highly potent and selective small molecule CDK7 inhibitor focused on cancers that are dependent on a high and constant
	expression of certain transcription factors for their growth and
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	110
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=113,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=184962,FOLIO='110',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DU79601_1_111">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	survival,
	a phenomenon known as transcriptional addiction. Using our platform, we have generated several potent and selective small molecule CDK7 inhibitors, including SY-1365. We chose SY-1365 as our
	development candidate based on its promising efficacy and safety observed in our preclinical studies. We have begun IND-enabling activities for SY-1365. We plan to initiate a Phase&nbsp;1/2 clinical
	trial in patients with acute leukemia, including AML and ALL, in in the first half of 2017.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Drugging Transcriptional Kinases
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using our CDK7 inhibitor SY-079, known in the scientific literature as THZ1, a "tool" or research compound, our scientific founders and
	collaborators demonstrated that transcriptionally addicted cancers are particularly sensitive to selective inhibition of CDK7. CDK7, a member of the cyclin-dependent kinase, or CDK, family, is a
	transcriptional kinase that plays a central role in the expression of transcription factors in these cancers. CDK7 is associated with super-enhancers that control the expression of the transcription
	factors driving the cancer's growth and survival. Inhibiting CDK7 preferentially lowers the expression of disease-driving transcription factors controlled by super-enhancers, and results in the
	selective killing of cancer cells over non-cancerous cells.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	scientific founders and collaborators conducted preclinical studies in cell lines of T-ALL, a form of ALL that originates in T-cells,
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma, a form of neuroblastoma resulting from
	amplification of the gene
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	, and
	small cell lung cancer. As shown in the graphic below, CDK7 inhibition resulted in reduced expression levels of the specific transcription factor contributing to each of these cancers:
</FONT>
<FONT SIZE=2>
<I>
	RUNX1
</I>
</FONT>
<FONT SIZE=2>
	in T-ALL
	and
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	in neuroblastoma and small cell lung cancer. These findings have been published
	in
</FONT>
<FONT SIZE=2>
<I>
	Cell
</I>
</FONT>
<FONT SIZE=2>
	,
</FONT>
<FONT SIZE=2>
<I>
	Nature
</I>
</FONT>
<FONT SIZE=2>
	and
</FONT>
<FONT SIZE=2>
<I>
	Cancer Cell
</I>
</FONT>
<FONT SIZE=2>
	.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G657957.JPG" ALT="GRAPHIC" WIDTH="684" HEIGHT="262">
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	111
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=114,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=83636,FOLIO='111',FILE='DISK124:[15ZCT1.15ZCT79601]DU79601A.;191',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_112">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As shown below, in additional preclinical studies conducted by our scientific founders and collaborators, SY-079 also demonstrated significant anti-tumor activity
	in cell line-derived, or CDX, models of T-ALL and
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma, as well as a survival benefit similar to chemotherapy in a genetically
	engineered mouse model of small cell lung cancer. In the T-ALL model, the tumor size was measured by the bioluminescence, or the aggregate brightness of chemically tagged tumor cells in an imaging
	study. In the
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma model, tumor size was estimated by total volume. In the small cell lung cancer model, researchers
	demonstrated a survival benefit similar to chemotherapy in genetically engineered mice treated with SY-079.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G332127.JPG" ALT="GRAPHIC" WIDTH="624" HEIGHT="261">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	scientific founders and collaborators have also demonstrated the strong potential of CDK7 inhibition, using SY-079, as a novel treatment strategy for triple negative breast cancer, a
	highly aggressive form of breast cancer that is transcriptionally addicted. In a PDX model of triple negative breast cancer, SY-079 selectively impacted the expression of a set of crucial genes,
	killing cancer cells and inhibiting tumor growth. This exemplifies our gene control approach of influencing multiple crucial genes driving cancer with one inhibitor in a targeted fashion. The graphic
	below illustrates the impact of increased exposure of SY-079 on cell growth on ER/PR+ breast cancer cell lines as compared to triple negative breast cancer cell lines.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G79917.JPG" ALT="GRAPHIC" WIDTH="276" HEIGHT="298">
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	112
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=115,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=222930,FOLIO='112',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_113">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	illustrated above, SY-079 was observed to have a dramatic impact on cell growth in triple negative breast cancer cell lines, as measured by the estimated percentage of proliferating
	cells. The ER/PR+ breast cancer cell lines were significantly less sensitive to treatment with SY-079. These findings were published in
</FONT>
<FONT SIZE=2>
<I>
	Cell
</I>
</FONT>
<FONT SIZE=2>
	.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	an AML cell line treated with a CDK7 inhibitor, expression levels of genes associated with super-enhancers that we studied were observed to be more highly repressed on average than
	those of the genes we studied that are not associated with super-enhancers. In this same cell line,
</FONT>
<FONT SIZE=2>
<I>
	MYB
</I>
</FONT>
<FONT SIZE=2>
	was observed to be one of the most highly
	repressed genes. We believe this finding is significant because
</FONT>
<FONT SIZE=2>
<I>
	MYB
</I>
</FONT>
<FONT SIZE=2>
	is a transcription factor gene known to contribute to AML. Notably, we have
	identified super-enhancers associated with
</FONT>
<FONT SIZE=2>
<I>
	MYB
</I>
</FONT>
<FONT SIZE=2>
	in nearly all AML patient samples we have analyzed.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G909941.JPG" ALT="GRAPHIC" WIDTH="351" HEIGHT="354">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Our Preclinical Data
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using our internal drug discovery capabilities, we have generated several potent and selective small molecule CDK7 inhibitors,
	including SY-1365, with significantly enhanced drug-like characteristics over&nbsp;SY-079. Our CDK7 inhibitors are covalent, meaning that they bind irreversibly and selectively to CDK7. We believe
	that selectivity is critical for a therapeutic index with CDK inhibition. CDK inhibitors known as pan-CDK inhibitors are not selective for a specific CDK. Though they have demonstrated anti-tumor
	activity, pan-CDK inhibitors have limited clinical utility due to dose-limiting toxicities. More recently, a selective inhibitor of CDK4/6, members of the CDK family involved in cell cycle, received
	accelerated approval in breast cancer, demonstrating the substantial clinical benefit of selective CDK inhibition.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have conducted a comprehensive set of biochemical and cellular experiments to characterize the potency and selectivity of SY-1365. In those experiments, SY-1365 demonstrated high
	biochemical and cellular potency with a high degree of selectivity. When SY-1365 was scanned against a panel of 468 kinase assays, it was observed to demonstrate significant binding, defined as 90%
	binding at a concentration of 1&nbsp;&micro;m, to only seven kinases, including CDK7. Notably, SY-1365 was not observed to significantly bind to members of the CDK family involved
	in cell cycle.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1365
	has been observed to selectively kill cancer cells in AML and ALL cell lines by inducing robust and sustained apoptosis, or programmed cell death. As shown below, in a
	comparative assay
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	113
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=116,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=335315,FOLIO='113',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_114">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	measuring
	a marker of apoptosis, SY-1365 preferentially kills cancer cells in AML, with a clear dose effect, meaning that as we increased the concentration of the drug, more apoptosis was observed.
	However, there was relatively little effect on non-cancerous cells regardless of dose.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G983587.JPG" ALT="GRAPHIC" WIDTH="576" HEIGHT="291">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
</FONT>
<FONT SIZE=2>
<I>
	in vivo
</I>
</FONT>
<FONT SIZE=2>
	studies that we conducted, SY-1365 was observed to have complete responses and survival benefit in CDX and PDX models of AML.
	In one such study, which is summarized in the graphic below, SY-1365 was observed to have significant anti-tumor activity and survival benefit in a PDX model of AML. In this study, treated mice
	received a dose of SY-1365 daily for the first 23&nbsp;days of the study and then were dosed intermittently, twice per week, through the 39
<SUP>
	th
</SUP>
	&nbsp;day of the study.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mice
	treated with SY-1365 in this model experienced initial clearance of the disease and maintained residual low levels of human leukemia cells. The treated mice were observed to
	maintain a stable body weight, which is an indicator of a promising safety profile, as well as an indicator of preclinical efficacy. In fact, beyond the dosing period, 80% of treated mice remained
	alive, and levels of human leukemia cells in the blood remained at less than 5%.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	contrast, in the untreated mice, the cancer progressed, reaching levels of human leukemia cells of greater than 50% in blood and greater than 90% in tissues, at which point all mice
	had died of their disease or were humanely sacrificed due to excessive tumor burden.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G57754.JPG" ALT="GRAPHIC" WIDTH="655" HEIGHT="217">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	preclinical studies, SY-1365 was observed to have markedly fewer negative effects on healthy cells than a pan-CDK inhibitor. Pan-CDK inhibitors have been observed to result in blood
	cell death, or myelosuppression. As shown in the graphic below, when we compared the effect of SY-1365 on four
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	114
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=117,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=396280,FOLIO='114',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_115">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	types
	of blood cells in mice to the effect of a pan-CDK inhibitor being developed for cancer, known as dinaciclib, the mice treated with SY-1365 did not demonstrate the same level of myelosuppression
	that occurred in mice treated with dinaciclib. Based on this data, we believe that SY-1365 will have a more favorable safety profile than pan-CDK inhibitors.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G721486.JPG" ALT="GRAPHIC" WIDTH="676" HEIGHT="438">
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SY-1365
	was observed to reduce expression of cancer-contributing genes associated with super-enhancers, including oncogenic transcription factors
</FONT>
<FONT SIZE=2>
<I>
	MYB
</I>
</FONT>
<FONT SIZE=2>
	and
</FONT>
<FONT SIZE=2>
<I>
	MYC
</I>
</FONT>
<FONT SIZE=2>
	, in
	an AML cell line. Additionally, SY-1365 also showed synergistic activity in
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	models of AML when combined with other targeted agents, including Flt3, Bcl-2 and BET inhibitors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365 Clinical Development Plan
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have begun IND-enabling activities for SY-1365. Our goal is to initiate a Phase 1/2 clinical trial in patients with acute leukemia,
	including AML and ALL, in the first half of 2017. We expect to have initial data from this study in the first half of 2018. We have chosen to enroll patients with acute leukemia in our first trial
	based on the high degree of efficacy observed in our preclinical studies, the high degree of transcriptional dysregulation in these particular cancers, the significant unmet medical need of these
	patients and the potential for accelerated development. We believe there is a well-defined path to clinical proof-of-concept in acute leukemia. We then plan to expand into a broader set of molecularly
	defined patient populations using our gene control platform to identify patient subgroups with transcriptionally addicted cancers such as small cell lung cancer, triple negative breast cancer and
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified neuroblastoma.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are leveraging our platform to identify biomarkers that will predict patients most likely to respond to SY-1365. We intend to use a pharmacodynamics marker of target engagement in the
	tumor to guide our dosing in clinical trials.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	115
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=118,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=972293,FOLIO='115',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_116">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365&nbsp;Market Opportunity
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With SY-1365, we believe we have the opportunity to address significant unmet medical needs across a range of transcriptionally
	addicted blood cancers and solid tumors. We will initially pursue clinical development of SY-1365 in AML and ALL.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	are an estimated 37,000 new AML diagnoses each year in the United States, Canada, the five largest European countries by population&#151;Germany, the United Kingdom, France,
	Spain and Italy&#151;and Japan, which we refer to as the developed pharmaceutical markets. In the United States, newly diagnosed patients have a 25% five-year survival rate. There has been
	little improvement in treatment options for AML in the past 20&nbsp;years, with typical treatments including older chemotherapeutics and stem cell transplantation. AML remains an area of significant
	unmet medical need. Our initial clinical trial will include patients with relapsed and refractory AML and patients who are elderly or unfit for treatment with standard therapies. We estimate this
	population to be 29,000 patients, of which 11,000 patients have relapsed or refractory AML and of which 18,000 patients are elderly or unfit for treatment with standard therapies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ALL
	is characterized by an excess of lymphoblastic cells, and approximately 12,000 patients are diagnosed annually in the developed pharmaceutical markets. Approximately 60% of patients
	diagnosed with ALL are younger than 20&nbsp;years old. Eighty percent of these patients are cured by current treatments such as chemotherapy and stem cell transplantation. However, only
	approximately 50% of patients older than 20&nbsp;years old are cured, highlighting the need for more effective therapies. Our initial clinical trial will include adult recurrent or refractory
	patients. We estimate there are 2,500 such patients in the developed pharmaceutical markets.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
	the broader AML and ALL patient populations, using our platform we expect to discover a biomarker that could enable us to identify patient subsets most likely to benefit from our
	therapies. Over time, we intend to evaluate SY-1365 in additional transcriptionally addicted cancers where there is a high mortality rate, high unmet medical need and few if any treatment options
	other than chemotherapy and radiation, including the following:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="112PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:65PT;">
<FONT SIZE=1>
<B>
	Metastatic Cancer
<!-- COMMAND=ADD_SCROPPEDRULE,65PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Approximate Number of
<BR>
	Patients Diagnosed
<BR>
	Annually in the
<BR>
	Developed Pharmaceutical
<BR>
	Markets
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Triple Negative Breast Cancer
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	42,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Small Cell Lung Cancer
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	65,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<I>
	MYCN
</I>
</FONT>
<FONT SIZE=2>
	-amplified Neuroblastoma
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	200
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Programs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are using our platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to
	identify optimal points of therapeutic intervention in specific subsets of patients and to create a pipeline of novel preclinical drug candidates targeting transcriptional and regulatory proteins, as
	well as to link existing drugs to novel genomically defined patient populations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Intellectual Property
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file patent applications directed to our gene control platform, proprietary composition of matter and product candidates in an
	effort to establish intellectual property positions regarding all aspects of our business, including new chemical entities, or NCEs, and uses of these NCEs in the treatment of diseases. As of
	June&nbsp;15, we own one pending U.S. provisional patent application, four U.S. pending patent applications, seven foreign applications pending in Europe, Australia and Canada,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	116
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=119,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=277378,FOLIO='116',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_117">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	and seven pending Patent Cooperation Treaty, or PCT, patent applications. In addition, as of June&nbsp;15, 2016, we are exclusively licensed to four issued U.S. patents, seven U.S. pending patent
	applications, five issued foreign patents and 18 foreign patent applications pending in a number of jurisdictions, including Australia, Canada, China, Europe, and Japan. A significant portion of our
	owned and
	licensed pending patent applications pertain to our product candidates, key discovery programs, specifically our CDK7 inhibitor program and transcription factor modulators, and our gene control
	platform.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our intellectual property portfolio as of June&nbsp;15, 2016 is summarized below. For some of our pending patent applications, prosecution has yet to commence. Prosecution is a lengthy
	process, during which the scope of the claims initially submitted for examination by the USPTO is often significantly narrowed by the time they issue, if they issue at all. We expect this to be the
	case with respect to our pending patent applications referred to below.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The intellectual property portfolio for SY-1425 contains one U.S. pending patent application, one pending PCT patent application and
	one provisional patent application directed to patient stratification methods and methods of use for agonists of RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	, as well as several licensed patents
	directed to various aspects of that compound. The U.S. pending application and any U.S. or non-U.S. applications claiming priority to these pending applications, if issued, will have a statutory
	expiration date of 2036 or 2037.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, we are exclusively licensed in North America and Europe to two issued U.S. patents, and five issued foreign patent applications in Canada and Europe, directed to
	pharmaceutical kits and drug combinations comprising tamibarotene and certain other chemotherapeutic agents, certain formulations of tamibarotene, and crystal forms of tamibarotene and their
	preparation. One licensed issued U.S. patent covering formulations has a statutory expiration date of April 2028. The other licensed issued U.S. patent covering crystals has a statutory expiration
	date of August 2021. Patent term adjustments or patent term extensions could result in later expiration dates for each of these patents. We do not have composition of matter patent protection with
	respect to SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The intellectual property portfolio for SY-1365 and our other CDK7 inhibitors contains patent applications directed to compositions of
	matter for our compounds and analogs, compositions of matter for CDK7 inhibitors having different structural features (
</FONT>
<FONT SIZE=2>
<I>
	i.e.,
</I>
</FONT>
<FONT SIZE=2>
	&nbsp;different compound
	families), as well as methods of use for these novel compounds. As of June&nbsp;15, 2016, we own two pending U.S. patent applications, six pending foreign applications in Europe, Canada and
	Australia and four pending PCT patent applications directed to this program. Any U.S. or non-U.S. patents issuing from these pending applications or applications claiming priority to the pending
	applications
	covering our compounds and related methods of use will have a statutory expiration date of October 2034, April 2035 or October&nbsp;2035. Patent term adjustments or patent term extensions could
	result in later expiration dates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	are also exclusively licensed to three pending U.S. patent applications and 10 pending foreign patent applications in a number of jurisdictions, including Australia, Canada, Europe,
	and Japan, directed to this program.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Programs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The intellectual property portfolio for our other programs contains patents and patent applications directed to compositions of matter
	for inhibiting transcription factors in multiple compound families, methods of treating various diseases through inhibition of specific transcription factor(s). As of June&nbsp;15, 2016, we own two
	pending PCT patent applications and were exclusively licensed to one issued U.S. patent and two U.S. and two pending foreign patent applications in Europe directed to our other
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	117
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=120,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=678982,FOLIO='117',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_118">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	programs. The licensed U.S. patent has a statutory expiration date of July 2032. Any U.S. or non-U.S. patents issuing from the pending applications or applications claiming priority to the pending
	applications covering transcription factor inhibitors and their use will have statutory expiration dates of February 2031, August 2032, November 2033 and June 2036.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Platform
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The intellectual property portfolio directed to our platform includes patent applications and patents directed to super-enhancers and
	their detection and uses thereof to detect novel disease targets, and methods for identifying protein binding sites in a genome. As of June&nbsp;15, 2016, we own one pending U.S. patent application
	and one pending patent application in Europe directed to these technologies which, if issued, will have a statutory expiration date of March 2034. In addition, we have an exclusive license to one
	issued U.S. patent, two U.S. pending patent applications and six pending foreign patent applications in a number of jurisdictions, including
	Australia, Canada, China, Europe and Japan, directed to these technologies. The U.S. and foreign patent applications that we own are directed to the identification of new super-enhancer components and
	methods of treating diseases by targeting those novel components, and if issued, will have a statutory expiration date of March 2034. The licensed U.S. patent has a statutory expiration date of
	October 2033 and the licensed pending applications directed to super-enhancers and their detection and uses thereof to detect novel disease targets, if issued, will have a statutory expiration date of
	October 2033. The licensed U.S. and foreign patent applications directed to methods for identifying protein binding sites in a genome, if issued, will have a statutory expiration date of June 2033.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is
	20&nbsp;years from the earliest filing date of a non-provisional patent application. In the United States, a patent's term may be lengthened by patent term adjustment, which compensates a patentee
	for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a
	drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. See "&#151;Government Regulation
	and Product Approvals&#151;Marketing Authorization and Exclusivity" below for additional information on such exclusivity. In the future, if and when our product candidates receive approval by
	the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each drug and
	other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustment to the term of any of our
	patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates and
	technologies will depend on our success in obtaining effective patent claims and enforcing those claims, if granted. However, our pending patent applications, and any patent applications that we may
	in the future file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued
	patents that we may receive in the future may be challenged, invalidated or circumvented. For example, we cannot be certain of the priority of inventions covered by pending third-party patent
	applications. If third parties prepare and file patent applications in the United States that also claim technology or therapeutics to which we have rights, we may have to participate in interference
	proceedings in the USPTO to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us, which is highly unpredictable. In addition,
	because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be
	commercialized, any related patent may expire or remain in force
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	118
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=121,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=167336,FOLIO='118',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_119">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	for
	only a short period following commercialization, thereby limiting protection such patent would afford the respective product and any competitive advantage such patent may provide.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect
	our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality, and invention
	assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality
	agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies
	that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that these agreements will afford us adequate protection of our intellectual property and
	proprietary information rights.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	License Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to a number of license agreements under which we license patents, patent applications and other intellectual property
	from third parties. We enter into these agreements to augment our proprietary intellectual property portfolio. The licensed intellectual property covers some of the compounds that we are researching
	and developing and some of the scientific processes that we use. These licenses impose various diligence and financial payment obligations on us. We expect to continue to enter into these types of
	license agreements in the future.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Dana-Farber Cancer Institute,&nbsp;Inc.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2013, we entered into a license agreement with Dana-Farber Cancer Institute,&nbsp;Inc., or Dana-Farber, pursuant to which
	we were granted an exclusive worldwide, sublicensable license under specified patents relating to CDK7 inhibitors and JNK inhibitors owned or controlled by Dana-Farber. The license is for all fields
	of use and subject to certain rights retained by Dana-Farber for internal non-commercial research, academic/teaching and government purposes. Subject to certain restrictions, Dana-Farber granted us an
	option to obtain an exclusive commercial license to certain improvements created by Dana-Farber during the first three years of the agreement, which would be negotiated in good faith and incorporated
	into this agreement. In connection with the agreement, we paid Dana-Farber an upfront licensing fee and a milestone payment based on our first round of funding, such payments totaling $175,000, in
	addition to past patent expenses. We are obligated to pay Dana-Farber annual license maintenance fees that are creditable against other payments and royalties due under the agreement and to make
	milestone payments of up to an aggregate of $3.4&nbsp;million for each of the first two products in connection with the achievement of certain clinical and regulatory milestones. In addition, we are
	required to pay Dana-Farber a tiered royalty on net sales by us, our affiliates and sublicensees ranging from low single digit to mid-single digit percentages, subject to certain adjustments, as well
	as a tiered mid-single digit to low double digit
	percentage of sublicense income. Our royalty and sublicensing income payment obligations are further subject to apportionment between designated agreements existing among us, Dana-Farber and the
	Whitehead Institute for Biomedical Research, or Whitehead. We are required to meet certain diligence milestones and to use commercially reasonable efforts to, among other things, develop and
	commercialize one or more licensed products or processes and to make one or more licensed products or processes reasonably available to the public. The agreement contains specified diligence
	activities that if met on an annual basis would be deemed to satisfy some of our diligence obligations for the particular year. The agreement, unless earlier terminated by us or Dana-Farber, will
	remain in effect until the expiration or abandonment of the licensed patent rights. We have the right to terminate the agreement for any reason provided that we provide Dana-Farber the required notice
	and we pay all undisputed amounts due to Dana-Farber at the time of termination. Dana-Farber has the right to terminate the agreement
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	119
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=122,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=283919,FOLIO='119',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_120">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	if
	we cease doing business, or if we do not pay them the amounts owed under the agreement and fail to cure, or if we commit and fail to cure a material breach under the agreement, or if our successor
	does not agree in writing to be bound by this agreement within the designated period following assignment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Whitehead Institute for Biomedical Research and Dana-Farber Cancer Institute,&nbsp;Inc.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2013, we entered into a license agreement with Whitehead and Dana-Farber, pursuant to which we were granted a worldwide,
	sublicensable with certain restrictions, license under specified patents relating to Chem-Seq or modulators of Myc/Max Screen owned or controlled by Whitehead and Dana-Farber, to make, have made, use,
	sell, offer for sale and import products and to perform and have performed licensed processes, in each case, in the applicable field. This license is exclusive, on a patent-by-patent basis in the
	designated fields, (i)&nbsp;during the term, with respect to patent rights relating to Myc/Max Screen, (ii)&nbsp;during the term, for use of Chem-Seq for human health and therapeutics,
	(iii)&nbsp;for a period of three years, with respect to Chem-Seq outside of human health and therapeutics and (iv)&nbsp;during the term, for other specified patent rights, with limited exceptions,
	including non-exclusive rights for research use reagents. We can automatically extend the period of exclusive rights with respect to Chem-Seq for an additional two years in exchange for an extension
	payment and we have been granted the first right for a limited extension after such period. We were granted a non-exclusive license to certain materials for the practice of our exclusive licenses. The
	licenses are subject to certain rights retained by Dana-Farber and Whitehead for internal non-commercial research, academic/teaching and government purposes. Subject to certain restrictions, we were
	granted an option to obtain an exclusive commercial license to certain improvements created by Whitehead or Dana-Farber during the first three years of the agreement. The option is exercisable within
	a certain period from the date of disclosure, and the license would be negotiated in good faith and incorporated into this agreement. Commencing five years after the effective date and subject to
	certain terms and conditions, the agreement requires us to negotiate and potentially issue mandatory sublicenses under the patent rights outside of human health and therapeutics for fields and
	products that are not directly competitive with products in active development or commercialization by us, our affiliates or sublicensees.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the agreement, we paid Whitehead an upfront licensing fee, and a milestone payment based on our first round of funding, such payments totaling $100,000, in addition to
	past patent expenses. We are obligated to pay Whitehead annual license maintenance fees that are creditable against other payments and royalties due under the agreement and to make milestone payments
	of up to an aggregate of $3.4&nbsp;million in connection with the achievement of certain clinical and regulatory milestones. In addition, we are required to pay Whitehead a royalty on net sales of
	the various products by us, our affiliates and sublicensees ranging from low single digit to mid-single digit percentages, subject to certain adjustments, including a lower royalty on products
	identified through the use of certain licensed products or processes. In addition, we are required to pay a tiered mid-single digit to low double digit percentage of our and our affiliates' sublicense
	income and income we receive from the performance of licensed processes. Our royalty, sublicensing and licensed process income payment obligations are further subject to apportionment between
	designated agreements existing among us, Dana-Farber and Whitehead. In connection with the agreement, we also issued an aggregate of 98,099 shares of our common stock to Whitehead. We are required to
	achieve certain diligence milestones within the specified timeframes, and failure to do so may result in our license under certain patent rights being converted to non-exclusive or otherwise be deemed
	a material breach of the agreement. The agreement further requires that we use commercially reasonable efforts to, among other things, develop and commercialize one or more licensed products or
	processes and to make one or more licensed products or processes reasonably available to the public. The agreement contains specified diligence activities that if met on an annual basis would be
	deemed to satisfy some of our diligence obligations for the particular year. The agreement, unless earlier terminated by us, Whitehead
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	120
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=123,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=969624,FOLIO='120',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_121">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	or
	Dana-Farber, will remain in effect until the expiration or abandonment of the licensed patent rights. We have the right to terminate the agreement for any reason, provided that we provide
	Dana-Farber and Whitehead the required notice and we pay all undisputed amounts due to Whitehead and Dana-Farber at the time of termination. Whitehead and Dana-Farber have the right to terminate the
	agreement if we cease doing business, or if we do not pay them the amounts owed under the agreement and fail to cure, or if we commit and fail to cure a material breach under the agreement, or if our
	successor does not agree in writing to be bound by this agreement within the designated period following assignment.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Whitehead Institute for Biomedical Research
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2013, we entered into a license agreement with Whitehead, which we refer to as the Whitehead license agreement, pursuant to
	which we were granted a worldwide license under specified patents relating to super-enhancers owned or controlled by Whitehead. This license is exclusive in all fields until April 2016, and can remain
	exclusive thereafter, on a field-by-field basis, as long as we can demonstrate that we are using commercially reasonable efforts in the applicable field, and if we are not using such commercially
	reasonable efforts in such applicable field, our license rights would become non-exclusive with respect to such field. We were also granted a non-exclusive license to use certain Whitehead materials
	in connection with the practice of the licensed Whitehead patents. In connection with the Whitehead license agreement, we paid Whitehead an upfront licensing fee of $30,000. In connection with the
	agreement, we also issued an aggregate of 73,575 shares of our common stock to Whitehead. We are obligated to pay Whitehead annual license maintenance fees that are creditable against other payments
	and royalties due under the agreement. In addition, we are required to pay Whitehead a tiered royalty on our net sales ranging from low single digit to mid-single digit percentages, a lower royalty on
	products identified through the use of licensed products or processes, and a tiered mid-single digit to low double digit percentage of sublicense income, which steps down depending on time,
	development stage of the products or processes and payments made to Whitehead, and patent expenses of Whitehead in connection with the licensed patents. We are required to use commercially reasonable
	efforts to, among other things, develop and commercialize one or more licensed products or processes and to make one or more licensed products or products reasonably available to the public. The
	Whitehead license agreement, unless earlier terminated by us or Whitehead, will remain in effect until the expiration or abandonment of the licensed patent rights. We have the right to terminate the
	Whitehead license agreement for any reason upon three months' notice to Whitehead, provided that we pay all undisputed amounts due to Whitehead at the time of termination. Whitehead has the right to
	terminate the Whitehead license agreement immediately if we cease doing business, or if we do not pay Whitehead the amounts owed under the agreement or commit a material breach under the agreement,
	Whitehead has the right to terminate after we have had an opportunity to cure the breach.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	TMRC
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2015, we entered into, and in April 2016, we amended and restated, a license agreement with TMRC, which we refer to as the
	TMRC license agreement, pursuant to which TMRC granted us an exclusive license, with the right to sublicense, under TMRC patent rights, data, regulatory filings and other intellectual property for the
	North American and European development and commercialization of SY-1425 (tamibarotene) products for the treatment of human cancer indications. Under the TMRC license agreement, we have agreed to pay
	TMRC single-digit royalties based on net sales if TMRC's patents cover our product and low single-digit royalties based on net sales with respect to know-how licensed by TMRC during a predefined
	royalty term, and to make payments to TMRC upon meeting specified clinical and regulatory milestones in an aggregate amount of approximately $13.0&nbsp;million per indication. Under the TMRC license
	agreement, we must use
	commercially reasonable efforts to, among other things, commence development activities within one year, to develop
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	121
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=124,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=861373,FOLIO='121',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_122">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	SY-1425
	in at least one cancer indication, and, following marketing approval, to market the product. The license agreement expires on the expiration of the subject patent rights or 15&nbsp;years
	after the date of first commercial sale of product, whichever is later. The TMRC license agreement may be terminated by either party if the other party is in breach and the breach is not cured within
	a required amount of time or if the other party is in bankruptcy. If we have reason to do so, we may also terminate the agreement after one year from the original effective date at our sole
	discretion.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	connection with the TMRC license agreement, in April 2016 we entered into a supply management agreement with TMRC. Pursuant to the supply management agreement, we and TMRC have agreed
	to establish a joint manufacturing committee to discuss strategy for supply of SY-1425. In addition, we have agreed to pay TMRC a fee for each kilogram of SY-1425 active pharmaceutical ingredient we
	procure. The supply management agreement terminates on the expiration or termination of the TMRC license agreement, and our obligation to pay these fees survives the termination of the supply
	management agreement. In April 2016, we also entered into a standby license with TMRC and Toko Pharmaceuticals Ind.&nbsp;Co.&nbsp;Ltd., or Toko, the owner of the patent rights licensed to TMRC
	from which our license agreement with TMRC derives its rights, pursuant to which we obtain a standby license from Toko if Toko's license with TMRC is terminated.
</FONT>
</P>
<EFX_COMPETITION>
<A NAME="FIS_COMPETITION"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Competition
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong
	emphasis on proprietary products. While we believe that our technology, development experience, and scientific knowledge provide us with competitive advantages, we face potential competition from many
	different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.
	Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	compete in the segments of the pharmaceutical, biotechnology and other related markets that address gene control and cancer. There are other companies working to develop therapies in
	the fields of gene control and cancer. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy. There are a variety
	of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and
	other therapies, they may also be used in combination with or as an adjunct to these therapies. Some of the currently approved drug therapies are branded and subject to patent protection, and others
	are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. In general, although there has
	been considerable progress over the past few decades in the treatment of cancer and the currently marketed therapies provide benefits to many patients, these therapies all are limited to some extent
	in their efficacy and frequency of adverse events. As a result, the level of morbidity and mortality from cancer remains high.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition to currently marketed therapies, there are also a number of medicines in late stage clinical development to treat cancer. These medicines in development may provide efficacy,
	safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we
	obtain market approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
	of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
	obtaining
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	122
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=125,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=498014,FOLIO='122',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DW79601_1_123">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	regulatory
	approvals and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being
	concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial
	sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early stage companies may also prove to be
	significant competitors, particularly through collaborative arrangements with large and established companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of
	companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective, have fewer or less severe side effects,
	are more
	convenient or are less expensive than any medicines that we may develop. Our competitors also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval
	for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by
	insurers or other third-party payors seeking to encourage the use of generic medicines. There are many generic medicines currently on the market for the indications that we are pursuing, and
	additional medicines are expected to become available on a generic basis over the coming years. If our therapeutic product candidates are approved, we expect that they will be priced at a significant
	premium over competitive generic medicines.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	the drug candidates of our priority programs are approved for the indications for which we are currently planning clinical trials, they will compete with the drugs discussed below and
	will likely compete with other drugs currently in development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1425
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to initially develop SY-1425, our RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist, for patients with AML or MDS. We will
	select patients for our clinical trials based on high-levels of RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	as measured by our proprietary biomarker. There has been little advancement in treatment
	options for patients with these cancers. Typical treatment includes chemotherapy followed by stem cell transplantation. SY-1425 may face competition from other drug candidates currently in clinical
	development for relapsed or refractory AML and MDS. Several companies are developing drugs for AML, including Daiichi Sankyo Company, Limited, Boehringer Ingelheim GmbH, Agios
	Pharmaceuticals,&nbsp;Inc., Novartis AG, Astellas Pharma&nbsp;Inc. and Karyopharm Therapeutics&nbsp;Inc. We believe that SY-1425 will be the only selective
	RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist in clinical development for relapsed or refractory AML in North America and Europe. Because the mechanism of action is different than the others
	currently on the market and in development, we believe that SY-1425 could be first-in-class and could be used in combination with other therapies, which could minimize competition, assuming that data
	from a registration-enabling trial warrants such use. We are aware of only one other selective RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	program, being pursued by IO Therapeutics,&nbsp;Inc. This
	program appears to be in clinical development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	SY-1365
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to initially develop SY-1365, our CDK7 inhibitor, for patients with relapsed or refractory AML or recurrent or refractory ALL.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	123
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=126,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=697931,FOLIO='123',FILE='DISK124:[15ZCT1.15ZCT79601]DW79601A.;117',USER='CHE106781',CD='18-JUN-2016;12:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_124">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The competitive landscape for AML is described above. In ALL, patients are typically treated with older chemotherapeutics. Targeted therapies such as kinase
	inhibitors, including imatinib and dasatinib, and monoclonal antibodies, including rituximab and blinatumamab, have been developed and used successfully for certain patient populations within ALL. If
	SY-1365 receives marketing approval, it may face competition from other drug candidates currently in development for relapsed and refractory ALL from several companies including Amgen&nbsp;Inc.,
	Novartis and Juno Therapeutics,&nbsp;Inc.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe that SY-1365 will be the only selective mechanism of its kind in clinical development. Because the mechanism of action is different than the others currently on the market and
	in development, we believe that it could be first-in-class and used in combination with other therapies, which could minimize competition, assuming that data from a registration-enabling trial
	warrants such use. We are aware of two other selective CDK7 inhibitor programs, both of which appear to be in early preclinical development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Sales and Marketing
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hold North American and European commercialization rights to SY-1425 and worldwide rights to SY-1365 and all of our other
	preclinical programs. Subject to receiving marketing approval, we intend to build a focused sales and marketing organization in the United States and potentially in Europe to sell our products. We
	believe that such an organization will be able to address the community of physicians who are key specialists in treating the patient populations for which our product candidates are being developed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to
	oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing
	relationships with researchers and practitioners in relevant fields of medicine.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside
	of the United States and potentially Europe, where appropriate, we may elect in the future to utilize strategic partners, distributors or contract sales forces to assist in the
	commercialization of our products. In certain instances, we may consider building our own commercial infrastructure.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Manufacturing
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product
	candidates. Although we intend to rely on third-party contract manufacturers to produce our product candidates and any products we may develop in the future, we have recruited personnel with
	experience to manage these third-party contract manufacturers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Government Regulation and Product Approvals
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including
	the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval,
	packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes
	for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory
	authorities, require the expenditure of substantial time and financial resources.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	124
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=127,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=179965,FOLIO='124',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_125">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Review and Approval of Drugs in the United States
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA approves and regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing
	regulations. The failure to comply with requirements under the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject an
	applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold,
	issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
	contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
	applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA's GLP regulations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	submission to the FDA of an IND, which must take effect before human clinical trials may begin;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be
	initiated;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the
	safety and efficacy of the proposed drug product for each indication;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	preparation and submission to the FDA of an NDA, requesting marketing for one or more proposed indications;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	review by an FDA advisory committee, where appropriate or if applicable;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components
	thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the
	product's identity, strength, quality and purity;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	payment of user fees and securing FDA approval of the NDA; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation
	Strategy, or REMS, and the potential requirement to conduct post-approval studies.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Preclinical Studies
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before an applicant begins testing a compound with potential therapeutic value in humans, the drug candidate enters the preclinical
	testing stage. Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	and animal studies
	to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal
	regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and
	plans for clinical trials, among other things,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	125
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=128,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=712825,FOLIO='125',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_126">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	are
	submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Human Clinical Trials in Support of an NDA
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
	investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in
	any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be
	used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An
	IND automatically becomes effective 30&nbsp;days after receipt
	by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must
	resolve any outstanding concerns before the clinical trial can begin. The FDA can place an IND on clinical hold at any point in development, and depending upon the scope of the hold, clinical trial(s)
	may not restart until resolution of the outstanding concerns to the FDA's satisfaction.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and
	the IRB must conduct a continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be
	provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of
	Health for public dissemination on their ClinicalTrials.gov website.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
	clinical trials are typically conducted in four sequential phases, which may overlap or be combined:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;1.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;The drug is initially introduced into healthy human subjects or, in
	certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an
	early indication of its effectiveness and to determine optimal dosage.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;2.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;The drug is administered to a limited patient population to identify
	possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;3.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;The drug is administered to an expanded patient population,
	generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to
	establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	Phase&nbsp;4.
</I>
</B>
</FONT>
<FONT SIZE=2>
	&nbsp;&nbsp;Post-approval studies may be conducted after initial marketing
	approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress
	reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety
	reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or
</FONT>
<FONT SIZE=2>
<I>
	in
	vitro
</I>
</FONT>
<FONT SIZE=2>
	testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that
	listed in the protocol or investigator brochure. The FDA or the sponsor or the data
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	126
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=129,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=687054,FOLIO='126',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_127">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	monitoring
	committee may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk.
	Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB's
	requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of
	the clinical data submitted.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
	with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
	drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
	quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate
	packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Review of an NDA by the FDA
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical
	trials, together with detailed information relating to the product's chemistry, manufacture, controls and proposed labeling, among other things,
	are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an
	application user fee, and the sponsor of an approved NDA is also subject to annual product and establishment user fees. These fees are typically increased annually. Certain exceptions and waivers are
	available for some of these fees, such as an exception from the application fee for drugs with orphan designation and a waiver for certain small businesses, an exception from the establishment fee
	when the establishment does not engage in manufacturing the drug during a particular fiscal year, and an exception from the product fee for a drug that is the same as another drug approved under an
	abbreviated pathway.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA conducts a preliminary review of an NDA generally within 60 calendar days of its receipt and strives to inform the sponsor by the 74th&nbsp;day after the FDA's receipt of the
	submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
	the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for
	filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of
	New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for
	"priority review" are meant to be reviewed within six months of the filing date. For applications seeking approval of drugs that are not NMEs, the ten-month and six-month review periods run from the
	date that FDA receives the application. The review process and the Prescription Drug User Fee Act goal date may be extended by the FDA for three additional months to consider new information or
	clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
	approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities
	associated with an NDA submission, including drug component manufacturing (e.g.,&nbsp;active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The
	FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
	product within required
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	127
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=130,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=743801,FOLIO='127',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_128">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	specifications.
	Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the
	benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease,
	expected benefit of the
	product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician
	communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing,
	dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk
	associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of
	independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
	conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Fast Track, Breakthrough Therapy and Priority Review Designations
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the
	treatment of a serious or life-threatening disease or condition. These programs are Fast Track designation, Breakthrough Therapy designation and priority review designation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
	the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or
	life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions
	with the FDA and the FDA may initiate review of sections of a Fast Track product's application before the application is complete. This rolling review may be available if the FDA determines, after
	preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of
	the remaining information and the sponsor must pay applicable user fees. However, the FDA's time period goal for reviewing a Fast Track application does not begin until the last section of the
	application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial
	process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Second,
	a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening
	disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such
	as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to
	Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving
	more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	128
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=131,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=871117,FOLIO='128',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_129">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third,
	the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or
	effectiveness. The FDA determines, on a case- by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may
	be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient
	compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and
	resources to the evaluation of such applications, and to shorten the FDA's goal for taking action on a marketing application from ten months to six months.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Accelerated Approval Pathway
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic
	advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also
	grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality,
	or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition
	and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
	the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to
	predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical
	endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with
	accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated
	approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is
	reasonably likely to predict the ultimate clinical benefit of a product.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical
	benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of
	products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and
	sometimes large trials to demonstrate a clinical or survival benefit.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	accelerated approval pathway is usually contingent on a sponsor's agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the
	product's clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&nbsp;4 or
	post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would
	allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the
	FDA.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	129
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=132,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=937162,FOLIO='129',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_130">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	The FDA's Decision on an NDA
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the FDA's evaluation of the NDA and accompanying information, including the results of the inspection of the
	manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information
	for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to
	reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to
	reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application
	does not satisfy the regulatory criteria for approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling,
	require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug's safety after approval, require testing and surveillance programs to monitor the
	product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market
	and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of
	changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Post-Approval Requirements
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
	among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product.
	After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee
	requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state
	agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
	often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
	upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
	control to maintain cGMP compliance.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
	an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
	the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
	regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition
	of
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	130
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=133,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=517650,FOLIO='130',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_131">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	distribution
	or other restrictions under a REMS program. Other potential consequences include, among other things:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	restrictions on the marketing or manufacturing of the product, suspension of the approval, or complete withdrawal of the product from
	the market or product recalls;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	fines, warning letters or holds on post-approval clinical trials;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	refusal of the FDA to approve pending NDAs or supplements to approved NDAs;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	product seizure or detention, or refusal to permit the import or export of products; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	injunctions or the imposition of civil or criminal penalties.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in
	accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to
	have improperly promoted off-label uses may be subject to significant liability.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementing regulations, as well as the Drug
	Supply Chain Security Act, or DSCA, which regulate the distribution and tracing of prescription drugs and prescription drug samples at the federal level, and set minimum standards for the regulation
	of drug distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCA imposes requirements to
	ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Abbreviated New Drug Applications for Generic Drugs
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the
	FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a
	generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information
	pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process
	validation data and quality control procedures. ANDAs are "abbreviated" because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support
	of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed
	drug, or RLD.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
	in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
	the dosage form, the strength of the drug and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is "bioequivalent" to the innovator drug. Under the
	statute, a generic drug is bioequivalent to a RLD if "the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug..."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	approval of an ANDA, the FDA indicates whether the generic product is "therapeutically equivalent" to the RLD in its publication "Approved Drug Products with Therapeutic Equivalence
	Evaluations," also referred to as the "Orange Book." Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of
	certain state laws and numerous health insurance programs, the FDA's designation of therapeutic equivalence often
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	131
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=134,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=622543,FOLIO='131',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_132">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	results
	in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years
	of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has
	previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE
	exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification, in which case the
	applicant may submit its application four years following the original product approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence
	studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug
	product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety,
	provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs
	seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product
	is approved.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	505(b)(2) NDAs
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to
	an NDA, an applicant may submit an NDA under Section&nbsp;505(b)(2) of the FDCA. Section&nbsp;505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at
	least some of the information required for approval comes from studies not conducted by, or for, the applicant. If the 505(b)(2) applicant can establish that reliance on FDA's previous findings of
	safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies
	to perform additional studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new product candidate for all,
	or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Hatch-Waxman Patent Certification and the 30-Month Stay
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
	applicant's product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the
	FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant
	is not seeking approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA
	concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
	the applicant must certify with respect to each patent that:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the required patent information has not been filed;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	132
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=135,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=425864,FOLIO='132',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_133">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the listed patent has expired;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the listed patent is invalid, unenforceable or will not be infringed by the new product.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph&nbsp;IV
	certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the
	listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the applicant is not seeking approval).
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	the ANDA or 505(b)(2) applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA
	and patent holders once the ANDA or the 505(b)(2) application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the
	notice of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days after the receipt of a Paragraph&nbsp;IV certification automatically prevents the
	FDA from approving the application until the earlier of 30&nbsp;months after the receipt of the Paragraph&nbsp;IV notice, expiration of the patent, or a decision in the infringement case that is
	favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has
	expired.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Pediatric Studies and Exclusivity
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act, an NDA or supplement thereto must contain data that are adequate to assess the safety and
	effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product
	is safe and effective. With enactment of the Food and Drug Safety and Innovation Act, or the FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans
	must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and any other information
	required by regulation. The applicant, the FDA, and the FDA's internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the
	applicant may request an amendment to the plan at any time.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults,
	or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA.
	Unless and until FDA
	promulgates a regulation stating otherwise, the pediatric data requirements do not apply to products with orphan designation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
	exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing
	protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that
	fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to
	fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever
	statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	133
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=136,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=819283,FOLIO='133',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_DY79601_1_134">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	extension,
	but it effectively extends the regulatory period during which the FDA cannot approve another application. With regard to patents, the six-month pediatric exclusivity period will not attach
	to any patents for which an ANDA or 505(b)(2) applicant submitted a paragraph&nbsp;IV patent certification, unless the NDA sponsor or patent owner first obtains a court determination that the patent
	if valid and infringed by the proposed product.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Orphan Drug Designation and Exclusivity
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may designate a drug product as an "orphan drug" if it is intended to treat a rare disease or
	condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a
	drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must request orphan drug designation before submitting an
	NDA for the drug and rare disease or condition. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten
	the goal dates under the Prescription Drug User Fee Act, or PDUFA, for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from
	the PDUFA application fee.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare
	disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug
	exclusivity means that the FDA may not approve another sponsor's marketing application for the same drug for the same indication for seven years, except in certain limited circumstances. Orphan
	exclusivity does not block the approval of a different drug for the same rare disease or condition, nor does it block the approval of the same drug for different indications. If a drug designated as
	an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. Orphan exclusivity will
	not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same indication is shown to be clinically superior to the approved product
	on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Patent Term Restoration and Extension
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A patent claiming a new drug product may be eligible for a limited patent term extension, also known as patent term restoration, under
	the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. Patent term extension is generally available
	only for drug products whose active ingredient has not previously been approved by the FDA. The restoration period granted is typically one-half the time between the effective date of an IND and the
	submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date. Patent term extension cannot be used to extend the remaining term of a patent past a
	total of 14&nbsp;years from the product's approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted
	prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The United States PTO
	reviews and approves the application for any patent term extension in consultation with the FDA.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	134
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=137,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=580259,FOLIO='134',FILE='DISK124:[15ZCT1.15ZCT79601]DY79601A.;47',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_135">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	FDA Approval and Regulation of Companion Diagnostics
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If safe and effective use of a therapeutic depends on an
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	diagnostic, then the
	FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued
	final guidance clarifying the requirements that will apply to approval of therapeutic products and
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	companion diagnostics. According to the
	guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the therapeutic
	product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the companion diagnostic device will ensure
	that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	companion
	diagnostics in conjunction with the review of our therapeutic treatments for cancer will, therefore, likely involve coordination of review by the FDA's Center for Drug Evaluation and Research and the
	FDA's Center for Devices and Radiological Health Office of In Vitro Diagnostics Device Evaluation and Safety.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	the FDCA,
</FONT>
<FONT SIZE=2>
<I>
	in vitro
</I>
</FONT>
<FONT SIZE=2>
	diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA
	and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket
	clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an
	exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical
	device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket
	review during which the applicant must prepare and provide the FDA with reasonable assurance of the device's safety and effectiveness and information about the device and its components regarding,
	among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee, which exceeds $250,000 for most PMAs. In addition, PMAs for certain devices must
	generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA
	approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically
	inspect the manufacturer's facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PMA
	approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional
	clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA's evaluation of the PMA application is favorable, the FDA
	typically issues an approvable letter requiring the applicant's agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling,
	in order to secure final approval of the PMA. If the FDA's evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A
	not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional
	clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the
	FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can
	include post-approval
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	135
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=138,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=449079,FOLIO='135',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_136">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	conditions
	that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once
	granted,
	PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following
	initial marketing.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
	a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are
	cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer's manufacturing processes and those of its suppliers are
	required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging
	and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that
	export products to the United States.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Review and Approval of Drugs in Europe and Other Foreign Jurisdictions
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the United States, a manufacturer is subject to a variety of regulations in foreign jurisdictions to the
	extent they choose to sell any drug products in those foreign countries. Even if a manufacturer obtains FDA approval of a product, it must still obtain the requisite approvals from regulatory
	authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. For other countries outside of the European Union, the requirements
	governing the conduct of clinical trials, product licensing, pricing and reimbursement vary.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Clinical Trial Approval in the European Union
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the currently applicable Clinical Trials Directive&nbsp;2001/20/EC and the Directive&nbsp;2005/28/EC on Good Clinical
	Practice, an applicant must obtain the approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. Furthermore, the applicant may only start a
	clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. In April 2014, the European Union adopted a new Clinical Trials Regulation (EU)
	No&nbsp;536/2014, which is set to replace the current Clinical Trials Directive&nbsp;2001/20/EC. The new Clinical Trials Regulation will overhaul the current system of approvals for clinical
	trials in the European Union, and it intended to simplify and streamline the approval of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials,
	the sponsor of a clinical trial will be required to submit a single application for approval of a clinical trial to a reporting EU Member State, or RMS, through an EU Portal. The new Regulation also
	aims to streamline and simplify the rules on safety reporting for clinical trials.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Marketing Authorization and Exclusivity
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the European Union, marketing authorizations for medicinal products may be obtained through different procedures founded on the same
	basic regulatory process. The centralized procedure provides for the grant of a single marketing authorization that is valid for all EU Member States. The centralized procedure is compulsory for
	medicinal products produced by certain biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of certain
	diseases. On the other hand, a decentralized procedure provides for approval by one or more other concerned EU Member States of an assessment of an application for marketing authorization conducted by
	one EU Member State, known as the reference EU Member State. In accordance with the mutual recognition procedure, the sponsor applies for national marketing authorization in one EU Member State. Upon
	receipt of this authorization the sponsor can then seek the recognition of this authorization by other EU Member States.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	136
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=139,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1006956,FOLIO='136',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_137">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the
	competent authority of the relevant EU Member State. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the relevant competent authority of
	the EU Member State decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any marketing authorization that is not followed by the
	marketing of the medicinal product on the EU market (in the case of the centralized procedure) or on the market of the EU Member State which delivered the marketing authorization within three years
	after authorization ceases to be valid.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the European Union, innovative medicinal products authorized in the European Union on the basis of a full marketing authorization are entitled to eight years of data exclusivity.
	During this period, applicants for authorization of generics of these innovative products cannot rely on data contained in the marketing authorization dossier submitted for the innovative medicinal
	product. Innovative medicinal products are also entitled to ten years' market exclusivity. During this ten year period no generic of this medicinal product can be placed on the EU market. The overall
	ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new
	therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Regulatory Requirements after Marketing Authorization
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As in the U.S., both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory
	oversight by the EMA and the competent authorities of the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. The holder of an EU marketing
	authorization for a medicinal product must, for example, comply with EU pharmacovigilance legislation and its related regulations and guidelines which entail many requirements for conducting
	pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the European Union is also highly regulated and regulators
	may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply
	with various requirements set out in the applicable EU laws, including compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the European Union, the advertising and promotion of approved products are subject to EU Member States' laws governing promotion of medicinal products, interactions with physicians,
	misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal
	products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product's Summary of Product Characteristics, or SmPC, as approved by the
	competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion, which is prohibited in the European Union.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Orphan Drug Designation and Exclusivity in the European Union
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the relevant EU Regulations, a product can be designated as an orphan medicinal product by the European Commission if its sponsor
	can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&nbsp;a life-threatening or chronically debilitating condition affecting not more than five in ten
	thousand persons in the European Union when the application is made, or (2)&nbsp;a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without
	incentives the medicinal product is unlikely to be developed. For either of these conditions, the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	137
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=140,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=355705,FOLIO='137',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_138">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	applicant
	must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method
	exists, the medicinal product will be of significant benefit to those affected by that condition. Once authorized, orphan medicinal products are entitled to ten years of market exclusivity in all EU
	Member States, along with a range of other benefits. However, marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more
	effective or otherwise clinically superior to the original orphan medicinal product.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Pharmaceutical Coverage, Pricing and Reimbursement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers
	performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is
	provided and reimbursement is adequate to cover at least a significant portion of the cost of our products. Significant uncertainty exists as to the coverage and reimbursement status of products
	approved by the FDA and other foreign government authorities. Even if our product candidate is approved, sales of our products will depend, in part, on the extent to which third-party payors,
	including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate
	reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate
	that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the
	cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary,
	which might not include all of the approved products for a particular indication.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
	the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be
	considered medically necessary or cost effective. A decision by a third-party payor not to cover our product candidate could reduce physician utilization and/or patient acceptance of our products once
	approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payor's decision to provide coverage for a product does not imply that an
	adequate reimbursement rate will be approved. Further, one payor's determination to provide coverage for a drug product does not assure that other payors will also provide coverage and reimbursement
	for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable us to maintain price
	levels sufficient to realize an appropriate return on our investment in product development.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown
	significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price
	controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company's revenue generated from the sale
	of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for
	which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	138
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=141,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1000573,FOLIO='138',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_139">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside
	the United States, ensuring adequate coverage and payment for our product candidate will face challenges. Pricing of prescription pharmaceuticals is subject to governmental
	control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical
	trial that compares the cost effectiveness of our product candidate or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our
	commercialization efforts.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has
	been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies or so called health
	technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their
	national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may
	instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products,
	but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on
	pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the
	European Union. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of
	new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference
	pricing used by various European Union member states, and parallel trade, i.e.,&nbsp;arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance
	that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in
	those countries.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Healthcare Law and Regulation
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are
	granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of
	payments to physicians and teaching physicians and patient data privacy and security laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial
	arrangements. Restrictions under applicable federal and state healthcare laws and regulations include the following:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the United States federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
	willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase,
	order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which
	prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or
	knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	139
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=142,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=242048,FOLIO='139',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_140">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that
	prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing
	regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, on certain types of people and entities with respect to
	safeguarding the privacy, security and transmission of individually identifiable health information;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and
	Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or collectively the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical
	supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid
	Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching
	hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare
	items or services that are reimbursed by non-governmental third-party payors, including private insurers.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
	state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the
	federal government in addition to requiring drug manufacturers to report information related to payments to certain health care providers or marketing expenditures. State and foreign laws also govern
	the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
	efforts.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Healthcare Reform
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A primary trend in the United States healthcare industry and elsewhere is cost containment. There have been a number of federal and
	state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government
	control and other changes to the healthcare system in the United States.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the United States Congress
	enacted the Affordable Care Act, which, among other things, includes changes to the coverage and payment for products under government health care programs. Among the provisions of the Affordable Care
	Act of importance to our potential drug candidates are:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents,
	apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for
	orphan indications;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain
	individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	140
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=143,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=291244,FOLIO='140',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_141">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expanded manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and
	generic drugs and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate
	liability to prescriptions for individuals enrolled in Medicare Advantage plans;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are
	inhaled, infused, instilled, implanted or injected;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	expansion of the types of entities eligible for the 340B drug discount program;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishment of the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50%
	point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient drugs to be
	covered under Medicare Part&nbsp;D;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
	research, along with funding for such research;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce
	expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation has been not been clearly defined. The Affordable Care Act provided that
	under certain circumstances, IPAB recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to
	lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011
	to 2019.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
	legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. For example, in August 2011, the Budget Control Act of 2011,
	among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion
	for fiscal years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions of
	Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2025 unless
	additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to
	several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three
	to five years. Further, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed drug products. For example, there have been
	several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer
	patient programs, and reform government program reimbursement methodologies for drug products.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and
	containing or lowering the cost of healthcare. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain
	marketing approval and may affect our overall financial condition and ability to develop product candidates.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	141
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=144,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=349392,FOLIO='141',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_142">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_COMPETITION>
<EFX_EMPLOYEES>
<A NAME="FIS_EMPLOYEES"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Employees
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, we had 49 full-time employees, including 25 employees with M.D. or Ph.D. degrees. Of these full-time
	employees, 39 employees are engaged in research and development activities and 10 employees are engaged in general and administrative activities. None of our employees is represented by a labor union
	or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Facilities
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We occupy approximately 21,488 rentable square feet of office and laboratory space in Cambridge, Massachusetts under a lease that
	expires on October&nbsp;31, 2020. We have an option to extend the lease term for five additional years. We believe that this office and laboratory space is sufficient to meet our current needs and
	that suitable additional space will be available as and when needed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Legal
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently party to any legal proceedings.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	142
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=145,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=528722,FOLIO='142',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_143">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_EMPLOYEES>
</EFX_BUSINESS>
<EFX_MANAGEMENT>
<A NAME="FIS_MANAGEMENT"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EA79601_MANAGEMENT">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EA79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	MANAGEMENT
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the name, age as of June&nbsp;15, 2016 and position of each of our executive officers and directors.
</FONT>
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="268PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:21PT;">
<FONT SIZE=1>
<B>
	Name
<!-- COMMAND=ADD_SCROPPEDRULE,21PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Age
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Position
</B>
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Nancy Simonian, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	55
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	President, Chief Executive Officer and Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Kyle D. Kuvalanka
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Chief Operating Officer
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Eric R. Olson, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	58
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Chief Scientific Officer
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	David A. Roth, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	54
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Chief Medical Officer
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Jorge Conde
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Chief Strategy Officer
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	St&eacute;phane Bancel(1)(2)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Marsha H. Fanucci(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Amir Nashat, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Robert Nelsen(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	53
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Sanj K. Patel
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	46
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Vicki L. Sato, Ph.D.(1)(2)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	67
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phillip A. Sharp, Ph.D.(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	71
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Richard A. Young, Ph.D.(2)(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Jonathan Leff(4)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_NAME_AND_TITLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Member
	of compensation committee
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Member
	of nominating and corporate governance committee
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Member
	of audit committee
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(4)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Mr.
	Leff intends to resign from our board of directors, effective as of immediately prior to the effectiveness of the registration statement of which this
	prospectus is a part. He has informed us that his resignation is not due to any disagreement with us or any matter relating to our operations, policies or practices.
</FONT>
</DD>
</DL>
</DIV>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Executive Officers
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Nancy Simonian, M.D.,
</I>
</FONT>
<FONT SIZE=2>
	has been our chief executive officer since July 2012. From 2001 to October 2011, Dr.&nbsp;Simonian was employed by
	Takeda Pharmaceuticals Company, a pharmaceutical company, and at Millennium Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, prior to its acquisition by Takeda, most recently serving as
	chief medical officer and senior vice president of clinical, medical and regulatory affairs. From 1995 to 2001, Dr.&nbsp;Simonian was at Biogen,&nbsp;Inc., a biotechnology company, and most
	recently served as vice president of clinical development. She is a member of the boards of directors of Seattle Genetics,&nbsp;Inc., a biotechnology company, and the Biotechnology Industry
	Organization. Prior to joining the biopharmaceutical industry, Dr.&nbsp;Simonian was on the faculty of Massachusetts General Hospital and Harvard Medical School as an assistant professor of
	neurology. She received a B.A. in biology from Princeton University and an M.D. from the University of Pennsylvania School of Medicine. Our board of directors believes Dr.&nbsp;Simonian is qualified
	to serve on our board because of her role as our chief executive officer, her experience in the biopharmaceutical industry and her other executive leadership and board of directors experience.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Kyle D. Kuvalanka
</I>
</FONT>
<FONT SIZE=2>
	has served as our chief operating officer since September 2015. Prior to joining Syros, Mr.&nbsp;Kuvalanka served as
	chief business officer and principal financial and accounting officer of Blueprint Medicines Corporation, a biopharmaceutical company, from September 2013 to September 2015. From 2002 to September
	2013, Mr.&nbsp;Kuvalanka worked at Takeda and at Millennium prior to its takeover by Takeda, including as vice president, corporate strategy, business development and alliance management from 2009
	to September 2013. Mr.&nbsp;Kuvalanka holds a B.A. from Wesleyan University and an M.B.A. from The Wharton Business School of the University of Pennsylvania.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	143
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=146,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=957796,FOLIO='143',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_144">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Eric R. Olson, Ph.D.,
</I>
</FONT>
<FONT SIZE=2>
	has been our chief scientific officer since April 2013. He previously served as research vice president for
	respiratory diseases at Vertex Pharmaceuticals Incorporated, a biotechnology company, from 2001 to May 2013. Dr.&nbsp;Olson has also held positions as the director of antibacterials and molecular
	sciences departments at Warner-Lambert as well as a research scientist focused on gene expression systems with The Upjohn Company, both of which were acquired by Pfizer, Inc., a
	pharmaceutical company. Dr.&nbsp;Olson received a B.S. in microbiology and immunology from the University of Minnesota and a Ph.D. in microbiology and immunology from the University of Michigan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	David A. Roth, M.D.,
</I>
</FONT>
<FONT SIZE=2>
	has been our chief medical officer since December 2015. Previously, Dr.&nbsp;Roth was employed by Infinity
	Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, from September 2013 until September 2015, serving most recently as its executive vice president and chief medical officer and previously as its
	senior vice president of clinical development and medical affairs. Prior to joining Infinity, Dr.&nbsp;Roth was the vice president, early development in the oncology business unit of
	Pfizer&nbsp;Inc., a pharmaceutical company, from 2009 to August 2013. Prior to joining the pharmaceutical industry, Dr.&nbsp;Roth's experience included over 10&nbsp;years in research and
	clinical practice as an academic hematologist, and he served on the full time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. Dr.&nbsp;Roth received his B.S.
	from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-MIT Division of Health Sciences and Technology, where he remains on the affiliated faculty.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Jorge Conde
</I>
</FONT>
<FONT SIZE=2>
	has been our chief strategy officer since April 2016 and previously served as our chief financial officer and chief product
	officer from May 2014 to May 2016. Prior to joining Syros, from 2007 to May 2014, Mr.&nbsp;Conde served in various roles at Knome,&nbsp;Inc., a genomics company, including founding chief executive
	officer, chief financial officer and chief product officer. Prior to Knome, Mr.&nbsp;Conde worked in marketing and operations at MedImmune,&nbsp;Inc. a biopharmaceutical company which was
	subsequently acquired by AstraZeneca, from 2006 to 2007. He has also worked in the life sciences group at Flagship Ventures and managed the business development function at Helicos Biosciences
	Corporation, a DNA sequencing company. Previously, he was an investment banker at Morgan Stanley&nbsp;&amp; Co. where he advised biotechnology and genomics companies on strategy, M&amp;A and capital
	fundraising. Mr.&nbsp;Conde received a B.A. in biology from Johns Hopkins University, an M.B.A. from Harvard Business School and an M.S. from the Harvard-MIT Division of Health Sciences and
	Technology.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Non-Management Directors
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	St&eacute;phane Bancel
</I>
</FONT>
<FONT SIZE=2>
	has served as a member of our board of directors since November 2013. He has been president and founding
	chief executive officer of Moderna Therapeutics, a biotechnology company since July 2011. Mr.&nbsp;Bancel was previously chief executive officer of bioM&eacute;rieux, a diagnostics company
	from 2006 to July 2011. Prior to his time at bioM&eacute;rieux, Mr.&nbsp;Bancel was managing director of Eli Lilly in Belgium and executive director of global manufacturing strategy and
	supply chain at Eli Lilly in Indianapolis, Indiana. Mr.&nbsp;Bancel serves as a supervisory director of Qiagen&nbsp;N.V., a biotechnology company. Mr.&nbsp;Bancel holds a M.E. from
	&Eacute;cole Central Paris, a M.S. in chemical engineering from the University of Minnesota and an M.B.A. from Harvard Business School. We believe Mr.&nbsp;Bancel is qualified to serve on
	our board because of his experience as a senior executive and his knowledge of our industry.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Marsha&nbsp;H. Fanucci
</I>
</FONT>
<FONT SIZE=2>
	has been a member of our board of directors since October 2015. Since 2009, Ms.&nbsp;Fanucci has been an
	independent consultant. From 2004 through 2009, she served as senior vice president and chief financial officer of Millennium, which was subsequently acquired by Takeda. She previously served in
	various other roles at Millennium, including as vice president, finance and corporate strategy and vice president, corporate development. Ms.&nbsp;Fanucci is a member of the boards of directors of
	Alnylam Pharmaceuticals,&nbsp;Inc., Ironwood Pharmaceuticals,&nbsp;Inc. and Momenta Pharmaceuticals,&nbsp;Inc. She received her B.S. in pharmacy from West Virginia University and her M.B.A.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	144
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=147,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=75608,FOLIO='144',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_145">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	from
	Northeastern University. We believe Ms.&nbsp;Fanucci is qualified to serve on our board of directors due to her expertise with public and financial accounting matters and her experience leading
	financial organizations in biotechnology companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Jonathan Leff
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since January 2016. Mr.&nbsp;Leff is a partner of Deerfield Management
	Company,&nbsp;LP, an investment management firm, and chairman of the Deerfield Institute, a research division of the firm. Prior to joining Deerfield in January 2013, Mr.&nbsp;Leff was with
	Warburg Pincus,&nbsp;LLC for more than 16&nbsp;years where he led the firm's investment efforts in biotechnology and pharmaceuticals. Mr.&nbsp;Leff currently serves on the board of directors of
	AveXis,&nbsp;Inc., a gene therapy biotech company, as well as the boards of directors of several private companies. He also serves on the boards of directors of the Spinal Muscular Atrophy
	Foundation, the Biotechnology Industry Organization, Friends of Cancer Research and the Reagan-Udall Foundation for the Food and Drug Administration, as well as on the board of advisors of Columbia
	University Medical Center. Mr.&nbsp;Leff received his A.B. from Harvard University, and earned his M.B.A. from Stanford University Graduate School of Business. Our board of directors believes
	Mr.&nbsp;Leff is qualified to serve as a director based upon his extensive experience in the pharmaceutical and biotechnology industry, including his almost 20&nbsp;years of experience as a
	director of multiple public and private biotechnology companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Amir Nashat, Ph.D.,
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since January 2016. He is a managing partner at Polaris Partners, a venture
	capital firm, where he has worked since 2002. Dr.&nbsp;Nashat also serves on the board of the Partners Innovation Fund and is a mentor with the Deshpande Center for Technological Innovation at MIT.
	Dr.&nbsp;Nashat serves on the boards of directors of Fate Therapeutics, Inc. and BIND Therapeutics,&nbsp;Inc. Dr.&nbsp;Nashat received a Sc.D. in chemical engineering from the Massachusetts
	Institute of Technology, and an M.S. and B.S. in materials science and mechanical engineering from the University of California, Berkeley. We believe Dr.&nbsp;Nashat is qualified to serve on our
	board of directors because of his experience on the boards of directors of other publicly traded companies and his experience as an investor in biotechnology and life sciences companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Robert Nelsen
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since our inception in November 2011. He currently serves as our lead independent
	director. Mr.&nbsp;Nelsen was a co-founder of ARCH Venture Partners, a venture capital firm, and has served in various capacities for ARCH and affiliated entities since 1986. He
	is currently a managing director of ARCH Venture Corporation. Mr.&nbsp;Nelsen is a director of Agios Pharmaceuticals,&nbsp;Inc., Bellerophon Therapeutics,&nbsp;Inc., Juno
	Therapeutics,&nbsp;Inc. and Sage Therapeutics,&nbsp;Inc., as well as a director of various private companies. Mr.&nbsp;Nelsen also serves as a trustee of the Fred Hutchinson Cancer Research
	Institute, a trustee of the Institute for Systems Biology, and a director of the National Venture Capital Association. Mr.&nbsp;Nelsen received a B.S. with majors in biology and economics from the
	University of Puget Sound and an M.B.A. from the University of Chicago. We believe Mr.&nbsp;Nelsen is qualified to serve on our board of directors due to his extensive experience as an investor in,
	and director of, early stage biopharmaceutical and life sciences companies.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Sanj K. Patel
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since May 2016. Mr.&nbsp;Patel is the founder, chief executive officer and chairman
	of Kiniksa Pharmaceuticals, Ltd., a biotechnology company. Before founding Kiniksa in June 2015, Mr.&nbsp;Patel was the president and chief executive officer and a director of Synageva BioPharma
	Corp., a pharmaceutical company, now a subsidiary of Alexion, from June 2008 to June 2015. From 1999 to 2008, Mr.&nbsp;Patel worked at Genzyme Corp., a biotechnology company, where most recently he
	was the head of U.S. sales, marketing and commercial operations for Genzyme Therapeutics' Lysosomal Storage Disorder franchise. Previously, Mr.&nbsp;Patel held several cross-functional senior
	leadership roles at Genzyme, including vice president, clinical research and head of the Global Clinical Research Operations Council. Prior to Genzyme, Mr.&nbsp;Patel held roles in clinical research
	and commercial development with increasing levels of responsibility at Burroughs Wellcome, a private foundation; Hoechst Marrion Roussel, a life sciences company; and Fujisawa Pharmaceuticals, a
	pharmaceutical company. Mr.&nbsp;Patel is a member of the board of directors of BioCryst
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	145
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=148,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=294938,FOLIO='145',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_146">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Pharmaceuticals,&nbsp;Inc.,
	a biotechnology company. Mr.&nbsp;Patel obtained his B.Sc. with honors in biotechnology from the University of the South Bank, London. He completed his post-graduate
	management and business degree, and doctorate level research program at Ealing College, London, and the Wellcome Foundation, respectively. Our board of directors believes that Mr.&nbsp;Patel is
	qualified to serve as a director based on his extensive healthcare industry leadership experience.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Vicki L. Sato, Ph.D.,
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since August 2013. She has been a professor of management practice at Harvard
	Business School since September 2006 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. She was previously president of
	Vertex. Dr.&nbsp;Sato is a member of the boards of directors of Bristol Myers Squibb Company, PerkinElmer Corporation and BorgWarner,&nbsp;Inc. Prior to becoming president of Vertex, she was the
	chief scientific officer and senior vice president of research and development. She joined Vertex in 1992, after serving as vice president of research at Biogen&nbsp;Inc., a biotechnology company.
	Dr.&nbsp;Sato received her A.B. from Radcliffe College and her&nbsp;A.M. and Ph.D. degrees from Harvard University. She conducted her postdoctoral work at both the University of California
	Berkeley and Stanford Medical Center. We believe Dr.&nbsp;Sato is qualified to serve on our board of directors because of her experience as a senior executive and as a director of several life
	sciences companies, and because of her knowledge of our industry.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Phillip A. Sharp, Ph.D.,
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since December 2012. Dr.&nbsp;Sharp has been an institute professor at the
	Massachusetts Institute of Technology since 1999. Much of Dr.&nbsp;Sharp's scientific work has been conducted at MIT's Center for Cancer Research (now the Koch Institute), which he joined in 1974
	and directed from 1985 to 1991. He subsequently led the Department of Biology from 1991 to 1999 before assuming the directorship of the McGovern Institute from 2000 to 2004. Dr.&nbsp;Sharp is the
	winner of the 1993 Nobel Prize in Physiology or Medicine. Dr.&nbsp;Sharp has served on the board of directors of Alnylam Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, since 2002. He
	earned his B.A. from Union College in 1966 and a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana in 1969. He did his postdoctoral training at the California Institute of
	Technology. We believe Dr.&nbsp;Sharp is qualified to serve on our board of directors due to his scientific expertise and his experience as a director of a publicly traded company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<I>
	Richard A. Young, Ph.D.,
</I>
</FONT>
<FONT SIZE=2>
	has served on our board of directors since our inception in November 2011. He is also one of our scientific
	co-founders and a member of our scientific advisory board. He has been a member of the Whitehead Institute and professor of Biology at the Massachusetts Institute of Technology since 1984. In May
	2012, he was elected into the National Academy of Sciences. Dr.&nbsp;Young has served as an advisor to
</FONT>
<FONT SIZE=2>
<I>
	Science
</I>
</FONT>
<FONT SIZE=2>
	magazine and the World Health
	Organization. Dr.&nbsp;Young received his Ph.D. in molecular biophysics and biochemistry from Yale University. We believe Dr.&nbsp;Young is qualified to serve on our board of directors because of
	his scientific expertise and his role as one of our scientific co-founders.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Board Composition and Election of Directors
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Board Composition
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors currently consists of seven members. Our directors hold office until their successors have been elected and
	qualified or until the earlier of their resignation or removal.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	directors were elected to and currently serve on the board of directors pursuant to a voting agreement among us and our stockholders. This agreement will terminate upon the closing
	of this offering, after which there will be no further contractual obligations regarding the election of our directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	accordance with the terms of our restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering, our board of
	directors will be
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	146
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=149,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1039864,FOLIO='146',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_147">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	divided
	into three classes, class&nbsp;I, class&nbsp;II and class&nbsp;III, with members of each class serving staggered three-year terms. Upon the closing of this offering, the members of the
	classes will be divided as follows:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the class&nbsp;I directors will be St&eacute;phane Bancel, Amir Nashat, Ph.D., and Robert Nelsen, and their term will expire
	at the first annual meeting of stockholders held after the closing of this offering;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the class&nbsp;II directors will be Vicki&nbsp;L. Sato, Ph.D., Phillip&nbsp;A. Sharp, Ph.D. and Richard&nbsp;A. Young, Ph.D.,
	and their term will expire at the second annual meeting of stockholders held after the closing of this offering; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the class&nbsp;III directors will be Marsha&nbsp;H. Fanucci, Sanj&nbsp;K. Patel and Nancy Simonian,&nbsp;M.D. and their term
	will expire at the third annual meeting of stockholders held after the closing of this offering.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering provide that the authorized number of directors may
	be changed only by resolution of our board of directors. Our restated certificate of incorporation and amended and restated bylaws will also provide that our directors may be removed only for cause by
	the affirmative vote of the holders of 75% of our shares of capital stock present in person or by proxy and entitled to vote, and that any vacancy on our board of directors, including a vacancy
	resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Director Independence
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicable NASDAQ Stock Market, or NASDAQ, rules require a majority of a listed company's board of directors to be comprised of
	independent directors within one year of listing. In addition, the NASDAQ rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and
	corporate governance committees be independent under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Audit committee members must also satisfy the independence criteria set forth
	in Rule&nbsp;10A-3 under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule&nbsp;10C-1 under the Exchange Act and be a non-employee
	member of our board of directors as defined in Rule&nbsp;16b-3 under the Exchange Act. Under applicable NASDAQ rules, a director will only qualify as an "independent director" if, in the opinion of
	the listed company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In
	order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee,
	the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or
	otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule&nbsp;10C-1, the board must consider, for each member of
	a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director's ability to be
	independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting
	advisory or other compensatory fee paid by such company to the director; and whether the director is affiliated with the company or any of its subsidiaries or affiliates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors
	has determined that each of St&eacute;phane Bancel, Marsha&nbsp;H. Fanucci, Amir Nashat, Robert Nelsen, Sanj K. Patel, Vicki&nbsp;L. Sato, Ph.D., Phillip&nbsp;A. Sharp, Ph.D. and
	Richard&nbsp;A. Young, Ph.D. is an "independent director" as defined under applicable NASDAQ rules. In making such determination, our board of
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	147
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=13,SEQ=150,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=805907,FOLIO='147',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EA79601_1_148">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	directors
	considered the relationships that each such non-employee director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or
	her independence, including the beneficial ownership of our capital stock by each non-employee director. Dr.&nbsp;Simonian is not deemed to be an independent director under these rules because she
	is our president and chief executive officer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
	are no family relationships among any of our directors or executive officers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Board Committees
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance
	committee. Each of these committees will operate under a charter that has been approved by our board of directors. The composition of each committee will be effective as of the date of this
	prospectus.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Audit Committee
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Marsha&nbsp;H. Fanucci, Robert Nelsen and Richard&nbsp;A. Young, Ph.D., and
	Ms.&nbsp;Fanucci is the chair of the audit committee. Effective at the time of this offering, our audit committee's responsibilities will include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	appointing, approving the compensation of, and assessing the independence of our registered public accounting firm;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports
	from that firm;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial
	statements and related disclosures;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	overseeing our internal audit function, if any;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	overseeing our risk assessment and risk management policies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt
	and retention of accounting related complaints and concerns;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	meeting independently with our internal auditing staff, if any, our independent registered public accounting firm and management;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and approving or ratifying any related person transactions; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	preparing the audit committee report required by Securities and Exchange Commission, or SEC, rules.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
	audit and non-audit services, other than
</FONT>
<FONT SIZE=2>
<I>
	de minimis
</I>
</FONT>
<FONT SIZE=2>
	non-audit services, to be provided to us by our independent registered public
	accounting firm must be approved in advance by our audit committee.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	December 2015, our board of directors determined that Ms.&nbsp;Fanucci and Mr.&nbsp;Nelsen satisfy the independence criteria for audit committee members set forth in
	Rule&nbsp;10A-3 under the Exchange Act. Dr.&nbsp;Young is not an independent director for the purpose of membership in our audit committee under Rule&nbsp;10A-3 because he receives consulting
	fees from us.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	148
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=14,SEQ=151,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=484460,FOLIO='148',FILE='DISK124:[15ZCT1.15ZCT79601]EA79601A.;96',USER='CHE107927',CD='18-JUN-2016;12:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_149">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under applicable NASDAQ rules, we are permitted to phase-in our compliance with the independence requirements for our audit committee. The phase-in periods with
	respect to director independence allow us to have only one independent member on our audit committee upon the listing date of our common stock, a majority of independent members on our audit committee
	within 90&nbsp;days of the listing date and a fully independent audit committee within one year of the listing date. We are taking advantage of these phase-in rules with respect to
	Dr.&nbsp;Young's service on our audit committee, and we expect that by the first anniversary of our listing on The NASDAQ Global Market, our audit committee will comply with the applicable
	independence requirements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	board of directors has determined that Marsha H. Fanucci is an "audit committee financial expert" as defined in applicable SEC rules and that each of the members of our audit
	committee possesses the financial sophistication required for audit committee members under NASDAQ rules.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Compensation Committee
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our compensation committee are Phillip A. Sharp, Ph.D., St&eacute;phane Bancel and Vicki L. Sato, Ph.D., and Dr.
	Sharp is the chair of the compensation committee. Effective at the time of this offering, our compensation committee's responsibilities will include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our chief executive
	officer and our other executive officers;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	overseeing an evaluation of our senior executives;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	overseeing and administering our cash and equity incentive plans;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and making recommendations to our board of directors with respect to director compensation and management succession
	planning;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and discussing annually with management our "Compensation Discussion and Analysis" disclosure if and to the extent then
	required by SEC rules; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	preparing the compensation committee report if and to the extent then required by SEC rules.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe that the members of our compensation committee meet the requirements for independence under Rule&nbsp;10C-1 under the Exchange Act and the criteria to be non-employee
	directors as defined in Rule&nbsp;16b-3 under the Exchange Act and outside directors as defined in Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Nominating and Corporate Governance Committee
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are Vicki L. Sato, Ph.D., St&eacute;phane Bancel and Richard
	A. Young, Ph.D., and Dr. Sato is the chair of the nominating and corporate governance committee. Effective at the time of this offering, our nominating and corporate governance committee's
	responsibilities will include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	identifying individuals qualified to become members of our board of directors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	recommending to our board of directors the persons to be nominated for election as directors and to each of our board's committees;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and making recommendations to our board of directors with respect to our board leadership structure and board committee
	structure;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	making recommendations to our board of directors with respect to accepting director resignations;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	149
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=152,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1037293,FOLIO='149',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_150">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reviewing and making recommendations to our board of directors with respect to management succession planning;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	developing and recommending to our board of directors corporate governance principles; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	overseeing an annual evaluation of our board of directors and an annual review of succession planning for senior executives.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	believe that the composition of our nominating and corporate governance committee will meet the requirements for independence under current NASDAQ and SEC rules and regulations.
</FONT>
</P>
<EFX_COMMITTEE_INTERLOCKS>
<A NAME="FIS_COMMITTEE_INTERLOCKS"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Compensation Committee Interlocks and Insider Participation
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee,
	or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None
	of the members of our compensation committee is, or has ever been, an officer or employee of our company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Code of Business Conduct and Ethics
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the closing of this offering, we will adopt a written code of business conduct and ethics that applies to our directors,
	officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Following this
	offering, we will post a copy of the code on the Corporate Governance section of our website, which is located at www.syros.com. Our board of directors will be responsible for overseeing the code of
	business conduct and ethics and must approve any waivers of the code for directors, officers and employees. If we make any substantive amendments to, or grant any waivers from, the code of business
	conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	150
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=153,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=954839,FOLIO='150',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_151">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_COMMITTEE_INTERLOCKS>
</EFX_MANAGEMENT>
<EFX_EXECUTIVE_COMPENSATION>
<A NAME="FIS_EXECUTIVE_COMPENSATION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EC79601_EXECUTIVE_COMPENSATION">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EC79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXECUTIVE COMPENSATION
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers in
	2014 and 2015. Our named executive officers for 2015 are Nancy Simonian, M.D., Kyle&nbsp;D. Kuvalanka and David&nbsp;A. Roth,&nbsp;M.D. This section also provides qualitative information
	regarding the manner and context in which compensation is awarded to and earned by our executive officers and is intended to place in perspective the data presented in the tables and narrative that
	follow.
</FONT>
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Summary Compensation Table
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers during
	2014 and 2015.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:57%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="140%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="67PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:102PT;">
<FONT SIZE=1>
<B>
	Name and Principal Position
<!-- COMMAND=ADD_SCROPPEDRULE,102PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Salary
<BR>
	($)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Bonus
<BR>
	($)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Option
<BR>
	Awards
<BR>
	($)(1)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	All Other
<BR>
	Compensation
<BR>
	($)(2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
<BR>
	($)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	Nancy Simonian, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	425,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	723,248
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	270
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,148,518
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	President&nbsp;and&nbsp;Chief&nbsp;Executive
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2014
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	425,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43,540
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	263
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	468,803
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	Officer(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Kyle&nbsp;D. Kuvalanka(4)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	106,692
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	122,500
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,262,638
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	68
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,491,898
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Chief Operating Officer
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	David A. Roth, M.D.(5)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26,064
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,437,272
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,463,336
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	Chief Medical Officer
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_COMPENSATION_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of stock-based compensation awarded during the year computed
	in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification, or ASC, Topic 718. Unlike the calculations contained in our consolidated financial
	statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the named executive officer will perform the requisite service for
	the award to vest in full. See Note&nbsp;11 to our financial statements included elsewhere in this prospectus regarding assumptions underlying the valuation of equity awards.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	amounts reported in the "All Other Compensation" column reflect, for each named executive officer, the cost to us of life insurance premiums paid for
	the named executive officer.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Dr.&nbsp;Simonian
	also serves as a member of our board of directors but does not receive any additional compensation for her service as a director.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(4)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Mr.&nbsp;Kuvalanka
	commenced employment with us on September&nbsp;21, 2015. Amounts shown represent compensation, including a sign-on bonus, earned by
	Mr.&nbsp;Kuvalanka during that partial year of employment.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(5)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Dr.&nbsp;Roth
	commenced employment with us on December&nbsp;7, 2015. Amounts shown represent compensation earned by Dr.&nbsp;Roth during that partial
	year of employment.
</FONT>
</DD>
</DL>
</DIV>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Narrative to Summary Compensation Table
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2014 and 2015, we paid a base salary of $425,000 to Dr.&nbsp;Simonian. Mr.&nbsp;Kuvalanka commenced employment with us in
	September 2015. In 2015, we paid him a base salary of $106,692 for his partial year of employment, and his annualized base salary was $380,000. Dr.&nbsp;Roth commenced employment with us in December
	2015. In 2015, we paid him a base salary of $26,064 for his partial year of employment, and his annualized base salary was $380,000. We use base salaries to recognize the experience, skills, knowledge
	and responsibilities required of all our employees, including our named
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	151
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=154,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=765846,FOLIO='151',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_152">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	executive
	officers. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base
	salary.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	do not have a formal performance-based bonus plan. Our offer letters with our executive officers provide that they will be eligible for annual performance-based bonuses up to a
	specific percentage of their salary, subject to approval by our board of directors. No such bonuses were paid in 2014. In 2015, we paid a sign-on bonus of $122,500 to Mr.&nbsp;Kuvalanka.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2015, we also made equity incentive grants to our executive officers, including Dr.&nbsp;Simonian, Mr.&nbsp;Kuvalanka and Dr.&nbsp;Roth. Dr.&nbsp;Simonian was granted three
	options to purchase up to 100,368, up to 43,048 and up to 43,047 shares of common stock, respectively. The first and second grants will vest as to 25% of the shares on February&nbsp;5, 2016 and
	June&nbsp;9, 2016, respectively, with the remaining shares vesting in equal monthly installments thereafter through February&nbsp;5, 2019 and June&nbsp;9, 2019, respectively.
	Dr.&nbsp;Simonian's third grant vests upon the achievement of performance-based criteria, with 50% of the shares vesting upon the closing of this offering and the remaining 50% of the shares vesting
	upon the earlier to occur of clinical proof-of-concept studies for a company drug candidate and a significant development or partnership deal, in each case as determined by our board of directors, and
	in any event will vest in full on June&nbsp;9, 2021. Mr.&nbsp;Kuvalanka was granted two options to purchase up to 189,252 and up to 68,819 shares of common stock, respectively. The first grant
	will vest as to 25% of the shares on September&nbsp;21, 2016, with the remaining shares vesting in equal monthly installments thereafter through September&nbsp;21, 2019. Mr.&nbsp;Kuvalanka's
	second grant vests upon the achievement of performance-based criteria, with 40% of the shares vesting upon the closing of this offering, 40% vesting upon the execution by us of a collaboration
	agreement and 20% of the shares vesting upon clinical proof-of-concept for a company drug candidate, in each case as determined by our board of directors, and in any event will vest in full on
	September&nbsp;21, 2021. Dr.&nbsp;Roth was granted two options to purchase up to 172,047 and up to 51,614 shares of common stock, respectively. The first grant will vest as to 25% of the shares on
	December&nbsp;7, 2016, with the remaining shares vesting in equal monthly installments thereafter through December&nbsp;7, 2019. Dr.&nbsp;Roth's second grant vests upon the achievement of
	performance-based criteria, with 75% of the shares vesting upon clinical proof-of-concept for a company drug candidate and 25% of the shares vesting upon execution by us of a collaboration agreement,
	in each case as determined by our board of directors, and in any event will vest in full on December&nbsp;7, 2021.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
	we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, or any formal equity ownership guidelines applicable to them, we
	believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders.
	In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incents our executive officers to remain in our employment during the
	vesting period, and equity grants with a performance-based feature incents our executive officers to focus on what we see as key business goals. Accordingly, our board of directors periodically
	reviews the equity incentive compensation of our
	named executive officers and from time to time may grant equity incentive awards to them in the form of stock options.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	152
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=155,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=95880,FOLIO='152',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_153">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Outstanding Equity Awards at Fiscal Year End
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding equity awards held by our named executive officers as of
	December&nbsp;31, 2015, which consisted entirely of stock options:
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:67%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="120%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="98PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="98PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:21PT;">
<FONT SIZE=1>
<B>
	Name
<!-- COMMAND=ADD_SCROPPEDRULE,21PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of Securities
<BR>
	Underlying
<BR>
	Unexercised
<BR>
	Options
<BR>
	Exercisable
<BR>
	(#)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of Securities
<BR>
	Underlying
<BR>
	Unexercised
<BR>
	Options
<BR>
	Unexercisable
<BR>
	(#)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Option
<BR>
	Exercise
<BR>
	Price
<BR>
	($/share)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Option
<BR>
	Expiration
<BR>
	Date
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	Nancy Simonian, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	46,906
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	54,724
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.01
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5/21/2023
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	37,525
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	75,050
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.01
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5/21/2023
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	6,250
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	13,750
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10/21/2024
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	100,368
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2/4/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	43,048
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6/8/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	43,047
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.04
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6/8/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Kyle&nbsp;D. Kuvalanka
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	189,252
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(7)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9/20/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	68,819
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(8)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9/20/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
	David A. Roth, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	172,047
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(9)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12/22/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	51,614
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12/22/2025
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
</EFX_UNIDENTIFIED_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on May&nbsp;22, 2013 and vested as to 25% of the shares on July&nbsp;2, 2013 with the remaining shares vesting in equal monthly
	installments thereafter through July&nbsp;2, 2016.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on May&nbsp;22, 2013 and vests upon the achievement of performance-based criteria, and in any event will vest in full on
	July&nbsp;2, 2018.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on October&nbsp;22, 2014 and vested as to 25% of the shares on September&nbsp;29, 2015 with the remaining shares vesting in
	equal monthly installments thereafter through September&nbsp;29, 2018.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(4)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on February&nbsp;5, 2015 and vested as to 25% of the shares on February&nbsp;5, 2016 with the remaining shares vesting in equal
	monthly installments thereafter through February&nbsp;5, 2019.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(5)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on June&nbsp;9, 2015 and vests as to 25% of the shares on June&nbsp;9, 2016 with the remaining shares vesting in equal monthly
	installments thereafter through June&nbsp;9, 2019.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(6)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on June&nbsp;9, 2015 and vests upon the achievement of performance-based criteria, and in any event will vest in full on
	June&nbsp;9, 2021.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(7)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on September&nbsp;21, 2015 and vests as to 25% of the shares on September&nbsp;21, 2016 with the remaining shares vesting in
	equal monthly installments thereafter through September&nbsp;21, 2019.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(8)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on September&nbsp;21, 2015 and vests upon the achievement of performance-based criteria, and in any event will vest in full on
	September&nbsp;21, 2021.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(9)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on December&nbsp;23, 2015 and vests as to 25% of the shares on December&nbsp;7, 2016 with the remaining shares vesting in equal
	monthly installments thereafter through December&nbsp;7, 2019.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(10)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	This
	option was granted on December&nbsp;23, 2015 and vests upon the achievement of performance-based criteria, and in any event will vest in full on
	December&nbsp;7, 2021.
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	153
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=156,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=98347,FOLIO='153',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_154">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Employment and Change in Control Arrangements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into written offer letters with each of our named executive officers. These agreements set forth the terms of the named
	executive officer's compensation, including his or her initial base salary, severance and annual cash bonus opportunity. In addition, the agreements provide that the named executive officers are
	eligible to participate in company-sponsored benefit programs that are available generally to all of our employees. In connection with the commencement of their employment with us, our named executive
	officers executed our standard invention and non-disclosure agreement and non-competition and non-solicitation agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	offer letter with Dr.&nbsp;Simonian provides that she is eligible to receive an annual incentive bonus equal to 50% of her then-current salary, subject to the terms of the
	applicable bonus plans approved by our board of directors. Dr.&nbsp;Simonian's offer letter also provides that if her employment is terminated by us without cause, or by her with good reason, as
	such terms are defined in her offer letter, she will receive monthly severance payments equal to her then-current monthly salary rate for 12&nbsp;months and payment of an incentive bonus pro-rated
	for the portion of the then-current calendar year during which she was employed by us, subject to certain conditions. In addition, in the event of a change in control of our company, as defined in the
	offer letter, all unvested stock options then held by Dr.&nbsp;Simonian will vest in full 12&nbsp;months after the change in control, or earlier if her employment is terminated by us without cause
	or by her for good reason in contemplation of, pursuant to or following a change in control, referred to as the CIC Equity Vesting.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	offer letter with each of Mr.&nbsp;Kuvalanka and Dr.&nbsp;Roth provides that if his employment is terminated by us without cause, or by him with good reason, as such terms are
	defined in his offer letter, he will receive monthly severance payments equal to his then-current monthly rate of salary for nine months, subject to certain conditions. Mr.&nbsp;Kuvalanka and
	Dr.&nbsp;Roth are also eligible for the CIC Equity Vesting.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Equity Compensation Plans
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The three equity incentive plans described in this section are our 2012 Equity Incentive Plan, as amended to date, or the 2012 plan,
	our 2016 Stock Incentive Plan, or the 2016 plan, and our 2016 Employee Stock Purchase Plan, or the 2016 ESPP. Prior to this offering, we granted awards to eligible participants under the 2012 plan.
	Following the effectiveness of this registration statement, we expect to grant awards to eligible participants only under the 2016 plan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	2012 Equity Incentive Plan
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2012 plan was adopted by our board of directors and approved by our stockholders in August 2012. The 2012 plan provides for the
	grant of incentive stock options, nonstatutory stock options, stock appreciation rights, awards of restricted stock, restricted stock units, other stock-based awards and cash-based awards. Our
	employees, officers, directors, consultants and advisors are eligible to receive awards under our 2012 plan; however, incentive stock options may only be granted to our employees. A maximum of
	2,749,681 shares of our common stock are authorized for issuance under the 2012 plan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	type of award granted under our 2012 plan and the terms of such award are set forth in the applicable award agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the terms of the 2012 plan, our board of directors (or a committee delegated by our board of directors) administers the plan and, subject to any limitations set forth in the
	plan, selects the recipients of awards and determines:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares of our common stock covered by options and the dates upon which the options become exercisable;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	154
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=157,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1038820,FOLIO='154',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_155">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the type of options to be granted;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the duration of options, which may not be in excess of ten years;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the exercise price of options, which price must be at least equal to the fair market value of our common stock on the date of grant;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the methods of payment of the exercise price of options; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares of our common stock subject to any stock appreciation rights, awards of restricted stock, restricted stock units
	or other stock-based awards and the terms and conditions of such awards and of any cash-based awards, including conditions for repurchase, measurement price, issue price and repurchase price and
	performance conditions (though the measurement price of stock appreciation rights must be at least equal to the fair market value of our common stock on the date of grant and the duration of such
	awards may not be in excess of ten years), if any.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	our board of directors delegates authority to an executive officer to grant awards under the 2012 plan, the executive officer will have the power to make awards to all of our
	employees, except executive officers. Our board of directors will fix the terms of the awards to be granted by such executive officer,
	including the exercise price of such awards (or a formula for establishing such price), and the maximum number of shares subject to awards that such executive officer may make.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in
	capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, we are required by the 2012 plan to make equitable adjustments (or make
	substitute awards, if applicable), in a manner determined by our board, to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number and class of securities available under the 2012 plan;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number and class of securities and exercise price per share of each outstanding option;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the share and per-share provisions and measurement price of each outstanding stock appreciation right;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares and repurchase price per share subject to, each outstanding restricted stock award or restricted stock unit
	award; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the share and per-share related provisions and purchase price, if any, of each outstanding other stock-based award.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	a merger or other reorganization event (as defined in the 2012 plan), our board of directors may, on such terms as our board determines (except to the extent specifically provided
	otherwise in an applicable award agreement or other agreement between the participant and us), take any one or more
	of the following actions pursuant to the 2012 plan as to all or any (or any portion of) outstanding awards other than awards of restricted stock:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that all outstanding awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or
	successor corporation (or an affiliate thereof);
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	upon written notice to a participant, provide that all of the participant's vested but unexercised awards will terminate immediately
	prior to the consummation of such reorganization event unless exercised by the participant;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award will lapse,
	in whole or in part, prior to or upon such reorganization event;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	155
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=158,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=676427,FOLIO='155',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_156">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	in the event of a reorganization event pursuant to which holders of shares of our common stock will receive a cash payment for each
	share surrendered in the reorganization event, make or provide for a cash payment to the participants with respect to each award held by a participant equal to (1)&nbsp;the number of shares of our
	common stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by
	(2)&nbsp;the excess, if any, of the cash payment for each share surrendered in the reorganization event over the exercise, measurement or purchase price of such award and any applicable tax
	withholdings, in exchange for the termination of such award;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that, in connection with our liquidation or dissolution, awards will convert into the right to receive liquidation proceeds
	(if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings); or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	any combination of the foregoing.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	board of directors is not obligated by the 2012 plan to treat all awards, all awards held by a participant, or all awards of the same type, identically.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the case of certain restricted stock units that are subject to Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, or the Code, no assumption or substitution is
	permitted, and the restricted stock units will instead be settled in accordance with the terms of the applicable restricted stock unit agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	the occurrence of a reorganization event other than our liquidation or dissolution, the repurchase and other rights with respect to outstanding awards of restricted stock will
	continue for the benefit of the successor company and will, unless our board of directors may otherwise determine, apply to the cash, securities or other property which our common stock is converted
	into or exchanged for pursuant to the reorganization event. However, our board of directors may provide for the termination or deemed satisfaction of such repurchase or other rights under the
	restricted stock award agreement or any other agreement between the participant and us, either initially or by amendment. Upon the occurrence of a reorganization event involving our liquidation or
	dissolution, all restrictions and conditions on each outstanding restricted stock award will automatically be deemed terminated or satisfied, unless otherwise provided in the agreement evidencing the
	restricted stock award or in any other agreement between the participant and us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	board of directors may, at any time, provide that any award under the 2012 plan will become immediately exercisable in whole or in part, free of some or all restrictions or
	conditions, or otherwise realizable in whole or in part, as the case may be.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, there were options to purchase 2,005,912 shares of our common stock outstanding under the 2012 plan, at a weighted-average exercise price of $4.76 per share.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	award may be granted under the 2012 plan on or after the effectiveness of the registration statement for this offering. Our board of directors may amend, suspend or terminate the 2012
	plan at
	any time, except that stockholder approval may be required to comply with applicable law or stock market requirements.
</FONT>
</P>
<EFX_STOCK_PLANS>
<A NAME="FIS_STOCK_PLANS"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	2016 Stock Incentive Plan
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has adopted, and our stockholders have approved, the 2016 plan, which will become effective immediately prior to
	the effectiveness of the registration statement for this offering. The 2016 plan will provide for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, awards of
	restricted stock, restricted stock units and other stock-based awards. Upon effectiveness of the 2016 plan, the number of shares of our common stock that will be reserved
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	156
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=159,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=780558,FOLIO='156',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EC79601_1_157">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	for issuance under the 2016 plan will be the sum of (1)&nbsp;3,120,000 shares plus; (2)&nbsp;the number of shares reserved for issuance (up to 2,112,203 shares) equal to the sum of the number of
	shares of our common stock then available for issuance under the 2012 plan and the number of shares of our common stock subject to outstanding awards under the 2012 plan that expire, terminate or are
	otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right; plus (3)&nbsp;an annual increase, to be added the first
	day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2017 and continuing until, and including, the fiscal year ending December&nbsp;31, 2026, equal to the lowest of
	1,600,000 shares of our common stock, 4.0% of the number of shares of our common stock outstanding on the first day of the fiscal year and an amount determined by our board of directors. Our
	employees, officers, directors, consultants and advisors will be eligible to receive awards under the 2016 plan; however, incentive stock options may only be granted to our employees.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to the terms of the 2016 plan, our board of directors (or a committee delegated by our board of directors) administers the plan and, subject to any limitations set forth in the
	plan, will select the recipients of awards and determine:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares of our common stock covered by options and the dates upon which those options become exercisable;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the type of options to be granted;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the duration of options, which may not be in excess of ten years;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the exercise price of options, which price must be at least equal to the fair market value of our common stock on the date of grant;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the methods of payment of the exercise price of options; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares of our common stock subject to and the terms and conditions of any stock appreciation rights, awards of
	restricted stock, restricted stock units or other stock-based awards, including conditions for repurchase, measurement price, issue price and repurchase price and performance conditions (though the
	measurement price of stock appreciation rights must be at least equal to the fair market value of our common stock on the date of grant and the duration of such awards may not be in excess of ten
	years), if any.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	our board of directors delegates authority to an executive officer to grant awards under the 2016 plan, the executive officer will have the power to make awards to all of our
	employees, except executive officers. Our board of directors will fix the terms of the awards to be granted by such executive officer, including the exercise price of such awards (or a formula for
	establishing such price), and the maximum number of shares subject to awards that such executive officer may make.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in
	capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, we are
	required by the 2016 plan to make equitable adjustments (or make substitute awards, if applicable), in a manner determined by our board, to:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number and class of securities available under the 2016 plan;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the share counting rules under the 2016 plan;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number and class of securities and exercise price per share of each outstanding option;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the share and per-share provisions and measurement price of each outstanding stock appreciation right;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	157
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=160,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=631597,FOLIO='157',FILE='DISK124:[15ZCT1.15ZCT79601]EC79601A.;81',USER='PANDERS',CD='18-JUN-2016;14:07' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_158">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the number of shares and repurchase price per share subject to each outstanding restricted stock award or restricted stock unit award;
	and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the share and per-share related provisions and purchase price, if any, of each outstanding other stock-based award.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	a merger or other reorganization event (as defined in our 2016 plan), our board of directors, may, on such terms as our board determines (except to the extent specifically provided
	otherwise in an applicable award agreement or other agreement between the participant and us), take any one or more
	of the following actions pursuant to the 2016 plan, as to all or any (or any portion of) outstanding awards, other than awards of restricted stock:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that all outstanding awards will be assumed or substantially equivalent awards will be substituted by the acquiring successor
	corporation (or an affiliate thereof);
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	upon written notice to a participant, provide that all of the participant's unvested and/or unexercised awards will terminate
	immediately prior to the consummation of such reorganization event unless exercised by the participant;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award will lapse,
	in whole or in part, prior to or upon such reorganization event;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	in the event of a reorganization event pursuant to which holders of shares of our common stock will receive a cash payment for each
	share surrendered in the reorganization event, make or provide for a cash payment to the participants with respect to each award held by a participant equal to (1)&nbsp;the number of shares of our
	common stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by
	(2)&nbsp;the excess, if any, of the cash payment for each share surrendered in the reorganization event over the exercise, measurement or purchase price of such award and any applicable tax
	withholdings, in exchange for the termination of such award;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that, in connection with our liquidation or dissolution, awards will convert into the right to receive liquidation proceeds
	(if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings); or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	any combination of the foregoing.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	board of directors is not obligated by the 2016 plan to treat all awards, all awards held by a participant, or all awards of the same type, identically.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the case of certain restricted stock units, no assumption or substitution is permitted, and the restricted stock units will instead be settled in accordance with the terms of the
	applicable restricted stock unit agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	the occurrence of a reorganization event other than our liquidation or dissolution, the repurchase and other rights with respect to outstanding awards of restricted stock will
	continue for the benefit of the successor company and will, unless our board of directors may otherwise determine, apply to the cash, securities or other property which our common stock is converted
	into or exchanged for pursuant to the reorganization event. However, our board of directors may provide for the termination or deemed satisfaction of such repurchase or other rights under the
	restricted stock award agreement or any other agreement between the participant and us, either initially or by amendment. Upon the occurrence of a reorganization event involving our liquidation or
	dissolution, all restrictions and conditions on each outstanding restricted stock award will automatically be deemed terminated or
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	158
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=161,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=850893,FOLIO='158',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_159">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	satisfied,
	unless otherwise provided in the agreement evidencing the restricted stock award or in any other agreement between the participant and us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	board of directors may at any time provide that any award under the 2016 plan will become immediately exercisable in whole or in part, free of some or all restrictions or conditions,
	or otherwise realizable in whole or in part, as the case may be.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
	with respect to certain actions requiring stockholder approval under the Code or NASDAQ rules, our board of directors may amend, modify or terminate any outstanding award under
	the 2016 plan, including but not limited to, substituting therefor another award of the same or a different type, changing the date of exercise or realization, and converting an incentive stock option
	into a nonstatutory stock option, subject to certain participant consent requirements. Unless our stockholders approve such action, the 2016 plan provides that we may not (except as otherwise
	permitted in connection with a change in capitalization or reorganization event):
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	amend any outstanding stock option or stock appreciation right granted under the 2016 plan to provide an exercise or measurement price
	per share that is lower than the then-current exercise or measurement price per share of such outstanding award;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	cancel any outstanding option or stock appreciation right (whether or not granted under the 2016 plan) and grant in substitution
	therefor new awards under the 2016 plan (other than substitute awards permitted in connection with a merger or consolidation of an entity with us or our acquisition of property or stock of another
	entity) covering the same or a different number of shares of our common stock and having an exercise or measurement price per share lower than the then-current exercise or measurement price per share
	of the cancelled award;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	cancel in exchange for a cash payment any outstanding option or stock appreciation right with an exercise or measurement price per
	share above the then-current fair market value of our common stock; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	take any other action that constitutes a "repricing" within the meaning of NASDAQ rules.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	award may be granted under the 2016 plan after ten years from the effectiveness of the 2016 plan. Our board of directors may amend, suspend or terminate the 2016 plan at any time,
	except that stockholder approval will be required to comply with applicable law or stock market requirements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	2016 Employee Stock Purchase Plan
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has adopted, and our stockholders have approved, the 2016 ESPP, to become effective upon the closing of this
	offering. The 2016 ESPP will be administered by our board of directors or by a committee appointed by our board of directors. The
	2016 ESPP initially will provide participating employees with the opportunity to purchase up to an aggregate of 586,666 shares of our common stock. The number of shares of our common stock reserved
	for issuance under the 2016 ESPP will automatically increase on the first day of each fiscal year, commencing on January&nbsp;1, 2017 and ending on December&nbsp;31, 2025, in an amount equal to
	the least of (i)&nbsp;1,173,333 shares of our common stock, (ii)&nbsp;1.0% of the total number of shares of our common stock outstanding on the first day of the applicable year, and
	(iii)&nbsp;an amount determined by our board of directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
	of our employees or employees of any designated subsidiary, as defined in the 2016 ESPP, are eligible to participate in the 2016 ESPP, provided
	that:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	such person is customarily employed by us or a designated subsidiary for more than 20&nbsp;hours a week and for more than five
	months in a calendar year;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	such person has been employed by us or by a designated subsidiary for at least six months prior to enrolling in the 2016 ESPP; and
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	159
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=162,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=637236,FOLIO='159',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_160">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	such person was our employee or an employee of a designated subsidiary on the first day of the applicable offering period under the
	2016 ESPP.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	employee may purchase shares of our common stock under the 2016 ESPP and any of our other employee stock purchase plans in excess of $25,000 of the fair market value of our common
	stock (as of the date of the option grant) in any calendar year. In addition, no employee may purchase shares of our common stock under the 2016 ESPP that would result in the employee owning 5% or
	more of the total combined voting power or value of our stock or the stock of any of our subsidiaries.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	expect to make one or more offerings to our eligible employees to purchase stock under the 2016 ESPP beginning at such time as our board of directors may determine. Each offering will
	consist of a six-month offering period during which payroll deductions will be made and held for the purchase of our common stock at the end of the offering period. Our board of directors may, at its
	discretion, choose a different period of not more than 12&nbsp;months for offerings.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
	the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of his or her compensation to be deducted by us during the offering period.
	Each employee who continues to be a participant in the 2016 ESPP on the last business day of the offering period will be deemed to have exercised an option to purchase from us the number of whole
	shares of our common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. Under the terms of the 2016 ESPP, the
	purchase price shall be determined by our board of directors for each offering period and will be at least 85% of the applicable closing price of our common stock. If our board of directors does not
	make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of our common stock on the first business day of the offering period or on the last
	business day of the offering period.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
	employee who is not a participant on the last day of the offering period is not entitled to purchase shares under the 2016 ESPP, and the employee's accumulated payroll deductions will
	be refunded. An employee's rights under the 2016 ESPP terminate upon voluntary withdrawal from an offering under the 2016 ESPP at any time, or when the employee ceases employment for any reason.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	will be required to make equitable adjustments to the number and class of securities available under the 2016 ESPP, the share limitations under the 2016 ESPP, and the purchase price
	for an offering period under the 2016 ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs and other
	similar changes in capitalization or events or any dividends or distributions to holders of our common stock other than ordinary cash dividends.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	connection with a merger or other reorganization event, as defined in the 2016 ESPP, our board of directors or a committee of our board of directors may take any one or more of the
	following actions as to outstanding options to purchase shares of our common stock under the 2016 ESPP on such terms as our board or committee
	determines:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that options shall be assumed, or substantially equivalent options shall be substituted, by the acquiring or succeeding
	corporation (or an affiliate thereof);
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	upon written notice to employees, provide that all outstanding options will be terminated immediately prior to the consummation of
	such reorganization event and that all such outstanding options will become exercisable to the extent of accumulated payroll deductions as of a date specified by our board or committee in such notice,
	which date shall not be less than ten days preceding the effective date of the reorganization event;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to the effective date of
	the reorganization event and that all accumulated payroll deductions will be returned to participating employees on such date;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	160
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=163,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=317249,FOLIO='160',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_161">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	in the event of a reorganization event under the terms of which holders of our common stock will receive upon consummation thereof a
	cash payment for each share surrendered in the reorganization event, change the last day of the offering period to be the date of the consummation of the reorganization event and make or provide for a
	cash payment to each employee equal to (1)&nbsp;the cash payment for each share surrendered in the reorganization event times the number of shares of our common stock that the employee's accumulated
	payroll deductions as of immediately prior to the reorganization event could purchase at the applicable purchase price, where the acquisition price is treated as the fair market value of our common
	stock on the last day of the applicable offering period for purposes of determining the purchase price and where the number of shares that could be purchased is subject to the applicable limitations
	under the 2016 ESPP minus (2)&nbsp;the result of multiplying such number of shares by the purchase price; and/or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provide that, in connection with our liquidation or dissolution, options shall convert into the right to receive liquidation proceeds
	(net of the purchase price thereof).
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
	board of directors may at any time, and from time to time, amend or suspend the 2016 ESPP or any portion thereof. We will obtain stockholder approval for any amendment if such
	approval is required by Section&nbsp;423 of the Code. Further, our board of directors may not make any amendment
	that would cause the 2016 ESPP to fail to comply with Section&nbsp;423 of the Code. The 2016 ESPP may be terminated at any time by our board of directors. Upon termination, we will refund all
	amounts in the accounts of participating employees.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	401(k) Retirement Plan
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of
	the Code. In general, all of our employees are eligible to participate, beginning on the first day of the quarter following commencement of their employment. The 401(k) plan includes a salary deferral
	arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $18,000 in 2015, and have the amount of the reduction
	contributed to the 401(k) plan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Limitations on Liability and Indemnification
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation that will become effective upon the closing of this offering limits the personal liability of
	directors for breach of fiduciary duty to the maximum extent permitted by the General Corporation Law of the State of Delaware and provides that no director will have personal liability to us or to
	our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our
	directors:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	for any breach of the director's duty of loyalty to us or our stockholders;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	for any transaction from which the director derived an improper personal benefit.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
	amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such
	amendment or repeal. If the General Corporation Law of the State of Delaware is amended to provide for further limitations on the personal liability of directors of corporations, then the personal
	liability of our
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	161
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=164,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=235131,FOLIO='161',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_162">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	directors
	will be further limited to the greatest extent permitted by the General Corporation Law of the State of Delaware.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, our restated certificate of incorporation that will become effective upon the closing of this offering provides that we must indemnify our directors and officers and we must
	advance expenses, including attorneys' fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	maintain a general liability insurance policy that covers specified liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
	directors or officers. In addition, we have entered into indemnification agreements with each of our directors, and we intend to enter into indemnification agreements with all of our directors and
	executive officers prior to the closing of this offering. These indemnification agreements may require us, among other things, to indemnify each such director or officer for some expenses, including
	attorneys' fees, judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or officers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
	of our non-employee directors may, through their relationships with their employers, be insured or indemnified against specified liabilities incurred in their capacities as members
	of our board of directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
	as indemnification for liabilities arising under the Securities Act may be permitted to directors, executive officers or persons controlling us, in the opinion of the SEC, such
	indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Rule&nbsp;10b5-1 Trading Plans
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our directors and executive officers may adopt written plans, known as Rule&nbsp;10b5-1 plans, in which they will contract with a
	broker to buy or sell shares of our common stock on a periodic basis. Under a Rule&nbsp;10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when
	entering into the plan, without subsequent direction from the director or officer. The director or officer may amend or terminate the plan in some circumstances. Our directors and executive officers
	may also buy or sell additional shares outside of a Rule&nbsp;10b5-1 plan when they are not in possession of material, nonpublic information.
</FONT>
</P>
</EFX_STOCK_PLANS>
</EFX_EXECUTIVE_COMPENSATION>
<EFX_DIRECTOR_COMPENSATION>
<A NAME="FIS_DIRECTOR_COMPENSATION"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Director Compensation
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2015, we adopted a director compensation program to be effective for periods prior to our initial public offering,
	pursuant to which non-founder, non-investor, non-employee members of our board of directors will receive annual cash compensation of $17,500 for service on our board of directors. This fee is payable
	in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not
	serving on our board of directors. Prior to the adoption of this program, during 2014, we paid Dr.&nbsp;Sato an annual retainer of $25,000 in return for her service on our board of directors, and in
	2015 we paid Dr.&nbsp;Sato an annual retainer of $15,000. In September 2015, we granted options to purchase 7,333 shares of our common stock to each of Dr.&nbsp;Sato, Dr.&nbsp;Sharp and
	Mr.&nbsp;Bancel and in October 2015, we granted an option to purchase 14,666 shares of our common stock to Ms.&nbsp;Fanucci, in return for their service on our board of directors. The options were
	granted at an exercise price per share of $6.94, which equalled the fair market value of our common stock on the date of grant, vest as to 25% of the shares underlying the option on the first
	anniversary of the date of grant, with the remainder of the shares underlying the option vesting in equal monthly installments for an additional three years, and have a term of 10&nbsp;years. No
	other directors have received compensation from us for their service on our board of directors. We also reimburse our non-employee directors for
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	162
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=165,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=782178,FOLIO='162',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_163">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	reasonable
	travel and out-of-pocket expenses incurred in connection with attending board of director and committee meetings.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	January 2016, our board of directors also approved a director compensation program to be effective at the closing of this offering. Under this director compensation program, we will
	pay our non-employee directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chair of each committee and the chair of
	the board of directors will receive higher retainers for such service. These fees will be payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the
	amount of such payment will be prorated for any portion of such quarter that the director is not serving on our board of directors, on such committee or in such position, and no fee shall be payable
	in respect of any period prior to the time of this offering. The fees paid to non-employee directors for service on the board of directors and for service on each committee of the board of directors
	on which the director is a member will be as follows:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Base
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Incremental&#151;
<BR>
	Chair
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Incremental&#151;
<BR>
	Non-Chair
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Board of Directors
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Audit Committee
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,500
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Compensation Committee
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Nominating and Corporate Governance Committee
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,500
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, under this director compensation program, on or around the closing of this offering for current directors, or upon their election to the board for new directors, we will
	grant to our non-employee directors an initial grant of an option to purchase 22,000 shares of our common stock, with an exercise price equivalent to fair market value of a share of common stock at
	the time of grant, which option will vest as to 16.66% of the shares on the six month anniversary of the date of grant and as to the remainder of the shares monthly thereafter until the third
	anniversary of the date of grant, subject to continued service, with full acceleration upon a change in control of us. The option will have a term of 10&nbsp;years. Immediately following each annual
	meeting of our stockholders, we will grant to each director who has served on our board of directors for at least six months as of the time of such grant an option to purchase 11,000 shares of our
	common stock, with an exercise price equivalent to fair market value of a share of common stock at the time of grant, which option will vest as to 50% of the shares on the six-month anniversary of the
	date of grant and as to the remainder of the shares monthly thereafter until the first anniversary of the date of grant, subject to continued service, with full acceleration upon a change in control
	of us. The option will have a term of 10&nbsp;years.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	also will continue to reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our board of director and committee
	meetings.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	do not pay any compensation to our president and chief executive officer in connection with her service on our board of directors. The compensation that we pay to our president and
	chief executive officer is discussed earlier in this "Executive Compensation" section.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	163
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=166,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=55602,FOLIO='163',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_164">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_DIRECTOR_COMPENSATION>
<EFX_CERTAIN_TRANSACTIONS>
<A NAME="FIS_CERTAIN_TRANSACTIONS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EE79601_TRANSACTIONS_WITH_RELATED_PERSONS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EE79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	TRANSACTIONS WITH RELATED PERSONS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2013, we have engaged in the following transactions in which the amount involved exceeded $120,000 and any of
	our directors or executive officers or beneficial holders of more than 5% of any class of our voting securities, or any immediate family member of the foregoing persons, or any person who was in any
	of those categories at the time of such transaction, had a material interest. We believe that all of these transactions were on terms comparable to terms that could have been obtained from unrelated
	third parties. All shares of preferred stock referenced in this section will convert into shares of common stock upon the completion of this offering at a ratio of 3.75 to 1.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Series&nbsp;A Preferred Stock Financings
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April and November 2013, we issued and sold an aggregate of 12,100,000 shares of our Series&nbsp;A-2 preferred stock at a price
	per share of $1.00, for an aggregate purchase price of $12.1&nbsp;million. The following table sets forth the number of shares of our Series&nbsp;A-2 preferred stock purchased by our directors,
	executive officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="94PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="72PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:21PT;">
<FONT SIZE=1>
<B>
	Name
<!-- COMMAND=ADD_SCROPPEDRULE,21PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares of Series&nbsp;A-2
<BR>
	Preferred Stock
<BR>
	Purchased
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Aggregate
<BR>
	Purchase Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Flagship Ventures
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	ARCH Venture Fund VII,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phillip A. Sharp, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	WuXi PharmaTech Healthcare Fund I,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Nancy Simonian, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	250,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	250,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	St&eacute;phane Bancel
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	100,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,850,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,850,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	March and August 2014, we issued and sold an aggregate of 15,750,000 shares of our Series&nbsp;A-3 preferred stock at a price per share of $1.00, for an aggregate purchase price of
	$15.75&nbsp;million. The following table sets forth the number of shares of our Series&nbsp;A-2 preferred stock purchased by our directors, executive officers and 5% stockholders and their
	affiliates and the aggregate purchase price paid for such shares.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="94PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="72PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:21PT;">
<FONT SIZE=1>
<B>
	Name
<!-- COMMAND=ADD_SCROPPEDRULE,21PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares of Series&nbsp;A-3
<BR>
	Preferred Stock
<BR>
	Purchased
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Aggregate
<BR>
	Purchase Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Flagship Ventures
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	ARCH Venture Fund VII,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	WuXi PharmaTech Healthcare Fund I,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Series&nbsp;B Preferred Stock Financings
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2014, we issued and sold an aggregate of 16,893,931 shares of our Series&nbsp;B preferred stock at a price per share of
	$3.1461, for an aggregate purchase price of $53.1&nbsp;million. The following table sets forth the number of shares of our Series&nbsp;B preferred stock purchased by our directors,
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	164
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=167,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=301699,FOLIO='164',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_165">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	executive
	officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="86PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="72PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:21PT;">
<FONT SIZE=1>
<B>
	Name
<!-- COMMAND=ADD_SCROPPEDRULE,21PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares of Series&nbsp;B
<BR>
	Preferred Stock
<BR>
	Purchased
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Aggregate
<BR>
	Purchase Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Fidelity
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,357,077
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19,999,999
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Polaris Partners VII,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,178,539
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,000,001
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Flagship Ventures
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,224,976
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,999,997
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	ARCH Venture Fund VII,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,589,269
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,999,993
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	WuXi PharmaTech Healthcare Fund I,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	953,561
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,999,998
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,303,422
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	44,999,988
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	January 2016, we issued and sold an aggregate of 12,714,150 shares of our Series&nbsp;B preferred stock at a price per share of $3.1461, for an aggregate purchase price of
	$40.0&nbsp;million. The following table sets forth the number of shares of our Series&nbsp;B preferred stock purchased by our directors, executive officers and 5% stockholders and their affiliates
	and the aggregate purchase price paid for such shares.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="86PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="72PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:21PT;">
<FONT SIZE=1>
<B>
	Name
<!-- COMMAND=ADD_SCROPPEDRULE,21PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares of Series&nbsp;B
<BR>
	Preferred Stock
<BR>
	Purchased
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Aggregate
<BR>
	Purchase Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Deerfield Management
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,357,077
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	20,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Fidelity
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,589,269
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,999,999
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	WuXi PharmaTech Healthcare Fund II,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,589,269
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,999,999
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Polaris
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,271,415
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,999,999
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,807,030
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	33,999,997
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Robert
	Nelsen, a member of our board of directors, is a general partner at ARCH Venture Fund VII,&nbsp;L.P. Douglas Cole, M.D., who was a member of our board of directors at the time
	of the Series&nbsp;A and October 2014 Series&nbsp;B preferred stock financings, is a general partner at Flagship Ventures and is the spouse of Dr.&nbsp;Simonian. Amir Nashat, Ph.D., a member of
	our board of directors, is a managing partner at Polaris. Jonathan Leff, a member of our board of directors, is a partner of Deerfield Management.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Investors' Rights Agreement
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to an amended and restated investors' rights agreement, dated as of October&nbsp;9, 2014, as amended, which we refer
	to as our investors' rights agreement, with holders of our preferred stock, including entities affiliated with Flagship Ventures, ARCH Venture Fund VII,&nbsp;L.P., entities affiliated with Fidelity,
	entities affiliated with Deerfield Management, entities affiliated with Polaris, entities affiliated with WuXi PharmaTech, Nancy Simonian, M.D., Phillip A. Sharp, Ph.D., and St&eacute;phane
	Bancel. The investors' rights agreement provides these holders the right, following the closing of this offering, to demand that we file&nbsp;a registration statement or request that their shares be
	covered by a registration statement that we are otherwise filing. See "Description of Capital Stock&#151;Registration Rights" for additional information regarding these registration rights.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Services Agreement with WuXi
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are party to a services agreement with WuXi AppTec (Hong Kong) Limited, or WuXi, an affiliate of our 5% stockholder WuXi PharmaTech,
	pursuant to which we engage WuXi to provide external research and preclinical development services, Prior to this agreement, we were party to a
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	165
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=168,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=506740,FOLIO='165',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_166">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	similar
	services agreement with WuXi. We paid WuXi $1.1&nbsp;million and $3.1&nbsp;million, during the years ended December&nbsp;31, 2014 and 2015, respectively, and $0.5&nbsp;million and
	$0.4&nbsp;million for the three months ended March&nbsp;31, 2015 and 2016, respectively, for services provided under these agreements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Employment Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See the "Executive Compensation&#151;Employment and Change in Control Agreements" section of this prospectus for a further
	discussion of these arrangements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Equity Grants to Directors and Executive Officers
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have granted stock options and stock awards to certain of our directors and named executive officers. For more information regarding
	the stock options and stock awards granted to our directors and named executive officers see "Executive Compensation."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Indemnification Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation that will become effective upon the closing of this offering provides that we will indemnify
	our directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into indemnification agreements with each of our directors, and we intend to enter into
	indemnification agreements with all of our directors and executive officers prior to the closing of this offering. See "Executive Compensation&#151;Limitations of Liability and Indemnification"
	for additional information regarding these agreements.
</FONT>
</P>
</EFX_CERTAIN_TRANSACTIONS>
<EFX_CERTAIN_TRANSACTIONS>
<A NAME="FIS_CERTAIN_TRANSACTIONS_2"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Policies and Procedures for Related Person Transactions
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors will adopt written policies and procedures, which will become effective at the closing of this offering, for the
	review of any transaction, arrangement or relationship in which our company is a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees or 5%
	stockholders, or their immediate family members, each of whom we refer to as a "related person," has a direct or indirect material interest.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
	a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a "related person transaction," the related person must report the
	proposed related person transaction to our chief financial officer. The policy calls for the proposed related person transaction to be reviewed and approved by our audit committee. Whenever
	practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the committee will review, and, in its discretion,
	may ratify the related person transaction. The policy also permits the chairman of the audit committee to review and, if deemed appropriate, approve proposed related person transactions that arise
	between committee meetings, subject to ratification by the committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the audit committee after full disclosure of the related person's
	interest in the transaction. As appropriate for the circumstances, the committee will review and consider:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the related person's interest in the related person transaction;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the approximate dollar value of the amount involved in the related person transaction;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any
	profit or loss;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	whether the transaction was undertaken in the ordinary course of our business;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	166
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=169,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=633836,FOLIO='166',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_167">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third
	party;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the purpose of, and the potential benefits to us of, the transaction; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	any other information regarding the related person transaction or the related person in the context of the proposed transaction that
	would be material to investors in light of the circumstances of the particular transaction.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	audit committee may approve or ratify the transaction only if the committee determines that, under all of the circumstances, the transaction is in our best interests. The committee
	may impose any conditions on the related person transaction that it deems appropriate.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	policy provides that transactions involving compensation of executive officers shall be reviewed and approved by the compensation committee in the manner specified in its charter.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	167
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=170,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=142847,FOLIO='167',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_168">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_CERTAIN_TRANSACTIONS>
<EFX_STOCKHOLDERS>
<A NAME="FIS_STOCKHOLDERS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EE79601_PRINCIPAL_STOCKHOLDERS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EE79601_2">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	PRINCIPAL STOCKHOLDERS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information with respect to the beneficial ownership of our common stock as of June&nbsp;15, 2016
	by:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	each of our directors;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	each of our named executive officers;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	all of our directors and executive officers as a group; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The column entitled "Percentage of Shares Beneficially Owned&#151;Before Offering" is based on a total of 18,760,161 shares of our common stock outstanding as of June&nbsp;15,
	2016, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,988,800 shares of our common stock upon the closing of this offering. The column
	entitled "Percentage of Shares Beneficially Owned&#151;After Offering" is based on 22,760,161 shares of our common stock to be outstanding after this offering, including the 4,000,000 shares of
	our
	common stock that we are selling in this offering, but not including any additional shares issuable upon exercise of outstanding options or any exercise by the underwriters of their overallotment
	option.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common
	stock subject to options that are currently exercisable or exercisable within 60&nbsp;days after June&nbsp;15, 2016 are considered outstanding and beneficially owned by the person holding the
	options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the
	persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where
	applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o Syros Pharmaceuticals,&nbsp;Inc., 620 Memorial Drive, Suite&nbsp;300, Cambridge Massachusetts 02139.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our existing principal stockholders have indicated an interest in purchasing an aggregate of $35.0&nbsp;million in shares of our common stock in this offering at the initial
	public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares to any of these
	existing stockholders and any of these existing stockholders could determine to purchase more, less or no shares in this offering. The following table does not reflect any potential purchases by these
	existing principal stockholders. If any shares are purchased by these stockholders, the number and percentage of shares of our common
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	168
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=11,SEQ=171,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=221204,FOLIO='168',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_169">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	stock beneficially owned by them after this offering will differ from those set forth in the following table.
</FONT>
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS_2"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Percentage of
<BR>
	Shares
<BR>
	Beneficially Owned
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:93PT;">
<FONT SIZE=1>
<B>
	Name of Beneficial Owner
<!-- COMMAND=ADD_SCROPPEDRULE,93PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares
<BR>
	Beneficially Owned
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Before
<BR>
	Offering
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	After
<BR>
	Offering
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
<I>
	5% Stockholders
</I>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Flagship Ventures
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,406,656
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23.5
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	19.4
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	ARCH Venture Fund VII,&nbsp;L.P.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,237,137
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22.6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18.6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Fidelity
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,119,021
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Deerfield Management
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,695,220
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9.0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.4
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with Polaris
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,186,653
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Entities affiliated with WuXi Pharmatech
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,078,086
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(6)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.7
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.7
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
<I>
	Named Executive Officers and Directors
</I>
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Nancy Simonian, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	594,860
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(7)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Kyle D. Kuvalanka
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	27,527
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(8)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	David A. Roth, M.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	St&eacute;phane Bancel
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	47,980
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(9)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Marsha H. Fanucci
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Jonathan Leff
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Amir Nashat, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,186,653
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.2
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Robert Nelsen
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,237,137
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	22.6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18.6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Sanj K. Patel
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Vicki L. Sato, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,951
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(12)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Phillip A. Sharp, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	300,413
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.6
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Richard A. Young, Ph.D.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	533,332
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.8
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<I>
	All Executive Officers and Directors as a Group (14&nbsp;persons)
</I>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,154,154
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(14)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	37.4
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	31.0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	*
</FONT>
</DT>
</EFX_BENEFICIAL_OWNERS>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Represents
	beneficial ownership of less than 1% of our outstanding stock.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of 213,332 shares of common stock held by Flagship VentureLabs IV,&nbsp;LLC ("Flagship VentureLabs"), 3,354,660 shares of common stock issuable
	upon the conversion of preferred stock held by Flagship Ventures Fund IV,&nbsp;L.P. ("Flagship Fund IV") and 838,664 shares of common stock issuable upon the conversion of preferred stock held by
	Flagship Ventures Fund IV-Rx,&nbsp;L.P. ("Flagship Fund IV-Rx" and together with Flagship VentureLabs and Flagship IV, the "Flagship Funds"). Flagship Fund IV is a member of Flagship VentureLabs and
	also serves as its manager. The general partner of each of Flagship Fund IV and Flagship Fund IV-Rx is Flagship Ventures Fund IV General Partner&nbsp;LLC ("Flagship Fund IV&nbsp;GP").
	St&eacute;phane Bancel is a director of Syros and a limited partner of Flagship Fund&nbsp;IV and a member of Flagship Fund IV&nbsp;GP. Mr.&nbsp;Bancel disclaims beneficial ownership of
	such shares. Noubar B. Afeyan, Ph.D. and Edwin M. Kania Jr. are the managers of Flagship Fund IV&nbsp;GP. Flagship Fund IV&nbsp;GP and each of these individuals may be deemed to share voting and
	investment power with respect to all shares held by the Flagship Funds. Each of the foregoing persons disclaims beneficial ownership of the shares except to the extent of any pecuniary interest
	therein. The address of such stockholder is One Memorial Drive, 7
<SUP>
	th
</SUP>
	&nbsp;Floor, Cambridge, Massachusetts 02142.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of 213,333 shares of common stock and 4,023,804 shares of common stock issuable upon the conversion of preferred stock held of record by ARCH
	Venture Fund VII,&nbsp;L.P., or ARCH VII. ARCH Venture Partners VII,&nbsp;L.P., or the&nbsp;GPLP, as the sole general partner of ARCH VII, may be deemed to beneficially own the shares held of
	record by ARCH VII. The&nbsp;GPLP disclaims
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	169
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=12,SEQ=172,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=451993,FOLIO='169',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_170">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	beneficial
	ownership of all shares held of record by ARCH VII in which the&nbsp;GPLP does not have an actual pecuniary interest. ARCH Venture Partners VII,&nbsp;LLC, or the&nbsp;GPLLC, as the
	sole general partner of the&nbsp;GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH VII. The&nbsp;GPLLC disclaims beneficial ownership of all shares held of
	record by ARCH VII in which it does not have an actual pecuniary interest. Keith Crandell, Clinton Bybee and Robert Nelsen are the managing directors of the&nbsp;GPLLC, and may be deemed to share
	voting and dispositive power over the shares held of record by ARCH VII. The managing directors disclaim beneficial ownership of all shares held of record by ARCH VII in which they do not have an
	actual pecuniary interest. ARCH Venture Fund VII,&nbsp;L.P. has an address at 8725 West Higgins Road, Suite&nbsp;290, Chicago, Illinois 60631.
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of shares of common stock issuable upon the conversion of preferred stock, 1,215,583 of which are held of record by Powhatan&nbsp;&amp; Co., LLC fbo
	Fidelity Mt.&nbsp;Vernon Street: Fidelity Growth Company Fund, 62,568 of which are held of record by Bangle&nbsp;&amp; Co fbo Fidelity Advisor Series&nbsp;VII: Fidelity Advisor Biotechnology Fund,
	236,248 of which are held of record by Mag&nbsp;&amp; Co fbo Fidelity Growth Company Comingled Pool, 303,621 of which are held of record by Mag&nbsp;&amp; Co fbi Fidelity Select Portfolios: Biotechnology
	Portfolio and 301,001 of which are held of record by WAVELENGTH&nbsp;+&nbsp;Co fbo Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund. These accounts are managed by direct or
	indirect subsidiaries of FMR&nbsp;LLC. Edward&nbsp;C. Johnson&nbsp;3d is a Director and the Chairman of FMR&nbsp;LLC and Abigail&nbsp;P. Johnson is a Director, Vice Chairman and the
	President of FMR&nbsp;LLC. Members of the family of Edward&nbsp;C. Johnson&nbsp;3d, including Abigail&nbsp;P. Johnson, are the predominant owners, directly or through trusts, of
	Series&nbsp;B voting common shares of FMR&nbsp;LLC, representing 49% of the voting power of FMR&nbsp;LLC. The Johnson family group and all other Series&nbsp;B shareholders have entered into a
	shareholders' voting agreement under which all Series&nbsp;B voting common shares will be voted in accordance with the majority vote of Series&nbsp;B voting common shares. Accordingly, through
	their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a
	controlling group with respect to FMR&nbsp;LLC. Neither FMR&nbsp;LLC nor Edward&nbsp;C. Johnson&nbsp;3d nor Abigail&nbsp;P. Johnson has the sole power to vote or direct the voting of the
	shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management &amp; Research Company ("FMR&nbsp;Co"), a wholly
	owned subsidiary of FMR&nbsp;LLC, which power resides with the Fidelity Funds' Board of Trustees. Fidelity Management &amp; Research Company carries out the voting of the shares under written guidelines
	established by the Fidelity Funds' Board of Trustees. The address for Fidelity Select Portfolios: Biotechnology Portfolio is Brown Brothers Harriman&nbsp;&amp; Co., 525&nbsp;Washington Blvd., Jersey
	City&nbsp;NJ 07310. The address for Fidelity Advisor Series&nbsp;VII: Fidelity Advisor Biotechnology Fund is State Street Bank&nbsp;&amp; Trust, PO&nbsp;Box 5756, Boston, Massachusetts 02206. The
	address for Fidelity Growth Company Commingled Pool is Brown Brothers Harriman&nbsp;&amp; Co., 525 Washington&nbsp;Blvd., Jersey City&nbsp;NJ 07310. The address for Fidelity Mt.&nbsp;Vernon Trust:
	Fidelity Series Growth Company Fund is State Street Bank&nbsp;&amp; Trust, PO&nbsp;Box 5756, Boston, Massachusetts 02206. The address for Fidelity Mt.&nbsp;Vernon Street Trust: Fidelity Growth
	Company Fund is BNY Mellon, 525 William Penn Place Rm&nbsp;0400, Pittsburgh,&nbsp;PA 15259.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(4)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of shares of common stock issuable upon the conversion of preferred stock, 508,566 of which are held by Deerfield Special Situations
	Fund,&nbsp;L.P. and 1,186,654 of which are held by Deerfield Private Design Fund III,&nbsp;L.P. Deerfield Mgmt,&nbsp;L.P. is the general partner of Deerfield Special Situations Fund,&nbsp;L.P.
	and Deerfield Mgmt III,&nbsp;L.P. is the general partner of Deerfield Private Design Fund III,&nbsp;L.P. Deerfield Management Company,&nbsp;L.P. is the investment manager of each of Deerfield
	Special Situations Fund,&nbsp;L.P. and Deerfield Private Design Fund III,&nbsp;L.P. Mr.&nbsp;James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt,&nbsp;L.P.,
	Deerfield Mgmt III,&nbsp;L.P. and Deerfield Management Company,&nbsp;L.P. Deerfield Mgmt,&nbsp;L.P.,
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	170
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=13,SEQ=173,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=336868,FOLIO='170',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_171">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Deerfield
	Management Company,&nbsp;L.P. and Mr.&nbsp;James E. Flynn may be deemed to beneficially own the securities held by Deerfield Special Situations Fund,&nbsp;L.P. Deerfield Mgmt III,
	L.P., Deerfield Management Company, L.P. and Mr. James E. Flynn may be deemed to beneficially own the securities held by Deerfield Private Design Fund&nbsp;III, L.P. Mr.&nbsp;Leff, a member of the
	board of directors, is a partner at Deerfield Management Company, L.P., an affiliate of Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund&nbsp;III, L.P. The address of each
	such entity is 780 Third Avenue, 37th&nbsp;Floor, New York, New York 10017.
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(5)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of shares of common stock issuable upon the conversion of preferred stock, 1,164,486 of which are held by Polaris Partners VII,&nbsp;L.P. and
	22,167 of which are held by Polaris Partners Entrepreneurs' Fund VII,&nbsp;L.P. The general partner of Polaris Partners VII,&nbsp;L.P. and Polaris Partners Entrepreneurs' Fund&nbsp;VII, L.P. is
	Polaris Management&nbsp;Co. VII, L.L.C. ("Polaris Management"), and Polaris Management may be deemed to have sole voting and investment power over such shares. Polaris Management disclaims
	beneficial ownership of these shares, except to the extent of its pecuniary interest therein. The address of such stockholders is One Marina Park Drive, 10
<SUP>
	th
</SUP>
	&nbsp;Floor, Boston,
	Massachusetts 02210.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(6)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of shares of common stock issuable upon the conversion of preferred stock, 654,281 of which are held by WuXi PharmaTech Healthcare Fund
	I,&nbsp;L.P. and 423,805 of which are held by WuXi Healthcare Ventures II,&nbsp;L.P. The general partner of WuXi PharmaTech Healthcare Fund&nbsp;I,&nbsp;L.P. is WuXi PharmaTech Investments
	(Cayman)&nbsp;Inc. Edward Hu is a director of WuXi PharmaTech Investments (Cayman)&nbsp;Inc. and may be deemed to have voting and investment power over the shares held by WuXi PharmaTech
	Healthcare Fund&nbsp;I,&nbsp;L.P. The general partner of WuXi Healthcare Ventures II,&nbsp;L.P. is WuXi Healthcare Management,&nbsp;LLC. Wei Li is a director of WuXi Healthcare
	Management,&nbsp;LLC and may be deemed to have voting and investment power over the shares held by WuXi Healthcare Ventures II,&nbsp;L.P. Each such person and entity disclaims beneficial ownership
	over such shares, except with respect to their pecuniary interest therein. The address of each such entity is 222&nbsp;Third Street, Suite&nbsp;1100, Cambridge, Massachusetts 02142.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(7)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of (i)&nbsp;66,666 shares of common stock issuable upon the conversion of preferred stock, (ii)&nbsp;304,034 shares of common stock
	(iii)&nbsp;80,000 shares of common stock held of record by the Douglas and Nancy Cole Family Trust f/b/o Bennett&nbsp;H. Cole, (iv) 80,000 shares of common stock held of record by the Douglas and
	Nancy Cole Family Trust f/b/o William&nbsp;B. Cole and (v)&nbsp;64,160&nbsp;shares of common stock issuable upon the exercise of options that vest on or prior to August&nbsp;14, 2016.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(8)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of shares of common stock issuable upon the exercise of options that vest on or prior to August&nbsp;14, 2016.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(9)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Includes
	26,666 shares of common stock issuable upon the conversion of preferred stock.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(10)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	See
	footnote 5.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(11)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	See
	footnote 2.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(12)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of shares of common stock issuable upon the exercise of options that vest on or prior to August&nbsp;14, 2016.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(13)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consists
	of (i)&nbsp;146,666 shares of common stock issuable upon the conversion of preferred stock held of record by Dr.&nbsp;Sharp,
	(ii)&nbsp;40,000 shares of common stock issuable upon the conversion of preferred stock held of record by Ann H. Sharp and Christine S. Carey, as Trustees of the Phillip&nbsp;A.&nbsp;Sharp 2008
	Irrevocable Trust f/b/o Christine S. Carey, (iii)&nbsp;40,000 shares of common stock issuable upon the conversion of preferred stock held of record by Ann H. Sharp and
	Helena&nbsp;S.&nbsp;Gordon, as Trustees of the Phillip A. Sharp 2008 Irrevocable Trust f/b/o Helena H. Sharp, (iv)&nbsp;40,000 shares of common stock issuable upon the conversion of preferred
	stock held of
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	171
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=14,SEQ=174,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=153797,FOLIO='171',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EE79601_1_172">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	record
	by Ann H. Sharp and Sarah S. Brokaw, as Trustees of the Phillip A. Sharp 2008 Irrevocable Trust f/b/o Sara S. Brokaw and (v)&nbsp;33,747 shares of common stock issuable upon the exercise of
	options that vest on or prior to August&nbsp;14, 2016.
</FONT>
</P>
</UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(14)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Includes
	5,570,455 shares of common stock issuable upon conversion of preferred stock and 351,686&nbsp;shares of common stock issuable upon the exercise
	of options that vest on or prior to August&nbsp;14, 2016.
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	172
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=15,SEQ=175,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=760310,FOLIO='172',FILE='DISK124:[15ZCT1.15ZCT79601]EE79601A.;85',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_173">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_STOCKHOLDERS>
<EFX_SECURITIES_DESCRIPTION>
<A NAME="FIS_SECURITIES_DESCRIPTION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EG79601_DESCRIPTION_OF_CAPITAL_STOCK">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EG79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	DESCRIPTION OF CAPITAL STOCK
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	General
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following the closing of this offering, our authorized capital stock will consist of 200,000,000 shares of common stock, par value
	$0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, all of which preferred stock will be undesignated. The following description of our capital stock and provisions
	of our restated certificate of incorporation and
	amended and restated bylaws are summaries and are qualified by reference to the restated certificate of incorporation and the amended and restated bylaws that will be in effect upon the closing of
	this offering. We have filed copies of these documents as exhibits to our registration statement of which this prospectus forms&nbsp;a part. The descriptions of the common stock and preferred stock
	reflect changes to our capital structure that will occur upon the closing of this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, we had outstanding 2,771,361&nbsp;shares of common stock. These shares of common stock were held by
	41&nbsp;stockholders of record. As of June&nbsp;15, 2016, there would have been outstanding 18,760,161&nbsp;shares of common stock, assuming the automatic conversion of all outstanding shares of
	our preferred stock into common stock upon the closing of this offering. These shares of common stock would have been held by 70&nbsp;stockholders of record.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
	of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of
	directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Other matters shall be decided by the affirmative vote of our
	stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter, except as otherwise disclosed below. Holders of common stock are
	entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the
	payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion
	rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we
	may designate and issue in the future.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Preferred Stock
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, there were outstanding 59,958,081 shares of preferred stock, consisting of 2,500,000 shares of
	Series&nbsp;A-1 preferred stock, 12,100,000 shares of Series&nbsp;A-2 preferred stock, 15,750,000 shares of Series&nbsp;A-3 preferred stock and 29,608,081 shares of Series&nbsp;B
	preferred stock. All currently outstanding shares of preferred stock will be converted into an aggregate of 15,988,800&nbsp;shares of common stock upon the closing of this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
	the terms of our restated certificate of incorporation that will become effective upon the closing of this offering, our board of directors is authorized to issue shares of
	preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting
	rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific
	issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it
	more difficult for a third
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	173
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=176,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=327037,FOLIO='173',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_174">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	party
	to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock
	outstanding, and we have no present plans to issue any shares of preferred stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stock Options
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, options to purchase 2,043,612&nbsp;shares of our common stock at a weighted-average exercise price of
	$4.67&nbsp;per share were outstanding, of which options to purchase 490,055&nbsp;shares of our common stock were exercisable, at a weighted-average exercise price of $1.61&nbsp;per share, and
	options to purchase 98,742&nbsp;shares of common stock were available for future issuance under our 2012 Equity Incentive Plan.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Registration Rights
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our investor's rights agreement provides specified holders of our currently outstanding preferred stock, including some of our
	directors and 5% stockholders and their respective affiliates and entities affiliated with our officers and directors, the right, following the closing of this offering, to require us to register the
	shares of common stock that will be issued upon conversion of the preferred stock under the Securities Act under specified circumstances as described below. After registration pursuant to these
	rights, these shares will become freely tradable without restriction under the Securities Act.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Demand Registration Rights
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning 180&nbsp;days after the effective date of the registration statement for this offering, subject to specified limitations
	set forth in the investor's rights agreement, at any time the holders of 25% of then outstanding registrable securities, as defined in the investor's rights agreement, acting together, may demand in
	writing that we register their registrable securities under the Securities Act so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering price
	to the public, net of selling expenses, as defined in the investors' rights agreement, that would exceed $5.0&nbsp;million. We are not obligated to effect a registration statement pursuant to this
	demand provision on more than two occasions, subject to specified exceptions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition, at any time after we become eligible to file&nbsp;a registration statement on Form&nbsp;S-3 under the Securities Act, subject to specified limitations, the holders of at
	least 25% of the registrable securities then outstanding may demand in writing that we register on Form&nbsp;S-3 registrable shares held by them so long as the total amount of registrable shares
	requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, as defined in the investors' rights agreement, of at least $2.0&nbsp;million. We are
	not obligated to effect a registration statement pursuant to this demand provision on more than two occasions in any twelve-month period, subject to specified exceptions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Incidental Registration Rights
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at any time after the closing of this offering, we propose to file&nbsp;a registration statement to register any of our
	securities under the Securities Act, either for our own
	account or for the account of any of our stockholders that are not holders of registrable shares, solely for cash and on a form that would also permit the registration of registrable shares, the
	holders of our registrable shares are entitled to notice of registration and, subject to specified exceptions, we will be required to register the registrable shares then held by them that they
	request that we register.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the investor's rights agreement, we are required to pay all registration expenses, including registration fees, printing
	expenses, fees and disbursements of our counsel and accountants and reasonable fees and disbursements of one counsel representing the selling stockholders, other than
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	174
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=177,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=482650,FOLIO='174',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_175">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	any
	underwriting discounts and commissions, related to any demand or incidental registration. The investor's rights agreement contains customary cross-indemnification provisions, pursuant to which we
	are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for
	material misstatements or omissions in the registration statement attributable to them.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Anti-Takeover Effects of Delaware Law and Our Charter and Bylaws
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware law contains, and upon the closing of this offering our restated certificate of incorporation and our amended and restated
	bylaws will contain, provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected
	to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of
	directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Staggered Board; Removal of Directors
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, our restated certificate of incorporation and our amended and restated bylaws will divide our board
	of directors into three classes with staggered three-year terms. In addition, a director will only be able to be removed for cause and only by the affirmative vote of the holders of at least 75% of
	the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our
	board of directors, will only be able to be filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors
	and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stockholder Action by Written Consent; Special Meetings
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, our restated certificate of incorporation will provide that any action required or permitted to be
	taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Upon the closing of this
	offering, our restated certificate of incorporation and our amended and restated bylaws will also provide that, except as otherwise required by law, special meetings of our stockholders can only be
	called by our chairman of the board, our chief executive officer or our board of directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Advance Notice Requirements for Stockholder Proposals
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, our amended and restated bylaws will establish an advance notice procedure for stockholder proposals
	to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to
	consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for
	the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder's intention to bring such business before the meeting.
	These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Delaware Business Combination Statute
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, we will be subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware.
	Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	175
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=178,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=968537,FOLIO='175',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_176">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	three
	years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the
	business combination is approved in a prescribed manner. A "business combination" includes, among other things, a merger or consolidation involving us and the "interested stockholder" and a sale
	involving us and the "interested stockholder" of 10% or more of our assets. In general, an "interested stockholder" is any entity or person beneficially owning 15% or more of our outstanding voting
	stock and any entity or person affiliated with or controlling or controlled by such entity or person.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Amendment of Certificate of Incorporation and Bylaws
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The General Corporation Law of the State of Delaware provides generally that the affirmative vote of a majority of the shares entitled
	to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless a corporation's certificate of incorporation or bylaws, as the case may be, requires a greater
	percentage. Effective upon the closing of this offering, our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of
	the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our
	stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of
	incorporation described above under "&#151;Staggered Board; Removal of Directors" and "&#151;Stockholder Action by Written Consent; Special Meetings."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Exclusive Forum Selection
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective upon closing of this offering, our restated certificate of incorporation will provide that, unless we consent in writing to
	the selection of an alternative forum, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware)
	shall be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on behalf of our company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by
	any of our directors, officers or employees to our company or our stockholders, (3)&nbsp;any action asserting a claim against our company arising pursuant to any provision of the General Corporation
	Law of the State of Delaware or our restated certificate of incorporation or amended and restated bylaws, or (4)&nbsp;any action asserting a claim against our company governed by the internal
	affairs doctrine. Although our restated certificate of incorporation contains the choice of forum provision described above, it is possible that a court could rule that such a provision is
	inapplicable for a particular claim or action or that such provision is unenforceable.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Listing on The NASDAQ Global Market
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied to have our common stock listed on The NASDAQ Global Market under the symbol "SYRS."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Authorized but Unissued Shares
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval,
	subject to any limitations imposed by the listing requirements of The NASDAQ Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and
	employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means
	of a proxy contest, tender offer, merger or otherwise.
</FONT>
</P>
</EFX_SECURITIES_DESCRIPTION>
<EFX_TRANSFER_AGENT>
<A NAME="FIS_TRANSFER_AGENT"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Transfer Agent and Registrar
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock will be Computershare Trust Company,&nbsp;N.A.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	176
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=179,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=174706,FOLIO='176',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_177">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_TRANSFER_AGENT>
<EFX_FUTURE_SALE>
<A NAME="FIS_FUTURE_SALE"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EG79601_SHARES_ELIGIBLE_FOR_FUTURE_SALE">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EG79601_2">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	SHARES ELIGIBLE FOR FUTURE SALE
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not
	develop or be sustained after this offering. Future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options, or the
	anticipation of these sales, could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through sales of equity securities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon the 2,771,361&nbsp;shares of our common stock that were outstanding on June&nbsp;15, 2016, upon the closing of this offering, we will have outstanding
	22,760,161&nbsp;shares of our common stock, after giving effect to the issuance of 4,000,000&nbsp;shares of our common stock in this offering and the conversion of all outstanding shares of our
	preferred stock into 15,988,800&nbsp;shares of common stock upon the closing of this offering, and assuming no exercise by the underwriters of their overallotment option and no exercise of options
	outstanding as of June&nbsp;15, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of the shares to be outstanding immediately after the closing of this offering, we expect that the 4,000,000&nbsp;shares to be sold in this offering will be freely tradable without
	restriction under the Securities Act unless purchased by our "affiliates," as that term is defined in Rule&nbsp;144 under the Securities Act. The remaining 18,760,161&nbsp;shares of our common
	stock outstanding after this offering will be "restricted securities" under Rule&nbsp;144, and we expect that substantially all of these restricted securities will be subject to the 180-day lock-up
	period under the lock-up agreements as described below. These restricted securities may be sold in the public market only if registered or pursuant to an exemption from registration, such as
	Rule&nbsp;144 or Rule&nbsp;701 under the Securities Act.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Rule&nbsp;144
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;144, beginning 90&nbsp;days after the date of this prospectus, any person who is not our affiliate and
	has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, subject to the availability of
	current public information about us. In addition, under Rule&nbsp;144, any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held
	their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the
	closing of this offering without regard to whether current public information about us is available.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
	90&nbsp;days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the preceding three months may sell any unrestricted
	securities, as well as restricted securities that the person has beneficially owned for at least six months, including the holding period of any prior owner other than one of our affiliates, under
	Rule&nbsp;144. Affiliates selling restricted or unrestricted securities may sell a number of shares within any three-month period that does not exceed the greater
	of:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1% of the number of shares of our common stock then outstanding, which will equal approximately 227,601&nbsp;shares immediately
	after this offering; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the average weekly trading volume of our common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing
	of a Notice of Proposed Sale of Securities Pursuant to Rule&nbsp;144 with respect to the sale.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales
	under Rule&nbsp;144 by our affiliates are also subject to manner of sale provisions and notice requirements and to the availability of current public information about us.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon expiration of the 180-day lock-up period described below, approximately 18,760,161&nbsp;shares of our common stock will be eligible for sale under Rule&nbsp;144, including
	shares eligible for resale
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	177
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=180,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=347514,FOLIO='177',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_178">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	immediately
	upon the closing of this offering as described above. We cannot estimate the number of shares of our common stock that our existing stockholders will elect to sell under Rule&nbsp;144.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Rule&nbsp;701
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;701 of the Securities Act, any of our employees, consultants or advisors, other than our affiliates, who
	purchased shares from us in connection with a qualified compensatory stock plan or other written agreement is eligible to resell these shares 90&nbsp;days after the date of this prospectus in
	reliance on Rule&nbsp;144, but without compliance with the holding period requirements of Rule&nbsp;144 and without regard to the volume of such sales or the availability of public information
	about us. Subject to the 180-day lock-up period described below, approximately 646,360&nbsp;shares of our common stock will be eligible for sale in accordance with Rule&nbsp;701, subject to
	satisfying applicable vesting schedules.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Lock-Up Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, and each of our executive officers and directors and the holders of substantially all of our outstanding stock have agreed that,
	without the prior written consent of Cowen&nbsp;and Company,&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co., on behalf of the underwriters, we and they will not, subject to limited exceptions,
	during the period ending 180&nbsp;days after the date of this prospectus: directly or indirectly, (i)&nbsp;offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, or
	announce the intention to otherwise dispose of, any shares of common stock or securities convertible into or exercisable or exchangeable for common stock; (ii)&nbsp;enter into any swap, hedge or
	similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of the common stock or securities convertible into or exercisable or exchangeable for common stock,
	whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition; or (iii)&nbsp;engage in any short selling of
	the common stock or securities convertible into or exercisable or exchangeable for common stock. These restrictions are subject to customary exceptions, including transfers made by an individual as
	gifts, to members of the individual's immediate family or a trust for the benefit of the individual or his or her immediate family, or by will, intestacy or operation of law; and transfers by an
	entity to its stockholders or other owners, to an affiliate, or in connection with a sale of the entity. See "Underwriting" for additional information.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Registration Rights
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the lock-up agreements described above, upon the closing of this offering, the holders of an aggregate of
	16,774,912&nbsp;shares of our common stock will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the
	Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See "Description of Capital
	Stock&#151;Registration Rights" for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the
	terms of lock-up agreements applicable to such shares.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stock Options
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;15, 2016, we had outstanding options to purchase 2,043,612&nbsp;shares of our common stock, of which options to
	purchase 490,055&nbsp;shares were vested. Following this offering, we intend to file one or more registration statements on Form&nbsp;S-8 under the Securities Act to register all of the shares of
	our common stock subject to outstanding options and options and other awards issuable pursuant to the 2016 stock incentive plan, the 2016 ESPP and our 2012 equity incentive plan. Shares covered by
	these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described above and Rule&nbsp;144 limitations
	applicable to affiliates.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	178
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=181,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1009535,FOLIO='178',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_179">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_FUTURE_SALE>
<EFX_TAXATION>
<A NAME="FIS_TAXATION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EG79601_MATERIAL_U_S__FEDERAL_INCOME_A__MAT03574">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EG79601_3">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS
<BR>
	FOR NON-U.S. HOLDERS OF COMMON STOCK
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a general discussion of material U.S. federal income and estate tax considerations relating to ownership and
	disposition of our common stock by a non-U.S. holder. For purposes of this discussion, the term "non-U.S. holder" means a beneficial owner (other than a partnership or other pass-through entity) of
	our common stock that is not, for U.S. federal income tax purposes:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an individual who is a citizen or resident of the United States;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the
	laws of the United States or of any political subdivision of the United States;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a trust if (1)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S.
	persons have authority to control all substantial decisions of the trust or (2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S.
	person.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes or persons who hold their common
	stock through partnerships or such other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its own tax advisor
	regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other pass-through entity, as applicable.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	discussion is based on current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder,
	current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with
	retroactive effect. Any change could alter the tax consequences to non-U.S. holders described in this prospectus. There can be no assurance that the Internal Revenue Service, or the IRS, will not
	challenge one or more of the tax consequences described in this prospectus.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	assume in this discussion that each non-U.S. holder holds shares of our common stock as a capital asset (generally, property held for investment) for U.S. federal income tax purposes.
	This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances
	nor does it address any aspects of U.S. state, local or non-U.S. taxes, the alternative minimum tax, or the Medicare tax on net investment income. This discussion also does not consider any specific
	facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such
	as:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	financial institutions;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	brokers or dealers in securities;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	tax-exempt organizations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	pension plans;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated
	investment or who have elected to mark securities to market;
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	179
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=182,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=964142,FOLIO='179',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_180">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	insurance companies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	controlled foreign corporations;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	passive foreign investment companies;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	non-U.S. governments; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	certain U.S. expatriates.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<B>
	THIS DISCUSSION IS FOR GENERAL INFORMATION ONLY AND IS NOT, AND IS NOT INTENDED TO BE, LEGAL OR TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX
	ADVISORS REGARDING THE U.S. FEDERAL, STATE, LOCAL, ESTATE AND NON-U.S. INCOME AND OTHER TAX CONSIDERATIONS OF ACQUIRING, HOLDING AND DISPOSING OF OUR COMMON STOCK.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Distributions
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed under "Dividend Policy" above, we do not expect to make cash dividends to holders of our common stock in the foreseeable
	future. If we make distributions in respect of our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or
	accumulated earnings and profits, as determined under U.S. federal income tax principles, and will be subject to the tax treatment described in this section. If a distribution exceeds our current and
	accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder's investment, up to the holder's tax basis in the common stock. Any remaining excess will be
	treated as capital gain, subject to the tax treatment described below under the heading "Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock." Any such distributions will also be
	subject to the discussion below under the headings "Information Reporting and Backup Withholding" and "FATCA."
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
	paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax
	treaty between the United States and such holder's country of residence.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
	that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States, and, if an applicable income tax treaty so provides,
	that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder
	satisfies applicable certification and disclosure requirements (generally including provision of a valid IRS Form&nbsp;W-8ECI (or applicable successor form) certifying that the dividends are
	effectively connected with the non-U.S. holder's conduct of a trade or business within the United States). However, such U.S. effectively connected income, net of specified deductions and credits,
	will be taxed in the hands of the non-U.S. holder at the same graduated U.S. federal income tax rates as would apply if such holder were a U.S. person (as defined in the Code). A non-U.S. holder that
	is classified as a corporation for U.S. federal income tax purposes may also, under certain circumstances, be subject to an additional "branch profits tax" at a 30% rate (or such lower rate as may be
	specified by an applicable income tax treaty between the United States and such holder's country of residence) on its "effectively connected earnings and profits," subject to certain adjustments.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder's country of residence generally will be
	required to provide a properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their
	own tax advisors regarding their entitlement to benefits under a relevant income tax treaty and the specific methods available to them to satisfy these requirements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	180
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=183,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=423584,FOLIO='180',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_181">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an
	appropriate claim for a refund with the IRS.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below under the headings "Information Reporting and Backup Withholding" and "FATCA," a non-U.S. holder
	generally will not be subject to U.S. federal income tax or withholding tax on any gain realized upon such non-U.S. holder's sale, exchange or other disposition of our common stock
	unless:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the gain is effectively connected with the non-U.S. holder's conduct of a trade or business in the United States, and, if an
	applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S.
	holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to U.S. persons, and, if the non-U.S. holder is a foreign corporation, an additional
	branch profits tax at a rate of 30% (or a lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence) may also apply;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the non-U.S. holder is a non-resident alien present in the United States for 183&nbsp;days or more in the taxable year of the
	disposition and certain other requirements are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between
	the United States and such holder's country of residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the non-U.S. holder recognized in
	the taxable year of the disposition, if any; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	we are or have been, at any time during the five-year period preceding such disposition (or the non-U.S. holder's holding period, if
	shorter) a "U.S. real property holding corporation" unless our common stock is regularly traded on an established securities market and the non-U.S. holder held no more than 5% of our outstanding
	common stock, directly or indirectly, at any time during the shorter of the five-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock.
	Generally, a corporation is a "U.S. real property holding corporation" if the fair market value of its "U.S. real property interests" (as defined in the Code and applicable regulations) equals or
	exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we
	believe that we are not currently, and we do not anticipate becoming, a "U.S. real property holding corporation" for U.S. federal income tax purposes. If we are a U.S. real property holding
	corporation and either our common stock is not regularly traded on an established securities market or a non-U.S. holder holds more than 5% of our outstanding common stock, directly or indirectly,
	during the applicable testing period, such non-U.S. holder's proceeds received on the disposition of shares of our common stock generally will be subject to withholding at a rate of 10% and such
	non-U.S. holder will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally
	will not apply.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Information Reporting and Backup Withholding
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such
	holder and the tax withheld, if any, with respect to such distributions. Non-U.S. holders generally will have to comply with specific certification procedures to establish that the holder is not a
	U.S. person (as defined in the Code) in order to avoid backup
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	181
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=184,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1037520,FOLIO='181',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EG79601_1_182">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	withholding
	at the applicable rate with respect to dividends on our common stock. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form&nbsp;W-8BEN or
	W-8BEN-E (or other applicable Form&nbsp;W-8), or otherwise meets documentary evidence requirements for establishing that it is not a U.S. person, or otherwise establishes an exemption. Dividends
	paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above under "Distributions," will generally be exempt from U.S. backup withholding.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
	reporting and backup withholding, currently at a rate of 28%, generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or
	through the U.S.
	office of any broker, whether U.S. or non-U.S., unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption from backup
	withholding. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United
	States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations
	generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors regarding the application of the
	information reporting and backup withholding rules to them.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
	of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific
	treaty or agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
	withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S.
	holder's U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	FATCA
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Foreign Account Tax Compliance Act, or FATCA, generally imposes a 30% withholding tax on dividends on, and gross proceeds from the
	sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a "foreign financial institution," the foreign entity undertakes certain due diligence,
	reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a "foreign financial institution," the foreign entity identifies certain U.S. holders of debt or equity
	interests in such foreign entity or (iii)&nbsp;the foreign entity is otherwise exempt from FATCA.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding
	under FATCA generally (1)&nbsp;applies to payments of dividends on our common stock and (2)&nbsp;will apply to payments of gross proceeds from a sale or other disposition
	of our common stock made after December&nbsp;31, 2018. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this
	section. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of the tax. Non-U.S. holders should consult their own tax advisors regarding the possible implications of
	FATCA on their investment in our common stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Federal Estate Tax
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of our common stock that are owned or treated as owned by an individual who is not a citizen or resident of the United States
	(as specially defined for U.S. federal estate tax purposes) at the time of death are considered U.S. situs assets and will be included in the individual's gross estate for U.S. federal estate tax
	purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT SIZE=2>
<B>
	The preceding discussion of material U.S. federal tax considerations is for general information only. It is not legal or tax advice. Prospective investors should
	consult their own tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock, including the consequences of
	any proposed changes in applicable laws.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	182
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=185,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=235406,FOLIO='182',FILE='DISK124:[15ZCT1.15ZCT79601]EG79601A.;49',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_183">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_TAXATION>
<EFX_UNDERWRITING>
<A NAME="FIS_UNDERWRITING"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EI79601_UNDERWRITING">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EI79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	UNDERWRITING
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the shares of common
	stock being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of common stock set forth
	opposite its name below. Cowen and Company,&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co. are the representatives of the underwriters.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="51PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:43PT;">
<FONT SIZE=1>
<B>
	Underwriter
<!-- COMMAND=ADD_SCROPPEDRULE,43PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Number of
<BR>
	Shares
</B>
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cowen and Company,&nbsp;LLC
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Piper Jaffray&nbsp;&amp;&nbsp;Co.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	JMP Securities&nbsp;LLC
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Wedbush Securities&nbsp;Inc.&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent and that the underwriters have agreed, severally and not jointly,
	to purchase all of the shares of common stock sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the overallotment option described below.
	If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required
	to make in respect thereof.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	underwriters are offering the shares of common stock, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and
	other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our existing principal stockholders have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million in shares of our common stock in this offering
	at the initial public offering
	price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares to any of these potential
	purchasers and any of these potential purchasers could determine to purchase more, less or no shares in this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Overallotment Option to Purchase Additional Shares
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have granted to the underwriters an option to purchase up to 600,000 additional shares of common stock at the public offering price,
	less the underwriting discount, in this offering of common stock. This option is exercisable for a period of 30&nbsp;days. The underwriters may exercise this option solely for the purpose of
	covering overallotments, if any, made in connection with the sale of common stock offered hereby. To the extent that the underwriters exercise this option, the underwriters will purchase additional
	shares from us in approximately the same proportion as shown in the table above.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Discounts and Commissions
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. These amounts are
	shown assuming both no exercise and full exercise of the underwriters' overallotment option.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	183
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=186,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=396430,FOLIO='183',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_184">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the total expenses of this offering of common stock, excluding underwriting discounts and commissions, will be approximately $3,000,000 and are payable by us. We have
	also agreed to reimburse the underwriters for certain of their expenses as set forth in the underwriting agreement, including legal fees incurred in the qualification of this offering and the
	concurrent offering of notes with the Financial Regulatory Authority, or FINRA, in an amount of up to $30,000, which amount is deemed to be underwriting compensation by FINRA.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="47PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=8 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Total
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Per Share
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Without
<BR>
	Overallotment
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	With
<BR>
	Overallotment
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Initial public offering price
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Underwriting discounts and commissions
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds, before expenses, to Syros
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the cover of this prospectus. The underwriters may offer the shares
	of common stock to securities dealers at the public offering price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. If all of the shares are not sold at the public offering price,
	the
	underwriters may change the offering price and other selling terms. Sales of shares of common stock made outside of the United States may be made by affiliates of certain of the underwriters. Certain
	of the underwriters may sell shares to the public through one or more of their affiliates as selling agents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Discretionary Accounts
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters do not intend to confirm sales of the shares of common stock to any accounts over which they have discretionary
	authority.
</FONT>
</P>
</EFX_UNDERWRITING>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Market Information
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for shares of our common stock. The initial public offering price will be
	determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations
	include:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the history of, and prospects for, our company and the industry in which we compete;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	our past and present financial information;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	an assessment of our management; its past and present operations, and the prospects for, and timing of, our future revenues;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the present state of our development; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to
	ours.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
	active trading market for our common stock may not develop, of if such a market develops, may not be sustained. It is also possible that after the offering the shares will not trade
	in the public market at or above the initial public offering price.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have applied to list our common stock on The NASDAQ Global Market under the symbol "SYRS."
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	184
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=187,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=929961,FOLIO='184',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_185">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Price Stabilization, Short Positions and Penalty Bids
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering of common stock, the underwriters may engage in stabilizing transactions, overallotment transactions,
	syndicate covering transactions, penalty bids and purchases to cover positions created by short sales.
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified
	maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares the
	underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of
	shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the overallotment option. In a naked short position, the number of shares involved is
	greater than the number of shares in the overallotment option. The underwriters may close out any short position by exercising their overallotment option and/or purchasing shares in the open market.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been completed in
	order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for
	purchase in the open market as compared with the price at which they may purchase shares through exercise of the overallotment option. If the underwriters sell more shares than could be covered by
	exercise of the overallotment option and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be
	created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the
	offering.
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold
	by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
	stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or
	retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these
	transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of shares of our common stock. These
	transactions may be effected on The NASDAQ Global Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Lock-Up Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to certain "lock-up" agreements, we and our executive officers, directors and stockholders, have agreed, subject to certain
	exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar
	agreement or arrangement that transfers, in whole or in part, the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the
	registration of, or file with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible into or exchangeable or exercisable for any common stock
	without the prior written consent of Cowen and Company,&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co., for a period of 180&nbsp;days after the date of the underwriting agreement.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	185
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=188,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=838757,FOLIO='185',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_186">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
	lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired
	later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. The lock-up agreements include customary exceptions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cowen
	and Company,&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co., in their sole discretion, may release our common stock and other securities subject to the lock-up agreements
	described above in whole or in part at any time. When determining whether or not to release our common stock and other securities from lock-up agreements, Cowen and Company,&nbsp;LLC and Piper
	Jaffray&nbsp;&amp;&nbsp;Co. will consider, among other factors, the holder's reasons for requesting the release, the number of shares for which the release is being requested and market conditions at
	the time of the request. In the event of such a release or waiver for one of our directors or officers, Cowen and Company,&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co. shall provide us with notice
	of the impending release or waiver at least three business days before the effective date of such release or waiver and we will announce the impending release or waiver by issuing a press release at
	least two business days before the effective date of the release or waiver.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Electronic Offer, Sale and Distribution of Shares
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group
	members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate
	a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members
	that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the
	registration statement of which this prospectus forms&nbsp;a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by
	investors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Relationships
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking, commercial
	banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Selling Restrictions
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No action has been taken in any jurisdiction except the United States that would permit a public offering of our common stock, or the
	possession, circulation or distribution of this prospectus or any other material relating to us or our common stock in any jurisdiction where action for that purpose is required. Accordingly, the
	shares may not be offered or sold, directly or indirectly, and neither this prospectus nor any other offering material or advertisements in connection with the shares may be distributed or published,
	in or from any country or jurisdiction except in compliance with any applicable rules and regulations of any such country or jurisdiction.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Canada
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
	defined in National Instrument&nbsp;45-106
</FONT>
<FONT SIZE=2>
<I>
	Prospectus Exemptions
</I>
</FONT>
<FONT SIZE=2>
	or subsection&nbsp;73.3(1) of the
</FONT>
<FONT SIZE=2>
<I>
	Securities
	Act
</I>
</FONT>
<FONT SIZE=2>
	(Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
</FONT>
<FONT SIZE=2>
<I>
	Registration Requirements, Exemptions and Ongoing Registrant
	Obligations
</I>
</FONT>
<FONT SIZE=2>
	. Any resale
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	186
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=189,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=300028,FOLIO='186',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_187">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	of
	the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
	legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
	contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's
	province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a
	legal advisor.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
	to section&nbsp;3A.3 of National Instrument&nbsp;33-105
</FONT>
<FONT SIZE=2>
<I>
	Underwriting Conflicts
</I>
</FONT>
<FONT SIZE=2>
	(NI&nbsp;33-105), the underwriters are not
	required to comply with the disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	United Kingdom
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the underwriters has, separately and not jointly, represented and agreed
	that:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	it has not made or will not make an offer of the securities to the public in the United Kingdom within the meaning of
	section&nbsp;102B of the Financial Services and Markets Act 2000 (as amended), or the FSMA, except to legal entities which are authorized or regulated to operate in the financial markets or, if not
	so authorized or regulated, whose corporate purpose is solely to invest in securities or otherwise in circumstances which do not require the publication by us of a prospectus pursuant to the
	Prospectus Rules of the Financial Services Authority, or FSA;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or
	inducement to engage in investment activity (within the meaning of section&nbsp;21 of FSMA) to persons who have professional experience in matters relating to investments falling within
	Article&nbsp;19(5) of the Financial Services and Markets Act&nbsp;2000 (Financial Promotion) Order 2005 or in circumstances in which section&nbsp;21 of FSMA does not apply to us; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	it has complied with and will comply with all applicable provisions of FSMA with respect to anything done by it in relation to the
	securities in, from or otherwise involving the United Kingdom.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Switzerland
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a
	public offering prospectus as that term is understood pursuant to article&nbsp;652a or 1156 of the Swiss Federal Code of Obligations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Israel
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the
	Israeli Securities Law, 5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of
	Section&nbsp;15 of the Israeli Securities Law, 5728&#151;1968, including,
</FONT>
<FONT SIZE=2>
<I>
	inter alia
</I>
</FONT>
<FONT SIZE=2>
	, if: (i)&nbsp;the offer is made, distributed or directed
	to not more than 35 investors, subject to certain conditions (the "Addressed Investors"); or (ii)&nbsp;the offer is
	made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions (the "Qualified
	Investors"). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The
	company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#151;1968. We have not and will not
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	187
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=190,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=292638,FOLIO='187',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_188">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	distribute
	this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed
	Investors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Qualified
	Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#151;1968. In
	particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it
	is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii)&nbsp;which of the categories listed in the First Addendum
	to the Israeli Securities Law, 5728&#151;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law,
	5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares of common stock that it will be issued are, subject
	to exemptions available under the Israeli Securities Law, 5728&#151;1968: (a)&nbsp;for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to
	resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of
	its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing,
</FONT>
<FONT SIZE=2>
<I>
	inter alia
</I>
</FONT>
<FONT SIZE=2>
	, the Addressed
	Investor's name, address and passport number or Israeli identification number.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	European Economic Area
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area, or the EEA, which has implemented the European Prospectus Directive
	(each, a "Relevant Member State"), an offer of our shares may not be made to the public in a Relevant Member State other than:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	to any legal entity which is a qualified investor, as defined in the European Prospectus Directive;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150
	natural or legal persons (other than qualified investors as defined in the European Prospectus Directive), subject to obtaining the prior consent of the relevant dealer or dealers nominated by us for
	any such offer; or
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	in any other circumstances falling within Article&nbsp;3(2) of the European Prospectus Directive;
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	provided
	that no such offer of our shares shall require us or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the European Prospectus Directive or supplement prospectus
	pursuant to Article&nbsp;16 of the European Prospectus Directive.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
	the purposes of this description, the expression an "offer to the public" in relation to the securities in any Relevant Member State means the communication in any form and by any
	means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the expression may be
	varied in that Relevant Member State by any measure implementing the European Prospectus Directive in that member state, and the expression "European Prospectus Directive" means Directive 2003/71/EC
	(and amendments hereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State) and includes any relevant implementing measure in each Relevant Member State.
	The expression 2010 PD Amending Directive means Directive 2010/73/EU.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers made by the underwriters and their
	respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to
	make any further offer of shares on our behalf or on behalf of the underwriters.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	188
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=191,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=948061,FOLIO='188',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_189">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Hong Kong
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The contents of this document have not been reviewed or approved by any regulatory authority in Hong Kong. This document does not
	constitute an offer or invitation to the public in Hong Kong to acquire shares. Accordingly, unless permitted by the securities laws of Hong Kong, no person may issue or have in its possession for the
	purposes of issue, this document or any advertisement, invitation or document relating to the shares, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be
	accessed or read by, the public in Hong Kong other than in relation to shares which are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" (as such term
	is defined in the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) ("SFO") and the subsidiary legislation made thereunder); or in circumstances which do not result in this document being
	a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32, Laws of Hong Kong) ("CO"); or which do not constitute an offer or an invitation to the public
	for the purposes of the SFO or the&nbsp;CO. The offer of the shares is personal to the person to whom this document has been delivered, and a subscription for shares will only be accepted from such
	person. No person to whom a copy of this document is issued may issue, circulate or distribute this document in Hong Kong, or make or give a copy of this document to any other person. You are advised
	to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Singapore
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any
	other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold,
	or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor pursuant to
	Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore ("SFA"), (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA), or any person pursuant
	to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other
	applicable provision of the SFA.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
	the shares are subscribed or purchased pursuant to an offer made in reliance on Section&nbsp;275 of the SFA by a relevant person which is:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a
	corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one
	or more individuals, each of whom is an accredited investor; or
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	a
	trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor;
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	shares,
	debentures and units of shares, and debentures of that corporation, or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferable for six months after
	that corporation or that trust has acquired the shares under Section&nbsp;275 except:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	to
	an institutional investor or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), or any person pursuant to Section&nbsp;275(1A) of
	the SFA (in the case of that corporation) or Section&nbsp;276(4)(i)(B) of the SFA (in the case of that trust);
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	where
	no consideration is or will be given for the transfer; or
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(3)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	where
	the transfer is by operation of law.
</FONT>
</DD>
</DL>
</UL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	189
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=192,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=109100,FOLIO='189',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_EI79601_1_190">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_MARKET>
<EFX_LEGAL_MATTERS>
<A NAME="FIS_LEGAL_MATTERS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EI79601_LEGAL_MATTERS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EI79601_2">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	LEGAL MATTERS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of our common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and
	Dorr&nbsp;LLP. The underwriters have been represented in this offering by Cooley&nbsp;LLP.
</FONT>
</P>
</EFX_LEGAL_MATTERS>
<EFX_EXPERTS>
<A NAME="FIS_EXPERTS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EI79601_EXPERTS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EI79601_3">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXPERTS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements at
	December&nbsp;31, 2014 and 2015, and for each of the years then ended, as set forth in their report. We have included our consolidated financial statements in the prospectus and elsewhere in the
	registration statement in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing.
</FONT>
</P>
</EFX_EXPERTS>
<EFX_MORE_INFORMATION>
<A NAME="FIS_MORE_INFORMATION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_EI79601_WHERE_YOU_CAN_FIND_MORE_INFORMATION">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_EI79601_4">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	WHERE YOU CAN FIND MORE INFORMATION
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of our
	common stock we are offering to sell. This prospectus, which constitutes a part of the registration statement, does not include all of the information contained in the registration statement and the
	exhibits, schedules and amendments to the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and
	schedules to the registration statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we
	refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference to such
	contract, agreement or document.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
	may read and copy the registration statement of which this prospectus is a part at the SEC's public reference room, which is located at 100&nbsp;F Street, N.E., Room&nbsp;1580,
	Washington, DC&nbsp;20549. You can request copies of the registration statement by writing to the Public Reference Section of the SEC and paying a fee for the copying cost. Please call the SEC at
	1-800-SEC-0330 for more information about the operation of the SEC's public reference room. In addition, the SEC maintains an Internet website, which is located at
</FONT>
<FONT SIZE=2>
<I>
	www.sec.gov
</I>
</FONT>
<FONT SIZE=2>
	, that contains reports,
	proxy and information statements and other information regarding issuers that file electronically with the SEC. You
	may access the registration statement of which this prospectus is a part at the SEC's Internet website.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with
	the SEC. We plan to fulfill our obligations with respect to such requirements by filing periodic reports and other information with the SEC. We intend to furnish our stockholders with annual reports
	containing consolidated financial statements certified by an independent registered public accounting firm. We also maintain a website at www.syros.com. Our website is not a part of this prospectus.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	190
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=193,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=526659,FOLIO='190',FILE='DISK124:[15ZCT1.15ZCT79601]EI79601A.;39',USER='KSEAMON',CD='19-JUN-2016;10:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FA79601_1_1">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_MORE_INFORMATION>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FA79601_INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMENTS">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FA79601_TOC">
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="22PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FC79601_REPORT_OF_INDEPENDENT___FC702287">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Report of Independent Registered Public Accounting Firm
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FC79601_REPORT_OF_INDEPENDENT___FC702287">
<FONT SIZE=2>
	F-2
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FE79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR04175">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Balance Sheets
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FE79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR04175">
<FONT SIZE=2>
<BR>
	F-3
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FG79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR05605">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Statements of Operations and Comprehensive
	Loss
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FG79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR05605">
<FONT SIZE=2>
<BR>
	F-4
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FI79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR06111">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Statements of Convertible Preferred Stock and
	Stockholders' (Deficit) Equity
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FI79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR06111">
<FONT SIZE=2>
<BR>
	F-5
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FK79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR03408">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Consolidated Statements of Cash Flows
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_FK79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR03408">
<FONT SIZE=2>
<BR>
	F-6
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_NOTES">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Notes to Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZS-1A_HTM_NOTES">
<FONT SIZE=2>
<BR>
	F-7
</FONT>
</A>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-1
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=194,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=469688,FOLIO='F-1',FILE='DISK124:[15ZCT1.15ZCT79601]FA79601A.;8',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FC79601_1_2">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FC79601_REPORT_OF_INDEPENDENT___FC702287">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_FC79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	Report of Independent Registered Public Accounting Firm
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	Board of Directors and Stockholders of
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have audited the accompanying consolidated balance sheets of Syros Pharmaceuticals,&nbsp;Inc. (the "Company") as of December&nbsp;31, 2014 and 2015, and the related consolidated
	statements of operations and comprehensive loss, convertible preferred stock and stockholders' (deficit) equity, and cash flows
	for each of the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our
	audits.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
	obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial
	reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose
	of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis,
	evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial
	statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Syros Pharmaceuticals,&nbsp;Inc. at
	December&nbsp;31, 2014 and 2015, and the consolidated results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	/s/ Ernst&nbsp;&amp; Young&nbsp;LLP
<BR>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Boston, Massachusetts
<BR>
	April&nbsp;18, 2016
<BR>
	except for Note 16(B), as to which the date is
<BR>
	June&nbsp;20, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-2
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=195,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=937227,FOLIO='F-2',FILE='DISK124:[15ZCT1.15ZCT79601]FC79601A.;18',USER='CHE105570',CD='18-JUN-2016;12:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FE79601_1_3">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FE79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR04175">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_FE79601_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
<BR>
<BR>
	Consolidated Balance Sheets
<BR>
<BR>
	(amounts in thousands, except share and per share data)
<BR>
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="41PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="6PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31, 2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Actual
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Pro forma
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Assets
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current assets:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash and cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,393
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,909
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Prepaid expenses and other current assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	150
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	540
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,092
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,092
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:24PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total current assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,543
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	36,449
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,225
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,225
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Property and equipment, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	881
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,799
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,857
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,857
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other long term assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,900
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,260
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,260
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Restricted cash
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	483
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	483
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	483
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:24PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	61,494
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43,631
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Liabilities, convertible preferred stock and stockholders' (deficit) equity
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Current liabilities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounts payable
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	928
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,035
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,260
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,260
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	287
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,504
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,692
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,692
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred rent, current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	37
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	284
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	293
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	293
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Capital lease obligations, current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	156
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	156
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:24PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total current liabilities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,252
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,956
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,401
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,401
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred rent, net of current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,420
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,341
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,341
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Restricted stock liability, net of current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Capital lease obligations, net of current portion
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	206
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	166
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	166
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Commitments and contingencies (Note&nbsp;8)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Series&nbsp;A convertible preferred stock, $0.001 par value; 30,350,000 shares authorized, issued and outstanding at December&nbsp;31, 2014 and 2015 and at
	March&nbsp;31, 2016 (unaudited); no shares issued and outstanding at March&nbsp;31, 2016 (pro forma) (unaudited); (aggregated liquidation preference of $31,238, $32,984, and $33,418 at December&nbsp;31, 2014 and 2015 and at March&nbsp;31, 2016
	(unaudited), respectively)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Series&nbsp;B convertible preferred stock, $0.001 par value; 16,893,931 shares authorized, issued and outstanding at December&nbsp;31, 2014 and 2015; and
	29,608,081 shares authorized, issued and outstanding at March&nbsp;31, 2016 (unaudited); no shares issued and outstanding at March&nbsp;31, 2016 (pro forma) (unaudited); (aggregated liquidation preference of $53,846, $57,034, and $98,337 at
	December&nbsp;31, 2014 and 2015 and at March&nbsp;31, 2016 (unaudited), respectively)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	52,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	52,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	92,792
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:8PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stockholders' (deficit) equity:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Preferred stock, $0.001 par value; no shares authorized, issued or outstanding actual; 10,000,000&nbsp;shares authorized, no shares issued and outstanding
	(pro forma)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Common stock, $0.001 par value; 64,571,908, 66,171,908 and 78,886,062 shares authorized at December&nbsp;31, 2014 and 2015 and at March&nbsp;31, 2016
	(unaudited), respectively; 1,640,009, 2,363,018 and 2,404,350 shares issued and outstanding at December&nbsp;31, 2014 and 2015 and at March&nbsp;31, 2016 (unaudited), respectively; 18,446,484 shares issued and outstanding at March&nbsp;31, 2016 (pro
	forma) (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Additional paid-in capital
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,922
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,547
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,209
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	128,725
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:16PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accumulated deficit
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(23,695
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(53,513
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(64,101
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(64,826
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:24PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total stockholders' (deficit) equity
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(21,772
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(47,964
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(57,890
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	63,917
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:24PT;TEXT-INDENT:-8PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total liabilities, convertible preferred stock and stockholders' (deficit) equity
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	61,494
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43,631
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	70,825
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_BALANCE_SHEET>
<P STYLE="FONT-FAMILY:TIMES;LINE-HEIGHT:1PT;MARGIN-LEFT:18PT;">
<FONT>
</FONT>
<FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
	&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;">
<FONT>
</FONT>
<FONT SIZE=2>
	The accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-3
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=196,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=558361,FOLIO='F-3',FILE='DISK124:[15ZCT1.15ZCT79601]FE79601A.;45',USER='PJAMES',CD='17-JUN-2016;18:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FG79601_1_4">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FG79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR05605">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_FG79601_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
<BR>
<BR>
	Consolidated Statements of Operations and Comprehensive Loss
<BR>
<BR>
	(amounts in thousands, except share and per share data)
<BR>
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	317
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Operating expenses:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,923
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24,408
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,736
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,265
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,512
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,729
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	836
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,371
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total operating expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13,435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	30,137
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,435
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,820
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,572
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,636
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other income, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss and comprehensive loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,431
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,568
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued dividends on preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2,211
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,934
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,217
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,737
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss applicable to common stockholders
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(15,642
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(34,752
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5,785
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(12,325
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss per share applicable to common stockholders&#151;basic and diluted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10.26
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(17.55
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3.44
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5.15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in net loss per share applicable to common stockholders&#151;basic and diluted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,525,018
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,980,286
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,682,690
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,394,470
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_INCOME_STATEMENT>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma net loss per share&#151;basic and diluted (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2.09
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.59
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in pro forma net loss per share&#151;basic and diluted (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,593,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17,947,602
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;LINE-HEIGHT:1PT;MARGIN-LEFT:18PT;">
<FONT>
</FONT>
<FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
	&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;">
<FONT>
</FONT>
<FONT SIZE=2>
	The accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-4
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=197,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=591655,FOLIO='F-4',FILE='DISK124:[15ZCT1.15ZCT79601]FG79601A.;26',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FI79601_1_5">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FI79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR06111">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_FI79601_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
<BR>
<BR>
	Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity
<BR>
<BR>
	(amounts in thousands except
	share data)
<BR>
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:54%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="150%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="47PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="36PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="47PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="36PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="25PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="54PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="4PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="56PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Series&nbsp;A Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Series&nbsp;B Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Common Stock
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	# of
<BR>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amount
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	# of
<BR>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amount
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	# of
<BR>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Par
<BR>
	Value
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Additional
<BR>
	Paid-In
<BR>
	Capital
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Accumulated
<BR>
	Deficit
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Stockholders'
<BR>
	(Deficit)
<BR>
	Equity
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
<B>
	Balance at December&nbsp;31, 2013
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	14,600,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	13,266
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	1,379,669
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	970
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(10,264
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(9,293
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Issuance of Series&nbsp;A convertible preferred stock, net of issuance costs of $1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	15,750,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	15,749
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Issuance of Series&nbsp;B convertible preferred stock, net of issuance costs of $152
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	16,893,931
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	52,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Exercise of stock options and vesting of restricted stock awards
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	260,340
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(13,431
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(13,431
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
<B>
	Balance at December&nbsp;31, 2014
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	30,350,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	16,893,931
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	52,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1,640,009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1,922
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(23,695
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(21,772
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Exercise of stock options and vesting of restricted stock awards
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	723,009
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	392
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	393
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	3,233
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	3,233
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
<B>
	Balance at December&nbsp;31, 2015
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	30,350,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	16,893,931
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	52,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,363,018
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	5,547
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(53,513
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(47,964
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Issuance of Series&nbsp;B convertible preferred stock, net of issuance costs of $206 (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	12,714,150
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	39,794
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Vesting of restricted stock (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	41,332
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	662
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	662
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Net loss (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
<B>
	Balance at March&nbsp;31, 2016 (unaudited)
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	30,350,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	29,608,081
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	92,792
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2,404,350
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	6,209
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(64,101
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(57,890
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Conversion of Series&nbsp;A convertible preferred stock into common stock (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(30,350,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	8,093,326
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	29,007
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	29,015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Conversion of Series&nbsp;B convertible preferred stock into common stock (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(29,608,081
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(92,792
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	7,895,474
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	92,784
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	92,792
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Stock-based compensation expense for stock-based awards that vest upon initial public offering (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	53,334
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	725
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(725
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:7PT;TEXT-INDENT:-7PT;">
<FONT SIZE=1>
</FONT>
<FONT SIZE=1>
	Pro forma balance at March&nbsp;31, 2016 (unaudited)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	18,446,484
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	128,725
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	(64,826
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	63,917
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT-FAMILY:TIMES;LINE-HEIGHT:1PT;MARGIN-LEFT:18PT;">
<FONT>
</FONT>
<FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
	&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;">
<FONT>
</FONT>
<FONT SIZE=2>
	The accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-5
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=198,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=792263,FOLIO='F-5',FILE='DISK124:[15ZCT1.15ZCT79601]FI79601A.;40',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FK79601_1_6">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_FK79601_SYROS_PHARMACEUTICALS,_INC__CO__SYR03408">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_FK79601_1">
</A>
</FONT>
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
<BR>
<BR>
	Consolidated Statements of Cash Flows
<BR>
<BR>
	(amounts in thousands)
<BR>
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months Ended
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
<B>
	(unaudited)
</B>
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Operating Activities
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(13,431
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(4,568
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Adjustments to reconcile net loss to net cash used in operating activities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:40PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Depreciation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	258
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	602
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	74
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	304
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:40PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Loss on disposal of assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:40PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock-based compensation expense
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	937
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,233
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	511
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	662
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:40PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Changes in operating assets and liabilities:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:50PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Prepaid expenses and other current assets
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(38
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(390
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(277
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(552
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:50PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Restricted cash
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(413
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:50PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounts payable
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	334
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,022
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	290
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(914
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:50PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accrued expenses
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,663
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	400
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	540
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:50PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred revenue
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	317
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:50PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred rent and lease incentive
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(36
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	54
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(70
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:60PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash used in operating activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(11,969
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(23,030
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3,269
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,618
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Investing Activities
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Purchases of property and equipment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(201
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,176
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(108
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,525
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash used in investing activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(201
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,176
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(108
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,525
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Financing Activities
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Payments of capital lease obligations
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(50
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(17
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from issuance of convertible preferred stock, net of issuance costs
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	68,747
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	39,811
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Proceeds from issuance of common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	392
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Payments of offering costs
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(620
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,427
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net cash provided by (used in) financing activities&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	68,762
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(278
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	38,367
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:30PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Increase (decrease) in cash and cash equivalents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	56,592
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(24,484
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3,377
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	26,224
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Cash and cash equivalents
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Beginning of period
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,801
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,393
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,393
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,909
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	End of period
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60,393
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,909
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	57,016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
<B>
	Supplemental disclosure of cash flow information:
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cash paid for interest
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Non-cash investing and financing activities
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Property and equipment received but unpaid as of period end
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,359
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	196
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_CASH_FLOW>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Assets acquired under capital lease
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	389
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	389
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Assets acquired through lease incentive
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,612
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Offering costs incurred but unpaid as of period end&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,280
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	235
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;LINE-HEIGHT:1PT;MARGIN-LEFT:18PT;">
<FONT>
</FONT>
<FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
	&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ALIGN=CENTER STYLE="FONT-FAMILY:TIMES;">
<FONT>
</FONT>
<FONT SIZE=2>
	The accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-6
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=199,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=818472,FOLIO='F-6',FILE='DISK124:[15ZCT1.15ZCT79601]FK79601A.;29',USER='CHE105536',CD='16-JUN-2016;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_7">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_NOTES">
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
</EFX_AUDITORS_OPINION>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	1. Nature of Business
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Syros Pharmaceuticals,&nbsp;Inc. (the "Company"), formerly known as LS22,&nbsp;Inc., a Delaware corporation formed in November 2011, is a biopharmaceutical company seeking an
	understanding of an unexploited region of the genome to advance new medicines with the goal of controlling the expression of disease-driving genes. The Company has built a proprietary platform
	designed to analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals; risks inherent in the development and
	commercialization of medicines to treat human disease; competition from other companies, many of which are larger and better capitalized; risks relating to obtaining and maintaining necessary
	intellectual property protection; and the need to obtain adequate additional financing to fund the development of its product candidates. If the Company is unable to raise capital when needed or on
	attractive terms, it would be forced to delay, reduce, eliminate or out-license certain of its research and development programs or future commercialization efforts.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company has an accumulated deficit as of March&nbsp;31, 2016 of approximately $64.1&nbsp;million and will require substantial additional capital for research and product
	development. The future success of the Company is dependent upon its ability to develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company believes
	that its cash and cash equivalents as of March&nbsp;31, 2016, totaling $62.1&nbsp;million, will be sufficient to allow the Company to fund its current operating plan for a period of at least
	12&nbsp;months past the issuance of its financial statements. Thereafter, the Company will be required to obtain additional funding and intends to pursue a public offering of its common stock to
	fund future operations. However, if the Company is unable to complete a sufficient public offering in a timely manner it would need to pursue other financing alternatives, such as private financing of
	debt or equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to
	the Company, or at all.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of significant accounting policies followed in the preparation of these financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Basis of Presentation
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States
	("U.S.&nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position and results of its operations for the periods presented. Any reference in these
	notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification ("ASC") and Accounting
	Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB").
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-7
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=200,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1027930,FOLIO='F-7',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_8">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Principles of Consolidation
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements include the accounts of Syros Pharmaceuticals,&nbsp;Inc. and its wholly owned
	subsidiary, Syros Securities Corporation, which is a Massachusetts subsidiary formed by the Company in December 2014 to exclusively engage in buying, selling and holding securities on its own behalf.
	All intercompany transactions and balances have been eliminated.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Use of Estimates
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that
	affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates
	and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, which
	include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are
	expected to be representative of future trends. Management's estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that
	range of reasonable estimates. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, stock-based
	compensation expense, including estimating the fair value of the Company's common stock (the "Common Stock"), accrued expenses and income taxes. Actual results may differ from those estimates or
	assumptions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Unaudited Pro Forma Financial Information
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of a qualified initial public offering, all of the Company's outstanding convertible preferred stock will
	automatically convert into Common Stock and certain of the Company's restricted stock and performance-based stock option awards will vest. The accompanying unaudited pro forma consolidated balance
	sheet and statement of convertible preferred stock and stockholders' (deficit) equity as of March&nbsp;31, 2016 assumes (1)&nbsp;the conversion of all outstanding convertible preferred stock into
	an aggregate of 15,988,800&nbsp;shares of common stock and (2)&nbsp;the vesting of certain restricted stock and performance-based stock option awards as if this proposed initial public offering
	was completed on March&nbsp;31, 2016. In the accompanying consolidated statements
	of operations and comprehensive loss, unaudited pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give effect to the automatic conversion of all
	outstanding shares of convertible preferred stock and vesting of certain restricted stock and performance-based stock option awards as if this proposed initial public offering had occurred on the
	later of the beginning of the reporting period or the issuance date of the convertible preferred stock or performance-based award. Accordingly, the unaudited pro forma net loss attributable to common
	stockholders used in the calculation of unaudited basic and diluted pro forma net loss per share attributable to common stockholders excludes the effects of dividends on preferred stock and includes
	additional compensation expense related to the vesting of certain of the Company's restricted stock and performance-based stock option awards.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-8
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=201,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=909609,FOLIO='F-8',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_9">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Segment Information
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for
	evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company's chief operating decision maker is the
	Chief Executive Officer. The Company and the chief operating decision maker view the Company's operations and manage its business in one operating segment. The Company operates only in the United
	States.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Comprehensive Loss
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and
	circumstances from non-owner sources. For the years ended December&nbsp;31, 2014 and 2015 and three months ended March&nbsp;31, 2015 and 2016, comprehensive loss was equal to net loss.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Cash and Cash Equivalents
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid instruments that have original maturities of three months or less when acquired to be cash
	equivalents. Cash equivalents, which consist of money market funds that invest in U.S. Treasury obligations, are stated at fair value. The Company maintains its bank accounts at one major financial
	institution.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Off-Balance Sheet Risk and Concentrations of Credit Risk
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other
	foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company's cash is held in
	accounts at a financial institution that may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant
	credit risk on these funds.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Fair Value of Financial Instruments
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC Topic 820,
</FONT>
<FONT SIZE=2>
<I>
	Fair Value Measurement
</I>
</FONT>
<FONT SIZE=2>
	("ASC 820"), establishes a fair value hierarchy
	for instruments measured at fair value that distinguished between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are
	inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the
	Company's assumption about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC
	820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
	transaction between market participants. As a basis for considering market participant assumptions in fair value
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-9
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=202,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=93589,FOLIO='F-9',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_10">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	measurements,
	ASC 820 established a three-tier fair value hierarchy that distinguishes between the following:
</FONT>
</P>
<UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Level&nbsp;1&#151;Quoted
	market prices (unadjusted) in active markets for identical assets or liabilities.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Level&nbsp;2&#151;Inputs
	other than quoted prices included within Level&nbsp;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield
	curves.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Level&nbsp;3&#151;Unobservable
	inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use.
</FONT>
</P>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
	the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly,
	the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument's level within the fair value hierarchy is
	based on the lowest level of any input that is significant to the fair value measurement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair
	values, due to their short-term nature.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Property and Equipment
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consists of laboratory equipment, computer equipment, furniture and fixtures and leasehold improvements, all of
	which are stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs that do not improve or extend the lives of the respective assets are recorded to expense as incurred.
	Major betterments are capitalized as additions to property and equipment. Depreciation is recognized over the estimated useful lives of the assets using the straight-line method.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction-in-progress
	is stated at cost, which relates to the cost of research equipment not yet placed into service. No depreciation expense is recorded on construction-in-progress
	until such time as the relevant assets are completed and put into use.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Impairment of Long-Lived Assets
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the
	carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are
	expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The
	Company has not recognized any impairment losses from inception through March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Other Long Term Assets
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long term assets consist of deferred issuance costs relating to its proposed initial public offering of common stock, and at
	December&nbsp;31, 2015, include direct incremental legal and accounting fees relating to the Company's Series B preferred stock financing that closed in January 2016. Deferred
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-10
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=203,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=853012,FOLIO='F-10',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_11">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	issuance
	costs are capitalized as incurred. The deferred issuance costs will be offset against proceeds upon the consummation of the offering. In the event the offering is terminated, deferred
	issuance costs will be expensed. Approximately $1.9 million and $2.3&nbsp;million of deferred issuance costs were incurred and capitalized as of December&nbsp;31, 2015 and March&nbsp;31, 2016,
	respectively. No amounts were capitalized as of December&nbsp;31, 2014. Such costs are included within other long term assets on the balance sheet.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Revenue Recognition
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, the Company's only source of revenue has been the research agreement with a multinational pharmaceutical company
	(Note&nbsp;13).
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company recognizes revenue in accordance with ASC Topic 605,
</FONT>
<FONT SIZE=2>
<I>
	Revenue Recognition
</I>
</FONT>
<FONT SIZE=2>
	("ASC&nbsp;605"). Accordingly, revenue is
	recognized when all of the following criteria are met:
</FONT>
</P>
<UL>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Persuasive evidence of an arrangement exists;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Delivery has occurred or services have been rendered;
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The seller's price to the buyer is fixed or determinable; and
</FONT>
<FONT SIZE=2>
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#149;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Collectability is reasonably assured.
</FONT>
</DD>
</DL>
</UL>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts
	received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company's consolidated balance sheets. Amounts expected to be recognized
	as revenue within the 12&nbsp;months following the balance sheet date are classified in current liabilities. Amounts not expected to be recognized as revenue within the 12&nbsp;months following
	the balance sheet date are classified as deferred revenue, net of current portion.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company analyzes arrangements with multiple deliverables based on the guidance in ASC Topic 605-25,
</FONT>
<FONT SIZE=2>
<I>
	Revenue Recognition&#151;Multiple Element
	Arrangements
</I>
</FONT>
<FONT SIZE=2>
	("ASC 605-25"). Pursuant to the guidance in ASC 605-25, the Company evaluates multiple element arrangements to determine (1)&nbsp;the deliverables included in
	the arrangement and (2)&nbsp;whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation
	involves subjective determinations and requires management to make judgements about the individual deliverables and whether such deliverables are separate from other aspects of the contractual
	relationship. Deliverables are considered separate units of accounting provided that: (i)&nbsp;the delivered item(s) has value to the customer on a standalone basis and (ii)&nbsp;if the
	arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within control of the
	Company. The Company's research agreement contains a single unit of accounting.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 605 are satisfied for that particular unit of
	accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company would recognize revenue from the combined unit of accounting over the contractual or estimated
	performance period for the undelivered items, which is typically the term of its research and development obligations. If there is no discernible pattern of performance or objectively measurable
	performance
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-11
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=204,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=2284,FOLIO='F-11',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_12">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	measures
	do not exist, then the Company would recognize revenue under the arrangement on a straight-line basis over the period it expects to complete its performance obligations or upon completion
	when the final act is of such significance to the overall arrangement that performance has not substantively occurred until the completion of that act. Conversely, if the pattern of performance over
	which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company would recognize revenue under the arrangement using the
	proportional performance method.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company recognizes service revenue under its research agreement based upon the completed performance method of revenue recognition as it is unable to reasonably estimate the period
	of performance of the services and the delivery of the final study report is significant to the arrangement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Research and Development
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenditures relating to research and development are expensed in the period incurred. Research and development expenses consist of
	both internal and external costs associated with the development of the Company's gene control platform and gene control medicines. Research and development costs include salaries and benefits,
	materials and supplies, external research and preclinical expenses, stock-based compensation expense and facilities costs. Facilities costs primarily include the allocation of rent, utilities and
	depreciation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and
	development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for the research and development, until
	related goods or services are provided.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the work being performed,
	including the phase or completion of the event, invoices received and costs. Significant judgements and estimates may be made in determining the accrued balances at the end of any reporting period.
	Actual results could differ from the Company's estimates.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company may in-license the rights to develop and commercialize product candidates. For each in-license transaction the Company evaluates whether it has acquired processes or
	activities along with inputs that would be sufficient to constitute a "business" as defined under U.S.&nbsp;GAAP. A "business" as defined under U.S.&nbsp;GAAP consists of inputs and processes
	applied to those inputs that have the ability to create outputs. Although businesses usually have outputs, outputs are not required for an integrated set of activities to qualify as a business. When
	the Company determines that it has not acquired sufficient processes or activities to constitute a business, any up-front payments, as well as milestone payments, are immediately expensed as research
	and development in the period in which they are achieved.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stock-Based Compensation Expense
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for its stock-based compensation awards in accordance with ASC Topic&nbsp;718,
</FONT>
<FONT SIZE=2>
<I>
	Compensation&#151;Stock Compensation
</I>
</FONT>
<FONT SIZE=2>
	("ASC 718"). ASC 718 requires all stock-based
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-12
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=205,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=766851,FOLIO='F-12',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_13">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	payments
	to employees and directors, including grants of restricted stock and stock options, to be recognized as expense in the consolidated statements of operations based on their grant date fair
	values. Grants of restricted stock and stock options to other service providers, referred to as non-employees, are required to be recognized as expense in the consolidated statements of operations
	based on their vesting date fair values. The Company estimates the fair value of options granted using the Black-Scholes option-pricing model. The Company uses the value of its common stock to
	determine the fair value of restricted stock awards.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	use of the Black-Scholes option-pricing model requires management to apply significant judgement and make estimates, including:
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected volatility
</I>
</B>
</FONT>
<FONT SIZE=2>
	&#151;Since the Company is privately held as of the date of these financial statements, it does not have relevant historical data to
	support its expected volatility. As such, the Company has used an average of expected volatility based on the volatilities of a representative group of publicly traded biopharmaceutical companies with
	similar characteristics to the Company, including stage of product development, length of trading history and life science industry focus. The expected volatility was determined using an average of
	the historical volatilities of the representative group of companies for a period equal to the expected term of the option grant. The Company intends to consistently apply this process using the same
	representative companies until a sufficient amount of historical information regarding the volatility of the Company's own share price becomes available or until circumstances change, such that the
	identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk-free interest rate
</I>
</B>
</FONT>
<FONT SIZE=2>
	&#151;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the
	expected life assumption.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected term
</I>
</B>
</FONT>
<FONT SIZE=2>
	&#151;The Company uses the "simplified method" as prescribed by the Securities and Exchange Commission ("SEC") Staff Accounting Bulletin
	No.&nbsp;107,
</FONT>
<FONT SIZE=2>
<I>
	Share-Based Payment
</I>
</FONT>
<FONT SIZE=2>
	to estimate the expected term of stock option grants made to employees. Under this approach, the weighted-average
	expected life is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of the Company's stock options, taking into consideration
	multiple vesting tranches. The Company utilizes this method as the Company has insufficient historical information regarding stock option exercises to provide a basis for an estimate. For options
	granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of the underlying common shares
</I>
</B>
</FONT>
<FONT SIZE=2>
	&#151;The fair value of the underlying common shares was determined using the option-pricing method, or OPM
	or a
	hybrid of the probability-weighted expected return method, or PWERM, and the OPM, and was approved by its board of directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
</I>
</B>
</FONT>
<FONT SIZE=2>
	&#151;The Company has never paid, and does not anticipate paying, any cash dividends in the foreseeable future, and therefore uses an expected
	dividend yield of zero.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	amount of stock-based compensation expense recognized during a period is based on the fair value of the portion of the awards that are ultimately expected to vest. Forfeitures are
	estimated at the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-13
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=206,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=233017,FOLIO='F-13',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_14">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	time
	of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term "forfeitures" is distinct from "cancellations" or "expirations" and
	represents only the unvested portion of the surrendered option. The Company evaluates its forfeiture rate at each reporting period. Ultimately, the actual expense recognized over the vesting period
	will be for only those options that vest.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company expenses the fair value of its stock-based awards to employees on a straight-line basis over the associated service period, which is generally the vesting period. For
	stock-based awards granted to consultants and non-employees, compensation expense is recognized over the period during which services are rendered by such consultants and non-employees until
	completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of such awards.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
	stock-based awards that contain performance-based milestones, the Company records stock-based compensation expense in accordance with the accelerated attribution model. Management
	evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction
	of the performance conditions as of the reporting date. For certain of the Company's performance-based awards, notwithstanding any vesting in accordance with the achievement of performance-based
	milestones, such awards vest in full on the sixth anniversary of the vesting commencement date.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Income Taxes
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes in accordance with ASC Topic 740,
</FONT>
<FONT SIZE=2>
<I>
	Income Taxes
</I>
</FONT>
<FONT SIZE=2>
	("ASC&nbsp;740"). The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax
	returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities
	using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the
	available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company early adopted the provisions of ASU No.&nbsp;2015-17,
</FONT>
<FONT SIZE=2>
<I>
	Income Taxes (Topic 740): Balance Sheet Classification of Deferred
	Taxes
</I>
</FONT>
<FONT SIZE=2>
	("ASU&nbsp;2015-17") on a prospective basis for the year ended December&nbsp;31, 2015. The standard requires that deferred tax assets and liabilities be classified as
	noncurrent on the balance sheet rather than being separated into current and noncurrent. The Company has no net deferred taxes as of December&nbsp;31, 2015.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions
	is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to
	audit, new audit activity, and changes in facts or circumstances related to a tax position.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-14
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=207,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1048477,FOLIO='F-14',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_15">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Net Loss per Share and Unaudited Pro Forma Net Loss per Share
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share applicable to common stockholders is calculated by dividing net loss applicable to common stockholders by the
	weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share applicable to common stockholders is calculated by adjusting the
	weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method and the if-converted method. For purposes
	of the dilutive net loss per share applicable to common stockholders calculation, convertible preferred stock, stock options, and unvested restricted stock are considered to be common stock
	equivalents but are excluded from the calculation of diluted net loss per share applicable to common stockholders, as their effect would be anti-dilutive; therefore, basic and diluted net loss per
	share applicable to common stockholders were the same for all periods presented.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them
	would have had an anti-dilutive effect.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	As&nbsp;of&nbsp;December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	As&nbsp;of&nbsp;March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Convertible preferred stock
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,598,370
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,598,370
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,598,370
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,988,800
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock options
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,330,077
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,226,698
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,545,282
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,217,953
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unvested restricted stock
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	595,541
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	256,881
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	534,209
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	142,215
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,523,988
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,081,949
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,677,861
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18,348,968
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaudited
	pro forma net loss per share applicable to common stockholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion
	of all outstanding convertible preferred stock into shares of common stock and the vesting of certain restricted stock awards, which occurs upon the closing of the initial public offering, as if such
	conversion or vesting had occurred at the beginning of the period presented, or the date of original issuance, if later. Accordingly, the pro forma basic and diluted net loss per share applicable to
	common stockholders does not include the effects of the cumulative preferred stock dividends and includes compensation expense for certain restricted stock and performance-based stock option awards
	with vesting contingent upon an initial public offering of the Company's common stock. Shares to be sold in the initial public offering are excluded from the unaudited pro forma basic and diluted loss
	per share applicable to common stockholders calculations.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-15
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=208,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=755226,FOLIO='F-15',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FM79601_1_16">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaudited
	pro forma net loss per share applicable to common stockholders is computed as follows (in thousands except for share and per share information):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="73PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year Ended
<BR>
	December&nbsp;31, 2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months
<BR>
	Ended
<BR>
	March&nbsp;31, 2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Numerator:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss applicable to common stockholders
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(34,752
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(12,325
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Plus: Accrued dividends on preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,934
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,737
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(29,818
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,588
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock-based compensation expense for stock-based awards with vesting contingent upon initial public offering
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(738
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	13
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma net loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(30,556
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(10,575
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Denominator:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in net loss per share applicable to common stockholders&#151;basic and diluted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,980,286
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,394,470
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma adjustment to reflect assumed conversion of convertible preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	12,598,370
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,499,798
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma adjustment to reflect shares outstanding as a result of restricted stock awards that vest upon initial public
	offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,342
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	53,334
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average number of common shares used in pro forma net loss per share&#151;basic and diluted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	14,593,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17,947,602
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Pro forma basic and diluted net loss per share
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(2.09
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(0.59
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Recent Accounting Pronouncements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the FASB issued ASU&nbsp;No.&nbsp;2014-09,
</FONT>
<FONT SIZE=2>
<I>
	Revenue From Contracts With
	Customers
</I>
</FONT>
<FONT SIZE=2>
	("ASU&nbsp;2014-09"). ASU&nbsp;2014-09 amends ASC 605,
</FONT>
<FONT SIZE=2>
<I>
	Revenue Recognition
</I>
</FONT>
<FONT SIZE=2>
	, by outlining a single comprehensive
	model for entities to use in accounting for revenue arising from contracts with customers. ASU&nbsp;2014-09 will be effective for the Company for interim and annual periods beginning after
	December&nbsp;15, 2017. The Company is evaluating the impact that this ASU may have on its financial statements, if any.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	August 2014, the FASB issued ASU No.&nbsp;2014-15,
</FONT>
<FONT SIZE=2>
<I>
	Presentation of Financial Statements&#151;Going Concern
</I>
</FONT>
<FONT SIZE=2>
	("ASU&nbsp;2014-15") which provides new guidance on management's responsibility in evaluating whether or not there is substantial doubt about a company's ability to continue as a going concern
	within one year from the date the financial statements are issued each reporting period. ASU&nbsp;2014-15 is effective for annual periods ending after December&nbsp;15, 2016. Early adoption is
	permitted. The Company is in the process of evaluating the new guidance and determining the expected effect on its financial statements.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-16
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=10,SEQ=209,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=317421,FOLIO='F-16',FILE='DISK124:[15ZCT1.15ZCT79601]FM79601A.;55',USER='PJAMES',CD='17-JUN-2016;18:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_17">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	2. Summary of Significant Accounting Policies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, the FASB issued ASU No.&nbsp;2016-02,
</FONT>
<FONT SIZE=2>
<I>
	Leases
</I>
</FONT>
<FONT SIZE=2>
	("ASU&nbsp;2016-02"), which applies to all leases and will require
	lessees to put most leases on the balance sheet, but recognize expense in a manner similar to the current standard. ASU 2016-02 is effective for fiscal years beginning after December&nbsp;15, 2018
	and interim periods within those years, which is the year ended December&nbsp;31, 2019 for the Company. Entities are required to use a modified retrospective approach of adoption for leases that
	exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is evaluating the new guidance
	and the expected effect on the Company's consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	March 2016, the FASB issued ASU No.&nbsp;2016-09,
</FONT>
<FONT SIZE=2>
<I>
	Compensation&#151;Stock Compensation (Topic&nbsp;718): Improvements to Employee Share-Based
	Payment Accounting
</I>
</FONT>
<FONT SIZE=2>
	("ASU&nbsp;2016-09"). ASU&nbsp;2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax
	consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, ASU&nbsp;2016-09 is effective for fiscal years
	beginning after December&nbsp;15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this guidance
	on its consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	3. Fair Value Measurements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="53PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:41PT;">
<FONT SIZE=1>
<B>
	Description
<!-- COMMAND=ADD_SCROPPEDRULE,41PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31, 2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Active
<BR>
	Markets
<BR>
	(Level&nbsp;1)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Observable
<BR>
	Inputs
<BR>
	(Level&nbsp;2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Unobservable
<BR>
	Inputs
<BR>
	(Level&nbsp;3)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Money market funds, included in cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,412
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,412
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
<BR>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="53PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:41PT;">
<FONT SIZE=1>
<B>
	Description
<!-- COMMAND=ADD_SCROPPEDRULE,41PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31, 2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Active
<BR>
	Markets
<BR>
	(Level&nbsp;1)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Observable
<BR>
	Inputs
<BR>
	(Level&nbsp;2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Unobservable
<BR>
	Inputs
<BR>
	(Level&nbsp;3)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Money market funds, included in cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,909
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	35,909
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
<BR>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="88PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="45PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="53PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:41PT;">
<FONT SIZE=1>
<B>
	Description
<!-- COMMAND=ADD_SCROPPEDRULE,41PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31, 2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Active
<BR>
	Markets
<BR>
	(Level&nbsp;1)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Observable
<BR>
	Inputs
<BR>
	(Level&nbsp;2)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Unobservable
<BR>
	Inputs
<BR>
	(Level&nbsp;3)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Money market funds, included in cash equivalents
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	62,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	4. Restricted Cash
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2014, the Company had $70,000 in restricted cash. This amount is comprised of a $20,000 certificate of deposit to collateralize a credit card account with the
	Company's primary financial institution and a $50,000 letter of credit, which served as the security deposit on the lease of the Company's prior facility in Watertown, Massachusetts. At
	December&nbsp;31, 2015 and March&nbsp;31, 2016 the Company had $483,000 in restricted cash which serves as the security deposit on the lease of the Company's current facility in Cambridge,
	Massachusetts (Note&nbsp;8).
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-17
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=210,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=559519,FOLIO='F-17',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_18">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	5. Property and Equipment
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consists of the following (in thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="56PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Estimated
<BR>
	useful life
<BR>
	(in years)
</B>
</FONT>
</TH>
<TH ROWSPAN=2 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31,
<BR>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Laboratory equipment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,080
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,676
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,004
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Computer equipment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	173
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	237
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	270
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Furniture and fixtures
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	56
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	349
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	349
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Leasehold improvements
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Shorter of 7&nbsp;years or life of lease
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,468
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,469
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,309
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,730
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,092
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Less: Accumulated depreciation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(428
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(931
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1,235
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total property and equipment, net
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	881
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,799
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,857
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
	expense, including depreciation expense for assets recorded under capital leases, amounted to $258,000 and $602,000 for the years ended December&nbsp;31, 2014 and 2015,
	respectively and $74,000 and $304,000 for the three months ended March&nbsp;31, 2015 and 2016, respectively. Lab equipment included assets recorded under capital leases of $389,000 at
	December&nbsp;31, 2015 (Note&nbsp;7). Accumulated depreciation from assets recorded under capital leases was $78,000 at March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	6. Accrued Expenses
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses consist of the following (in thousands):
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="64PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="49PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Employee compensation and benefits
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	132
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	709
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	857
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	External research and preclinical development
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	106
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	981
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,476
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Facilities
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	414
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	69
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Professional fees
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	48
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	399
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	290
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Restricted stock liability
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	287
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,504
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,692
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	7. Indebtedness
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Equipment Financing
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, the Company entered into a lease agreement with a vendor for certain laboratory equipment. The Company financed $389,000
	of the amount owed under the lease agreement and is required to make consecutive monthly payments of principal, plus accrued interest at 6.44%, over 36&nbsp;months through March 2018. As of
	March&nbsp;31, 2016, the Company had made payments of $90,000, of which $23,000 related to interest. At March&nbsp;31, 2016, $322,000 of principal was outstanding with respect to the equipment
	financing arrangement.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-18
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=211,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=316834,FOLIO='F-18',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_19">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	7. Indebtedness (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scheduled
	monthly future minimum lease payments with respect to the equipment financing arrangement are as follows (in thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:79PT;">
<FONT SIZE=1>
<B>
	At December&nbsp;31, 2015:
<!-- COMMAND=ADD_SCROPPEDRULE,79PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2016
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	152
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2017
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	172
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2018
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	43
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	367
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	8. Commitments and Contingencies
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Operating Leases
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2012, the Company entered into an operating lease for office and laboratory space in Watertown, Massachusetts (the "2012
	Lease"). The lease agreement was with Alexandria Real Estate, a related party (see Note&nbsp;14). The lease agreement expired in August 2015. The Company's lease agreement had escalating rent
	payments and the Company recorded rent expense on a straight-line basis. The Company recorded rent expense of $265,000 and $177,000 for the years ended December&nbsp;31, 2014 and 2015, respectively,
	and $66,000 for the three months ended March&nbsp;31, 2015. The lease agreement required the Company to issue an original letter of credit in the amount of $50,000, which is included in other
	current assets in the accompanying balance sheets at December&nbsp;31, 2015.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	March 2015, the Company entered into an operating lease for approximately 21,488 rentable square feet of office and laboratory space in Cambridge, Massachusetts (the "2015 Lease"),
	with a lease term commencing in August 2015 and ending in October 2020, assuming occupancy in August 2015. The Company has an option to extend the lease for five additional years. The Company's lease
	agreement has escalating rent payments and the Company records rent expense on a straight-line basis over the term of the lease, including any rent-free periods. The Company recorded rent expense of
	$320,000 for the year ended December&nbsp;31, 2015 and $220,000 for the three months ended March&nbsp;31, 2016 related to the 2015 Lease. The lease agreement required the Company to issue an
	original letter of credit in the amount of $483,000, which is included in restricted cash in the accompanying balance sheet at December&nbsp;31, 2015 and March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	2015 Lease includes certain lease incentives in the form of tenant allowances. The Company has capitalized the improvements made with the tenant allowance into fixed assets and
	established a liability for the deferred lease incentive upon occupancy. The Company recorded these incentives as a component of deferred rent and will amortize these incentives as a reduction of rent
	expense over the lease term. The related fixed assets will be amortized over the lease term. The 2012 Lease and 2015 Lease require the Company to share in prorated operating expenses and property
	taxes based upon actual amounts incurred. The Company recorded operating expenses and taxes of $189,000 and $328,000 for the years ended December&nbsp;31, 2014 and 2015, respectively, and $47,000
	and $147,000 for the three months ended March&nbsp;31, 2015 and 2016, respectively; those amounts are not fixed for future periods and, therefore, are not included in the future commitments listed
	below.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-19
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=212,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=579180,FOLIO='F-19',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_20">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	8. Commitments and Contingencies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	minimum aggregated future lease commitment at December&nbsp;31, 2015 is as follows (in thousands):
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:79PT;">
<FONT SIZE=1>
<B>
	At December&nbsp;31, 2015:
<!-- COMMAND=ADD_SCROPPEDRULE,79PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2016
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,217
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2017
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,252
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2018
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,288
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2019
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,325
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	2020
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,130
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6,212
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	License Agreements
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Dana-Farber Cancer Institute,&nbsp;Inc.
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2013, the Company entered into a license agreement with Dana-Farber Cancer Institute,&nbsp;Inc. ("Dana-Farber") pursuant
	to which the Company was granted an exclusive worldwide, sublicensable license under specified patents relating to CDK7 inhibitors and JNK inhibitors owned or controlled by Dana-Farber. The Company
	paid a $50,000 license initiation fee to Dana-Farber, which was recorded as research and development expense. A funding milestone payment of $125,000 was paid in April 2014 upon the close of the
	Series&nbsp;A-3 convertible preferred stock financing. Payments totaling $3.4&nbsp;million are due when the Company achieves certain clinical and regulatory milestones for any product to
	Dana-Farber, none of which have been achieved as of December&nbsp;31, 2015. The future potential milestone payments have not been accrued as of December&nbsp;31, 2014 and 2015 and March&nbsp;31,
	2016, respectively, as no milestones have been achieved and the agreement can be cancelled at the Company's option. Therefore, the Company had no obligation to pay any of these amounts. After the
	Company begins commercial sale of products in any country subject to the license, the Company will owe a tiered royalty on net sales. Royalty payments continue for the duration of the licensed
	patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the event the Company grants a sublicense to a third party, the Company will pay a royalty equal to a percentage of the revenue it receives from the sublicense. The specific
	percentage payable is dependent on the stage of development of the product subject to the sublicense at the time the sublicense is granted.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Whitehead Institute for Biomedical Research and Dana-Farber
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective April&nbsp;1, 2013, the Company entered into a license agreement with the Whitehead Institute for Biomedical Research
	("Whitehead") and Dana-Farber, pursuant to which the Company was granted a worldwide, sublicensable license under specified patents relating to modulators of Myc/Max Screen, relating to Chem-Seq owned
	or controlled by Whitehead and Dana-Farber. In April 2013, related to such license, the Company paid a $50,000 license initiation fee to Whitehead, which was recorded as a research and development
	expense. A funding milestone
	payment of $50,000 was paid in April 2014. Payments totaling $3.4&nbsp;million are due when the Company achieves certain clinical and regulatory milestones, none of which have been achieved as of
	December&nbsp;31, 2015. The future potential
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-20
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=213,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=982189,FOLIO='F-20',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_21">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	8. Commitments and Contingencies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	milestone
	payments have not been accrued as of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, respectively, as no milestones have been achieved and the agreement can be cancelled at the
	Company's option, and therefore the Company had no obligation to pay any of these amounts. After the Company begins commercial sale of products in any country subject to the license, the Company will
	owe a tiered royalty on net sales. Royalty payments continue for the duration of the licensed patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the event the Company grants a sublicense to a third party, the Company will pay a royalty equal to a percentage of the revenue it receives from the sublicense. The specific
	percentage payable is dependent on the stage of development of the product subject to the sublicense at the time the sublicense is granted.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Whitehead Institute for Biomedical Research
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective April&nbsp;4, 2013, the Company entered into an additional license agreement with Whitehead, pursuant to which the Company
	was granted a worldwide license under specified patents relating to super-enhancers owned or controlled by Whitehead. In April 2013, related to such license, the Company paid a $30,000 license
	initiation fee to Whitehead, which was recorded as a research and development expense. A milestone payment of $100,000 is due upon the issuance of a patent under patent rights in the United States for
	a product or licensed service in commercial development and another $100,000 is due upon the receipt by the Company of $1.0&nbsp;million from a commercial partner or licensee. These amounts have not
	been accrued as of December&nbsp;31, 2014 and 2015 and March&nbsp;31, 2016, respectively, because the milestones had not been achieved, and therefore, the Company had no obligation to pay any of
	these amounts. After the Company begins commercial sale of products in any country subject to the license, the Company will owe a tiered royalty on net sales. Royalty payments continue for the
	duration of the licensed patents.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	the event the Company grants a sublicense to a third party, the Company will pay a royalty equal to a percentage of the revenue it receives from the sublicense. The specific
	percentage payable is dependent on the stage of development of the product subject to the sublicense at the time the sublicense is granted.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Whitehead agreements, the Company issued 171,674 shares of its common stock to Whitehead in April&nbsp;2013. The Company paid the Whitehead Institute Genome
	Technology Core $0.6&nbsp;million and $0.4&nbsp;million for the years ended December&nbsp;31, 2014 and 2015, respectively, and $0.1&nbsp;million and $0.3&nbsp;million for the three months
	ended March&nbsp;31, 2015 and 2016, respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	TMRC&nbsp;Co.&nbsp;Ltd.
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2015, the Company entered into an exclusive license agreement with the Japanese oncology company
	TMRC&nbsp;Co.&nbsp;Ltd., ("TMRC") to develop and commercialize tamibarotene in North America and Europe for cancer. Tamibarotene is an agonist of retinoic acid receptor alpha
	("RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	") and is currently marketed in Japan for acute promyelocytic leukemia, a form of acute myeloid leukemia ("AML"). The Company identified the
	genomic biomarker that identifies AML and myelodysplastic syndrome patient subgroup to be sensitive to or likely to respond to RAR
<FONT FACE="SYMBOL">
	a
</FONT>
	agonist therapy through the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-21
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=214,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=71681,FOLIO='F-21',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_22">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	8. Commitments and Contingencies (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Company's
	proprietary gene control target discovery platform. The Company has identified this product candidate as SY-1425.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	exchange for this license, the Company made a one-time, non-refundable upfront payment of $500,000 in September 2015 and may make additional payments upon the successful achievement
	of clinical and regulatory milestones of approximately $13.0&nbsp;million per indication. In addition, the Company will pay TMRC single-digit percentage royalties, on a country-by-country,
	product-by-product basis, on net product sales in North America and Europe.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
	any time after the first anniversary of the TMRC Agreement, the Company has the ability to terminate the agreement at its sole discretion for any reason.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize tamibarotene in North America and Europe. None of the
	assets acquired had alternative future uses. As no processes or activities that would constitute a "business" were acquired as part of the license agreement, the transaction was accounted for as an
	asset acquisition and
	the upfront payment of $500,000 was recorded as research and development expense. The additional payments will also be recorded as research and development and expensed as achieved.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Litigation
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not party to any litigation and does not have contingency reserves established for any litigation liabilities as of
	December&nbsp;31, 2014, December&nbsp;31, 2015 or March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	9. Convertible Preferred Stock
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Series&nbsp;A Convertible Preferred Stock Financing
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;8, 2012, the Company issued 2,500,000 shares of Series&nbsp;A-1 Convertible Preferred Stock ("Series&nbsp;A-1") at
	a purchase price of $0.50 per share. The issuance resulted in cash proceeds of $1,208,000, net of issuance costs of $42,000. The Series&nbsp;A-1 has a liquidation preference amount of $1,523,000 at
	March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
	various dates in 2013, the Company issued 12,100,000 shares of Series&nbsp;A-2 Convertible Preferred Stock ("Series&nbsp;A-2") at a purchase price of $1.00 per share. The shares
	were issued for cash proceeds of
	$10,021,000, net of issuance costs of $42,000, and the exchange of outstanding Convertible Notes, including accrued interest, of approximately $2,036,000, as disclosed in Note&nbsp;7. The
	Series&nbsp;A-2 has a liquidation preference amount of $14,251,000 at March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
	various dates in 2014, the Company issued 15,750,000 shares of Series&nbsp;A-3 Convertible Preferred Stock ("Series&nbsp;A-3") at a purchase price of $1.00 per share. The
	issuances resulted in cash proceeds of $15,749,000, net of issuance costs of $1,000. The Series&nbsp;A-3 has a liquidation preference amount of $17,644,000 at March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Series&nbsp;A-1, Series&nbsp;A-2 and Series&nbsp;A-3 preferred stock is collectively referred to as "Series&nbsp;A" or "Series&nbsp;A Preferred Stock."
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-22
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=215,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=802410,FOLIO='F-22',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_23">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	9. Convertible Preferred Stock (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Series&nbsp;B Convertible Preferred Stock Financing
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2014, the Company issued 16,893,931 shares of Series&nbsp;B Convertible Preferred Stock ("Series&nbsp;B") at a purchase
	price of $3.1461 per share. The issuance resulted in cash proceeds of $52,998,000, net of issuance costs of $152,000.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	January 2016, the Company issued 12,714,150 shares of Series&nbsp;B at a purchase price of $3.1461&nbsp;per share. The issuance resulted in cash proceeds of $39,794,000, net of
	issuance costs of $206,000. The Series&nbsp;B has a liquidation preference of $98,337,000 at March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	rights, preferences, and privileges of the Series&nbsp;A-1, Series&nbsp;A-2, Series&nbsp;A-3 and Series&nbsp;B (collectively the "Preferred Stock") are listed below:
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Conversion
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without
	the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issuance price by the
	conversion price in effect at the time of conversion. The conversion price currently in effect is $1.875 per share for Series&nbsp;A-1, $3.75 per share for Series&nbsp;A-2 and Series&nbsp;A-3
	and $11.7979 per share for Series&nbsp;B, in each case subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the
	Preferred Stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion is at the option of the preferred stockholders, although conversion is automatic upon either of the consummation of an initial public offering resulting in gross proceeds of
	$30.0&nbsp;million and at a price of $18.75 per share of the Common Stock or the vote or written consent of the majority of outstanding shares of the Preferred Stock.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Voting
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the
	Company (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole
	shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as
	provided by law or by other provisions of the Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of common stock as a single class.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	holders of Series&nbsp;B Preferred Stock have certain protective voting rights as defined. These protective rights require the written consent or affirmative vote of the holders of
	at least sixty-six and two thirds percent of the then outstanding shares of Series&nbsp;B before action can be taken to (i)&nbsp;modify, amend, or waive any provision of the Certificate of
	Incorporation in any way that adversely affects the holders of the Series&nbsp;B Preferred Stock, (ii)&nbsp;purchase or redeem or pay or declare any dividend or make any distribution on any shares
	of capital stock prior to the Series&nbsp;B Preferred Stock, other than repurchases in connection with the cessation of employment or service, or (iii)&nbsp;increase or decrease the authorized
	number of shares of Series&nbsp;B Preferred Stock.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-23
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=216,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=443701,FOLIO='F-23',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_24">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	9. Convertible Preferred Stock (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	addition to the Series&nbsp;B protective rights, all holders of Preferred Stock have certain protective voting rights as defined. These protective rights require the written consent
	or affirmative vote of the holders of at least sixty-six and two thirds percent of the then outstanding shares of Preferred Stock before action can be taken to (i)&nbsp;liquidate, dissolve or
	wind-up the business and affairs of the Company, effect any merger or consolidation or any other deemed liquidation event, (ii)&nbsp;amend, alter or repeal any provision of the Certificate of
	Incorporation or Bylaws of the Company, (iii)&nbsp;create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital stock unless such
	series ranks junior to the Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption,
	or increase the authorized number of shares of Preferred Stock unless the same ranks junior to the Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding
	up of the Company, the payment of dividends and rights of redemption, (iv)&nbsp;purchase or redeem or pay or declare any dividend or make any distribution on any shares of capital stock prior to the
	Preferred Stock, other than repurchases in connection with the cessation of employment or service.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Dividends
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of the Preferred Stock are entitled to receive, before any cash is paid out or set aside for any Common Stock, dividends at the
	annual rate of $0.03 per share on shares of Series&nbsp;A-1, $0.06 per share on shares of Series&nbsp;A-2 and Series&nbsp;A-3 and $0.1887 per share on shares of Series&nbsp;B, in each case
	subject to adjustment for any stock dividend, stock split, combination or other similar recapitalization. The dividends are cumulative and are payable only when, as, and if, declared by the board of
	directors, or liquidation, dissolution, sale or winding up of the Company. No dividends have been declared since the Company's inception. Aggregate cumulative preferred dividends at
	December&nbsp;31, 2014, December&nbsp;31, 2015 and March&nbsp;31, 2016 were $2.8&nbsp;million, $7.8&nbsp;million and $9.5&nbsp;million, respectively.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Redemption
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preferred stock is redeemable upon a deemed liquidation event, provided that the Company does not effect a dissolution of the
	Company within ninety days after such deemed liquidation event.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	following events are considered deemed liquidation events unless the holders of at least sixty-six and two thirds percent of the outstanding shares of Preferred Stock and at least
	sixty-six and two thirds percent of the outstanding shares of Series&nbsp;B elect otherwise: (a)&nbsp;a merger or consolidation in which (i)&nbsp;the Company is a constituent party or
	(ii)&nbsp;a subsidiary of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation in
	which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock
	that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of the surviving or resulting corporation, or the parent corporation of
	the surviving or resulting corporation if the surviving or resulting corporation is a wholly owned subsidiary of another corporation, or (b)&nbsp;the sale, lease, transfer, exclusive license or
	other disposition of all or substantially all the assets of the Company.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-24
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=217,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=539480,FOLIO='F-24',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FO79601_1_25">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	9. Convertible Preferred Stock (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Liquidation
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of Series&nbsp;B have preference in the event of a liquidation, dissolution, sale or winding up of the Company equal to the
	greater of $3.1461 per share, plus any accrued but unpaid dividends whether or not declared, plus any dividends declared but unpaid thereon or such amount per share as would have been payable had all
	shares of Series&nbsp;B been converted into Common Stock immediately prior to such liquidation, dissolution, sale or winding up of the Company. If upon any such liquidation, dissolution, sale or
	winding up of the Company or a deemed liquidation event, the assets of the Company available for distribution are insufficient to pay the holders of Series&nbsp;B the full amount to which they would
	be entitled, the holders of shares of Series&nbsp;B shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
	payable if all amounts payable with respect to such shares were paid in full.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
	the payment of all liquidation preferences to holders of Series&nbsp;B, holders of Series&nbsp;A have preference in the event of a liquidation, dissolution, sale or winding up
	of the Company equal to the greater of the original issue price per share, or $0.50 per share for Series&nbsp;A-1 and $1.00 per share for Series&nbsp;A-2 and Series&nbsp;A-3, plus any dividends
	declared but unpaid thereon, or such amount per share as would have been payable had all shares of Series&nbsp;A been converted into Common Stock immediately prior to such liquidation, dissolution,
	sale or winding up of the Company. If upon any such liquidation, dissolution, sale or winding up of the Company or a deemed liquidation event, the assets of the Company available for distribution are
	insufficient to pay the holders of Series&nbsp;A the full amount to which they would be entitled, the holders of shares of Series&nbsp;A shall share ratably in any distribution of the assets
	available for distribution in proportion to the respective amounts which would otherwise be payable if all amounts payable with respect to such shares were paid in full.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thereafter,
	if assets remain in the Company, the holders of the Common Stock shall receive all of the remaining assets of the Company pro rata based on the number of shares of Common
	Stock held by each.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	the Preferred Stock may become redeemable upon an event that is outside of the control of the Company, the Preferred Stock has been classified outside of stockholders' (deficit)
	equity. Since the Preferred Stock is not initially redeemable and it is not probable that it will become redeemable, the initial carrying value of the Preferred Stock has not been adjusted to
	redemption value.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company assessed the Series&nbsp;A and Series&nbsp;B Preferred Stock for any beneficial conversion features or embedded derivatives, including the conversion option, that would
	require bifurcation from the Series&nbsp;A and Series&nbsp;B Preferred Stock and receive separate accounting treatment. Based on the Company's determination that the Preferred Stock is an "equity
	host," all features of the Preferred Stock are either clearly and closely related to the equity host or did not meet the definition of a derivative, and do not require bifurcation as a derivative
	liability. On the date of issuance, the fair value of Common Stock into which the Series&nbsp;A and Series&nbsp;B Preferred Stock was convertible was less than the effective conversion price of
	the Series&nbsp;A and Series&nbsp;B Preferred Stock, and as such, there was no beneficial conversion feature at the commitment date.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-25
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=9,SEQ=218,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=3415,FOLIO='F-25',FILE='DISK124:[15ZCT1.15ZCT79601]FO79601A.;82',USER='VSTEFAN',CD='16-JUN-2016;22:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_26">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	10. Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of the Company's common stock are entitled to one vote for each share of common stock held. Common stockholders are not entitled to receive dividends unless declared by the board
	of directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company has reserved the following shares of Common Stock for the potential conversion of Preferred Stock and the issuance of Common Stock in connection with stock options:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	As of December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	As of
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Series&nbsp;A Preferred Stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,093,326
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,093,326
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8,093,326
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Series&nbsp;B Preferred Stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,505,044
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,505,044
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,895,474
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock options outstanding
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,330,077
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,226,698
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,217,953
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Shares available for future issuance under the 2012 Plan
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,019,455
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	140,452
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	149,197
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Shares reserved for vesting of restricted stock awards
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	595,541
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	256,881
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	142,215
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,543,443
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,222,401
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	18,498,165
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	11. Stock-Based Payments
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	2012 Stock Option Plan
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company grants restricted stock awards, incentive stock options ("ISO") and nonstatutory stock options ("NSO") under the Syros
	Pharmaceuticals,&nbsp;Inc. 2012 Equity Incentive Plan (the "2012 Plan"). As of March&nbsp;31, 2016, the Company had reserved 2,749,681 shares of Common Stock under the 2012 Plan, of which 149,197
	shares remained available for future issuance under the 2012 Plan. Under the 2012 Plan, stock options may not be granted at less than fair value on the date of grant.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terms
	of restricted stock and stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2012 Plan. Restricted
	stock awards granted by the Company generally vest based on each grantee's continued service with the Company during a specified period following grant. Stock option awards granted by the Company
	generally vest over four years, with 25% vesting on the one year anniversary of the vesting commencement date and 75% vesting ratably, on a monthly basis, over the remaining three years. Such awards
	are exercisable from the date of grant for a period of ten years. The Company also grants performance-based stock option awards and restricted stock for which vesting accelerates upon the achievement
	of performance-based milestones. For certain of such awards, notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth
	anniversary of the vesting commencement date.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-26
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=219,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=137827,FOLIO='F-26',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_27">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	11. Stock-Based Payments (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stock Options
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Performance-Based Stock Options
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has granted stock options to management for which the vesting of such stock options accelerates upon the achievement of
	performance-based criteria. Milestone events are specific to the Company's corporate goals, including but not limited to certain preclinical and clinical development milestones and the Company's
	ability to execute on its corporate development and financing strategies. Stock-based compensation expense associated with these performance-based stock options is recognized based on the accelerated
	attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.
	Notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. For the year ended
	December&nbsp;31, 2015, the Company recorded additional stock-based compensation expense of $26,000 related to the achievement of certain performance-based milestones. No milestones were achieved
	during the three months ended March&nbsp;31, 2016. As of March&nbsp;31, 2016, there is $1,013,000 of unrecognized stock-based compensation expense related to the performance-based stock options.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	summary of the status of stock options as of December&nbsp;31, 2014, December&nbsp;31, 2015 and March&nbsp;31, 2016 and changes during the year ended December&nbsp;31, 2015 and
	three months ended March&nbsp;31, 2016 is presented below:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="55PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="67PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="68PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="69PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Weighted
<BR>
	Average
<BR>
	Exercise Price
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Remaining
<BR>
	Contractual
<BR>
	Life (in years)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
<BR>
	(in thousands)
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Outstanding at December&nbsp;31, 2014
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	1,330,077
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.16
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,494
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Granted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,321,881
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(384,349
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cancelled
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(40,911
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Outstanding at December&nbsp;31, 2015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	2,226,698
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.83
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,185
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Granted
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	125,253
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.51
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exercised
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Cancelled
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	(133,998
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.06
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Outstanding at March&nbsp;31, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	2,217,953
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,863
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exercisable at December&nbsp;31, 2015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	521,813
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.35
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.7
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,915
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Vested and expected to vest at December&nbsp;31, 2015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	2,226,698
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.83
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,185
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Exercisable March&nbsp;31, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	625,133
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.46
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4,410
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Vested and expected to vest at March&nbsp;31, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	2,217,953
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	8.6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,863
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="BOTTOM">
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-27
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=220,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=460151,FOLIO='F-27',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_28">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	11. Stock-Based Payments (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	intrinsic value of options exercised during the years ended December&nbsp;31, 2014 and December&nbsp;31, 2015 was $6,000 and $1,980,000, respectively. No options were exercised
	in the three months ended March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Restricted Common Stock
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At various dates in 2012 and 2013, upon approval by its board of directors, the Company issued an aggregate of 1,621,310 shares of
	restricted Common Stock to certain advisors. Of the restricted Common Stock issued by the Company, 1,599,996 shares begin vesting upon the achievement of certain performance objectives as well as
	continued service to the Company, as set forth in each grantee's individual restricted stock purchase agreement. The remaining 21,314 shares of restricted Common Stock were issued to a member of the
	Company's board of directors and vest over four years, based on the director's continued service to the Company, as set forth in the director's individual restricted stock purchase agreement. The
	shares of restricted Common Stock are subject to repurchase rights. Accordingly, the Company has recorded the proceeds from the issuance of restricted Common Stock as a liability in the accompanying
	balance sheets. The restricted stock liability is reclassified into stockholders' (deficit) equity as the restricted Common Stock vests.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
	summary of the status of unvested restricted Common Stock as of December&nbsp;31, 2014, December&nbsp;31, 2015, March&nbsp;31, 2016 and changes during the year ended
	December&nbsp;31, 2015 and three months ended March&nbsp;31, 2016 is presented below:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="74PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Shares
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Weighted
<BR>
	Average Grant
<BR>
	Date Fair Value
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unvested at December&nbsp;31, 2014
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	595,541
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Issued
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Vested
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	(338,660
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Repurchased
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unvested at December&nbsp;31, 2015
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	256,881
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Vested
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	(41,332
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Repurchased
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	(73,334
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Unvested at March&nbsp;31, 2016
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	142,215
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.38
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	non-employee restricted Common Stock is revalued as it vests. The expense related to the restricted Common Stock issued to non-employees for the years ended December&nbsp;31, 2014
	and 2015 was $0.6&nbsp;million and $2.2&nbsp;million, respectively, and for the three months ended March&nbsp;31, 2015 and 2016 was $0.3&nbsp;million and $0.3&nbsp;million, respectively.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-28
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=221,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=180151,FOLIO='F-28',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_29">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	11. Stock-Based Payments (Continued)
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<B>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	Stock-based Compensation Expense
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on
	the following weighted-average assumptions:
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="32PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Weighted-average risk-free interest rate
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.78
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.47
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.39
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expected dividend yield
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Expected option term
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7.03
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.09
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	6.08
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Volatility
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	85.51
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	82.71
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	84.32
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	85.52
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The weighted-average grant date fair value per share of options granted during the years ended December&nbsp;31, 2014 and 2015 was $1.46 and $4.88, respectively. The weighted-average
	grant date fair value per share of options granted during the three months ended March&nbsp;31, 2016 was $6.13.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	following table summarizes the stock-based compensation expense for stock options and restricted common stock granted to employees and non-employees recorded in the Company's
	statements of operations:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="39PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="30PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Three Months
<BR>
	Ended
<BR>
	March&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2016
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Research and development
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	830
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2,733
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	462
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	560
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	General and administrative
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	107
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	500
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	49
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	102
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total share-based compensation expense
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	937
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,233
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	511
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	662
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of March&nbsp;31, 2016, there was $7.1&nbsp;million of total unrecognized compensation cost related to non-vested stock options and unvested restricted Common Stock, which is
	expected to be recognized over a weighted-average period of 3.1&nbsp;years.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-29
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=222,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=379929,FOLIO='F-29',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_30">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	12. Income Taxes
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company's effective income tax rate is as follows:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="37PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="24PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="37PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Federal income tax computed at federal statutory tax rate
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	34.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	34.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	State income tax, net of federal benefit
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.86
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.70
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Permanent items
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(1.94
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(3.33
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Federal and state research and development credits
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.73
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2.66
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.12
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Change in valuation allowance
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(41.65
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(38.15
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Effective income tax rate
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	0.00
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	%
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	principal components of the Company's deferred tax assets and liabilities consist of the following at December&nbsp;31, 2014 and 2015, respectively (in thousands):
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="44PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="50PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=5 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Year ended
<BR>
	December&nbsp;31,
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2014
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	2015
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred tax assets:
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Federal and state net operating loss carryforwards
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,969
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	17,569
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Tax credit carryforwards
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,121
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,953
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Intangible assets
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	430
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	313
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Stock-based compensation
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	87
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	186
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Leasehold incentive
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	589
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Other
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	83
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	545
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total deferred tax assets
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	9,690
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21,155
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Less valuation allowance
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(9,690
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(21,095
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net deferred tax assets
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	60
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Deferred tax liabilities:
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Fixed assets
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(60
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total deferred tax liabilities
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	(60
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	)
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Net deferred taxes
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of December&nbsp;31, 2015 the Company had federal net operating loss ("NOL") carryforwards of approximately $44.8&nbsp;million and state net operating loss
	carryforwards of $44.3&nbsp;million, which are available to reduce future taxable income. The Company also had federal tax credits of approximately $1.4&nbsp;million and state tax credits of
	$0.9&nbsp;million, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2035. The NOL and tax credit carryforwards are
	subject to review and possible adjustment by the Internal Revenue Service ("IRS") and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-30
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=5,SEQ=223,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=889285,FOLIO='F-30',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_31">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	12. Income Taxes (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	annual
	limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections&nbsp;382 and
	383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax
	liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the
	limitation in future years. The Company has not determined whether an ownership change has occurred and as such, the Company's NOLs may be limited.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC
	740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the
	deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at
	December&nbsp;31, 2014 and 2015, respectively, because the Company's management has determined that it is more likely than not that these assets will not be fully realized. The increase in the
	valuation allowance in 2015 primarily relates to the net loss incurred by the Company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
	of December&nbsp;31, 2015, the Company had $0.3 million of federal and state net operating losses related to excess tax deductions that have been excluded from the above table. The
	benefit of these net operating losses will be recognized as an increase in additional paid in capital when it results in a reduction in taxes payable.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company has not yet conducted a study of its research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being
	presented as an uncertain tax position. This study may result in an adjustment to the Company's research and development credit carryforwards. A full valuation allowance has been provided against the
	Company's research and development credits, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance
	sheets or statements of operations if an adjustment were required.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company's reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not
	to be realized following resolution of any potential contingencies present related to the tax benefit. At December&nbsp;31, 2014 and 2015, the Company had no unrecognized tax benefits. The Company's
	policy is to recognize both interest and penalties related to unrecognized tax benefits in income tax expense.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	statute of limitations for assessment by the IRS, and state tax authorities remains open for all tax years. The Company files income tax returns in the U.S. federal and Massachusetts
	jurisdictions. There are currently no federal or state audits in process.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	13. Research Agreement
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2014, the Company entered into a research agreement with a multinational pharmaceutical company (the "Counterparty") for purposes of mapping immune cell super-enhancers
	("SE") and transcriptional targets in autoimmune disease. Under the research agreement, the Company will be responsible for the conduct of all activities under separate projects, as defined in the
	research
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-31
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=6,SEQ=224,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=906057,FOLIO='F-31',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_32">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	13. Research Agreement (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	agreement,
	associated with generating SE and transcriptional maps of the cell/tissue supplied by the pharmaceutical company. Upon the completion of each project, the Counterparty will determine
	whether to commence the next project under the research agreement upon written notification.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	research agreement expires on the earlier of November&nbsp;30, 2016 or completion of the research program, unless otherwise terminated earlier. The research agreement terminates
	automatically if the Counterparty does not notify the Company that it would like to commence the next research project.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	exchange for these research services, the Company may receive funding of up to $3.0&nbsp;million over the term of the agreement. The Company will recognize revenue on a completed
	performance basis for each project performed under the agreement, as the Company does not have the ability to reasonably estimate the period of performance and the final study report for each project
	is significant to the overall arrangement. The Company recognized revenue of $0.3&nbsp;million during the year ended December&nbsp;31, 2015 related to the pilot project of the research agreement.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	14. Related Party Transactions
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company paid to WuXi AppTec (Hong Kong) Limited ("WuXi"), an affiliate of WuXi PharmaTech, $1.1&nbsp;million and $3.1 million, for the years ended December&nbsp;31, 2014 and 2015
	respectively, and $0.5&nbsp;million and $0.4&nbsp;million for the three months ended March&nbsp;31, 2015 and 2016, respectively, in cash for external research and preclinical development
	services. In August 2012, as part of the Series&nbsp;A-1 Preferred Stock financing, WuXi purchased 500,000 shares of Series&nbsp;A-1 Preferred Stock at a purchase price of $0.50 per share, for a
	total purchase value of $250,000. In April 2013, as part of the Series&nbsp;A-2 Preferred Stock financing, WuXi purchased 500,000 shares of Series&nbsp;A-2 Preferred Stock at a purchase price of
	$1.00 per share, for a total purchase value of $500,000. In March 2014, as part of the Series&nbsp;A-3 Preferred Stock financing, WuXi purchased 500,000 shares of Series&nbsp;A-3 Preferred Stock
	at a
	purchase price of $1.00 per share, for a total purchase value of $500,000. In October 2014, as part of the Series&nbsp;B Preferred Stock financing, WuXi purchased 953,561 shares of Series&nbsp;B
	Preferred Stock at a purchase price per share of $3.1461, for a total purchase value of $3,000,000. In January 2016, as part of the Series&nbsp;B Preferred Stock financing, WuXi purchased 1,589,269
	shares of Series&nbsp;B Preferred Stock at a purchase price per share of $3.1461, for a total purchase value of $5,000,000.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	October 2012, the Company entered into an operating lease for office and laboratory space in Watertown, Massachusetts with Alexandria Real Estate Equities ("ARE"). As part of the
	lease agreement, the Company granted ARE the right to participate in the Company's Series&nbsp;A-2 Preferred Stock financing. In April 2013, as part of the Series&nbsp;A-2 Preferred Stock
	financing, ARE purchased 250,000 shares of Series&nbsp;A-2 Preferred Stock at a purchase price of $1.00 per share, for a total purchase value of $250,000. In August 2014, as part of the Series A-3
	Preferred Stock financing, ARE purchased 250,000 shares of A-3 Preferred Stock at a purchase price of $1.00 per share, for a total purchase value of $250,000. In October 2014, as part of the
	Series&nbsp;B Preferred Stock financing, ARE purchased 206,605 shares of Series&nbsp;B Preferred Stock at a purchase price per share of $3.1461, for a total purchase value of $650,000. In January
	2016, as part of the Series&nbsp;B Preferred Stock financing, ARE purchased 158,926 shares of Series&nbsp;B Preferred Stock at a purchase price per share of $3.1461, for a total purchase value of
	$500,000. The Company paid ARE $0.5&nbsp;million and $0.3 million, during
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-32
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=7,SEQ=225,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=697339,FOLIO='F-32',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_FQ79601_1_33">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<BR>
	Syros Pharmaceuticals,&nbsp;Inc.
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	Notes to Consolidated Financial Statements (Continued)
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	(information as of March&nbsp;31, 2016 and for the three months ended March&nbsp;31, 2015 and 2016 is unaudited)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	14. Related Party Transactions (Continued)
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	the
	years ended December&nbsp;31, 2014 and 2015, respectively, and $0.1&nbsp;million for the three months ended March&nbsp;31, 2015 in cash for rent and miscellaneous facilities costs. No
	payments were made to ARE for the three months ended March&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	15. Defined Contribution Plan
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company established a defined contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age
	and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Company contributions to the plan may be made at the discretion of the board of
	directors. Through March&nbsp;31, 2016, no contributions had been made to the plan by the Company.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;">
<FONT SIZE=2>
<B>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:0PT;TEXT-INDENT:-0PT;" -->
	16. Subsequent Event
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	(A)&nbsp;TMRC&nbsp;Co.&nbsp;Ltd.
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2016, the Company amended and restated its license agreement with TMRC. Under the amended and restated license agreement, in
	addition to royalties owed on patents rights, the Company is obligated to pay the remainder of the upfront license fee of $1.0&nbsp;million and will pay low single-digit royalties on net sales with
	respect to know-how licensed by TMRC during a predefined royalty term. The Company paid the remaining license fee of $500,000 in May 2016.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company also entered into a supply management agreement with TMRC and agreed to pay TMRC a fee for each kilogram of SY-1425 active pharmaceutical ingredient produced.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;;MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;">
<FONT SIZE=2>
<I>
<!-- COMMAND=STYLE_ADDED,"MARGIN-LEFT:10.0PT;TEXT-INDENT:-10.0PT;" -->
	(B)&nbsp;Amendment of Certificate of Incorporation; Stockholder Consent
</I>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with preparing for its initial public offering, the Company's board of directors and stockholders approved an amendment
	to the Company's certificate of incorporation. This amendment became effective on June&nbsp;17, 2016. Pursuant to this amendment, the Company effected a reverse stock split at a ratio one-for-3.75
	as determined by the pricing committee of the board of directors.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All share and per share amounts in the financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock split,
	including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. As a result of the reverse stock split, the conversion ratio of the Company's
	outstanding preferred stock was adjusted to reflect the reverse stock split and, accordingly, all shares of preferred stock referenced in these consolidated financial statements will convert into
	shares of common stock upon the completion of the Company's initial public offering at a ratio of 3.75 to 1.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, on June&nbsp;17, 2016, the Company's stockholders approved an amended and restated certificate of incorporation, which authorizes 200&nbsp;million shares of common stock
	and 10&nbsp;million shares of "blank check" preferred stock, and amended and restated bylaws, each of which will become effective upon the closing of the initial public offering. The stockholders
	also adopted the Company's 2016 stock incentive plan and 2016 employee stock purchase plan. They also approved the initial public offering as a "qualified public offering," which permits the
	outstanding preferred stock to automatically convert into common stock upon the closing of the initial public offering.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	F-33
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=8,SEQ=226,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=612274,FOLIO='F-33',FILE='DISK124:[15ZCT1.15ZCT79601]FQ79601A.;93',USER='PANDERS',CD='18-JUN-2016;13:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
<BR>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 3.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:3.0PT;">
</DIV>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 1.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:4.0PT;">
</DIV>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	4,000,000 Shares
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G778263.JPG" ALT="LOGO" WIDTH="631" HEIGHT="130">
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<B>
	Common Stock
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=4>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=4>
<B>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=3>
<B>
	PROSPECTUS
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=3>
<I>
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER">
</I>
</FONT>
<FONT SIZE=3>
<B>
<!-- COMMAND=ADDING_LINEBREAK -->
<BR>
</B>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	Cowen and Company
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	Piper Jaffray
</B>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	JMP Securities
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=5>
<B>
	Wedbush PacGrow
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT SIZE=2>
<B>
	Through and including July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 (the 25
<SUP>
	th
</SUP>
	&nbsp;day after the date of this prospectus), all dealers that buy, sell or trade
	shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers' obligation to deliver a
	prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 1.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:3.0PT;">
</DIV>
<DIV STYLE="WIDTH:100%;BORDER-TOP:SOLID #000000 3.0PT;PADDING:0IN 0IN 0IN 0IN;FONT-SIZE:4.0PT;">
</DIV>
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=227,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=641097,FOLIO='BLANK',FILE='DISK124:[15ZCT1.15ZCT79601]HO79601A.;14',USER='GPEARMO',CD='17-JUN-2016;20:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_JA79601_1_1">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FINANCIAL_STATEMENTS>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JA79601_PART_II_INFORMATION_NOT_REQUIRED_IN_PROSPECTUS">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JA79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	PART II
<BR>
<BR>
	INFORMATION NOT REQUIRED IN PROSPECTUS
<BR>
</B>
</FONT>
</P>
<EFX_OFFERING_EXPENSE>
<A NAME="FIS_OFFERING_EXPENSE"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JA79601_ITEM_13__OTHER_EXPENSE__JA701996">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JA79601_2">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the expenses to be incurred in connection with the offering described in this Registration Statement,
	other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and
	Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority,&nbsp;Inc., or FINRA, filing fee and the NASDAQ listing fee.
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:70%;MARGIN-LEFT:15%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="61PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
<BR>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Amount
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	SEC registration fee
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	7,412
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	FINRA filing fee
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	11,540
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	NASDAQ listing fee
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	125,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Accounting fees and expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Legal fees and expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1,500,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Blue sky fees and expenses (including legal fees)
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Transfer agent and registrar fees and expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	15,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Printing and engraving expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	300,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Miscellaneous fees and expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	36,048
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="WHITE" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:20PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	Total expenses
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- -->
	$
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3,000,000
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0.75PT;FONT-SIZE:0.75PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->
<!-- COMMAND=ADD_GUTTERGRID,"LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;" -->
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=2>
</FONT>
	&#8203;
<!-- COMMAND=ADD_GRID,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="LINE-HEIGHT:0PT;FONT-SIZE:1.5PT;FONT-FAMILY:TIMES;">
<FONT SIZE=2>
</FONT>
	&#8203;
<FONT>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
</EFX_OFFERING_EXPENSE>
<EFX_INDEMNIFICATION>
<A NAME="FIS_INDEMNIFICATION"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JA79601_ITEM_14__INDEMNIFICATION_OF_DIRECTORS_AND_OFFICERS_">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JA79601_3">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of
	its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged
	in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal
	benefit. Upon the closing of this offering, our restated certificate of incorporation will provide that none of our directors shall be personally liable to us or our stockholders for monetary damages
	for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits
	the elimination or limitation of liability of directors for breaches of fiduciary duty.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145
	of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the
	corporation and certain other
	persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred
	by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner
	he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was
	unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
	have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in
	view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-1
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=228,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=11615,FOLIO='II-1',FILE='DISK124:[15ZCT1.15ZCT79601]JA79601A.;26',USER='CHE105570',CD='18-JUN-2016;12:23' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_JA79601_1_2">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
	the closing of this offering, our restated certificate of incorporation will provide that we will indemnify each person who was or is a party or threatened to be made a party to or
	is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of
	the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee
	of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an "Indemnitee"), or by reason of any action
	alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection
	with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests,
	and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our restated certificate of incorporation that will be effective
	upon the closing of the offering also provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of
	the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or
	trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such
	capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or
	proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no
	indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication
	but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits
	or otherwise, he or she will be indemnified by us against all expenses (including attorneys' fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If we
	do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the director or executive officer
	to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of our company or in connection with their service at our request for another corporation or
	entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain
	presumptions that are favorable to the director or executive officer.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
	maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
	directors or officers.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	underwriting agreement we will enter into in connection with the offering of common stock being registered hereby provides that the underwriters will indemnify, under certain
	conditions, our directors and officers (as well as certain other persons) against certain liabilities arising in connection with such offering.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
	as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended,
	or the Securities Act, we have been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is
	therefore unenforceable.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-2
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=229,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=550450,FOLIO='II-2',FILE='DISK124:[15ZCT1.15ZCT79601]JA79601A.;26',USER='CHE105570',CD='18-JUN-2016;12:23' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_JA79601_1_3">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_INDEMNIFICATION>
<EFX_SALE_OF_UNREGISTERED_SECURITIES>
<A NAME="FIS_SALE_OF_UNREGISTERED_SECURITIES"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JA79601_ITEM_15__RECENT_SALES_OF_UNREGISTERED_SECURITIES_">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JA79601_4">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below is information regarding shares of our common stock and shares of our preferred stock, and stock options granted, by us
	within the past three years that were not registered under the Securities Act. Included is the consideration, if any, we received for such shares and options and information relating to the section of
	the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	(a)&nbsp;&nbsp;&nbsp;Issuance of shares of capital stock
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2013, we issued and sold 533,332 shares of our common stock at a price per share of $0.00375 for an aggregate purchase price of $2,000.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	April and November 2013, we issued and sold an aggregate of 12,100,000 shares of our Series&nbsp;A-2 preferred stock at a price per share of $1.00, for an aggregate purchase price
	of $12.1&nbsp;million.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2013, we issued 171,674 shares of common stock to the Whitehead Institute for Biomedical Research pursuant to the terms of certain license agreements between us and the
	Whitehead Institute for Biomedical Research.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, we issued and sold 21,314 shares of common stock pursuant to our 2012 equity incentive plan at a price per share of $1.01 for an aggregate purchase price of $21,581.37.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	March and August 2014, we issued and sold an aggregate of 15,750,000 shares of our Series&nbsp;A-3 preferred stock at a price per share of $1.00, for an aggregate purchase price of
	$15.75&nbsp;million.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	October 2014, we issued and sold an aggregate of 16,893,931 shares of our Series&nbsp;B preferred stock at a price per share of $3.1461, for an aggregate purchase price of
	$53.1&nbsp;million.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
	January 2016, we issued and sold an aggregate of 12,714,150 shares of our Series&nbsp;B preferred stock at a price per share of $3.1461, for an aggregate purchase price of
	$40.0&nbsp;million.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	underwriters were involved in the foregoing issuances of securities. The securities described in this section&nbsp;(a) of Item&nbsp;15 were issued to investors in reliance upon
	the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation&nbsp;D promulgated thereunder relative to
	transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above
	represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any
	distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments
	representing such securities issued in such transactions.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	(b)&nbsp;&nbsp;&nbsp;Stock option grants and option exercises
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From January&nbsp;1, 2013 through the date of the prospectus that is a part of this registration statement, we granted options to purchase an aggregate of
	2,803,995 shares of common stock, with exercise prices ranging from $1.01 to $11.66 per share, to employees, directors, consultants and advisors pursuant to our 2012 equity incentive plan. From
	January&nbsp;1, 2013 through the date of the prospectus that is a part of this registration statement, we issued an aggregate of 625,046 shares of common stock upon the exercise of options for
	aggregate consideration of $0.7&nbsp;million.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	underwriters were involved in the foregoing issuances of securities. The issuances of stock options and the shares of our common stock issued upon the exercise of the options
	described in this paragraph&nbsp;(b) of Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with our
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-3
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=3,SEQ=230,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1020343,FOLIO='II-3',FILE='DISK124:[15ZCT1.15ZCT79601]JA79601A.;26',USER='CHE105570',CD='18-JUN-2016;12:23' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_JA79601_1_4">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	employees,
	directors and consultants, in reliance on the exemption provided by Rule&nbsp;701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act,
	relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or
	had access, through employment or other relationships, to such information.
</FONT>
</P>
</EFX_SALE_OF_UNREGISTERED_SECURITIES>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JA79601_ITEM_16__EXHIBITS_AND_FINANCIAL_STATEMENT_SCHEDULES_">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JA79601_5">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	(a)&nbsp;&nbsp;&nbsp;Exhibits.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
<I>
	(b)&nbsp;&nbsp;&nbsp;Financial Statement Schedules.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes.
</FONT>
</P>
</EFX_EXHIBITS>
<EFX_UNDERTAKINGS>
<A NAME="FIS_UNDERTAKINGS"></A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JA79601_ITEM_17__UNDERTAKINGS_">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JA79601_6">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.
<BR>
</B>
</FONT>
</P>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(a)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such
	denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(b)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Insofar
	as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
	registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the
	Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
	director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
	the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
	question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(c)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	The
	undersigned registrant hereby undertakes that:
<BR>
<BR>
</FONT>
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(1)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	For
	purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration
	statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be
	deemed to be part of this registration statement as of the time it was declared effective.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	(2)
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	For
	the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to
	be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
</FONT>
<FONT SIZE=2>
<I>
	bona
	fide
</I>
</FONT>
<FONT SIZE=2>
	offering thereof.
</FONT>
</DD>
</DL>
</DD>
</DL>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-4
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=4,SEQ=231,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=410836,FOLIO='II-4',FILE='DISK124:[15ZCT1.15ZCT79601]JA79601A.;26',USER='CHE105570',CD='18-JUN-2016;12:23' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_JC79601_1_5">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_UNDERTAKINGS>
</EFX_PART_II>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JC79601_SIGNATURES">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JC79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	SIGNATURES
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No.&nbsp;1 to
	Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 20
<SUP>
	th
</SUP>
	day of June, 2016.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="22PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="46%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD COLSPAN=3 STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<B>
	SYROS PHARMACEUTICALS,&nbsp;INC.
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:10PT;TEXT-INDENT:-10PT;">
<FONT SIZE=2>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	By:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<P STYLE="FONT-FAMILY:TIMES;MARGIN-TOP:12PT;MARGIN-LEFT:0PT;TEXT-INDENT:0PT;">
<FONT SIZE=2>
</FONT>
<FONT SIZE=2>
	/s/&nbsp;NANCY SIMONIAN, M.D.
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Nancy Simonian, M.D.
<BR>
</FONT>
<FONT SIZE=2>
<I>
	President, Chief Executive Officer and Director
</I>
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No.&nbsp;1 to Registration Statement has been signed by the following persons in the capacities
	held on the dates indicated.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="36%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="79PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:34PT;">
<FONT SIZE=1>
<B>
	Signature
<!-- COMMAND=ADD_SCROPPEDRULE,34PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Title
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Date
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/&nbsp;NANCY SIMONIAN, M.D.
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Nancy Simonian, M.D.
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	President, Chief Executive Officer and Director (principal executive officer)
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	/s/&nbsp;KYLE KUVALANKA
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Kyle Kuvalanka
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Chief Operating Officer (principal financial and principal accounting officer)
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	St&eacute;phane Bancel
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Marsha H. Fanucci
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Jonathan Leff
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Amir&nbsp;Nashat, Ph.D.
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-5
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=232,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=720808,FOLIO='II-5',FILE='DISK124:[15ZCT1.15ZCT79601]JC79601A.;33',USER='NDEWIND',CD='17-JUN-2016;18:47' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_JC79601_1_6">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="36%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="79PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP COLSPAN=3 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:34PT;">
<FONT SIZE=1>
<B>
	Signature
<!-- COMMAND=ADD_SCROPPEDRULE,34PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Title
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH NOWRAP ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<DIV STYLE="BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;WIDTH:17PT;">
<FONT SIZE=1>
<B>
	Date
<!-- COMMAND=ADD_SCROPPEDRULE,17PT -->
</B>
</FONT>
</DIV>
</TH>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Robert Nelsen
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Sanj K. Patel
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Vicki L. Sato, Ph.D.
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Phillip A. Sharp, Ph.D.
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	*
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Richard A. Young, Ph.D.
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	Director
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	June&nbsp;20, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	*By:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	/s/&nbsp;NANCY SIMONIAN, M.D.
<BR>
<HR NOSHADE SIZE="1.0PT" WIDTH="100%" COLOR="#000000">
</FONT>
<FONT SIZE=2>
	Nancy Simonian, M.D.
<BR>
</FONT>
<FONT SIZE=2>
<I>
	Attorney-in-Fact
</I>
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<BR>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<BR>
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-6
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=233,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=289480,FOLIO='II-6',FILE='DISK124:[15ZCT1.15ZCT79601]JC79601A.;33',USER='NDEWIND',CD='17-JUN-2016;18:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_PAGE_JE79601_1_7">
</A>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
</EFX_SIGNATURES>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZS-1A_HTM_JE79601_EXHIBIT_INDEX">
</A>
<A NAME="A2228976ZS-1A_HTM_TOC_JE79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	EXHIBIT INDEX
<BR>
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Description of Exhibit
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	1.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Underwriting Agreement
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amended and Restated Certificate of Incorporation of the Registrant, as amended
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Bylaws of the Registrant
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	3.4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Specimen stock certificate evidencing the shares of common stock
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	4.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Second Amended and Restated Investors' Rights Agreement, dated as of October&nbsp;9, 2014, as amended, among the Registrant and the other parties thereto
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	5.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Opinion of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2012 Equity Incentive Plan, as amended
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Incentive Stock Option Agreement under 2012 Equity Incentive Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.3
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Nonstatutory Stock Option Agreement under 2012 Equity Incentive Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.4
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Restricted Stock Agreement under 2012 Equity Incentive Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2016 Stock Incentive Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.6
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Incentive Stock Option Agreement under 2016 Stock Incentive Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.7
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Nonstatutory Stock Option Agreement under 2016 Stock Incentive Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.8
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	2016 Employee Stock Purchase Plan
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.9
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Offer Letter, dated November&nbsp;13, 2012 and effective as of July&nbsp;2, 2012, by and between the Registrant and Nancy Simonian, M.D., as amended
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.10
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Offer Letter, dated August&nbsp;25, 2015, by and between the Registrant and Kyle&nbsp;D. Kuvalanka, as amended
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.11
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&#134;*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Offer Letter, dated December&nbsp;2, 2015, by and between the Registrant and David&nbsp;A. Roth, M.D., as amended
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.12
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Form of Director and Officer Indemnification Agreement by and between the Registrant and each of Nancy Simonian, M.D., Jorge Conde, Kyle D. Kuvalanka, Eric&nbsp;R. Olson, David&nbsp;A. Roth, M.D., St&eacute;phane Bancel,
	Marsha H. Fanucci, Amir Nashat, Ph.D., Robert Nelsen, Vicki L. Sato, Ph.D., Phillip A. Sharp, Ph.D. and Richard A. Young, Ph.D.
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.13
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	+*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Exclusive License Agreement, by and between the Registrant and the Dana-Farber Cancer Institute,&nbsp;Inc., dated as of February&nbsp;22, 2013
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	+*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Exclusive Patent License Agreement, by and among the Registrant, the Whitehead Institute for Biomedical Research and the Dana-Farber Cancer Institute, dated as of April&nbsp;1, 2013
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.15
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	+*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Exclusive Patent License Agreement, by and between the Registrant and the Whitehead Institute for Biomedical Research, dated as of April&nbsp;4, 2013
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<BR>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-7
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=234,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=385101,FOLIO='II-7',FILE='DISK124:[15ZCT1.15ZCT79601]JE79601A.;34',USER='KSEAMON',CD='19-JUN-2016;13:08' -->
<A NAME="A2228976ZS-1A_HTM_PAGE_JE79601_1_8">
</A>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A HREF="#A2228976ZS-1A_HTM_BG79601A_MAIN_TOC">
	Table of Contents
</A>
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7PT" ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="40PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="20PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</TH>
<TH STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=1>
	&nbsp;
</FONT>
</TH>
<TH ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;BORDER-BOTTOM:SOLID #000000 1.0PT;">
<FONT SIZE=1>
<B>
	Description of Exhibit
</B>
</FONT>
</TH>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.16
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	+*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Amended and Restated Cancer License Agreement, by and between the Registrant and TMRC&nbsp;Co.,&nbsp;Ltd., dated as of April&nbsp;28, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.17
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Lease, by and between the Registrant and 620 Memorial Leasehold&nbsp;LLC, dated as of March&nbsp;13, 2015
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.18
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	+*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Supply Management Agreement, by and between the Registrant and TMRC Co., Ltd., dated as of April&nbsp;28, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	10.19
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consent and Stand-by License Agreement, by and among the Registrant, Toko Pharmaceutical Ind. Co., Ltd. and TMRC Co., Ltd., dated as of April 28, 2016
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	21.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Subsidiaries of the Registrant
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm.
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	23.2
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Consent of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP (included in Exhibit&nbsp;5.1)
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	24.1
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	*
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Power of Attorney (included on signature page)
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
<!-- COMMAND=ADD_LINERULETXT,NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT">
</DIV>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;TEXT-ALIGN:LEFT;MARGIN-LEFT:10%;">
<DL COMPACT>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	*
</FONT>
</DT>
</EFX_UNIDENTIFIED_TABLE>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Previously
	filed.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	+
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Confidential
	treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
<BR>
<BR>
</FONT>
</DD>
<DT STYLE='FONT-FAMILY:TIMES;MARGIN-BOTTOM:-11PT;'>
<FONT SIZE=2>
	&#134;
</FONT>
</DT>
<DD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Indicates
	management contract or compensatory plan.
</FONT>
</DD>
</DL>
</DIV>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	II-8
</FONT>
</P>
<HR NOSHADE>
</EFX_EXHIBIT_INDEX>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=2,SEQ=235,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="1",CHK=1032754,FOLIO='II-8',FILE='DISK124:[15ZCT1.15ZCT79601]JE79601A.;34',USER='KSEAMON',CD='19-JUN-2016;13:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage2"></A>
<A NAME="A2228976ZEX-1_1_HTM"></A>
<EFX_EXHIBIT_1>
<A NAME="FIS_EXHIBIT_1"></A>
<BR>
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit 1.1
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	[Number of Shares]
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Common Stock
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<U>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	UNDERWRITING AGREEMENT
</FONT>
</U>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="RIGHT" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	June [
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	], 2016
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:10.0PT;">
	COWEN AND COMPANY, LLC
<BR>
</FONT>
	PIPER JAFFRAY&nbsp;&amp; CO.
<BR>
	as Representatives of the several Underwriters named in
<U>
	Schedule A
</U>
	hereto
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	c/o Cowen and Company, LLC
<BR>
	599 Lexington Avenue
<BR>
	New York, New York 10022
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	c/o Piper Jaffray&nbsp;&amp; Co.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	345 Park Avenue
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	New York, New York 9300
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Dear Sirs and Madams:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	INTRODUCTORY
</I>
	.&#160; Syros Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Company
</I>
</B>
	&#148;), proposes to sell, pursuant to the terms of this Underwriting Agreement (this &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Agreement
</I>
</B>
	&#148;), to the several underwriters named in
<U>
	Schedule A
</U>
	hereto (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Underwriters
</I>
</B>
	,&#148; or, each, an &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Underwriter
</I>
</B>
	&#148;), an aggregate of [
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] shares of Common Stock, $0.001 par value per share (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Common Stock
</I>
</B>
	&#148;) of the Company.&#160; The aggregate of [
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] shares so proposed to be sold is hereinafter referred to as the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Firm Stock
</I>
</B>
	&#148;.&#160; The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section&nbsp;3 hereof, up to an additional [
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] shares of Common Stock (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Optional Stock
</I>
</B>
	&#148;).&#160; The Firm Stock and the Optional Stock are hereinafter collectively referred to as the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Stock
</I>
</B>
	&#148;.&#160; Cowen and Company, LLC (&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Cowen
</I>
</B>
	&#148;) and Piper Jaffray&nbsp;&amp; Co. are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Representatives
</I>
</B>
	.&#148;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.&#160;
</I>
	The Company represents and warrants to the several Underwriters, as of the date hereof and as of each Closing Date (as defined below), and agrees with the several Underwriters, that:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	A registration statement of the Company on Form&nbsp;S-1 (File No.&nbsp;333-211818) (including all pre-effective amendments thereto, and all post-effective amendments thereto filed before execution of this Agreement, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Initial Registration Statement
</I>
</B>
	&#148;) in respect of the Stock has been filed with the Securities and Exchange Commission (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Commission
</I>
</B>
	&#148;).&#160; The Initial Registration Statement and any post-effective amendment thereto, each in the form heretofore delivered to the Representatives, and, excluding exhibits thereto, to the Representatives for each of the other Underwriters, have been declared effective by the Commission in such form and meet, in all material respects, the requirements of the Securities Act of 1933, as amended (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Securities Act
</I>
</B>
	&#148;), and the rules&nbsp;and regulations of the Commission thereunder (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Rules&nbsp;and Regulations
</I>
</B>
	&#148;).&#160; Other than (i)&nbsp;the Initial Registration Statement, (ii)&nbsp;a registration statement, if any, increasing the size of the offering filed pursuant to Rule&nbsp;462(b)&nbsp;under
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=1,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=24228,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage3"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	the Securities Act and the Rules&nbsp;and Regulations (a &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Rule&nbsp;462(b)&nbsp;Registration Statement
</I>
</B>
	&#148;), (iii)&nbsp;any Preliminary Prospectus (as defined below), (iv)&nbsp;the Prospectus (as defined below) contemplated by this Agreement to be filed pursuant to Rule&nbsp;424(b)&nbsp;of the Rules&nbsp;and Regulations in accordance with Section&nbsp;4(a)&nbsp;hereof and (iii)&nbsp;any Issuer Free Writing Prospectus (as defined below), no other document with respect to the offer and sale of the Stock has heretofore been filed with the Commission.&#160; No stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule&nbsp;462(b)&nbsp;Registration Statement, if any, has been issued, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act has been initiated or, to the Company&#146;s knowledge, threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement or filed with the Commission pursuant to Rule&nbsp;424(a)&nbsp;of the Rules&nbsp;and Regulations is hereinafter called a &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Preliminary Prospectus
</I>
</B>
	&#148;).&#160; The Initial Registration Statement and the Rule 462(b) Registration Statement, if any, in each case including all exhibits thereto and including (y)&nbsp;the information contained in the Prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;of the Rules&nbsp;and Regulations and deemed by virtue of Rule&nbsp;430A under the Securities Act to be part of the Initial Registration Statement at the time it became effective and (z)&nbsp;the documents incorporated by reference in the Rule&nbsp;462(b)&nbsp;Registration Statement at the time the Rule&nbsp;462(b)&nbsp;Registration Statement became effective, are hereinafter collectively called the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Registration Statement
</I>
</B>
	.&#148; The final prospectus, in the form filed pursuant to and within the time limits described in Rule&nbsp;424(b)&nbsp;under the Rules&nbsp;and Regulations, is hereinafter called the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Prospectus
</I>
</B>
	.&#148;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	As of the Applicable Time (as defined below) and as of the Closing Date or the Option Closing Date (as defined below), as the case may be, neither (i)&nbsp;the General Use Free Writing Prospectus(es) (as defined below) issued at or prior to the Applicable Time, the Pricing Prospectus (as defined below) and the information included on
<U>
	Schedule C
</U>
	hereto, all considered together (collectively, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	General Disclosure Package
</I>
</B>
	&#148;), (ii)&nbsp;any individual Limited Use Free Writing Prospectus (as defined below), (iii)&nbsp;the bona fide electronic road show (as defined in Rule&nbsp;433(h)(5)&nbsp;of the Rules&nbsp;and Regulations), nor (iv)&nbsp;any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included or will include any untrue statement of a material fact or omitted or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the Company makes no representations or warranties as to information contained in or omitted from the Pricing Prospectus or any Issuer Free Writing Prospectus (as defined below), in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in Section&nbsp;17 hereof).&#160; As used in this paragraph (b)&nbsp;and elsewhere in this Agreement:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Applicable Time
</I>
</B>
	&#148; means [
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] [A/P].M., New York time, on the date of this Agreement or such other time as agreed to by the Company and the Representatives.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Pricing Prospectus
</I>
</B>
	&#148; means the Preliminary Prospectus relating to the Stock that is included in the Registration Statement immediately prior to the Applicable Time.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Issuer Free Writing Prospectus
</I>
</B>
	&#148; means any &#147;issuer free writing prospectus,&#148; as defined in Rule 433 of the Rules and Regulations relating to the Stock in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule&nbsp;433(g)&nbsp;of the Rules&nbsp;and Regulations.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	General Use Free Writing Prospectus
</I>
</B>
	&#148; means any Issuer Free Writing Prospectus that is identified on
<U>
	Schedule B
</U>
	to this Agreement.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	2
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_2_001149_8728">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=2,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=761020,FOLIO='2',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage4"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Limited Use Free Writing Prospectuses
</I>
</B>
	&#148; means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Written Testing-the-Waters Communication
</I>
</B>
	&#148; means any Testing-the-Waters Communication (as defined below) that is a written communication within the meaning of Rule&nbsp;405 of the Rules&nbsp;and Regulations.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	No order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus relating to the proposed offering of the Stock has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act has been instituted or, to the Company&#146;s knowledge, threatened by the Commission, and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Securities Act and the Rules&nbsp;and Regulations, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the Company makes no representations or warranties as to information contained in or omitted from any Preliminary Prospectus, in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	At the respective times the Registration Statement and any amendments thereto became or become effective and at each Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and the Rules&nbsp;and Regulations, and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at each Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and the Rules&nbsp;and Regulations, and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the foregoing representations and warranties in this paragraph (d)&nbsp;shall not apply to information contained in or omitted from the Registration Statement or the Prospectus or any amendment or supplement thereto, in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in Section&nbsp;17 hereof).&#160; The Prospectus contains or will contain all required information under Rule&nbsp;430A.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Stock or until any earlier date that the Company notified or notifies the Representatives as described in Section&nbsp;4(g)&nbsp;hereof, did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus, or included or would include an untrue statement of a material fact or, when taken together with the General Disclosure Package, omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the foregoing representations and warranties in this paragraph (e)&nbsp;shall not apply to information contained in or omitted from any Issuer Free Writing Prospectus, or any amendment or supplement thereto, in reliance upon, and in conformity with, written information
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	3
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_3_001159_5335">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=3,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=280791,FOLIO='3',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage5"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(f)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company has not, directly or indirectly, distributed and will not distribute any offering material in connection with the offering and sale of the Stock other than any Preliminary Prospectus, the Prospectus and other materials, if any, permitted under the Securities Act and consistent with Section&nbsp;4(d)&nbsp;below.&#160; The Company will file with the Commission all Issuer Free Writing Prospectuses in the time and manner required under Rules&nbsp;163(b)(2)&nbsp;and 433(d)&nbsp;of the Rules&nbsp;and Regulations.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(g)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communications) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Emerging Growth Company
</I>
</B>
	&#148;).&#160; &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Testing-the-Waters Communication
</I>
</B>
	&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(h)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	At the time of filing the Initial Registration Statement, any Rule&nbsp;462(b)&nbsp;Registration Statement and any post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an &#147;ineligible issuer,&#148; as defined in Rule&nbsp;405 of the Rules&nbsp;and Regulations.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company (a)&nbsp;has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule&nbsp;144A under the Securities Act or institutions that are accredited investors within the meaning of Rule&nbsp;501 under the Securities Act and (b)&nbsp;has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications.&#160; The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Testing-the-Waters Communications.&#160; The Company has not distributed any Written Testing-the-Waters Communications in each case in connection with the offering of the Stock.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(j)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company has been duly organized and is validly existing as a corporation under the laws of the State of Delaware.&#160; Each subsidiary of the Company has been duly organized and is validly existing as a corporation under the laws of its jurisdiction of formation.&#160; The Company and each of its subsidiaries are duly qualified to do business and in good standing as a foreign corporation&#160; in each jurisdiction in which its ownership or lease of property or the conduct of its business requires such qualification and has all power and authority (corporate or other) necessary to own or hold its properties and to conduct the business in which it is engaged, except where the failure to so qualify or have such power or authority would not (i)&nbsp;have, individually or in the aggregate, a material adverse effect on the business, properties, assets, general affairs, management, financial condition, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries, taken as a whole, or (ii)&nbsp;impair in any material respect the ability of the Company to perform its obligations under this Agreement or to consummate any transactions contemplated by this Agreement, the General Disclosure Package or the Prospectus (any such effect as described in clauses (i)&nbsp;or (ii), a &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Material Adverse Effect
</I>
</B>
	&#148;).&#160; The Company does not own or control, directly or indirectly, any interest in any corporation, partnership, limited liability company, association or other entity, other than its wholly owned subsidiary, Syros Pharmaceuticals Securities Corporation.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(k)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	This Agreement has been duly authorized, executed and delivered by the Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	4
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_4_001211_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=4,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=744868,FOLIO='4',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage6"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(l)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Stock to be issued and sold by the Company to the Underwriters hereunder has been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid, nonassessable and free of any preemptive or other similar rights, and will conform to the descriptions thereof in the Registration Statement, the General Disclosure Package and the Prospectus; and the issuance of the Stock is not subject to any preemptive or similar rights.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(m)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company has an authorized capitalization as set forth under the heading &#147;Capitalization&#148; in the Pricing Prospectus, and all of the issued shares of capital stock of the Company have been duly and validly authorized and issued, are fully paid, nonassessable and free of any preemptive or other similar rights, have been issued in compliance with federal and state securities laws, and conform to the description thereof contained in the General Disclosure Package and the Prospectus under the heading &#147;Description of Capital Stock.&#148;&#160; All of the Company&#146;s options and other rights to purchase or exchange any securities for shares of the Company&#146;s capital stock have been duly authorized and validly issued and were issued in compliance with federal and state securities laws.&#160; None of the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.&#160; As of the date set forth in the General Disclosure Package, there were no authorized or outstanding shares of capital stock, options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries, other than those described above or accurately described in the General Disclosure Package.&#160; Since such date, the Company has not issued any securities other than Common Stock issued upon the exercise of stock options or other awards outstanding under the Company&#146;s stock option plans, options or other securities granted or issued pursuant to the Company&#146;s existing equity compensation plans or other plans, and the issuance of Common Stock pursuant to employee stock purchase plans.&#160; The description of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, as described in the General Disclosure Package and the Prospectus, accurately and fairly present the information required to be shown with respect to such plans, arrangements, options and rights.&#160; All of the outstanding capital stock of each subsidiary of the Company has been duly and validly authorized and issued, is fully paid, nonassessable and free of any preemptive or other similar rights, has been issued in compliance with federal and state securities laws and is owned by the Company free and clear of any claim, lien, encumbrance, security interest, restriction on voting or transfer or other claim of any third party.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(n)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The execution, delivery and performance of this Agreement by the Company, the issue and sale of the Stock by the Company and the consummation of the transactions contemplated hereby will not (with or without notice or lapse of time or both) (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, constitute a default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, encumbrance, security interest, claim or charge upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or by-laws (or analogous governing instruments, as applicable) of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law, statute, rule, regulation, judgment, order or decree of any court or governmental or regulatory agency or authority, domestic or foreign, having jurisdiction over the Company or any of its subsidiaries or any of their respective properties or assets except, in the case of clauses (i)&nbsp;and (iii)&nbsp;above, to the extent that any such conflict, breach, violation or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.&#160; A &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Debt Repayment Triggering Event
</I>
</B>
	&#148; means any event or condition that gives, or with the giving of notice or lapse of time would give the holder of any note, debenture or other evidence of
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	5
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_5_001228_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=5,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=86825,FOLIO='5',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage7"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(o)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Except for the registration of the Stock under the Securities Act and Exchange Act (as defined below) and applicable state securities laws, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority,&nbsp;Inc. (&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	FINRA
</I>
</B>
	&#148;) and The Nasdaq Global Market in connection with the purchase and distribution of the Stock by the Underwriters and the listing of the Stock on The Nasdaq Global Market, no consent, approval, authorization or order of, or filing, qualification or registration (each, an &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Authorization
</I>
</B>
	&#148;) with, any court, governmental or regulatory agency or authority, foreign or domestic, which has not been made, obtained or taken and is not in full force and effect, is required for the execution, delivery and performance of this Agreement by the Company, the issuance and sale of the Stock or the consummation of the transactions contemplated hereby; and no event has occurred that allows or results in, or after notice or lapse of time or both would allow or result in, revocation, suspension, termination or invalidation of any such Authorization or any other impairment of the rights of the holder or maker of any such Authorization.&#160; All corporate approvals (including those of stockholders) necessary for the Company to consummate the transactions contemplated by this Agreement have been obtained and are in effect.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(p)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Ernst&nbsp;&amp; Young LLP, who have certified certain financial statements of the Company and its subsidiaries included in the Registration Statement, General Disclosure Package and the Prospectus, is an independent registered public accounting firm with respect to the Company within the meaning of Article&nbsp;2-01 of Regulation S-X and the Public Company Accounting Oversight Board (United States) (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	PCAOB
</I>
</B>
	&#148;).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(q)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The financial statements, together with the related notes, included in the General Disclosure Package, the Prospectus and in the Registration Statement fairly present the financial condition and the results of operations and changes in financial condition of the Company and its subsidiaries at the respective dates or for the respective periods therein specified.&#160; Such statements and related notes have been prepared in accordance with the generally accepted accounting principles in the United States (&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	GAAP
</I>
</B>
	&#148;) applied on a consistent basis throughout the periods involved except as may be set forth in the related notes included in the General Disclosure Package.&#160; The financial statements, together with the related notes, included in the General Disclosure Package and the Prospectus comply in all material respects with Regulation S-X.&#160; No other financial statements or supporting schedules or exhibits are required by Regulation S-X to be described or included in the Registration Statement, the General Disclosure Package or the Prospectus. The pro forma and pro forma as adjusted financial information included in the Registration Statement, the General Disclosure Package and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of Rule&nbsp;11-02 of Regulation S-X and present fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.&#160; The summary and selected financial data included in the General Disclosure Package, the Prospectus and the Registration Statement fairly present, in all material respects, the information shown therein as at the respective dates and for the respective periods specified and are derived from the consolidated financial statements set forth in the Registration Statement, the Pricing Prospectus and the Prospectus and other financial information.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(r)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither the Company nor any of its subsidiaries has sustained, since the date of the latest audited financial statements included in the General Disclosure Package, (i)&nbsp;any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or action, order or decree of any court or governmental or regulatory
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	6
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_6_001239_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=6,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=394694,FOLIO='6',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage8"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	authority, otherwise than as set forth or contemplated in the General Disclosure Package, or (ii)&nbsp;any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration statement, the General Disclosure Package and the Prospectus) or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse changes, or any development involving a prospective material adverse change, in or affecting the business, properties, assets, general affairs, management, financial condition, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries, taken as a whole, otherwise than as set forth or contemplated in the General Disclosure Package.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(s)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Except as set forth in the General Disclosure Package, there is no legal or governmental proceeding to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries is the subject, including any proceeding before the U.S. Food and Drug Administration of the U.S. Department of Health and Human Services (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	FDA
</I>
</B>
	&#148;) or comparable federal, state, local or foreign governmental authorities (it being understood that the interaction between the Company and the FDA and such comparable governmental authorities relating to the clinical development and product approval process shall not be deemed proceedings for purposes of this representation), which is required to be described in the Registration Statement, the General Disclosure Package or the Prospectus and is not described therein, or which, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; and, to the Company&#146;s knowledge no such proceedings are contemplated by governmental or regulatory authorities or threatened by others.&#160; The Company is in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees governing its business as prescribed by the FDA, or any other federal, state or foreign agencies or bodies engaged in the regulation of pharmaceuticals or biohazardous substances or materials, except where noncompliance would not, individually or in the aggregate, have a Material Adverse Effect.&#160; All preclinical and clinical studies conducted by or on behalf of the Company to support approval for commercialization of the Company&#146;s products have been conducted by the Company, or to the Company&#146;s knowledge by third parties, in compliance with all applicable federal, state or foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance which would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(t)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither the Company nor any of its subsidiaries is in (i)&nbsp;violation of its charter or by-laws (or analogous governing instrument, as applicable), (ii)&nbsp;default in any respect, and no event has occurred which, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) or (iii)&nbsp;violation in any respect of any law, ordinance, governmental rule, regulation or court order, decree or judgment to which it or its property or assets may be subject except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such violation or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(u)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company possesses all licenses, certificates, authorizations and permits issued by, and has made all declarations and filings with, the appropriate local, state, federal or foreign governmental or regulatory agencies or bodies (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) that are necessary for the ownership or lease of the Company&#146;s
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	7
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_7_001247_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=7,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=137614,FOLIO='7',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage9"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	properties or the conduct of the Company&#146;s businesses as described in the Registration Statement, General Disclosure Package and the Prospectus (collectively, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Governmental Permits
</I>
</B>
	&#148;) except where any failures to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.&#160; The Company is in compliance with all such Governmental Permits, and all such Governmental Permits are valid and in full force and effect, except where such non-compliance, invalidity or failure to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.&#160; The Company has not received notification of any revocation, modification, suspension, termination or invalidation (or proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental Permit will not be renewed.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The studies, tests and preclinical studies conducted by or on behalf of the Company that are described in the General Disclosure Package and the Prospectus (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Company Studies and Trials
</I>
</B>
	&#148;) were and, if still pending, are being, conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional scientific standards; the descriptions of the results of the Company Studies and Trials contained in the Registration Statement, General Disclosure Package and the Prospectus are accurate in all material respects; the Company has no knowledge of any other studies or trials not described in the General Disclosure Package and the Prospectus, the results of which are inconsistent with or call in question the results described or referred to in the General Disclosure Package and the Prospectus; and the Company has not received any notices or correspondence from the FDA or any foreign, state or local governmental authority exercising comparable authority requiring the termination, suspension or material modification of any Company Studies and Trials that termination, suspension or material modification would reasonably be expected to have a Material Adverse Effect and, to the Company&#146;s knowledge, there are no reasonable grounds for the same.&#160; The Company has obtained (or caused to be obtained) informed consent by or on behalf of each human subject who participated in the Company Studies and Trials.&#160; In using or disclosing patient information received by the Company in connection with the Company Studies and Trials, the Company has complied in all material respects with all applicable laws and regulatory rules&nbsp;or requirements, including, without limitation, the Health Insurance Portability and Accountability Act of 1996 and the rules&nbsp;and regulations thereunder.&#160; To the Company&#146;s knowledge, none of the Company Studies and Trials involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct.&#160; To the Company&#146;s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the FDA and comparable governmental authorities outside of the United States to which the Company is subject.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(w)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither the Company nor any of its subsidiaries is and, after giving effect to the offering of the Stock and the application of the proceeds thereof as described in the General Disclosure Package and the Prospectus, will be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules&nbsp;and regulations of the Commission thereunder.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(x)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither the Company nor, to the Company&#146;s knowledge, any of its officers, directors or affiliates has taken or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or resulted in, or which might in the future reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(y)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company owns or possesses the valid&#160; right to use all (i)&nbsp;valid and enforceable patents, patent applications, trademarks, trademark registrations, service marks, service mark registrations,&nbsp;Internet domain name registrations, copyrights, copyright registrations, licenses and&#160; trade
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	8
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_8_001306_141">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=8,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=139732,FOLIO='8',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage10"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	secret rights (collectively, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Intellectual Property Rights
</I>
</B>
	&#148;) and (ii)&nbsp;inventions, software, works of authorships, trademarks, service marks, trade names, databases, formulae, know how,&nbsp;Internet domain names and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures) (collectively, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Intellectual Property Assets
</I>
</B>
	&#148;) necessary to conduct its business as currently conducted, and as proposed to be conducted and described in the Registration Statement, General Disclosure Package and the Prospectus.&#160; The Company has not received any opinion from its legal counsel concluding that any activities of its business infringes, misappropriates, or otherwise violates, valid and enforceable Intellectual Property Rights of any other person, and has not received written notice of any challenge, which is to its knowledge still pending, by any other person to the rights of the Company with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company.&#160; To the Company&#146;s knowledge, the Company&#146;s business as now conducted does not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual Property Rights of any other person.&#160; All licenses for the use of the Intellectual Property Rights described in the Registration Statement, the General Disclosure Package and the Prospectus are valid, binding upon and enforceable by or against the Company and, to the Company&#146;s knowledge, by or against the other parties thereto in accordance to their terms.&#160; The Company has complied in all material respects with, and is not in breach of, nor has it received any asserted or threatened claim of breach of all intellectual property licenses for the use of the Intellectual Property Rights, and the Company has no knowledge of any breach or anticipated breach by any other person of any such intellectual property licenses.&#160; Except as described in the General Disclosure Package, no claim has been made or is pending against the Company alleging the infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person.&#160; The Company has taken all reasonable steps to protect, maintain and safeguard its Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements.&#160; The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the Company&#146;s right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for use in the conduct of the business as currently conducted.&#160; The Company has at all times complied with all applicable laws relating to privacy, data protection, and the collection and use of personal information collected, used, or held for use by the Company in the conduct of the Company&#146;s business.&#160; No claims have been asserted or threatened against the Company alleging a violation of any person&#146;s privacy or personal information or data rights and the consummation of the transactions contemplated hereby will not breach or otherwise cause any violation of any law related to privacy, data protection, or the collection and use of personal information collected, used, or held for use by the Company in the conduct of the Company&#146;s business.&#160; The Company takes reasonable measures to ensure that such information is protected against unauthorized access, use, modification or other misuse.&#160; The Company has taken all reasonable actions to obtain ownership of all works of authorship and inventions made by its employees, consultants and contractors during the time they were employed by or under contract with the Company and which relate to the Company&#146;s business. All founders and key employees have signed confidentiality and invention assignment agreements with the Company.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(z)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company and its subsidiaries own no real property.&#160; The Company and its subsidiaries have valid and marketable rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company and its subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that, individually or in the aggregate, materially affect the value of such property or materially interfere with the use made and proposed to be made of such property by the Company; and all of the leases and subleases material to the business of the Company, and under which the Company holds properties described in the General Disclosure Package and the Prospectus, are in full force and effect and the Company has not received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	9
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_9_001318_7608">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=9,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=504644,FOLIO='9',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<A NAME="eolPage11"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Company under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company to the continued possession of the leased or subleased premises under any such lease or sublease.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(aa)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	There is (A)&nbsp;no unfair labor practice complaint pending against the Company, nor, to the Company&#146;s knowledge, threatened against it, before the National Labor Relations Board, any state or local labor relations board or any foreign labor relations board, and no significant grievance or significant arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company, or, to the Company&#146;s knowledge, threatened against it and (B)&nbsp;no labor disturbance by or dispute with, employees of the Company exists or, to the Company&#146;s knowledge, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers, customers or contractors, that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.&#160; The Company is not aware that any key employee or significant group of employees of the Company plans to terminate employment with the Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(bb)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	No &#147;prohibited transaction&#148; (as defined in Section&nbsp;406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	ERISA
</I>
</B>
	&#148;), or Section&nbsp;4975 of the Internal Revenue Code of 1986, as amended from time to time (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Code
</I>
</B>
	&#148;)) or &#147;accumulated funding deficiency&#148; (as defined in Section&nbsp;302 of ERISA) or any of the events set forth in Section&nbsp;4043(b)&nbsp;of ERISA (other than events with respect to which the thirty (30)-day notice requirement under Section&nbsp;4043 of ERISA has been waived) has occurred or is reasonably expected to occur with respect to any employee benefit plan of the Company which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.&#160; Each employee benefit plan of the Company is in compliance in all material respects with applicable law, including ERISA and the Code.&#160; The Company has not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA).&#160; Each pension plan for which the Company would have any liability that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would, individually or in the aggregate, reasonably be expected to cause the loss of such qualification.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(cc)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company is in compliance in all material respects with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment which are applicable to its businesses (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Environmental Laws
</I>
</B>
	&#148;).&#160; There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company (or, to the Company&#146;s knowledge, any other entity for whose acts or omissions the Company is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule&nbsp;(including rule&nbsp;of common law), regulation, order, judgment, decree or permit, give rise to any liability; and there has been no disposal, discharge, emission or other release of any kind on to such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(dd)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company and its subsidiaries (i)&nbsp;have timely filed all necessary federal, state, local and foreign tax returns (or timely filed extensions with respect to such returns), and all such returns were true, complete and correct, (ii)&nbsp;have paid all federal, state, local and foreign taxes, assessments, governmental or other charges due and payable for which it is liable, including, without limitation, all sales and use taxes and all taxes which the Company or any of its subsidiaries is obligated
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	10
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-01_PB_10_001329_8146">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=10,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=1016660,FOLIO='10',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-01_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:39 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	to withhold from amounts owing to employees, creditors and third parties, and (iii)&nbsp;do not have any tax deficiency or claims outstanding or assessed or, to its knowledge, proposed against it, except those, in each of the cases described in clauses (i), (ii)&nbsp;and (iii)&nbsp;above, that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.&#160; The Company and its subsidiaries have not engaged in any transaction which is a corporate tax shelter or which could be characterized as such by the Internal Revenue Service or any other taxing authority.&#160; The accruals and reserves on the books and records of the Company and its subsidiaries in respect of tax liabilities for any taxable period not yet finally determined are adequate to meet any assessments and related liabilities for any such period, and since December&nbsp;31, 2014 the Company and its subsidiaries have not incurred any liability for taxes other than in the ordinary course.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ee)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company carries or is covered by insurance in such amounts and covering such risks as is adequate for the conduct of its business and the value of its properties and as the Company reasonably believes is customary for companies engaged in similar businesses at a similar stage of development in similar industries.&#160; The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect.&#160; All policies of insurance owned by the Company are, to the Company&#146;s knowledge, in full force and effect and the Company is in compliance in all material respects with the terms of such policies.&#160; The Company has not received written notice from any insurer, agent of such insurer or the broker of the Company that any material capital improvements or any other material expenditures (other than premium payments) are required or necessary to be made in order to continue such insurance.&#160; Except for customary deductibles, the Company does not insure risk of loss through any captive insurance, risk retention group, reciprocal group or by means of any fund or pool of assets specifically set aside for contingent liabilities other than as described in the General Disclosure Package.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ff)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company and each of its subsidiaries maintains a system of&#160; &#147;
<I>
	internal control over financial reporting
</I>
	&#148; (as such term is defined in Rule&nbsp;13a-15(f)&nbsp;of the General Rules&nbsp;and Regulations under the Securities Exchange Act of 1934, as amended (such act, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Exchange Act
</I>
</B>
	,&#148; and such rules&nbsp;and regulations, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Exchange Act Rules
</I>
</B>
	&#148;) that is designed to comply with the requirements of the Exchange Act and has been designed by its principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the General Disclosure Package, the internal control over financial reporting of the Company and its subsidiaries are effective. Except as described in the General Disclosure Package, since the end of the Company&#146;s most recently audited fiscal year, there has been (A)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (B)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting.&#160; The Company&#146;s internal control over financial reporting is overseen by the Audit Committee of the board of directors of the Company (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Audit Committee
</I>
</B>
	&#148;) in accordance with the Exchange Act Rules. Except as described in the General Disclosure Package and the Prospectus, the Company has not publicly disclosed or reported to the Audit Committee or to the board of directors of the Company (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Board
</I>
</B>
	&#148;), and within the next ninety (90) days the Company does not reasonably expect to publicly disclose or report to the Audit Committee or the Board, a significant deficiency, material weakness, change in internal control over financial reporting or fraud involving management or other employees who have a significant role in the internal control over financial
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	11
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_11_001629_4184">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=11,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=499999,FOLIO='11',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage12"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	reporting (each, an &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Internal Control Event
</I>
</B>
	&#148;) or any material violation of, or failure to comply in all material respects with, U.S. federal securities laws.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(gg)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	A member of the Audit Committee has confirmed to the Chief Executive Officer or Chief Financial Officer of the Company that, except as set forth in the General Disclosure Package, the Audit Committee is not reviewing or investigating, and neither the Company&#146;s independent auditors nor its internal auditors is currently recommending that the Audit Committee review or investigate, (i)&nbsp;adding to, deleting, changing the application of or changing the Company&#146;s disclosure with respect to, any of the Company&#146;s material accounting policies, (ii)&nbsp;any matter which could result in a restatement of the Company&#146;s financial statements for any annual or interim period during the current or prior three (3)&nbsp;fiscal years, or (iii)&nbsp;any Internal Control Event.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(hh)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company maintains disclosure controls and procedures (as such is defined in Rule 13a-15(e) of the Exchange Act Rules) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules&nbsp;and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management to allow timely decisions regarding disclosures.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The minute books of the Company and its subsidiaries have been made available to the Underwriters and counsel to the Underwriters, and such books (i)&nbsp;contain a complete summary in all material respects of all meetings and actions of the Board (including each Board committee) and stockholders of the Company and its subsidiaries (or analogous governing bodies and interest holders, as applicable) since the time of its incorporation through the date of the latest meeting and action, and (ii)&nbsp;accurately in all material respects reflect all transactions referred to in such minutes.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(jj)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	There is no franchise agreement, lease, contract, or other agreement or document required by the Securities Act or by the Rules&nbsp;and Regulations to be described in the General Disclosure Package or to be filed as an exhibit to the Registration Statement which is not so described or filed therein as required; and all descriptions of any such franchise agreements, leases, contracts, or other agreements or documents contained in the General Disclosure Package are accurate and complete descriptions of such documents in all material respects.&#160; Other than as described in the General Disclosure Package, no such franchise agreement, lease, contract or other agreement has been suspended or terminated for convenience or default by the Company or any of the other parties thereto, and the Company has not received notice of and the Company does not have knowledge of any such pending or threatened suspension or termination.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(kk)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders (or analogous interest holders), customers or suppliers of the Company or any of its affiliates, on the other hand, which is required to be described in the General Disclosure Package and the Prospectus and which is not so described.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ll)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	No person or entity has the right to require registration of shares of Common Stock or other securities of the Company or any of its subsidiaries because of the filing or effectiveness of the Registration Statement or otherwise, except for persons and entities who have expressly waived such right in writing or who have been given timely and proper written notice and have failed to exercise such right within the time or times required under the terms and conditions of such right.&#160; Except as described in the General Disclosure Package, there are no persons with registration rights or similar rights to have any securities registered by the Company or any of its subsidiaries under the Securities Act.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	12
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_12_001638_7056">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=12,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=164531,FOLIO='12',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage13"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(mm)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company does not own any &#147;margin securities&#148; as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Federal Reserve Board
</I>
</B>
	&#148;), and none of the proceeds of the sale of the Stock will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Stock to be considered a &#147;purpose credit&#148; within the meanings of Regulation T, U or X of the Federal Reserve Board.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(nn)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Other than this Agreement, neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person that would give rise to a valid claim against the Company or any of its subsidiaries, or the Underwriters for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Stock or any transaction contemplated by this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(oo)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The exercise price of each option issued under the Company&#146;s stock option or other employee benefit plans has been no less than the fair market value of a share of common stock as determined on the date of grant of such option.&#160; All grants of options were validly issued and properly approved by the Board (or a duly authorized committee thereof) in material compliance with all applicable laws and regulations and recorded in the Company&#146;s financial statements in accordance with GAAP and, to the Company&#146;s knowledge, no such grants involved &#147;back dating,&#148; &#147;forward dating&#148; or similar practice with respect to the effective date of grant.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(pp)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Since the date as of which information is given in the General Disclosure Package through the date hereof, and except for the obligations created by this Agreement and as set forth in the Pricing Prospectus, the Company has not (i)&nbsp;issued or granted any securities other than shares of Common Stock issued or issuable upon the conversion of the Company&#146;s outstanding preferred stock and options to purchase common stock pursuant to the Company&#146;s stock option plan, (ii)&nbsp;incurred any material liability or obligation, direct or contingent, other than liabilities and obligations which were incurred in the ordinary course of business, (iii)&nbsp;entered into any material transaction other than in the ordinary course of business or (iv)&nbsp;declared or paid any dividend on its capital stock.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(qq)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If applicable, all of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rule&nbsp;5110 or 5121 (i)&nbsp;with respect to the Company is true, correct and complete in all material respects as of the date hereof, and (ii)&nbsp;with respect to all other persons except for the Company, to the Company&#146;s knowledge, is true, correct and complete in all material respects as of the date hereof.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(rr)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Except as described in the General Disclosure Package, no subsidiary of the Company is currently prohibited, directly or indirectly, under&#160; any agreement or other instrument to which it is a party or is subject, from paying any dividends&#160; to&#160; the Company, &#160;from making&#160; any&#160; other&#160; distribution on such subsidiary&#146;s&#160; capital stock,&#160; from repaying&#160; to&#160; the Company&#160; any&#160; loans&#160; or&#160; advances&#160; to&#160; such&#160; subsidiary&#160; from&#160;&#160; the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ss)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) contained in either the General Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	13
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_13_001646_5335">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=13,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=314422,FOLIO='13',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage14"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(tt)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Stock has been approved for listing subject to notice of issuance on The Nasdaq Global Market (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Exchange
</I>
</B>
	&#148;).&#160; A registration statement has been filed on Form&nbsp;8-A pursuant to Section&nbsp;12 of the Exchange Act, which registration statement complies in all material respects with the Exchange Act.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(uu)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company has taken all actions reasonably necessary to ensure that, upon and at all times after the effectiveness of the Registration Statement, it will be in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules&nbsp;and regulations promulgated in connection therewith (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Sarbanes-Oxley Act
</I>
</B>
	&#148;) that are then in effect.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(vv)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither the Company nor any of its subsidiaries nor, to the Company&#146;s knowledge, any employee or agent of the Company or any of its subsidiaries, has (i)&nbsp;used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;violated any provision of the Foreign Corrupt Practices Act of 1977, as amended or (iv)&nbsp;made any other unlawful payment.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ww)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is defined in Rule&nbsp;405 of the Rules&nbsp;and Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that would reasonably be expected to materially affect the Company&#146;s liquidity or the availability of or requirements for its capital resources required to be described in the General Disclosure Package and the Prospectus which have not been described as required.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(xx)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their respective family members, except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus. All transactions by the Company with office holders or control persons of the Company have been duly approved by Board, or duly appointed committees or officers thereof, if and to the extent required under U.S. law.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(yy)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The statistical and market-related data included in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and such data agree with the sources from which they are derived.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(zz)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The operations of the Company and&#160; its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Money Laundering Laws
</I>
</B>
	&#148;), and no action, suit or proceeding by or before any court or governmental or regulatory authority or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending, or to the Company&#146;s knowledge, threatened.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(aaa)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither Company nor any of its subsidiaries nor, to the Company&#146;s knowledge, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department of Treasury, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Sanctions
</I>
</B>
	&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	14
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_14_001655_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=14,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=812426,FOLIO='14',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage15"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any Sanctions or in any manner that will result in a violation by any such person (including any person participating in the transactions, whether as an underwriter, advisor, investor or otherwise) of Sanctions.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(bbb)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Neither the Company nor, to the Company&#146;s knowledge, any of its affiliates (within the meaning of FINRA Rule&nbsp;5121(f)(1)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article&nbsp;I, Section&nbsp;1(ff) of the By-laws of FINRA) of, any of the Underwriters.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Any certificate signed by or on behalf of the Company and delivered to the Representatives or to counsel to the Underwriters shall be deemed to be a representation and warranty by the Company to each Underwriter as to the matters covered thereby.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	PURCHASE, SALE AND DELIVERY OF OFFERED SECURITIES
</I>
	.&#160; On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to sell to the Underwriters, and the Underwriters agree, severally and not jointly, to purchase from the Company the respective numbers of shares of Firm Stock set forth opposite the names of the Underwriters in
<U>
	Schedule A
</U>
	hereto.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The purchase price per share to be paid by the Underwriters to the Company for the Stock will be $[
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] per share (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Purchase Price
</I>
</B>
	&#148;).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The Company will deliver the Firm Stock to the Representatives for the respective accounts of the several Underwriters, through the facilities of The Depository Trust Company, issued in such names and in such denominations as the Representatives may direct by notice in writing to the Company given at or prior to 12:00 Noon, New York time, at least one full business day preceding the Closing Date against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an account at a bank specified by the Company and reasonably acceptable to the Representatives payable to the order of the Company for the Firm Stock sold by them all at the offices of Cooley LLP, 1114 Avenue of the Americas, New York, New York, 10036-7798.&#160; Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is a further condition of the obligations of each Underwriter hereunder.&#160; The time and date of the delivery and payment shall be at 10:00 A.M., New York time, on July [
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	], 2016, in accordance with Rule&nbsp;15c6-1 of the Exchange Act.&#160; The time and date of such payment and delivery are herein referred to as the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Closing Date
</I>
</B>
	&#148;.&#160; The Closing Date and the location of delivery of, and the form of payment for, the Firm Stock may be varied by agreement among the Company and the Representatives.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For the purpose of covering any over-allotments in connection with the distribution and sale of the Firm Stock as contemplated by the Prospectus, the Underwriters may purchase all or less than all of the Optional Stock.&#160; The purchase price per share to be paid for the Optional Stock shall be the Purchase Price.&#160; The Company agrees to sell to the Underwriters the number of shares of Optional Stock specified in the written notice delivered by the Representatives to the Company described below and the Underwriters agree, severally and not jointly, to purchase such shares of Optional Stock.&#160; Such shares of Optional Stock shall be purchased from the Company for the account of each Underwriter in the same proportion as the number of shares of Firm Stock set forth opposite such Underwriter&#146;s name on
<U>
	Schedule A
</U>
	bears to the total number of shares of Firm Stock (subject to adjustment by the Representatives to eliminate fractions).&#160; The option granted hereby may be exercised as to all or any part of the Optional Stock at any time, and from time to time, not more than thirty (30) days subsequent to the date of this Agreement.&#160; No Optional Stock shall be sold and delivered unless the Firm Stock previously has been, or
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	15
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_15_001704_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=15,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=574188,FOLIO='15',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage16"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	simultaneously is being, sold and delivered.&#160; The right to purchase the Optional Stock or any portion thereof may be surrendered and terminated at any time upon notice by the Representatives to the Company.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The option granted hereby may be exercised by written notice being given to the Company by Representatives setting forth the number of shares of the Optional Stock to be purchased by the Underwriters and the date and time for delivery of and payment for the Optional Stock.&#160; Each date and time for delivery of and payment for the Optional Stock (which may be the Closing Date, but not earlier) is herein called the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Option Closing Date
</I>
</B>
	&#148; and shall in no event be earlier than two (2)&nbsp;business days nor later than five (5)&nbsp;business days after written notice is given.&#160; The Option Closing Date and the Closing Date are herein called the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Closing Dates
</I>
</B>
	.&#148;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The Company will deliver the Optional Stock to the Representatives for the respective accounts of the several Underwriters through the facilities of The Depository Trust Company issued in such names and in such denominations as the Representatives may direct by notice in writing to the Company given at or prior to 12:00 Noon, New York time, at least one (1)&nbsp;full business day preceding the Option Closing Date against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an account at a bank specified by the Company and reasonably acceptable to the Representatives payable to the order of the Company, at the offices of Cooley LLP, 1114 Avenue of the Americas, New York, New York, 10036-7798.&#160; Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is a further condition of the obligations of each Underwriter hereunder.&#160; The Option Closing Date and the location of delivery of, and the form of payment for, the Optional Stock may be varied by agreement between the Company and the Representatives.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The several Underwriters propose to offer the Stock for sale upon the terms and conditions set forth in the Prospectus.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	FURTHER AGREEMENTS OF THE COMPANY.&#160;
</I>
	The Company agrees with the several Underwriters:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To prepare the Rule&nbsp;462(b)&nbsp;Registration Statement, if necessary, in a form approved by the Representatives and file such Rule&nbsp;462(b)&nbsp;Registration Statement with the Commission by 10:00 P.M., New York time, on the date hereof, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Rules&nbsp;and Regulations; to prepare the Prospectus in a form approved by the Representatives containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rules&nbsp;430A of the Rules&nbsp;and Regulations and to file such Prospectus pursuant to Rule&nbsp;424(b)&nbsp;of the Rules&nbsp;and Regulations not later than the second (2
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	nd
</FONT>
	) business day following the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by Rule&nbsp;430A of the Rules&nbsp;and Regulations; to notify the Representatives promptly of the Company&#146;s intention to file or prepare any supplement or amendment to any Registration Statement or to the Prospectus and to make no amendment or supplement to the Registration Statement, the General Disclosure Package or to the Prospectus to which the Representatives shall reasonably object by notice to the Company after a reasonable period to review; to advise the Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the General Disclosure Package or the Prospectus or any amended Prospectus or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication has been filed and to furnish the Underwriters with copies thereof; to file promptly all material required to be filed by the Company with the Commission pursuant to Rules&nbsp;433(d)&nbsp;or 163(b)(2)&nbsp;of the Rules&nbsp;and Regulations, as the case may be; to advise the Representatives, promptly after it receives notice thereof, of the issuance by the Commission of any stop
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	16
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_16_001741_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=16,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=481535,FOLIO='16',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage17"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus or any Written Testing-the-Waters Communication, of the suspension of the qualification of the Stock for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure Package or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use its best efforts to obtain the withdrawal of such order.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;the completion of the distribution of the Firm Stock within the meaning of the Securities Act and (ii)&nbsp;completion of the Lock-Up Period (as defined below).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company represents and agrees that, unless it obtains the prior written consent of the Representatives, and each Underwriter represents and agrees that, unless it obtains the prior written consent of the Company and the Representatives, it has not made and will not, make any offer relating to the Stock that would constitute a &#147;free writing prospectus&#148; as defined in Rule&nbsp;405 of the Rules&nbsp;and Regulations (each, a &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Permitted Free Writing Prospectus
</I>
</B>
	&#148;);
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the prior written consent of the Company and the Representatives hereto shall be deemed to have been given in respect of the Issuer Free Writing Prospectuses included in
<U>
	Schedule B
</U>
	hereto.&#160; The Company represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply with the requirements of Rules&nbsp;164 and 433 of the Rules&nbsp;and Regulations applicable to any Issuer Free Writing Prospectus, including the requirements relating to timely filing with the Commission, legending and record keeping, and will not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;of the Rules&nbsp;and Regulations a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.&#160; The Company will satisfy the condition in Rule&nbsp;433 of the Rules&nbsp;and Regulations to avoid a requirement to file with the Commission any electronic road show.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If at any time prior to the expiration of nine (9)&nbsp;months after the later of (i)&nbsp;the latest effective date of the Registration Statement or (ii)&nbsp;the date of the Prospectus, when a prospectus relating to the Stock is required to be delivered (or in lieu thereof, the notice referred to in Rule&nbsp;173(a)&nbsp;of the Rules&nbsp;and Regulations) any event occurs or condition exists as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact, or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made when the Prospectus is delivered (or in lieu thereof, the notice referred to in Rule&nbsp;173(a)&nbsp;of the Rules&nbsp;and Regulations), not misleading, or if it is necessary at any time to amend or supplement the Registration Statement or the Prospectus to comply with the Securities Act, then the Company will promptly notify the Representatives thereof and upon their request will prepare an appropriate
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	17
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_17_001759_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=17,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=462373,FOLIO='17',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage18"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	amendment or supplement in form and substance satisfactory to the Representatives which will correct such statement or omission or effect such compliance and will use its reasonable best efforts to have any amendment to any Registration Statement declared effective as soon as possible.&#160; The Company will furnish without charge to each Underwriter and to any dealer in securities as many copies as the Representatives may from time to time reasonably request of such amendment or supplement.&#160; In case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule&nbsp;173(a)&nbsp;of the Rules&nbsp;and Regulations) relating to the Stock nine (9)&nbsp;months or more after the later of (i)&nbsp;the latest effective date of the Registration Statement or (ii)&nbsp;the date of the Prospectus, the Company upon the request of the Representatives will prepare promptly an amended or supplemented Prospectus as may be necessary to permit compliance with the requirements of Section&nbsp;10(a)(3)&nbsp;of the Securities Act and deliver to such Underwriter as many copies as such Underwriter may request of such amended or supplemented Prospectus complying with Section&nbsp;10(a)(3)&nbsp;of the Securities Act.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(f)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If the General Disclosure Package is being used to solicit offers to buy the Stock at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment of the Company or in the reasonable opinion of the Underwriters, it becomes necessary to amend or supplement the General Disclosure Package in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, or to make the statements therein not conflict with the information contained in the Registration Statement then on file and not superseded or modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company promptly will prepare, file with the Commission (if required) and furnish to the Underwriters and any dealers an appropriate amendment or supplement to the General Disclosure Package.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(g)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the information contained in the Registration Statement, Pricing Prospectus or Prospectus and not superseded or modified or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly notify the Representatives so that any use of the Issuer Free Writing Prospectus may cease until it is amended or supplemented and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.&#160; The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in Section&nbsp;17 hereof).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(h)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To the extent not available on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system or any successor system (&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	EDGAR
</I>
</B>
	&#148;), upon the request of the Representatives, to furnish promptly to the Representatives and to counsel for the Underwriters a signed copy of each of the Registration Statement as originally filed with the Commission, and of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To deliver promptly to the Representatives in New York such number of the following documents as the Representatives shall reasonably request:&#160; (i)&nbsp;conformed copies of the Registration Statement as originally filed with the Commission (excluding exhibits); (ii)&nbsp;each Preliminary Prospectus; (iii)&nbsp;any Issuer Free Writing Prospectus; (the delivery of the documents referred to in clauses (i), (ii)&nbsp;and (iii)&nbsp;of this paragraph (i)&nbsp;to be made not later than 10:00 A.M., New York time, on the business day following the execution and delivery of this Agreement); (iv)&nbsp;the Prospectus; (v)&nbsp;conformed
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	18
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_18_001812_141">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=18,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=885497,FOLIO='18',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage19"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	copies of any amendment to the Registration Statement (excluding exhibits); and (vi)&nbsp;any amendment or supplement to the General Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (iv), (v)&nbsp;and (vi)&nbsp;of this paragraph (i)&nbsp;to be made not later than 10:00 A.M., New York time, on the business day following the date of such amendment or supplement).
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(j)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To make generally available to its stockholders as soon as practicable, but in any event not later than sixteen (16) months after the effective date of the Registration Statement (as defined in Rule&nbsp;158(c)&nbsp;of the Rules&nbsp;and Regulations), an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a)&nbsp;of the Securities Act (including, at the option of the Company, Rule&nbsp;158).&#160; The Company, during the period when a Prospectus relating to the Stock is (or, but for the exception afforded by Rule&nbsp;172 of the Rules&nbsp;and Regulations, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(k)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To take promptly from time to time such actions as the Representatives may reasonably request to qualify the Stock for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Representatives may designate and to continue such qualifications in effect, and to comply with such laws, for so long as required to permit the offer and sale of Stock in such jurisdictions;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the Company shall not be obligated to (i)&nbsp;qualify as a foreign corporation in any jurisdiction in which it is not so qualified, (ii)&nbsp;file a general consent to service of process in any jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(l)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Upon request, during the period of five (5)&nbsp;years from the date hereof, to deliver to each of the Underwriters, (i)&nbsp;as soon as they are available, copies of all reports or other communications (financial or other) furnished to stockholders of the Company, and (ii)&nbsp;as soon as they are available, copies of any reports and financial statements furnished or filed with the Commission or any national securities exchange on which the Stock is listed.&#160; However, so long as the Company is subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Exchange Act and is timely filing reports with the Commission on its EDGAR system, it is not required to furnish such reports or statements to the Underwriters.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(m)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	During the period commencing on and including the date hereof and ending on and including the one hundred and eightieth (180th) day following the date of this Agreement (as the same may be extended as described below, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Lock-Up Period
</I>
</B>
	&#148;), the Company will not, without the prior written consent of the Representatives (which consent may be withheld at the sole discretion of the Representatives), directly or indirectly offer, sell (including, without limitation, any short sale), assign, transfer, pledge, contract to sell, establish an open &#147;put equivalent position&#148; within the meaning of Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act, or otherwise dispose of, or announce the offering of, or file any registration statement under the Securities Act in respect of, any Common Stock, options, rights or warrants to acquire Common Stock or securities exchangeable or exercisable for or convertible into Common Stock (other than as contemplated by this Agreement with respect to the Stock) or publicly announce any intention to do any of the foregoing;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the Company may: (i)&nbsp;sell the Stock pursuant to this Agreement; (ii)&nbsp;issue Common Stock and options to purchase Common Stock, shares of Common Stock underlying options granted and other securities, each pursuant to any director or employee incentive plan, stock ownership plan or dividend reinvestment plan of the Company in effect on the date hereof and described in the General Disclosure Package; (iii)&nbsp;issue Common Stock pursuant to the conversion of securities or the exercise of warrants, which securities or warrants are outstanding on the date hereof and described in the General Disclosure Package; (iv)&nbsp;adopt a new equity incentive plan, file a registration statement on Form&nbsp;S-8 under the Securities Act to register the offer and sale of
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	19
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_19_001828_7608">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=19,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=446540,FOLIO='19',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<A NAME="eolPage20"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	securities on such new equity incentive plan or on equity incentive plans described in the General Disclosure Package, and issue securities pursuant to such equity incentive plans (including, without limitation, the issuance of shares of Common Stock upon the exercise of options or other securities issued pursuant to such equity incentive plans);
<I>
	provided
</I>
	that (1)&nbsp;such equity incentive plans satisfy the transaction requirements of General Instruction A.1 of Form&nbsp;S-8 under the Securities Act and (2)&nbsp;this clause (iii)&nbsp;shall not be available unless each recipient of shares of Common Stock, or securities exchangeable or exercisable for or convertible into Common Stock, pursuant to such equity incentive plans shall be contractually prohibited from selling, offering, disposing of or otherwise transferring any such shares or securities during the remainder of the Lock-Up Period or (v)&nbsp;issue Common Stock or other securities&#160; in connection any acquisition, collaboration, licensing or other strategic transaction or&#160; debt financing transactions, provided that (x)&nbsp;the aggregate number of shares of Stock issued pursuant to this clause (v)&nbsp;shall not exceed ten percent (10%) of the total number of outstanding shares of Common Stock immediately following the completion of this offering and (y)&nbsp;each recipient of&#160; any such shares of Common Stock or securities issued pursuant to this clause (v)&nbsp;has entered into an&#160; agreement substantially in the form of Exhibit&nbsp;I hereto.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(n)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in a lock-up letter described in Section&nbsp;4(m)&nbsp;hereof for an officer or director of the Company, the Representatives will provide the Company with notice of the impending release or waiver at least three (3)&nbsp;business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of
<U>
	Exhibit&nbsp;II
</U>
	hereto through a major news service at least two (2)&nbsp;business days before the effective date of the release or waiver.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(o)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To supply the Representatives with copies of all written correspondence and to advise the Representative of all oral correspondence to and from, and all documents issued to and by, the Commission in connection with the registration of the Stock under the Securities Act or any of the Registration Statements, any Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(p)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Prior to the latest of the Closing Dates, not to issue any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with the past practices of the Company and of which the Representatives are notified), without the prior written consent of the Representatives, unless in the judgment of the Company and its counsel, and after notification to the Representatives, such press release or communication is required by law.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(q)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Until the Representatives shall have notified the Company of the completion of the resale of the Stock, that the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation M under the Exchange Act Rules) not to, either alone or with one or more other persons, bid for or purchase, for any account in which it or any of its affiliated purchasers has a beneficial interest, any Stock, or attempt to induce any person to purchase any Stock; and not to, and to use its reasonable best efforts to cause its affiliated purchasers not to, make bids or purchases for the purpose of creating actual, or apparent, active trading in or of raising the price of the Stock.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(r)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Not to take any action prior to the latest of the Closing Dates which would require the Prospectus to be amended or supplemented pursuant to Section&nbsp;4(e).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	20
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-03_PB_20_001841_8146">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=20,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=908874,FOLIO='20',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-03_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:40 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(s)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To at all times comply in all material respects with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time and to file with the Commission such information on Form&nbsp;10-Q or Form&nbsp;10-K as may be required by Rule&nbsp;463 of the Rules&nbsp;and Regulations.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(t)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To maintain, at its expense, a registrar and transfer agent for the Stock.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(u)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To apply the net proceeds from the sale of the Stock as set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds,&#148; and except as disclosed in the General Disclosure Package, the Company does not intend to use any of the proceeds from the sale of the Stock hereunder to repay any outstanding debt owed to any affiliate of any Underwriter.&#160; The Company shall manage its affairs and investments in such a manner as not to be or become an &#147;investment company&#148; within the meaning of the Investment Company Act and the rules&nbsp;and regulations thereunder.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To use its reasonable best efforts to list, subject to notice of issuance, the Stock on the Exchange.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(w)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	To use its reasonable best efforts to do and perform all things required to be done or performed under this Agreement by the Company prior to each Closing Date and to satisfy all conditions precedent to the delivery of the Firm Stock and the Optional Stock.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(x)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Upon request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company&#146;s trademarks, service marks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the on-line offering of the Stock (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	License
</I>
</B>
	&#148;);
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	PAYMENT OF EXPENSES
</I>
	.&#160; The Company agrees to pay, or reimburse if paid by any Underwriter, whether or not the transactions contemplated hereby are consummated or this Agreement is terminated:&#160; (a)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Stock and any taxes payable in that connection; (b)&nbsp;the costs incident to the registration of the Stock under the Securities Act and the Exchange Act; (c)&nbsp;the costs incident to the preparation, printing and distribution of the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits thereto and the costs of printing, reproducing and distributing this Agreement and any closing documents by mail, telex or other means of communications; (d)&nbsp;the fees and expenses (including related fees and expenses of counsel for the Underwriters) incurred in connection with securing any required review by FINRA of the terms of the sale of the Stock and any filings made with FINRA relating to the offering of the Stock up to a maximum of $30,000 in the aggregate; (e)&nbsp;any applicable listing or other fees; (f)&nbsp;the fees and expenses (including related fees and expenses of counsel to the Underwriters) of qualifying the Stock under the securities laws of the several jurisdictions as provided in Section&nbsp;4(l)&nbsp;and of preparing, printing and distributing wrappers, Blue Sky memoranda and legal investment surveys; (g)&nbsp;the cost of preparing and printing stock certificates; (h)&nbsp;all fees and expenses of the registrar and transfer agent of the Stock; (i)&nbsp;the costs and expenses (including, without limitation, any damages or other amounts payable in connection with the legal or contractual liability) associated with the reforming of any contracts for sale of the Stock made by the Underwriters caused by a breach of the representation contained in Section&nbsp;2(b); (j) the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Stock, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	21
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_21_001106_1483">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=21,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=676024,FOLIO='21',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage21"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	expenses of the officers of the Company and such consultants;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the Company shall be responsible for 50% of the cost of any aircraft chartered in connection with the road show and the Underwriters shall be responsible for the balance; and (k) all other costs and expenses of the Company incident to the offering of the Stock or the performance of the obligations of the Company under this Agreement (including, without limitation, the fees and expenses of the Company&#146;s counsel and the Company&#146;s independent accountants);
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that, except to the extent otherwise provided in this Section&nbsp;5 and in Sections 9 and 10, the Underwriters shall pay their own costs and expenses, including the fees and expenses of their counsel not contemplated herein, any transfer taxes on the resale of any Stock by them and the expenses of advertising any offering of the Stock made by the Underwriters.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	6.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	CONDITIONS OF UNDERWRITERS&#146; OBLIGATIONS.
</I>
	&#160; The respective obligations of the several Underwriters hereunder are subject to the accuracy, when made and as of the Applicable Time and on each Closing Date, of the representations and warranties of the Company contained herein, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Registration Statement has become effective under the Securities Act, and no stop order suspending the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Preliminary Prospectus, the Prospectus or any Permitted Free Writing Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section&nbsp;8A under the Securities Act shall have been initiated or threatened by the Commission, and all requests for additional information on the part of the Commission (to be included in the Registration Statement or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Representatives; the Rule&nbsp;462(b)&nbsp;Registration Statement, if any, each Issuer Free Writing Prospectus and the Prospectus shall have been filed with, the Commission within the applicable time period prescribed for such filing by, and in compliance with, the Rules&nbsp;and Regulations and in accordance with Section&nbsp;4(a), and the Rule&nbsp;462(b)&nbsp;Registration Statement, if any, shall have become effective immediately upon its filing with the Commission and FINRA shall have raised no unresolved objection to the fairness and reasonableness of the terms of this Agreement or the transactions contemplated hereby.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	None of the Underwriters shall have discovered and disclosed to the Company on or prior to such Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of counsel for the Underwriters, is material or omits to state any fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package, any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion of such counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is necessary in order to make the statements, in the light of the circumstances in which they were made, not misleading.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement, the Stock, the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and all other legal matters relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel to the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Wilmer Cutler Pickering Hale and Dorr LLP shall have furnished to the Representatives such counsel&#146;s written opinion and negative assurance letter, as counsel to the Company,
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	22
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_22_001140_7056">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=22,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=874590,FOLIO='22',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage22"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	addressed to the Underwriters and each dated as of such Closing Date, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in
<U>
	Exhibit&nbsp;III
</U>
	hereto.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Lando&nbsp;&amp; Anastasi, LLP shall have furnished to the Representatives such counsel&#146;s written opinion, as intellectual property counsel to the Company, addressed to the Underwriters and each dated such Closing Date, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in
<U>
	Exhibit&nbsp;IV
</U>
	hereto.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(f)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Representatives shall have received from Cooley LLP, counsel for the Underwriters, such opinion or opinions, dated as of such Closing Date, with respect to such matters as the Underwriters may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling them to pass upon such matters.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(g)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	At the time of the execution of this Agreement, the Representatives shall have received from Ernst&nbsp;&amp; Young LLP, a letter, addressed to the Underwriters, executed and dated such date, in form and substance satisfactory to the Representatives (i)&nbsp;confirming that they are an independent registered accounting firm with respect to the Company and its subsidiaries within the meaning of the Securities Act and the Rules&nbsp;and Regulations and PCAOB and (ii)&nbsp;stating the conclusions and findings of such firm, of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters, with respect to the financial statements and certain financial information contained in the Registration Statements, the General Disclosure Package and the Prospectus.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(h)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	On the effective date of any post-effective amendment to the Registration Statement and on such Closing Date, the Representatives shall have received a letter (the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	bring-down letter
</I>
</B>
	&#148;) from Ernst&nbsp;&amp; Young LLP addressed to the Underwriters and dated such Closing Date confirming, as of the date of the bring-down letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the General Disclosure Package and the Prospectus, as the case may be, as of a date not more than three (3)&nbsp;business days prior to the date of the bring-down letter), the conclusions and findings of such firm, of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters, with respect to the financial information and other matters covered by its letter delivered to the Representatives concurrently with the execution of this Agreement pursuant to paragraph (g)&nbsp;of this Section&nbsp;6.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company shall have furnished to the Representatives a certificate, dated such Closing Date, of its Chief Executive Officer and its Chief Financial Officer stating in their respective capacities as officers of the Company on behalf of the Company and not in their individual capacities that (i)&nbsp;no stop order suspending the effectiveness of the Registration Statement (including, for avoidance of doubt, any Rule&nbsp;462(b)&nbsp;Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for such purpose shall have been instituted or, to their knowledge, threatened by the Commission, (ii)&nbsp;for the period from and including the date of this Agreement through and including such Closing Date, there has not occurred a Material Adverse Effect, (iii)&nbsp;to their knowledge, after reasonable investigation, as of such Closing Date, the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to such Closing Date, and (iii)&nbsp;there has not been, subsequent to the date of the most recent audited financial statements included in the General Disclosure Package, any material adverse change in the financial condition or results of operations of the Company, or any change or development that, individually or in the aggregate, would reasonably be expected to involve a material adverse change in the financial condition or results of operations of the Company, except as set forth in the General Disclosure Package and the Prospectus.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	23
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_23_001151_5335">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=23,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=720163,FOLIO='23',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage23"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(j)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Since the date of the latest audited financial statements included in the General Disclosure Package, (i)&nbsp;neither the Company nor any of its subsidiaries shall have sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package, and (ii)&nbsp;there shall not have been any change in the capital stock (other than stock option exercises and stock repurchases in the ordinary course of business and the grant of stock awards under existing equity incentive plans described in the Registration Statement, the General Disclosure Package and the Prospectus) or long-term debt of the Company or any of its subsidiaries, or any change, or any development involving a prospective change, in or affecting the business, properties, assets, general affairs, management, financial condition, stockholders&#146; equity or results of operations of the Company and its subsidiaries, taken as a whole, otherwise than as set forth in the General Disclosure Package or the Prospectus, the effect of which, in any such case described in clause (i)&nbsp;or (ii)&nbsp;of this paragraph 6(j), is, in the judgment of the Representatives, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Stock on the terms and in the manner contemplated in the General Disclosure Package.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(k)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	No action shall have been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental or regulatory authority that would prevent the issuance or sale of the Stock or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Stock or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(l)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Subsequent to the execution and delivery of this Agreement (i)&nbsp;no downgrading shall have occurred in the Company&#146;s corporate credit rating or the rating accorded the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization,&#148; as that term is defined by the Commission for purposes of Rule&nbsp;436(g)(2)&nbsp;of the Rules&nbsp;and Regulations, and (ii)&nbsp;no such organization shall have publicly announced that it has under surveillance or review (other than an announcement with positive implications of a possible upgrading), the Company&#146;s corporate credit rating or the rating of any of the Company&#146;s debt securities.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(m)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following:&#160; (i)&nbsp;trading in any of the Company&#146;s securities shall have been suspended or materially limited by the Commission or the Exchange, or trading in securities generally on the New York Stock Exchange, Nasdaq Global Select Market, Nasdaq Global Market, Nasdaq Capital Market or the NYSE MKT LLC or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established on any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or governmental authority having jurisdiction, (ii)&nbsp;a banking moratorium shall have been declared by federal or state authorities or a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States, (iii)&nbsp;the United States shall have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or escalation in hostilities involving the United States, or there shall have been a declaration of a national emergency or war by the United States or (iv)&nbsp;there shall have occurred such a material adverse change in general economic, political or financial conditions (or the effect of international conditions on the financial markets in the United States shall be such) as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the sale or delivery of the Stock on the terms and in the manner contemplated in the General Disclosure Package and the Prospectus.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	24
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_24_001210_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=24,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=20384,FOLIO='24',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage24"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(n)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Exchange shall have approved the Stock for listing therein, subject only to official notice of issuance and evidence of satisfactory distribution.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(o)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Representatives shall have received on and as of such Closing Date satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign corporations in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(p)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Representatives shall have received the written agreements, substantially in the form of
<U>
	Exhibit&nbsp;I
</U>
	hereto, of the officers, directors, and all stockholders and optionholders of the Company listed in
<U>
	Schedule D
</U>
	to this Agreement.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(q)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company shall have furnished to the Representatives a Secretary&#146;s Certificate of the Company, in form and substance reasonably satisfactory to counsel to the Underwriters and customary for the type of offering contemplated by this Agreement.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(r)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company shall have furnished to the Representatives a certificate, dated such Closing Date, of its Chief Financial Officer, substantially in the form of
<U>
	Exhibit&nbsp;V
</U>
	hereto.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(s)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	On or prior to such Closing Date, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	All opinions, letters, evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	7.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	INDEMNIFICATION AND CONTRIBUTION.
</I>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company shall indemnify and hold harmless each Underwriter and its affiliates, directors, officers, managers, members, employees, representatives and agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Underwriter Indemnified Parties
</I>
</B>
	,&#148; and each, an &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Underwriter Indemnified Party
</I>
</B>
	&#148;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), joint or several, to which such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Written Testing-the-Waters Communication, any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Registration Statement, the Prospectus, or in any amendment or supplement thereto or in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Common Stock, including any road show or investor presentations made to investors by the Company (whether in person or electronically) (&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Marketing Materials
</I>
</B>
	&#148;) or (ii)&nbsp;the omission or alleged omission to state in any Written Testing-the-Waters Communication, any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Registration Statement or the Prospectus, or in any amendment or supplement thereto or in any Marketing Materials, a material fact required to be stated therein or necessary to make the statements therein not misleading, and shall reimburse each Underwriter Indemnified Party promptly upon demand for any legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	25
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_25_001225_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=25,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=891731,FOLIO='25',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage25"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	are incurred;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from any Preliminary Prospectus, any Registration Statement or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus or any Marketing Materials made in reliance upon and in conformity with written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriter&#146;s Information. Each indemnity agreement in this Section&nbsp;7(a) is not exclusive and is in addition to each other indemnity agreement in this Section&nbsp;7(a)&nbsp;and each other liability which the Company might have under this Agreement or otherwise, and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to any Underwriter Indemnified Party.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Each Underwriter, severally and not jointly, shall indemnify and hold harmless the Company and its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Company Indemnified Parties
</I>
</B>
	,&#148; and each, a &#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	Company Indemnified Party
</I>
</B>
	&#148;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), joint or several, to which such Company Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, or (ii)&nbsp;the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only to the extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company through the Representatives by or on behalf of that Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriters&#146; Information, and shall reimburse the Company Indemnified Parties for any legal or other expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing as a third-party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and expenses are incurred.&#160; This indemnity agreement is not exclusive and will be in addition to any liability which the Underwriters might otherwise have and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to the Company Indemnified Parties.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Promptly after receipt by an indemnified party under this Section&nbsp;7 of notice of the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;7, notify such indemnifying party in writing of the commencement of that action;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section&nbsp;7 except to the extent it has been materially prejudiced by such failure;
<I>
	provided
</I>
	,
<I>
	further
</I>
	, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section&nbsp;7.&#160; If any such action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party).&#160; After notice from the indemnifying party to the indemnified party of its election to assume the defense of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	26
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_26_001242_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=26,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=697459,FOLIO='26',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage26"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	under Section&nbsp;7 for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs of investigation;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i)&nbsp;the employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification under Section&nbsp;7(a)&nbsp;or the Representatives in the case of a claim for indemnification under Section&nbsp;7(b), (ii)&nbsp;such indemnified party shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or additional to those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently incurred by such indemnified party in connection with the defense of such action;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in writing by the Representatives if the indemnified parties under this Section&nbsp;7 consist of any Underwriter Indemnified Party or by the Company if the indemnified parties under this Section&nbsp;7 consist of any Company Indemnified Parties.&#160; Subject to this Section&nbsp;7(c), the amount payable by an indemnifying party under Section&nbsp;7 shall include, but not be limited to, (x)&nbsp;reasonable documented legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third-party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding or claim, and (y)&nbsp;all amounts paid in settlement of any of the foregoing.&#160; No indemnifying party shall, without the prior written consent of the indemnified parties (which consent shall not be unreasonably withheld or delayed), settle or compromise or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section&nbsp;7 (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (A)&nbsp;includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability arising out of such action or claim and (B)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.&#160; Subject to the provisions of the following sentence, no indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such settlement or judgment.&#160; In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;7(a) effected without its written consent if (i)&nbsp;such settlement is entered into more than forty-five (45) days after receipt by such indemnifying party of the request for reimbursement, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	27
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_27_001308_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=27,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=65576,FOLIO='27',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage27"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	If the indemnification provided for in this Section&nbsp;7 is unavailable or insufficient to hold harmless an indemnified party under Section&nbsp;7(a)&nbsp;or 7(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i)&nbsp;in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Stock, or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;of this Section&nbsp;7(d)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;of this Section&nbsp;7(d), but also the relative fault of the Company on the one hand and the Underwriters on the other with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations.&#160; The relative benefits received by the Company on the one hand and the Underwriters on the other with respect to such offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Stock purchased under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters with respect to the Stock purchased under this Agreement, in each case as set forth in the table on the cover page&nbsp;of the Prospectus.&#160; The relative fault of the Company on the one hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the parties hereto agree that the written information furnished to the Company through the Representatives by or on behalf of the Underwriters for use in the Preliminary Prospectus, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriters&#146; Information.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to Section&nbsp;7(d) above were to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations referred to Section&nbsp;7(d)&nbsp;above.&#160; The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to in Section&nbsp;7(d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding.&#160; Notwithstanding the provisions of this Section&nbsp;7, no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Stock exceeds the amount of any damages which the Underwriter has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&#160; The Underwriters&#146; obligations to contribute as provided in this Section&nbsp;7 are several in proportion to their respective underwriting obligations and not joint.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	8.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	TERMINATION
</I>
	.&#160; The obligations of the Underwriters hereunder may be terminated by the Representatives, in their absolute discretion, by notice given to the Company prior to delivery of and payment for the Firm Stock if, prior to that time, any of the events described in Sections 6(j), 6(l)&nbsp;or 6(m)&nbsp;have occurred or if the Underwriters shall decline to purchase the Stock for any reason permitted under this Agreement.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	28
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_28_001341_141">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=28,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=746218,FOLIO='28',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage28"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	9.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	REIMBURSEMENT OF UNDERWRITERS&#146; EXPENSES
</I>
	.&#160; Notwithstanding anything to the contrary in this Agreement, if (a)&nbsp;this Agreement shall have been terminated pursuant to Section&nbsp;8 or 10, (b)&nbsp;the Company shall fail to tender the Stock for delivery to the Underwriters for any reason not permitted under this Agreement, (c)&nbsp;the Underwriters shall decline to purchase the Stock for any reason permitted under this Agreement or (d)&nbsp;the sale of the Stock is not consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement herein or to satisfy any condition or to comply with the provisions hereof, then, in addition to the payment of amounts in accordance with Section&nbsp;5, the Company shall reimburse the Underwriters in accordance with this Section&nbsp;9 for the reasonable fees and expenses of Underwriters&#146; counsel and for such other documented out-of-pocket expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the Stock, including, without limitation, reasonable and documented travel and lodging expenses of the Underwriters, and upon demand the Company shall pay the full amount thereof to the Representatives;
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that if this Agreement is terminated pursuant to Section&nbsp;10 by reason of the default of one or more Underwriters, the Company shall not be obligated to reimburse any defaulting Underwriter on account of expenses to the extent incurred by such defaulting Underwriter;
<I>
	provided
</I>
	,
<I>
	further
</I>
	, that the foregoing shall not limit any reimbursement obligation of the Company to any non-defaulting Underwriter under this Section&nbsp;9.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	10.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	SUBSTITUTION OF UNDERWRITERS
</I>
	. &#160;If any Underwriter or Underwriters shall default in its or their obligations to purchase the shares of Stock hereunder on any Closing Date, and the aggregate number of shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed ten percent (10%) of the total number of shares to be purchased by all Underwriters on such Closing Date, the other Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the shares which such defaulting Underwriter or Underwriters agreed but failed to purchase on such Closing Date.&#160; If any Underwriter or Underwriters shall so default and the aggregate number of shares with respect to which such default or defaults occur is more than ten percent (10%) of the total number of shares to be purchased by all Underwriters on such Closing Date, and arrangements satisfactory to the Representatives and the Company for the purchase of such shares by other persons are not made within forty-eight (48) hours after such default, this Agreement shall terminate.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	If the remaining Underwriters or substituted Underwriters are required hereby or agree to take up all or part of the shares of Stock of a defaulting Underwriter or Underwriters on such Closing Date as provided in this Section&nbsp;10, (i)&nbsp;the Company shall have the right to postpone such Closing Dates for a period of not more than five (5)&nbsp;full business days in order that the Company may effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees promptly to file any amendments to the Registration Statement or supplements to the Prospectus which may thereby be made necessary, and (ii)&nbsp;the respective numbers of shares to be purchased by the remaining Underwriters or substituted Underwriters shall be taken as the basis of their underwriting obligation for all purposes of this Agreement.&#160; Nothing herein contained shall relieve any defaulting Underwriter of its liability to the Company or the other Underwriters for damages occasioned by its default hereunder.&#160; Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of any non-defaulting Underwriter or the Company, except that the representations, warranties, covenants, indemnities, agreements and other statements set forth in Section&nbsp;2, the obligations with respect to expenses to be paid or reimbursed pursuant to Sections 5 and 9 and the provisions of Section&nbsp;7 and Sections 11 through 21, inclusive, shall not terminate and shall remain in full force and effect.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	29
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_29_001352_7608">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=29,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=890574,FOLIO='29',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage29"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	11.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	ABSENCE OF FIDUCIARY RELATIONSHIP.
</I>
	&#160;The Company acknowledges and agrees that:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	each Underwriter&#146;s responsibility to the Company is solely contractual in nature, the Representatives have been retained solely to act as underwriters in connection with the sale of the Stock and no fiduciary, advisory or agency relationship between the Company and the Representatives have been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether any of the Representatives has advised or is advising the Company on other matters;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the price of the Stock set forth in this Agreement was established by the Company following discussions and arm&#146;s-length negotiations with the Representatives, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	it has been advised that the Representatives and their affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that the Representatives have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	it waives, to the fullest extent permitted by law, any claims it may have against the Representatives for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that the Representatives shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors of the Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	12.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT
</I>
	.&#160; This Agreement shall inure to the benefit of and be binding upon the several Underwriters, the Company and their respective successors and assigns.&#160; Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations, warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also be for the benefit of the Underwriter Indemnified Parties, and the indemnities of the several Underwriters shall be for the benefit of the Company Indemnified Parties.&#160; It is understood that each Underwriter&#146;s responsibility to the Company is solely contractual in nature and the Underwriters do not owe the Company, or any other party, any fiduciary duty as a result of this Agreement.&#160; No purchaser of any of the Stock from any Underwriter shall be deemed to be a successor or assign by reason merely of such purchase.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	13.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	SURVIVAL OF INDEMNITIES, REPRESENTATIONS, WARRANTIES,&nbsp;ETC.
</I>
	&#160;The respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter, the Company or any person controlling any of them and shall survive delivery of and payment for the Stock.&#160; Notwithstanding any termination of this Agreement, including without limitation any termination pursuant to Section&nbsp;8 or Section&nbsp;10, the indemnities, covenants, agreements, representations, warranties and other statements forth in Sections 2, 5, 7 and 9 and Sections 11 through 21, inclusive, of this Agreement shall not terminate and shall remain in full force and effect at all times.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	14.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	NOTICES
</I>
	.&#160; All statements, requests, notices and agreements hereunder shall be in writing, and:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	30
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_30_001402_8146">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=30,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=945426,FOLIO='30',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage30"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	if to the Underwriters, shall be delivered or sent by mail, telex, facsimile transmission or email to (i)&nbsp;Cowen and Company, LLC, Attention: Head of Equity Capital Markets, Fax: 646-562-1249 with a copy to the General Counsel, Fax: 646-562-1124; (ii)&nbsp;Piper Jaffray&nbsp;&amp; Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402, Attention: General Counsel with a copy to Legal, Fax: 612-303-1068; and (iii)&nbsp;Divakar Gupta, Cooley LLP, 1114 Avenue of the Americas, New York, New York 10036-7798; Fax: 212-479-6275 and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	if to the Company shall be delivered or sent by mail, telex, facsimile transmission or email to Syros Pharmaceuticals,&nbsp;Inc., Attention: Nancy Simonian, M.D., Fax: [
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	], email nsimonian@syros.com, with a copy to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109, Attention:&#160; Steven D. Singer, Fax:&#160; 617-526-5000, email steven.singer@wilmerhale.com;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<I>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-STYLE:ITALIC;">
	provided
</FONT>
</I>
	,
<I>
	however
</I>
	, that any notice to an Underwriter pursuant to Section&nbsp;7 shall be delivered or sent by mail, or facsimile transmission to such Underwriter at its address set forth in its acceptance telex to the Representatives, which address will be supplied to any other party hereto by the Representatives upon request.&#160; Any such statements, requests, notices or agreements shall take effect at the time of receipt thereof.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	15.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	DEFINITION OF CERTAIN TERMS
</I>
	.&#160; For purposes of this Agreement, (i)&nbsp;&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	affiliate
</I>
</B>
	&#148; has the meaning set forth in Rule&nbsp;405 under the Rules&nbsp;and Regulations,&#160; (ii)&nbsp;&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	business day
</I>
</B>
	&#148; means any day on which the New York Stock Exchange,&nbsp;Inc. is open for trading and (iii)&nbsp;&#147;
<B>
<I STYLE="FONT-WEIGHT:BOLD;">
	subsidiary&#148;
</I>
</B>
	has the meaning set forth in Rule&nbsp;405 of the Rules&nbsp;and Regulations.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	16.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	GOVERNING LAW.
</I>
<B>
	&#160; This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation Section&nbsp;5-1401 of the New York General Obligations.
</B>
	&#160; The Company irrevocably (i)&nbsp;submits to the non-exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other proceeding arising out of this Agreement or the transactions contemplated by this Agreement, the Registration Statement and any Preliminary Prospectus or the Prospectus, (ii)&nbsp;agrees that all claims in respect of any such suit, action or proceeding may be heard and determined by any such court, (iii)&nbsp;waives to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or from any legal process, (iv)&nbsp;agrees not to commence any such suit, action or proceeding other than in such courts, and (v)&nbsp;waives, to the fullest extent permitted by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	17.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	UNDERWRITERS&#146; INFORMATION.
</I>
	&#160; The parties hereto acknowledge and agree that, for all purposes of this Agreement, the Underwriters&#146; Information consists solely of the following information in the Prospectus: (i)&nbsp;the last paragraph on the front cover page&nbsp;concerning the terms of the offering by the Underwriters; and (ii)&nbsp;the statements concerning the Underwriters contained in the second sentence of the ninth paragraph, the tenth paragraph, the second sentence of the eighteenth paragraph and the first three sentences of the nineteenth paragraph (without regard to &#147;bullet point&#148; subparagraphs) under the heading &#147;Underwriting.&#148;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	18.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	AUTHORITY OF THE REPRESENTATIVES
</I>
	.&#160; In connection with this Agreement, the Representatives will act for and on behalf of the several Underwriters, and any action taken under this Agreement by the Representatives, will be binding on all the Underwriters.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	19.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	PARTIAL UNENFORCEABILITY
</I>
	.&#160; The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision hereof.&#160; If any section, paragraph, clause or provision of this
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	31
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_31_001417_7091">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=31,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=17512,FOLIO='31',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage31"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	20.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	GENERAL
</I>
	.&#160; This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.&#160; In this Agreement, the masculine, feminine and neuter genders and the singular and the plural include one another.&#160; The section headings in this Agreement are for the convenience of the parties only and will not affect the construction or interpretation of this Agreement.&#160; This Agreement may be amended or modified, and the observance of any term of this Agreement may be waived, only by a writing signed by the Company and the Representatives.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	21.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<I>
	COUNTERPARTS
</I>
	.&#160; This Agreement may be signed in any number of counterparts, including by facsimile or other electronic transmission, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	[
<I>
	Signature page&nbsp;follows
</I>
	]
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	32
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-05_PB_32_001434_455">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=32,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=244588,FOLIO='32',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<A NAME="eolPage32"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	If the foregoing is in accordance with your understanding of the agreement between the Company and the several Underwriters, kindly indicate your acceptance in the space provided for that purpose below.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Very truly yours,
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:45.42%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.42%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name:
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.42%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Title:
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Accepted as of
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	the date first above written:
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	COWEN AND COMPANY, LLC
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	PIPER JAFFRAY&nbsp;&amp; CO.
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="47%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:47.26%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Acting on their own behalf
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	and as Representatives of several
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Underwriters listed on
<U>
	Schedule A
</U>
	to this Agreement.
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	COWEN AND COMPANY, LLC
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name:
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Title:
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	PIPER JAFFRAY&nbsp;&amp; CO.
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name:
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="42%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:42.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Title:
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.76%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<I>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-STYLE:ITALIC;FONT-WEIGHT:BOLD;">
	[Signature Page to Syros Pharmaceuticals, Inc. Underwriting Agreement]
</FONT>
</I>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=33,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=260971,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-05_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:53 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SCHEDULE A
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="44%" VALIGN="BOTTOM" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="1" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:8.0PT;FONT-WEIGHT:BOLD;">
	Name
</FONT>
</B>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="1" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;FONT-WEIGHT:BOLD;">
	&nbsp;
</FONT>
</B>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="1" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:8.0PT;FONT-WEIGHT:BOLD;">
	Number of Shares of
<BR>
	Firm Stock to be
<BR>
	Purchased
</FONT>
</B>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="1" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;FONT-WEIGHT:BOLD;">
	&nbsp;
</FONT>
</B>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="1" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:8.0PT;FONT-WEIGHT:BOLD;">
	Number of Shares of
<BR>
	Optional Stock to be
<BR>
	Purchased
</FONT>
</B>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="1" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;FONT-WEIGHT:BOLD;">
	&nbsp;
</FONT>
</B>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Cowen and Company, LLC
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Piper Jaffray &amp; Co.
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	JMP Securities LLC
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Wedbush Securities Inc.
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD WIDTH="44%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 10.1PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="44%" VALIGN="TOP" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:44.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT 20.2PT;TEXT-INDENT:-10.1PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Total
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:2.5%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="25%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;BORDER:NONE;BORDER-BOTTOM:DOUBLE WINDOWTEXT 2.25PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:25.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="1%" VALIGN="BOTTOM" BGCOLOR="#CCEEFF" STYLE="BACKGROUND:#CCEEFF;PADDING:0IN 0IN 0IN 0IN;WIDTH:1.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Sch.
</FONT>
	A
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_A_001345_5990">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=34,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=985586,FOLIO='SCH. A',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage33"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SCHEDULE B
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	[General Use Free Writing Prospectuses]
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Sch.
</FONT>
	B
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_B_001402_7056">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=35,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=938706,FOLIO='SCH. B',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage34"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SCHEDULE C
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Pricing Information
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Firm Stock to be Sold:
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	[
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] shares
</P>
</TD>
</TR>
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Offering Price:
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	$[
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] per share
</P>
</TD>
</TR>
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Underwriting Discounts and Commissions:
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	[
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	]%
</P>
</TD>
</TR>
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Estimated Net Proceeds to the Company (after underwriting discounts and commissions, but before transaction expenses):
</FONT>
</P>
</TD>
<TD WIDTH="2%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:2.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="BOTTOM" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.04%;">
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	$[
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	]
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Sch.
</FONT>
	C
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_C_001442_5335">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=36,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=52930,FOLIO='SCH. C',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage35"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SCHEDULE D
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Sch.
</FONT>
	D
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_D_001452_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=37,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=518081,FOLIO='SCH. D',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage36"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit I
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Form of Lock-Up Agreement
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="RIGHT" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	[
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	]
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	COWEN AND COMPANY, LLC
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 9.0PT;TEXT-INDENT:-9.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	PIPER JAFFRAY &amp; CO.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 9.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	As Representatives of the several Underwriters
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	c/o Cowen and Company, LLC
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	599 Lexington Avenue
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	New York, New York 10022
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	c/o Piper Jaffray &amp; Co.
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	345 Park Avenue, 12
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
	&#160;Fl.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	New York, New York 10154
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Re:&#160; Syros Pharmaceuticals, Inc. &#151; Registration Statement on Form S-1 for Shares of Common Stock
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Dear Sir or Madam:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	This Agreement is being delivered to you in connection with the proposed Underwriting Agreement (the &#147;Underwriting Agreement&#148;) by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), and Cowen and Company, LLC (&#147;Cowen&#148;) and Piper Jaffray &amp; Co. (&#147;Piper&#148;), as representatives (the &#147;Representatives&#148;) of a group of underwriters (collectively, the &#147;Underwriters&#148;), to be named therein, and the other parties thereto (if any), relating to the proposed public offering of shares of the common stock (the &#147;Offering&#148;), par value $0.001 per share (the &#147;Common Stock&#148;), of the Company.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	In order to induce you and the other Underwriters to enter into the Underwriting Agreement, and in light of the benefits that the offering of the Common Stock will confer upon the undersigned in its capacity as a securityholder and/or an officer, director or employee of the Company, and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees with each Underwriter that, during the period beginning on the date hereof through and including the date that is the one hundred and eightieth (180
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
	) day after the date of the Underwriting Agreement (the &#147;Lock-Up Period&#148;), the undersigned will not, without the prior written consent of Cowen and Piper, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of Common Stock (including, without limitation, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated under the Securities Act of 1933, as amended (such shares, the &#147;Beneficially Owned Shares,&#148; and such act, the &#147;Securities Act&#148;)), or securities convertible into or exercisable or exchangeable for Common Stock, (ii) enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of the Beneficially Owned Shares or securities convertible into or exercisable or exchangeable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=38,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=328252,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage37"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	undersigned has or hereafter acquires the power of disposition, or (iii) engage in any short selling of the Common Stock or securities convertible into or exercisable or exchangeable for Common Stock.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	If the undersigned is an officer or director of the Company, (i) Cowen and Piper agree that, at least three (3) business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, Cowen and Piper will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two (2) business days before the effective date of the release or waiver.&#160; Any release or waiver granted by Cowen and Piper hereunder to any such officer or director shall only be effective two (2) business day after the publication date of such press release.&#160; The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of the transfer.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The restrictions set forth in the second paragraph shall not apply to:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(1)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	if the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift, (b) to any member of the immediate family (as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members of the undersigned&#146;s immediate family, (c) by will or intestate succession upon the death of the undersigned; or (d) by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(2)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers to any stockholder, partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer is not for value; and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(3)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#146;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the undersigned&#146;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this agreement or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate (as defined below) of the undersigned and such transfer is not for value;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<I>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-STYLE:ITALIC;">
	provided
</FONT>
</I>
	,
<I>
	however
</I>
	, that in the case of any transfer described in clause (1), (2) or (3) above, it shall be a condition to the transfer that (A) the transferee executes and delivers to Cowen and Piper, acting on behalf of the Underwriters, not later than one (1) business day prior to such transfer, a written agreement, in substantially the form of this agreement (it being understood that any references to &#147;immediate family&#148; in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the immediate family of the transferee) and otherwise satisfactory in form and substance to Cowen and Piper, and (B) in the case of any transfer described in clause (1) or (2) above, if the undersigned is required to file a report under Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), reporting a reduction in beneficial ownership of shares of Common Stock or Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable for Common Stock or Beneficially Owned Shares during the Lock-Up Period, the undersigned shall include a statement in such report to the effect that, (A) in the case of any transfer pursuant to clause (1) above, such transfer is being made as a gift or by will or intestate succession, (B) in the case of any transfer pursuant to clause (2) above, such transfer is being made to a stockholder, partner or member of, or owner
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	3
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_3_001532_5514">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=39,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=92432,FOLIO='3',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage38"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	of a similar equity interest in, the undersigned and is not a transfer for value, and (C) in the case of any transfer pursuant to clause (3) above, such transfer is being made either (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#146;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the undersigned&#146;s assets or (b) to another corporation, partnership, limited liability company or other business entity that is an affiliate of the undersigned and such transfer is not for value. For purposes of this paragraph, &#147;immediate family&#148; shall mean a spouse, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned; and &#147;affiliate&#148; shall have the meaning set forth in Rule 405 under the Securities Act.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For avoidance of doubt, nothing in this Agreement prohibits the undersigned from exercising any options or warrants to purchase Common Stock (which exercises may be effected on a cashless basis to the extent the instruments representing such options or warrants permit exercises on a cashless basis), it being understood that any Common Stock issued upon such exercises will be subject to the restrictions of this Agreement.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Notwithstanding the foregoing, the restrictions set forth in the second paragraph of this Agreement shall not apply to: (i) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock,
<I>
	provided
</I>
	that there will be no transfer of shares of the undersigned&#146;s Common Stock during the Lock-Up Period, and such a plan may only be established if no public announcement of the establishment or existence thereof and no filing with the SEC or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned, the Company or any other person, shall be required, and no such announcement or filing is made voluntarily, by the undersigned, the Company or any other person during the Lock-Up Period; (ii) the conversion of outstanding preferred stock of the Company into Common Stock,
<I>
	provided
</I>
	that any shares of Common Stock received upon such conversion shall be subject to the restrictions provided for in this Agreement; (iii) a transfer of shares of Common Stock to the Company in connection with the termination of the undersigned&#146;s employment with or provision of services to the Company; (iv) a transfer or disposition of shares of Common Stock purchased in the Offering from the Underwriters (other than any issuer-directed shares of Common Stock purchased in the Offering by an officer or director of the Company) or on the open market following the Offering,
<I>
	provided
</I>
	that no public announcement and no filing with the SEC or other regulatory authority in respect thereof by the undersigned, the Company or any other person shall be required, and no such announcement or filing is made voluntarily by the undersigned, the Company or any other person in each case during the Lock-Up Period; or (v) the transfer of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to a
<I>
	bona fide
</I>
	third party tender offer, merger, consolidation or other similar transaction made to all holders involving a Change of Control (as defined below) of the Company that is approved by the Board of Directors of the Company (including, without limitation, the entry into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or other such securities in favor of any such transaction, or vote any securities in favor of such transaction),
<I>
	provided
</I>
	that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Common Stock owned by the undersigned shall remain subject to the restrictions contained in this Agreement.&#160; For purposes of this Lock-Up Agreement, &#147;Change of Control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an Underwriter pursuant to the Offering), of the Company&#146;s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 90% of the outstanding voting securities of the Company (or the surviving entity).
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	4
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_4_001542_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=40,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=530601,FOLIO='4',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage39"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	In order to enable this covenant to be enforced, the undersigned hereby consents to the placing of legends or stop transfer instructions with the Company&#146;s transfer agent with respect to any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The undersigned further agrees that it will not, during the Lock-Up Period (as the same may be extended as described above), make any demand or request for or exercise any right with respect to the registration under the Securities Act, of any shares of Common Stock or other Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable for Common Stock or other Beneficially Owned Shares.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	[If any percentage of the shares of Common Stock of the Company (or any security convertible into or exercisable or exchangeable for shares of Common Stock) held by any person or entity (other than the undersigned) that (i) is the holder of 5% or more of the outstanding shares of the Company&#146;s Common Stock (calculated on a fully diluted, post-Offering basis) or (ii) is a director or officer of the Company, that is subject to a lock-up agreement related to the Offering similar in form to this Lock-Up Agreement is released from any restrictions set forth in such lock-up agreement during the Lock-Up Period, the same percentage of shares of Common Stock and such other securities held by the undersigned shall be immediately and fully released on the same terms from the lock-up restrictions set forth herein (the &#147;Pro-rata Release&#148;);
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that such Pro-rata Release shall not occur (A) unless and until the Representatives have first waived such restrictions with respect to an aggregate number of shares of Common Stock and such other securities representing more than 3.0% of the Company&#146;s total outstanding shares of Common Stock calculated as of immediately following the closing of the Offering and assuming conversion, exercise and exchange of all securities convertible into or exercisable or exchangeable for Common Stock, or (B) in the event of a release in connection with any underwritten public offering, whether or not such offering or sale is wholly or partially a secondary offering of the Company&#146;s Common Stock during the Lock-Up Period (the &#147;Underwritten Sale&#148;);
<I>
	provided
</I>
	,
<I>
	however
</I>
	, that the undersigned, to the extent the undersigned has a contractual right to demand or require the registration of the undersigned&#146;s Common Stock or such other securities or otherwise &#147;piggyback&#148; on a registration statement filed by the Company for the offer and sale of securities, is offered the opportunity to participate on a basis consistent with such contractual rights in such Underwritten Sale.] [
<I>
	To be included only in the lock-up agreements of IRA signatories and their affiliated directors who are not officers of the Company
</I>
	]
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:10.0PT;">
	This Agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the undersigned and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned
</FONT>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this agreement and that this agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned. This agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the undersigned (if a natural person) and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	5
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_5_001553_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=41,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=656481,FOLIO='5',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage40"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	If (i) the Company notifies Cowen and Piper in writing that it does not intend to proceed with the Offering, (ii) Cowen and Piper notify the Company in writing that they do not intend to proceed with the Offering, (iii) the Underwriting Agreement is not executed by September 30, 2016, or (iv) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and delivery of any Common Stock to be sold thereunder, then this Agreement shall immediately be terminated and the undersigned shall automatically be released from all of his or her obligations under this Agreement.&#160; The undersigned acknowledges and agrees that whether or not any public offering of Common Stock actually occurs depends on a number of factors, including market conditions.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	[
<I>
	Signature page follows
</I>
	]
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	6
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_6_001604_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=42,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=468066,FOLIO='6',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<A NAME="eolPage41"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Very truly yours,
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Name of Stockholder - Please Print)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Signature)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Name of Signatory if Stockholder is an entity - Please Print)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Title of Signatory if Stockholder is an entity - Please Print)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="8%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:8.08%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Address:
</FONT>
</P>
</TD>
<TD WIDTH="41%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:41.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="8%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:8.08%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="41%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:41.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="8%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:8.08%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="41%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:41.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="8%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:8.08%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="41%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:41.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="8%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:8.08%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="41%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:41.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<I>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-STYLE:ITALIC;FONT-WEIGHT:BOLD;">
	[SIGNATURE PAGE TO SYROS PHARMACEUTICALS, INC. LOCK-UP AGREEMENT]
</FONT>
</I>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Ex. I-
</FONT>
	5
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-07_PB_5_001639_276">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=43,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=967513,FOLIO='EX. I-5',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-07_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:43 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit&nbsp;II
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Syros Pharmaceuticals,&nbsp;Inc.
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	[Date]
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Syros Pharmaceuticals,&nbsp;Inc. announced today that Cowen and Company, LLC and Piper Jaffray&nbsp;&amp; Co., the lead book-running managers in the Company&#146;s recent public sale of [
</FONT>
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] shares of common stock, is [waiving][releasing] a lock-up restriction with respect to [
<FONT FACE="SYMBOL">
	&#183;
</FONT>
	] shares of the Company&#146;s common stock held by [certain officers or directors][an officer or director] of the Company.&#160; The [waiver][release] will take effect on&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 20&#160;&#160; , and the shares may be sold on or after such date.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or exemption from registration under the United States Securities Act of 1933, as amended.
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Ex.
</FONT>
	II
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-09_PB_II_002032_9770">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=44,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=970,FOLIO='EX. II',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-09_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:41 2016' -->
<A NAME="eolPage42"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit&nbsp;III
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Form&nbsp;of Company Counsel Opinion
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Ex.
</FONT>
	III
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-09_PB_III_002042_7608">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=45,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=687768,FOLIO='EX. III',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-09_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:41 2016' -->
<A NAME="eolPage43"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit&nbsp;IV
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Opinion of Intellectual Property Counsel to the Company
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Ex.
</FONT>
	IV
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-09_PB_IV_002051_8146">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=46,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=493943,FOLIO='EX. IV',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-09_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:41 2016' -->
<A NAME="eolPage44"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit&nbsp;V
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	CFO Certificate
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Ex.
</FONT>
	V
<A NAME="A2228976ZEX-1_1_HTM_22596-2-KA-09_PB_V_002056_7091">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=47,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="2",CHK=839556,FOLIO='EX. V',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KA-09_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 22:41 2016' -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_1>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage45"></A>
<A NAME="A2228976ZEX-3_1_HTM"></A>
<EFX_EXHIBIT_3>
<A NAME="FIS_EXHIBIT_3"></A>
<BR>
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit 3.1
</FONT>
</B>
</P>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	&nbsp;
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	THIRD AMENDED AND RESTATED
<EFX_CERTIFICATE_OF_INCORPORATION>
<A NAME="FIS_CERTIFICATE_OF_INCORPORATION"></A>
<BR>
	CERTIFICATE OF INCORPORATION
<BR>
	OF
<BR>
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Pursuant to Sections 242 and 245 of the
<BR>
	General Corporation Law of the State of Delaware)
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Syros Pharmaceuticals,&nbsp;Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#147;
<B>
	General Corporation Law
</B>
	&#148;),
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	DOES HEREBY CERTIFY:
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	1.
</FONT>
</B>
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That the name of this corporation is Syros Pharmaceuticals,&nbsp;Inc., and that this corporation was originally incorporated under the name LS22,&nbsp;Inc. pursuant to the General Corporation Law on November&nbsp;9, 2011.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	2.
</FONT>
</B>
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	RESOLVED
</FONT>
</B>
	, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	FIRST:&#160;
</FONT>
</B>
	The name of this corporation is Syros Pharmaceuticals,&nbsp;Inc. (the
<B>
	&#147;Corporation&#148;
</B>
	).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SECOND:&#160;
</FONT>
</B>
	The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801.&#160; The name of its registered agent at such address is The Corporation Trust Company.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	THIRD:&#160;
</FONT>
</B>
	The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	FOURTH:&#160;
</FONT>
</B>
	The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i)&nbsp;64,571,908&#160; shares of Common Stock, $0.001 par value per share (&#147;
<B>
	Common Stock
</B>
	&#148;), and (ii)&nbsp;47,243,931 shares of Preferred Stock, $0.001 par value per share (&#147;
<B>
	Preferred Stock
</B>
	&#148;), of which 2,500,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-1 Preferred Stock
</B>
	,&#148; 12,100,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-2 Preferred Stock
</B>
	,&#148; 15,750,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-3 Preferred Stock
</B>
	&#148; (together, the &#147;
<B>
	Series&nbsp;A Preferred Stock
</B>
	&#148;) and 16,893,931 shares have been designated as &#147;
<B>
	Series&nbsp;B Preferred Stock
</B>
	.&#148;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=1,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=971326,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage46"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; COMMON STOCK
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	General
</U>
	.&#160; The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Voting
</U>
	.&#160; The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings);
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the General Corporation Law.&#160; There shall be no cumulative voting.&#160; The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2)&nbsp;of the General Corporation Law.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; PREFERRED STOCK
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Preferred Stock may be issued from time to time in one or more series, each of such series to consist of such number of shares and to have such terms, rights, powers and preferences, and the qualifications and limitations with respect thereto, as stated or expressed herein.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 1.0IN;TEXT-INDENT:-.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	C.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	SERIES A-1 PREFERRED STOCK, SERIES A-2 PREFERRED STOCK, SERIES A-3 PREFERRED STOCK AND SERIES B PREFERRED STOCK
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The Preferred Stock shall have the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to &#147;Sections&#148; or &#147;Subsections&#148; in this Part&nbsp;C of this Article&nbsp;Fourth refer to sections and subsections of Part&nbsp;C of this Article&nbsp;Fourth.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Dividends
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Series&nbsp;B Preferred Stock Dividends
</U>
	. From and after the date of the issuance of any shares of Series&nbsp;B Preferred Stock, dividends at the rate per annum of 0.1887 per share shall accrue on such shares of Series&nbsp;B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;B Preferred Stock), from and after the date of issuance of any shares of
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	2
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_2_140626_2936">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=2,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=620366,FOLIO='2',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage47"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Series&nbsp;B Preferred Stock&#160; (the &#147;
<B>
<FONT STYLE="FONT-WEIGHT:BOLD;">
	Series&nbsp;B
</FONT>
	Accruing Dividends
</B>
	&#148;).&#160; Series&nbsp;B Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that except as set forth in the following sentence of this
<U>
	Subsection 1.1
</U>
	or in
<U>
	Subsection 2.1
</U>
	, such Series&nbsp;B Accruing Dividends shall be payable only when, as, and if declared by a majority of the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;B Accruing Dividends.&#160; The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series&nbsp;B Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;B Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series&nbsp;B Accruing Dividends then accrued on such share of Series&nbsp;B Preferred Stock and not previously paid and (ii)&nbsp;(A)&nbsp;in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series&nbsp;B Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series&nbsp;B Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series&nbsp;B Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Series&nbsp;B Original Issue Price (as defined below);
<U>
	provided that
</U>
	, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series&nbsp;B Preferred Stock pursuant to this
<U>
	Subsection 1.1
</U>
	shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series&nbsp;B Preferred Stock dividend.&#160; The &#147;
<B>
	Series&nbsp;B Original Issue Price
</B>
	&#148; shall mean $3.1461 per share subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;B Preferred Stock.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Series&nbsp;A-1 Preferred Stock, Series&nbsp;A-2 Preferred Stock and Series&nbsp;A-3 Preferred Stock Dividends
</U>
	. From and after the date of the issuance of any shares of Series&nbsp;A-1 Preferred Stock, dividends at the rate per annum of $0.03 per share shall accrue on such shares of Series&nbsp;A-1 Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;A-1 Preferred Stock), from and after the date of issuance of any shares of Series&nbsp;A-2 Preferred Stock, dividends at the rate per annum of $0.06 per share shall accrue on such shares of Series&nbsp;A-2 Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;A-2 Preferred Stock) and from and after the date of issuance of any shares of Series&nbsp;A-3 Preferred Stock, dividends at the rate per annum of $0.06 per share shall accrue on such shares of Series&nbsp;A-3 Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;A-3 Preferred Stock)&#160; (together, the &#147;
<B>
<FONT STYLE="FONT-WEIGHT:BOLD;">
	Series&nbsp;A
</FONT>
	Accruing Dividends
</B>
	&#148;).&#160; Series&nbsp;A Accruing Dividends shall accrue from day to day,
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	3
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_3_140820_7056">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=3,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=678693,FOLIO='3',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage48"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	whether or not declared, and shall be cumulative;
<U>
	provided however
</U>
	, that except as set forth in the following sentence of this
<U>
	Section&nbsp;1
</U>
	or in
<U>
	Subsection 2.1
</U>
	, such Series&nbsp;A Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series&nbsp;A Accruing Dividends.&#160; The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than the Series&nbsp;B Accruing Dividends payable pursuant to
<U>
	Subsection 1.1
</U>
	, or dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series&nbsp;A Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;A Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series&nbsp;A Accruing Dividends then accrued on such share of Series&nbsp;A Preferred Stock and not previously paid and (ii)&nbsp;(A)&nbsp;in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series&nbsp;A Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series&nbsp;A Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series&nbsp;A Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Series&nbsp;A-1 Original Issue Price, Series&nbsp;A-2 Original Issue Price, or Series&nbsp;A-3 Original Issue Price, as applicable (each as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, other than the Series&nbsp;B Preferred Stock, the dividend payable to the holders of Series&nbsp;A Preferred Stock pursuant to this
<U>
	Section&nbsp;1.2
</U>
	shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series&nbsp;A Preferred Stock dividend.&#160; The &#147;
<B>
	Series&nbsp;A-1 Original Issue Price
</B>
	&#148; shall mean $0.50 per share, the &#147;
<B>
	Series&nbsp;A-2 Original Issue Price
</B>
	&#148; shall mean $1.00 per share, and the &#147;
<B>
	Series&nbsp;A-3 Original Issue Price
</B>
	&#148; shall mean $1.00 per share, in each case subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;A Preferred Stock.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Other Dividends
</U>
	. After payment of dividends in the amounts set forth above, any additional dividends declared shall be distributed among all holders of Preferred Stock and Common Stock in proportion to the number of shares of Common Stock that would be held by each such holder if all shares of Preferred Stock were converted to Common Stock.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Preferential Payments to Holders of Series&nbsp;B Preferred Stock
</U>
	.&#160; In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event (as defined below), the holders of shares of Series&nbsp;B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	4
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_4_141013_5335">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=4,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=203188,FOLIO='4',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage49"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	available for distribution to its stockholders before any payment shall be made to the holders of Series&nbsp;A Preferred Stock, Common Stock, or any other securities of the Corporation by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the Series&nbsp;B Original Issue Price, plus any Series&nbsp;B Accruing Dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon, or (ii)&nbsp; such amount per share as would have been payable had all shares of Series&nbsp;B Preferred Stock been converted into Common Stock pursuant to
<U>
	Section&nbsp;4
</U>
	immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;
<B>
	Series&nbsp;B Liquidation Amoun
</B>
	t&#148;).&#160; If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series&nbsp;B Preferred Stock the full amount to which they shall be entitled under this
<U>
	Subsection 2.1
</U>
	, the holders of shares of Series&nbsp;B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Preferential Payments to Holders of Series&nbsp;A Preferred Stock
</U>
	.&#160; In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Series&nbsp;B Preferred Stock pursuant to
<U>
	Subsection 2.1
</U>
	hereof, the holders of shares of Series&nbsp;A-1 Preferred Stock, Series&nbsp;A-2 Preferred Stock and Series&nbsp;A-3 Preferred stock then outstanding shall be entitled to be paid out of the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Series&nbsp;A Preferred Stock then outstanding before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the Series&nbsp;A-1 Original Issue Price, Series&nbsp;A-2 Original Issue Price, or Series&nbsp;A-3 Original Issue Price, as applicable, plus any Series&nbsp;A Accruing Dividends declared but unpaid thereon, or (ii)&nbsp; such amount per share as would have been payable had all shares of Series&nbsp;A Preferred Stock been converted into Common Stock pursuant to
<U>
	Section&nbsp;4
</U>
	immediately prior to such liquidation, dissolution or, winding up or Deemed Liquidation Event (the amounts payable pursuant to this sentence are hereinafter referred to as the &#147;
<B>
	Series&nbsp;A Liquidation Amoun
</B>
	t&#148;).&#160; If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series&nbsp;A Preferred Stock the full amount to which they shall be entitled under this
<U>
	Subsection 2.2
</U>
	, the holders of shares of Series&nbsp;A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Payments to Holders of Common Stock
</U>
	.&#160; In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	5
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_5_141053_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=5,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=673616,FOLIO='5',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage50"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Deemed Liquidation Events
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.4.1.&#160;&#160;&#160;&#160;&#160;
<U>
	Definition
</U>
	.&#160; Each of the following events shall be considered a &#147;
<B>
	Deemed Liquidation Event
</B>
	&#148; unless the holders of at least sixty six and two thirds percent (66 2/3%) of the outstanding shares of Preferred Stock and at least sixty six and two thirds percent (66 2/3%) of the outstanding shares of Series&nbsp;B Preferred Stock elect otherwise by written notice sent to the Corporation at least twenty (20) days prior to the effective date of any such event:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a merger or consolidation in which
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the Corporation is a constituent party or
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation,
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.4.2.&#160;&#160;&#160;&#160;&#160;
<U>
	Effecting a Deemed Liquidation Event
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in
<U>
	Subsection 2.4.1(a)(i)
</U>
	&nbsp;unless the agreement or plan of merger or consolidation for such transaction (the &#147;
<B>
	Merger Agreement
</B>
	&#148;) provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>
	Subsections 2.1
</U>
	,
<U>
	2.2
</U>
	, and
<U>
	2.3
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event of a Deemed Liquidation Event referred to in
<U>
	Subsection 2.4.1(a)(ii)
</U>
	&nbsp;or
<U>
	2.4.1(b)
</U>
	, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	6
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_6_141250_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=6,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=807548,FOLIO='6',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage51"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Stock no later than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following
<U>
	clause (ii)
</U>
	&nbsp;to require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Preferred Stock so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Corporation), together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the
<B>
	&#147;Available Proceeds
</B>
	&#148;), on the 150th day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the Series&nbsp;A Liquidation Amount, or Series&nbsp;B Liquidation Amount, as applicable.&#160; Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall ratably redeem the shares of Preferred Stock in accordance with the preferences and priorities set forth in
<U>
	Subsections 2.1
</U>
	,
<U>
	2.2
</U>
	and
<U>
	2.4.4
</U>
	to the fullest extent of such Available Proceeds, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders in accordance with the preferences and priorities set forth in
<U>
	Subsections 2.1
</U>
	,
<U>
	2.2
</U>
	and
<U>
	2.4.4
</U>
	.&#160; The provisions of
<U>
	Section&nbsp;6
</U>
	shall apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this
<U>
	Subsection 2.4.2(b).
</U>
	&#160; Prior to the distribution or redemption provided for in this
<U>
	Subsection 2.4.2(b)
</U>
	, the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.4.3.&#160;&#160;&#160;&#160;&#160;
<U>
	Amount Deemed Paid or Distributed
</U>
	.&#160; The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person, firm or other entity.&#160; The value of such property, rights or securities shall be determined in good faith by the Board of Directors of the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.4.4.&#160;&#160;&#160;&#160;&#160;
<U>
	Allocation of Escrow
</U>
	.&#160; In the event of a Deemed Liquidation Event pursuant to
<U>
	Subsection 2.4.1(a)(i)
</U>
	, if any portion of the consideration payable to the stockholders of the Corporation is placed into escrow and/or is payable to the stockholders of the Corporation subject to contingencies, the Merger Agreement shall provide that (a)&nbsp;the portion of such consideration that is not placed in escrow and not subject to any contingencies (the &#147;
<B>
	Initial Consideration
</B>
	&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>
	Subsections 2.1
</U>
	,
<U>
	2.2
</U>
	and
<U>
	2.3
</U>
	as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event and (b)&nbsp;any additional consideration which becomes payable to the stockholders of the Corporation upon release from escrow or satisfaction of contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>
	Subsections 2.1
</U>
	,
<U>
	2.2
</U>
	and
<U>
	2.3
</U>
	after taking into account the previous payment of the Initial Consideration as part of the same transaction.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	7
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_7_141333_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=7,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=1032495,FOLIO='7',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage52"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Voting
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	General
</U>
	.&#160; On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.&#160; Except as provided by law or by the other provisions of the Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Election of Directors
</U>
	.&#160; The holders of record of the shares of Series&nbsp;A Preferred Stock, exclusively and as a separate class, shall be entitled to elect two directors of the Corporation (the &#147;
<B>
	Series&nbsp;A Directors
</B>
	&#148;).&#160; Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of shares of Series&nbsp;A Preferred Stock, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.&#160; If the holders of shares of Series&nbsp;A Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this
<U>
	Subsection 3.2
</U>
	, then any directorship not so filled shall remain vacant until such time as the holders of the Series&nbsp;A Preferred Stock elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock), exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation.&#160; At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director.&#160; Except as otherwise provided in this
<U>
	Subsection 3.2
</U>
	, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this
<U>
	Subsection 3.2
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Series&nbsp;B Preferred Stock Protective Provisions
</U>
	.&#160; At any time when shares of Series&nbsp;B Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Series&nbsp;B Preferred Stock, given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void
<I>
	ab initio
</I>
	, and of no force or effect.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	8
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_8_141414_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=8,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=621528,FOLIO='8',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage53"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.3.1.&#160;&#160;&#160;&#160;&#160; modify, amend, or waive any provision of the Certificate of Incorporation of the Corporation in a manner adverse to the rights, preferences or privileges of the Series&nbsp;B Preferred Stock;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.3.2.&#160;&#160;&#160;&#160;&#160; purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation prior to the Series&nbsp;B Preferred Stock other than repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof; or
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.3.3.&#160;&#160;&#160;&#160;&#160; increase or decrease the authorized number of shares of Series&nbsp;B Preferred Stock of the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Preferred Stock Protective Provisions
</U>
	.&#160; At any time when shares of Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Preferred Stock, given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void
<I>
	ab initio
</I>
	, and of no force or effect.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.4.1.&#160;&#160;&#160;&#160;&#160; liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event,&#160; or consent to any of the foregoing;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.4.2.&#160;&#160;&#160;&#160;&#160; amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Corporation;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.4.3.&#160;&#160;&#160;&#160;&#160; create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital stock unless the same ranks junior to the Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption, or increase the authorized number of shares of Preferred Stock unless the same ranks junior to the Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption; or
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.4.4.&#160;&#160;&#160;&#160;&#160; purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation prior to the Preferred Stock other than repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	9
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_9_141453_141">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=9,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=614288,FOLIO='9',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<A NAME="eolPage54"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Optional Conversion
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The holders of the Preferred Stock shall have conversion rights as follows (the &#147;
<B>
	Conversion Rights
</B>
	&#148;):
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Right to Convert
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.1.1.&#160;&#160;&#160;&#160;&#160;
<U>
	Conversion Ratio
</U>
	. &#160;Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing the Series&nbsp;A-1 Original Issue Price by the Series&nbsp;A-1 Conversion Price (as defined below), in the case of the Series&nbsp;A-1 Preferred Stock, by dividing the Series&nbsp;A-2 Original Issue Price by the Series&nbsp;A-2 Conversion Price (as defined below), in the case of the Series&nbsp;A-2 Preferred Stock, by dividing the Series&nbsp;A-3 Original Issue Price by the Series&nbsp;A-3 Conversion Price (as defined below), in the case of the Series&nbsp;A-3 Preferred Stock and by dividing the Series&nbsp;B Original Issue Price by the Series&nbsp;B Conversion Price (as defined below), in the case of the Series&nbsp;B Preferred Stock in each case, in effect at the time of conversion.&#160; The
<B>
	&#147;Series&nbsp;A-1 Conversion Price&#148;
</B>
	shall initially be equal to $0.50.&#160; The &#147;
<B>
	Series&nbsp;A-2 Conversion Price
</B>
	&#148; shall initially be equal to $1.00.&#160; The &#147;
<B>
	Series&nbsp;A-3 Conversion Price
</B>
	&#148; shall initially be equal to $1.00.&#160; The &#147;
<B>
	Series&nbsp;B Conversion Price
</B>
	&#148; shall initially be equal to $3.1461. The Series&nbsp;A-1 Conversion Price, Series&nbsp;A-2 Conversion Price, Series&nbsp;A-3 Conversion Price and Series&nbsp;B Conversion Price shall be known individually or collectively, as applicable, as the &#147;
<B>
	Conversion Price
</B>
	&#148;).&#160; Such initial Conversion Price, and the rate at which shares of Series&nbsp;A Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.1.2.&#160;&#160;&#160;&#160;&#160;
<U>
	Termination of Conversion Rights
</U>
	.&#160; In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Series&nbsp;A-1 Preferred Stock, Series&nbsp;A-2 Preferred Stock, Series&nbsp;A-3 Preferred Stock and Series&nbsp;B Preferred Stock, as the case may be.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Fractional Shares
</U>
	.&#160; No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock.&#160; In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors of the Corporation.&#160; Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Mechanics of Conversion
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.3.1.&#160;&#160;&#160;&#160;&#160;
<U>
	Notice of Conversion
</U>
	.&#160; In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	10
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-01_PB_10_141545_7608">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=10,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=596062,FOLIO='10',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-01_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:53 2015' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the applicable series of Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent), together with written notice that such holder elects to convert all or any number of the shares of the Preferred Stock represented by such certificate or certificates and, if applicable, any event on which such conversion is contingent.&#160; Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the certificate or certificates for shares of Common Stock to be issued.&#160; If required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing.&#160; The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such certificates (or lost certificate affidavit and agreement) and notice shall be the time of conversion (the &#147;
<B>
	Conversion Time
</B>
	&#148;), and the shares of Common Stock issuable upon conversion of the shares represented by such certificate shall be deemed to be outstanding of record as of such date.&#160; The Corporation shall, as soon as practicable after the Conversion Time, (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in
<U>
	Subsection 4.2
</U>
	in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.3.2.&#160;&#160;&#160;&#160;&#160;
<U>
	Reservation of Shares
</U>
	.&#160; The Corporation shall at all times when any Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation.&#160; Before taking any action which would cause an adjustment reducing any of the Conversion Prices below the then par value of the shares of Common Stock issuable upon conversion of the applicable series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and nonassessable shares of Common Stock at such adjusted applicable Conversion Price.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.3.3.&#160;&#160;&#160;&#160;&#160;
<U>
	Effect of Conversion
</U>
	.&#160; All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, and to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in
<U>
	Subsection 4.2
</U>
	and to receive payment of any
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	11
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_11_141135_5441">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=11,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=238726,FOLIO='11',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage55"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	dividends declared but unpaid thereon.&#160; Any shares of Series&nbsp;A Preferred Stock or Series&nbsp;B Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of such series of Preferred Stock accordingly.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.3.4.&#160;&#160;&#160;&#160;&#160;
<U>
	No Further Adjustment
</U>
	.&#160; Upon any such conversion, no adjustment to the applicable Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.3.5.&#160;&#160;&#160;&#160;&#160;
<U>
	Taxes
</U>
	.&#160; The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this
<U>
	Section&nbsp;4
</U>
	.&#160; The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Adjustments to Applicable Conversion Price for Diluting Issues
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4.1.&#160;&#160;&#160;&#160;&#160;
<U>
	Special Definitions
</U>
	.&#160; For purposes of this Article&nbsp;Fourth, the following definitions shall apply:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Option
</B>
	&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Series&nbsp;A-1 Original Issue Date
</B>
	&#148; shall mean the date on which the first share of Series&nbsp;A-1 Preferred Stock was issued.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Series&nbsp;A-2 Original Issue Date
</B>
	&#148; shall mean the date on which the first share of Series&nbsp;A-2 Preferred Stock was issued.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Series&nbsp;A-3 Original Issue Date
</B>
	&#148; shall mean the date on which the first share of Series&nbsp;A-3 Preferred Stock was issued.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Series&nbsp;B Original Issue Date
</B>
	&#148; shall mean the date on which the first share of Series&nbsp;B Preferred Stock was issued.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Convertible Securities
</B>
	&#148; shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;
<B>
	Additional Shares of Common Stock
</B>
	&#148; shall mean all shares of Common Stock issued (or, pursuant to
<U>
	Subsection 4.4.3
</U>
	below, deemed to be issued) by the Corporation after the Series&nbsp;B Original Issue Date, other than (1)&nbsp;the following
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	12
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_12_141329_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=12,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=934546,FOLIO='12',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage56"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;
<B>
	Exempted Securities
</B>
	&#148;):
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock, provided (a)&nbsp;the number of shares of Common Stock issued as a dividend or distribution on a share of Series&nbsp;A Preferred Stock multiplied by the number of shares of Common Stock into which a share of Series&nbsp;A Preferred Stock is then convertible is equal (b)&nbsp;to the number of shares of Common Stock issued as a dividend or distribution on a share of Series&nbsp;B Preferred Stock multiplied by the number of shares of Common Stock into which a share of Series&nbsp;B Preferred Stock is then convertible;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by
<U>
	Subsection 4.5
</U>
	,
<U>
	4.6
</U>
	,
<U>
	4.7
</U>
	or
<U>
	4.8
</U>
	;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Corporation, including at least one Series&nbsp;A Director;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iv)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	13
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_13_141739_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=13,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=500041,FOLIO='13',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage57"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 3.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	leasing transaction approved by the Board of Directors of the Corporation, including at least one Series&nbsp;A Director;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(vi)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors of the Corporation, including at least one Series&nbsp;A Director;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(vii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued to WuXi Pharmatech Healthcare Fund I, L.P. or any of its affiliates (collectively, &#147;
<B>
	Wuxi
</B>
	&#148;) pursuant to any research and development services agreement entered into by and between the Corporation and Wuxi;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 236.15PT;TEXT-INDENT:-20.15PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(viii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided, that such issuances are approved by the Board of Directors of the Corporation, including at least one Series&nbsp;A Director; or
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ix)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors of the Corporation, including at least one Series&nbsp;A Director.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4.2.&#160;&#160;&#160;&#160;&#160;
<U>
	No Adjustment of Conversion Prices
</U>
	.&#160; No adjustment in the Series&nbsp;A-1 Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Series&nbsp;A-1 Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.&#160; No adjustment in the Series&nbsp;A-2 Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	14
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_14_142319_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=14,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=928352,FOLIO='14',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage58"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Series&nbsp;A-2 Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series&nbsp;A-3 Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Series&nbsp;A-3 Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series&nbsp;B Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Series&nbsp;B Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4.3.&#160;&#160;&#160;&#160;&#160;
<U>
	Deemed Issue of Additional Shares of Common Stock
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the Corporation at any time or from time to time on or after the Series&nbsp;B Original Issue Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the applicable Conversion Price pursuant to the terms of
<U>
	Subsection 4.4.4
</U>
	, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such applicable Conversion Price as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security.&#160; Notwithstanding the foregoing, no readjustment pursuant to this
<U>
	clause&nbsp;(b)
</U>
	&nbsp;shall have the effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (i)&nbsp;the applicable Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the applicable Conversion Price that would have resulted from any issuances of Additional
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	15
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_15_142411_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=15,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=91054,FOLIO='15',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage59"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:10.0PT;">
	(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to a Conversion Price pursuant to the terms of
<U>
	Subsection 4.4.4
</U>
	(either because the consideration per share (determined pursuant to
<U>
	Subsection 4.4.5
</U>
	) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Series&nbsp;B Original Issue Date), are revised on or after the Series&nbsp;B Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise,
</FONT>
</FONT>
	conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in
<U>
	Subsection 4.4.3(a)
</U>
	&nbsp;shall be deemed to have been issued effective upon such increase or decrease becoming effective.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the applicable Conversion Price pursuant to the terms of
<U>
	Subsection 4.4.4
</U>
	, the applicable Conversion Price shall be readjusted to such applicable Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the applicable Conversion Price provided for in this
<U>
	Subsection 4.4.3
</U>
	shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c)&nbsp;of this
<U>
	Subsection 4.4.3
</U>
	.)&#160; If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the applicable Conversion Price that would result under the terms of this
<U>
	Subsection 4.4.3
</U>
	at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the applicable Conversion Price that such issuance or amendment took place at the time such calculation can first be made.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	16
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_16_142443_141">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=16,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=742591,FOLIO='16',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage60"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4.4.&#160;&#160;&#160;&#160;&#160;
<U>
	Adjustment of Conversion Prices Upon Issuance of Additional Shares of Common Stock
</U>
	.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event the Corporation shall at any time after the Series&nbsp;B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>
	Subsection 4.4.3
</U>
	), without consideration or for a consideration per share less than the Series&nbsp;A-1 Conversion Price in effect immediately prior to such issue, then the Series&nbsp;A-1 Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	CP
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#160;= CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	*&#160; (A + B) &#247; (A + C).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For purposes of the foregoing formula, the following definitions shall apply:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#148; shall mean the Series&nbsp;A-1 Conversion Price in effect immediately after such issue of Additional Shares of Common Stock
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#148; shall mean the Series&nbsp;A-1 Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Series&nbsp;A Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iv)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a price per share equal to CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#160;(determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	); and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued in such transaction.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	17
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_17_142535_7608">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=17,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=893659,FOLIO='17',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage61"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event the Corporation shall at any time after the Series&nbsp;B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>
	Subsection 4.4.3
</U>
	), without consideration or for a consideration per share less than the Series&nbsp;A-2 Conversion Price in effect immediately prior to such issue, then the Series&nbsp;A-2 Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	CP
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#160;= CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	*&#160; (A + B) &#247; (A + C).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For purposes of the foregoing formula, the following definitions shall apply:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#148; shall mean the Series&nbsp;A-2 Conversion Price in effect immediately after such issue of Additional Shares of Common Stock
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#148; shall mean the Series&nbsp;A-2 Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Series&nbsp;A Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iv)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a price per share equal to CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#160;(determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	); and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued in such transaction.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event the Corporation shall at any time after the Series&nbsp;B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>
	Subsection 4.4.3
</U>
	), without consideration or for a consideration per share less than the Series&nbsp;A-3 Conversion Price in effect
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	18
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_18_142633_8146">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=18,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=390222,FOLIO='18',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage62"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	immediately prior to such issue, then the Series&nbsp;A-3 Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	CP
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#160;= CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	*&#160; (A + B) &#247; (A + C).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For purposes of the foregoing formula, the following definitions shall apply:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#148; shall mean the Series&nbsp;A-3 Conversion Price in effect immediately after such issue of Additional Shares of Common Stock
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#148; shall mean the Series&nbsp;A-3 Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Series&nbsp;A Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iv)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a price per share equal to CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#160;(determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	); and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued in such transaction.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event the Corporation shall at any time after the Series&nbsp;B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>
	Subsection 4.4.3
</U>
	), without consideration or for a consideration per share less than the Series&nbsp;B Conversion Price in effect immediately prior to such issue, then the Series&nbsp;B Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	19
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_19_142714_7091">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=19,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=940761,FOLIO='19',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<A NAME="eolPage63"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	CP
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#160;= CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	*&#160; (A + B) &#247; (A + C).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	For purposes of the foregoing formula, the following definitions shall apply:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	2
</FONT>
	&#148; shall mean the Series&nbsp;B Conversion Price in effect immediately after such issue of Additional Shares of Common Stock;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;CP
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:1.0PT;">
	1
</FONT>
	&#148; shall mean the Series&nbsp;B Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iv)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a price per share equal to the Series&nbsp;B Conversion Price in effect immediately prior to such issuance (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by the Series&nbsp;B Conversion Price in effect immediately prior to such issuance); and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(v)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	&#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued in such transaction.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4.5.&#160;&#160;&#160;&#160;&#160;
<U>
	Determination of Consideration
</U>
	.&#160; For purposes of this
<U>
	Subsection&nbsp;4.4
</U>
	, the consideration received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Cash and Property
</U>
	:&#160; Such consideration shall:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	insofar as it consists of cash, be computed at the aggregate amount of cash received by the
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	20
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-03_PB_20_142731_455">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=20,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=81452,FOLIO='20',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-03_ZCT79602.CHC",USER="JVANGB",CD='NOV 9 05:25 2015' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 3.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Corporation, excluding amounts paid or payable for accrued interest;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board of Directors of the Corporation; and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(iii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in
<U>
	clauses (i)
</U>
	&nbsp;and
<U>
	(ii)
</U>
	&nbsp;above, as determined in good faith by the Board of Directors of the Corporation.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Options and Convertible Securities
</U>
	.&#160; The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to
<U>
	Subsection 4.4.3
</U>
	, relating to Options and Convertible Securities, shall be determined by dividing
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(i)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 3.25IN;TEXT-INDENT:-.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(ii)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	21
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_21_143215_8556">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=21,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=375910,FOLIO='21',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage64"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 3.25IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Options for Convertible Securities and the conversion or exchange of such Convertible Securities.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.4.6.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Multiple Closing Dates
</U>
	.&#160; In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the applicable Conversion Price pursuant to the terms of
<U>
	Subsection 4.4.4
</U>
	then, upon the final such issuance, the applicable Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.5
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Adjustment for Stock Splits and Combinations
</U>
	.&#160; If the Corporation shall at any time or from time to time on or after the Series&nbsp;B Original Issue Date effect a subdivision of the outstanding Common Stock, the applicable Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding.&#160; If the Corporation shall at any time or from time to time on or after the Series&nbsp;B Original Issue Date combine the outstanding shares of Common Stock, the applicable Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding.&#160; Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.6
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Adjustment for Certain Dividends and Distributions
</U>
	.&#160; In the event the Corporation at any time or from time to time on or after the Series&nbsp;B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the applicable Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(1)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(2)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Notwithstanding the foregoing, (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the applicable Conversion Price shall be recomputed accordingly as of the close of business on such record date
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	22
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_22_143340_7056">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=22,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=945704,FOLIO='22',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage65"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	and thereafter the applicable Conversion Price shall be adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of the applicable series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.7
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Adjustments for Other Dividends and Distributions
</U>
	.&#160; In the event the Corporation at any time or from time to time on or after the Series&nbsp;B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of
<U>
	Section&nbsp;1
</U>
	do not apply to such dividend or distribution, then and in each such event the holders of each series of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.8
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Adjustment for Merger or Reorganization,&nbsp;etc
</U>
	.&#160; Subject to the provisions of
<U>
	Subsection 2.3
</U>
	, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by
<U>
	Subsections 4.4
</U>
	,
<U>
	4.6
</U>
	or
<U>
	4.7
</U>
	), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of each series of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one each share of such series of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors of the Corporation) shall be made in the application of the provisions in this
<U>
	Section&nbsp;4
</U>
	with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this
<U>
	Section&nbsp;4
</U>
	(including provisions with respect to changes in and other adjustments of the applicable Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.&#160; For the avoidance of doubt, nothing in this
<U>
	Subsection 4.8
</U>
	shall be construed as preventing the holders of Preferred Stock from seeking any appraisal rights to which they are otherwise entitled under the DGCL in connection with a merger triggering an adjustment hereunder, nor shall this
<U>
	Subsection 4.8
</U>
	be deemed conclusive evidence of the fair value of the shares of Preferred Stock in any such appraisal proceeding.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.9
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Certificate as to Adjustments
</U>
	.&#160; Upon the occurrence of each adjustment or readjustment of the applicable Conversion Price pursuant to this
<U>
	Section&nbsp;4
</U>
	, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10)&nbsp;days thereafter, compute such adjustment or readjustment in accordance with the
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	23
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_23_143413_5335">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=23,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=983960,FOLIO='23',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage66"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	terms hereof and furnish to each holder of the applicable series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the applicable series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based.&#160; The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than ten (10)&nbsp;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the applicable Conversion Price then in effect, and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each series of Preferred Stock owned and held by such holder.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.10
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Notice of Record Date
</U>
	.&#160; In the event:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(a)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any other security; or
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(b)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:2.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(c)
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to each series of Preferred Stock and the Common Stock.&#160; Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Mandatory Conversion
</U>
	.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5.1
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Trigger Events
</U>
	.&#160; Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public at a price of at least $5.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $30,000,000 of proceeds, net of the underwriting discount and
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	24
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_24_143516_5796">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=24,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=521086,FOLIO='24',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage67"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	commissions, to the Corporation (a &#147;
<B>
	Qualified Public Offering
</B>
	&#148;) or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least sixty six and two thirds percent (66 2/3%) of the then outstanding shares of Preferred Stock and at least sixty six and two thirds percent (66 2/3%) of the outstanding shares Series&nbsp;B Preferred Stock (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the &#147;
<B>
	Mandatory Conversion Time
</B>
	&#148;), (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective applicable conversion rate and (ii)&nbsp;such shares may not be reissued by the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5.2
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Procedural Requirements
</U>
	.&#160; All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this
<U>
	Section&nbsp;5
</U>
	.&#160; Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time.&#160; Upon receipt of such notice, each holder of shares of Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice.&#160; If so required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing.&#160; All rights with respect to the Preferred Stock converted pursuant to
<U>
	Subsection 5.1
</U>
	, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender the certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of their certificate or certificates (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this
<U>
	Subsection 5.2
</U>
	.&#160; As soon as practicable after the Mandatory Conversion Time and the surrender of the certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof, together with cash as provided in
<U>
	Subsection 4.2
</U>
	in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted.&#160; Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	6.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Redeemed or Otherwise Acquired Shares
</U>
	.&#160; Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred.&#160; Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	25
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_25_143602_2897">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=25,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=708280,FOLIO='25',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage68"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	7.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Waiver
</U>
	.&#160; Any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the shares of Preferred Stock then outstanding, considered as a single class.&#160; Any of the rights, powers, preferences and other terms of the Series&nbsp;A-1 Preferred Stock set forth herein may be waived on behalf of all holders of Series&nbsp;A-1 Preferred Stock by the affirmative written consent or vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the shares of Series&nbsp;A-1 Preferred Stock then outstanding.&#160; Any of the rights, powers, preferences and other terms of the Series&nbsp;A-2 Preferred Stock set forth herein may be waived on behalf of all holders of Series&nbsp;A-2 Preferred Stock by the affirmative written consent or vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the shares of Series&nbsp;A-2 Preferred Stock then outstanding.&#160; Any of the rights, powers, preferences and other terms of the Series&nbsp;A-3 Preferred Stock set forth herein may be waived on behalf of all holders of Series&nbsp;A-3 Preferred Stock by the affirmative written consent or vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the shares of Series&nbsp;A-3 Preferred Stock then outstanding.&#160; Any of the rights, powers, preferences and other terms of the Series&nbsp;B Preferred Stock set forth herein may be waived on behalf of all holders of Series&nbsp;B Preferred Stock by the affirmative written consent or vote of the holders of at least sixty six and two thirds percent (66 2/3%) of the shares of Series&nbsp;B Preferred Stock then outstanding.&#160; The rights, powers, preferences and other terms of the Series&nbsp;A-1 Preferred Stock, Series&nbsp;A-2 Preferred Stock, Series&nbsp;A-3 Preferred Stock or Series&nbsp;B Preferred Stock as the case may be, may not be waived with respect to any particular holder without such holder&#146;s consent unless such waiver applies to all holders of the same class and series of stock in the same fashion.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	8.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Notices
</U>
	.&#160; Any notice required or permitted by the provisions of this Article&nbsp;Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	FIFTH:&#160;
</FONT>
</B>
	Subject to any additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SIXTH:&#160;
</FONT>
</B>
	Subject to any additional vote required by the Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SEVENTH:&#160;
</FONT>
</B>
	Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	EIGHTH:&#160;
</FONT>
</B>
	Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide.&#160; The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	26
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_26_143633_3020">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=26,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=897846,FOLIO='26',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage69"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	NINTH:&#160;
</FONT>
</B>
	To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.&#160; If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article&nbsp;Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Any repeal or modification of the foregoing provisions of this Article&nbsp;Ninth by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	TENTH:&#160;
</FONT>
</B>
	To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Any amendment, repeal or modification of the foregoing provisions of this Article&nbsp;Tenth shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	*&#160;&#160;&#160;&#160; *&#160;&#160;&#160;&#160; *
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	3.
</FONT>
</B>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	4.
</FONT>
</B>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	That this Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	27
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-05_PB_27_143706_7748">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=27,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=75822,FOLIO='27',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<A NAME="eolPage70"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:1.0IN;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	IN WITNESS WHEREOF
</FONT>
</B>
	, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 8
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
	&#160;day of October, 2014.
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="46%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:46.66%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Nancy Simonian, M.D.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="46%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:46.66%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name: Nancy Simonian, M.D.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.34%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="46%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:46.66%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Title: Chief Executive Officer and President
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=28,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=883058,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-05_ZCT79602.CHC",USER="JVANGB",CD='NOV 8 23:55 2015' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	CERTIFICATE OF AMENDMENT OF
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<HR SIZE="1" WIDTH="25%" NOSHADE ALIGN="CENTER" STYLE="COLOR:BLACK;">
</DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Pursuant to Section&nbsp;242 of the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	General Corporation Law of the State of Delaware)
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<HR SIZE="1" WIDTH="25%" NOSHADE ALIGN="CENTER" STYLE="COLOR:BLACK;">
</DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Syros Pharmaceuticals,&nbsp;Inc. (the &#147;
<B>
	Corporation
</B>
	&#148;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended (the &#147;
<B>
	Restated Certificate
</B>
	&#148;), and declaring such amendment to be advisable.&#160; The stockholders of the Corporation duly approved and adopted such proposed amendment by written consent in accordance with Sections 228 and 242 of the General Corporation Law of the State of Delaware.&#160; Accordingly, to effect such proposed amendment, it is:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 99.0PT;TEXT-INDENT:-99.0PT;">
<B>
<U>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	RESOLVED
</FONT>
</U>
	:
</B>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	That the first paragraph of Article&nbsp;FOURTH of the Restated Certificate be and hereby is deleted in its entirety and the following is inserted in lieu thereof:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 99.0PT;TEXT-INDENT:27.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
</FONT>
	The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 66,171,908 shares of Common Stock, and (ii)&nbsp;47,243,931 shares of Preferred Stock, par value $0.001 per share (&#147;
<B>
	Preferred Stock
</B>
	&#148;), of which 2,500,000 shares have been designated as &#147;
<B>
	Series A-1 Preferred Stock
</B>
	,&#148; 12,100,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-2 Preferred Stock
</B>
	,&#148; 15,750,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-3 Preferred Stock
</B>
	&#148; (together, the &#147;
<B>
	Series&nbsp;A Preferred Stock
</B>
	&#148;) and 16,893,931 shares have been designated as &#147;
<B>
	Series&nbsp;B Preferred Stock
</B>
	.&#148;&#148;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=29,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=790429,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-13_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 03:19 2016' -->
<A NAME="eolPage71"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	IN WITNESS WHEREOF, the Corporation has caused its corporate seal to be affixed hereto and this Certificate of Amendment of Third Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of December, 2015.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	&nbsp;
</FONT>
</B>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Kyle D. Kuvalanka
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Kyle D. Kuvalanka
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Chief Operating Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	2
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-13_PB_2_234713_7980">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=30,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=788742,FOLIO='2',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-13_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 03:19 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	&nbsp;
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	CERTIFICATE OF AMENDMENT TO THIRD
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	(Pursuant to Section&nbsp;242 of the
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	General Corporation Law of the State of Delaware)
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	It is hereby certified that:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The name of the corporation (the &#147;
<B>
	Corporation
</B>
	&#148;) is Syros Pharmaceuticals,&nbsp;Inc.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The first sentence of Article&nbsp;Fourth of the Corporation&#146;s Third Amended and Restated Certificate of Incorporation is hereby amended by deleting such sentence and substituting the following in lieu thereof:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;
<B>
	FOURTH:
</B>
	The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 78,886,062 shares of Common Stock, $0.001 par value per share (&#147;
<B>
	Common Stock
</B>
	&#148;), and (ii)&nbsp;59,958,085 shares of Preferred Stock, $0.001 par value per share (&#147;
<B>
	Preferred Stock
</B>
	&#148;), of which 2,500,000 shares have been designated as &#147;
<B>
	Series A-1 Preferred Stock
</B>
	,&#148; 12,100,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-2 Preferred Stock
</B>
	,&#148; 15,750,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-3 Preferred Stock
</B>
	&#148; (together, the &#147;
<B>
	Series&nbsp;A Preferred Stock
</B>
	&#148;) and 29,608,085 shares have been designated as &#147;
<B>
	Series&nbsp;B Preferred Stock
</B>
	.&#148;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Subsection 1.2 of Part&nbsp;C of Article&nbsp;Fourth of the Corporation&#146;s Third Amended and Restated Certificate of Incorporation is hereby amended by deleting the reference to Subsection 2.1 contained therein and substituting a reference to Subsection 2.2 in lieu thereof.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Subsection 3.2 of Part&nbsp;C of Article&nbsp;Fourth of the Corporation&#146;s Third Amended and Restated Certificate of Incorporation is hereby amended by deleting such subsection in its entirety and substituting the following in lieu thereof:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;3.2
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<U>
	Election of Directors
</U>
	.&#160; The holders of record of the shares of Series&nbsp;A Preferred Stock, exclusively and as a separate class, shall be entitled to elect two directors of the Corporation (the &#147;
<B>
	Series&nbsp;A Directors
</B>
	&#148;), and the holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect two directors of the Corporation (the &#147;
<B>
	Series&nbsp;B Directors
</B>
	&#148;).&#160; Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of shares of Series&nbsp;A Preferred Stock or Series&nbsp;B Preferred Stock, as applicable, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.&#160; If the holders of shares of Series&nbsp;A Preferred Stock or the holders of shares of Series&nbsp;B Preferred Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this
<U>
	Subsection 3.2
</U>
	, then any directorship not so filled shall
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=31,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=815731,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-15_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 00:05 2016' -->
<A NAME="eolPage72"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	remain vacant until such time as the holders of the Series&nbsp;A Preferred Stock or the holders of the Series&nbsp;B Preferred Stock, as the case may be, elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series&nbsp;A Preferred Stock and Series B Preferred Stock), voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation.&#160; At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director.&#160; Except as otherwise provided in this
<U>
	Subsection 3.2
</U>
	, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this
<U>
	Subsection 3.2
</U>
	.&#148;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	5.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The last sentence of Subsection 4.1.1 of Part&nbsp;C of Article&nbsp;Fourth of the Corporation&#146;s Third Amended and Restated Certificate of Incorporation is hereby amended by deleting such sentence and substituting the following in lieu thereof:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;Such initial Conversion Prices, and the rates at which shares of each series of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below.&#148;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	6.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Subsection 4.4.1(g)&nbsp;of Part&nbsp;C of Article&nbsp;Fourth of the Corporation&#146;s Third Amended and Restated Certificate of Incorporation is hereby amended by deleting each instance of the phrase &#147;including at least one Series&nbsp;A Director&#148; contained therein and substituting the phrase &#147;including at least one Series&nbsp;A Director and at least one Series&nbsp;B Director&#148; in lieu thereof.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	7.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	Subsections 4.4.4(a)(iii)&nbsp;and 4.4.4(b)(iii)&nbsp;of Part&nbsp;C of Article&nbsp;Fourth of the Corporation&#146;s Third Amended and Restated Certificate of Incorporation are hereby amended by deleting each instance of the parenthetical &#147;(including the Series A Preferred Stock)&#148; contained therein and substituting the parenthetical &#147;(including the Preferred Stock)&#148; in lieu thereof.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	8.
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	The Board of Directors of the Corporation duly adopted, pursuant to Section&nbsp;141 and Section 242 of the General Corporation Law of the State of Delaware, a resolution setting forth this amendment to the Third Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that the amendment proposed be considered by the stockholders of the Corporation.&#160; The amendment to the Third Amended and Restated Certificate of Incorporation herein certified has been duly approved by written consent of the stockholders of the Corporation in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=32,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=524384,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-15_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 00:05 2016' -->
<A NAME="eolPage73"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its President this 11th day of January, 2016.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Nancy Simonian
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Name: Nancy Simonian, M.D.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Title: Chief Executive Officer and President
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Certificate of Amendment to Third Amended and Restated Certificate of Incorporation
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=33,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=335839,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-15_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 00:05 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	CERTIFICATE OF AMENDMENT OF
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF
</FONT>
</B>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<HR SIZE="1" WIDTH="25%" NOSHADE ALIGN="CENTER" STYLE="COLOR:BLACK;">
</DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	(Pursuant to Section&nbsp;242 of the
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	General Corporation Law of the State of Delaware)
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<HR SIZE="1" WIDTH="25%" NOSHADE ALIGN="CENTER" STYLE="COLOR:BLACK;">
</DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Syros Pharmaceuticals,&nbsp;Inc. (the &#147;
<B>
	Corporation
</B>
	&#148;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section&nbsp;242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended (the &#147;
<B>
	Restated Certificate
</B>
	&#148;), and declaring such amendment to be advisable.&#160; The stockholders of the Corporation duly approved and adopted such proposed amendment by written consent in accordance with Sections 228 and 242 of the General Corporation Law of the State of Delaware.&#160; Accordingly, to effect such proposed amendment, it is:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 99.0PT;TEXT-INDENT:-99.0PT;">
<B>
<U>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	RESOLVED
</FONT>
</U>
	:
</B>
<FONT SIZE="1" STYLE="FONT-SIZE:3.0PT;">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
	That the first paragraph of Article&nbsp;FOURTH of the Restated Certificate be and hereby is deleted in its entirety and the following is inserted in lieu thereof:
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 99.0PT;TEXT-INDENT:27.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;Upon the filing of this Certificate of Amendment of Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#147;
<B>
	Effective Time
</B>
	&#148;), a one-for-3.75 reverse stock split of the Corporation&#146;s common stock, $0.001 par value per share (the &#147;
<B>
	Common Stock
</B>
	&#148;), shall become effective, pursuant to which each 3.75 shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares designated as the
<B>
	&#147;Reverse Stock Split&#148;
</B>
	). The par value of the Common Stock following the Reverse Stock Split shall be $0.001 par value per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=34,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=164663,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-17_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 00:05 2016' -->
<A NAME="eolPage74"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 99.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	receive a cash payment equal to the fraction of which such holder would otherwise be entitled multiplied by the fair value per share as determined by the Board of Directors of the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT 99.0PT;TEXT-INDENT:45.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT 99.0PT;TEXT-INDENT:27.0PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:10.0PT;">
	The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 76,171,908 shares of Common Stock, and (ii)&nbsp;47,243,931 shares of Preferred Stock, par value $0.001 per share (&#147;
<B>
	Preferred Stock
</B>
	&#148;),
</FONT>
	of which 2,500,000 shares have been designated as &#147;
<B>
	Series A-1 Preferred Stock
</B>
	,&#148; 12,100,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-2 Preferred Stock
</B>
	,&#148; 15,750,000 shares have been designated as &#147;
<B>
	Series&nbsp;A-3 Preferred Stock
</B>
	&#148; (together, the &#147;
<B>
	Series&nbsp;A Preferred Stock
</B>
	&#148;) and 16,893,931 shares have been designated as &#147;
<B>
	Series&nbsp;B Preferred Stock
</B>
	.&#148;
</FONT>
	&#148;
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	2
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-17_PB_2_235814_8831">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=35,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=1018750,FOLIO='2',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-17_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 00:05 2016' -->
<A NAME="eolPage75"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	IN WITNESS WHEREOF, the Corporation has caused its corporate seal to be affixed hereto and this Certificate of Amendment of Third Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 17
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
	&#160;day of June, 2016.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Nancy Simonian
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Nancy Simonian, M.D.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	President and Chief Executive Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
	3
<A NAME="A2228976ZEX-3_1_HTM_22596-2-KK-17_PB_3_235826_7056">
</A>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=36,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=780467,FOLIO='3',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-17_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 00:05 2016' -->
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF AMENDMENT OF
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Syros Pharmaceuticals,&nbsp;Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware,
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	DOES HEREBY CERTIFY:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	1.&#160; The name of the Corporation is Syros Pharmaceuticals,&nbsp;Inc.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	2.&#160; That a Certificate of Amendment (&#147;Certificate&#148;) of Third Amended and Restated Certificate of Incorporation (&#147;Certificate of Incorporation&#148;) was filed with the Secretary of State of Delaware on June&nbsp;17, 2016 and that said Certificate requires correction as permitted by Section&nbsp;103 of the General Corporation Law of the State of Delaware.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	3.&#160; The inaccuracy or defect of said Certificate to be corrected is as follows:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The amendment to the Certificate of Incorporation set forth in the Certificate incorrectly restated the first paragraph of Article FOURTH
</FONT>
	of the Certificate of Incorporation.&#160; Instead, the amendment set forth in the Certificate should have amended Article FOURTH of the Certificate of Incorporation merely to add to said Article&nbsp;the language necessary to effect the reverse stock split described therein.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	4.&#160; The amendment set forth in the Certificate is hereby corrected to read as follows:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	That Article&nbsp;FOURTH of the Restated Certificate be and hereby is amended in order to add the following two paragraphs as the first two paragraphs of such Article&nbsp;FOURTH:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&#147;Upon the filing of this Certificate of Amendment of Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#147;
<B>
	Effective Time
</B>
	&#148;), a one-for-3.75 reverse stock split of the Corporation&#146;s common stock, $0.001 par value per share (the &#147;
<B>
	Common Stock
</B>
	&#148;), shall become effective, pursuant to which each 3.75 shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares designated as the
<B>
	&#147;Reverse Stock Split&#148;
</B>
	). The par value of the Common Stock following the Reverse Stock Split shall be $0.001 par value per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=37,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=632454,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-19_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 01:32 2016' -->
<A NAME="eolPage76"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment equal to the fraction of which such holder would otherwise be entitled multiplied by the fair value per share as determined by the Board of Directors of the Corporation.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT .5IN;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified.&#148;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=38,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=532488,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-19_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 01:32 2016' -->
<A NAME="eolPage77"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV STYLE="FONT-FAMILY:TIMES NEW ROMAN;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE:10.0PT;MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	IN WITNESS WHEREOF, the Corporation has caused this Certificate of Correction to be signed by its Chief Executive Officer this 20
</FONT>
<FONT SIZE="1" STYLE="FONT-SIZE:6.5PT;POSITION:RELATIVE;TOP:-3.0PT;">
	th
</FONT>
	&#160;day of June, 2016.
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	SYROS PHARMACEUTICALS,&nbsp;INC.
</FONT>
</B>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="4%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:4.16%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="45%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:45.84%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Kyle D. Kuvalanka
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Kyle D. Kuvalanka
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Chief Operating Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
</EFX_CERTIFICATE_OF_INCORPORATION>
<!-- ZEQ.=1,SEQ=39,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="3",CHK=712965,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KK-19_ZCT79602.CHC",USER="JVANGB",CD='JUN 20 01:32 2016' -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_3>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage78"></A>
<A NAME="A2228976ZEX-5_1_HTM"></A>
<EFX_EXHIBIT_5>
<A NAME="FIS_EXHIBIT_5"></A>
<BR>
<DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_56"></A>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Exhibit 5.1
</FONT>
</B>
</P>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN">
<IMG WIDTH="148" HEIGHT="28" SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G225962KII001.GIF">
</FONT>
</P>
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<B>
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;FONT-WEIGHT:BOLD;">
	Steven D. Singer
</FONT>
</B>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	+1 617 526 6410 (t)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	June 20, 2016
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	+1 617 526 5000 (f)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="50%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.0%;">
<P ALIGN="RIGHT" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:RIGHT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	steven.singer@wilmerhale.com
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Syros Pharmaceuticals, Inc.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	620 Memorial Drive
<BR>
	Suite 300
<BR>
	Cambridge, MA
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Re:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<U>
	Registration Statement on Form S-1
</U>
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Ladies and Gentlemen:
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	This opinion is furnished to you in connection with a Registration Statement on Form S-1 (File No. 333-211818) (the &#147;Registration Statement&#148;) filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for the registration of 4,600,000 shares of Common Stock, $0.001 par value per share (the &#147;Shares&#148;), of Syros Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), including 600,000 Shares issuable upon exercise of an over-allotment option granted by the Company.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	The Shares are to be sold by the Company pursuant to an underwriting agreement (the &#147;Underwriting Agreement&#148;) to be entered into by and among the Company and Cowen and Company, LLC and Piper Jaffray &amp; Co. as representatives of the several underwriters named in the Underwriting Agreement, the form of which has been filed as Exhibit 1 to the Registration Statement.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares.&#160; We have examined signed copies of the Registration Statement as filed with the Commission.&#160; We have also examined and relied upon the Underwriting Agreement, minutes of meetings of the stockholders and the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided to us by the Company, the Certificate of Incorporation and By-Laws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN">
<IMG WIDTH="720" HEIGHT="51" SRC="http://content.edgar-online.com/edgar_conv_img/2016/06/20/0001047469-16-013884_G225962KII002.GIF">
</FONT>
</P>
<P ALIGN="CENTER" STYLE="MARGIN:0IN 0IN .0001PT;TEXT-ALIGN:CENTER;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=1,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="4",CHK=808676,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KI_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 08:42 2016' -->
<A NAME="eolPage79"></A>
<BR CLEAR="ALL" STYLE="PAGE-BREAK-BEFORE:ALWAYS;">
<DIV>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.&#160; This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;TEXT-INDENT:.5IN;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus under the caption &#147;Validity of Common Stock.&#148;&#160; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
</FONT>
</P>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="BORDER-COLLAPSE:COLLAPSE;">
<TR>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Very truly yours,
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	WILMER CUTLER PICKERING
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	HALE AND DORR LLP
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="50%" COLSPAN="2" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:50.02%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	By:
</FONT>
</P>
</TD>
<TD WIDTH="46%" VALIGN="TOP" STYLE="BORDER:NONE;BORDER-BOTTOM:SOLID WINDOWTEXT 1.0PT;PADDING:0IN 0IN 0IN 0IN;WIDTH:46.1%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	/s/ Steven D. Singer
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD WIDTH="3%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:3.92%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
<TD WIDTH="46%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:46.1%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	Steven D. Singer, a Partner
</FONT>
</P>
</TD>
<TD WIDTH="49%" VALIGN="TOP" STYLE="PADDING:0IN 0IN 0IN 0IN;WIDTH:49.98%;">
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:1.0PT;">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN:0IN 0IN .0001PT;">
<FONT SIZE="2" FACE="TIMES NEW ROMAN" STYLE="FONT-SIZE:10.0PT;">
	&nbsp;
</FONT>
</P>
<DIV STYLE="MARGIN:0IN 0IN .0001PT;">
<HR SIZE="3" WIDTH="100%" NOSHADE ALIGN="LEFT" STYLE="COLOR:#010101;">
</DIV>
</DIV>
<!-- ZEQ.=1,SEQ=2,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="4",CHK=717327,FOLIO='',FILE="DISK125:[15ZCT2.15ZCT79602]22596-2-KI_ZCT79602.CHC",USER="JVANGB",CD='JUN 18 08:42 2016' -->
<BR>
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_5>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage80"></A>
<A NAME="A2228976ZEX-23_1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<BR>
<FONT SIZE=3>
<A HREF="#A2228976ZEX-23_1_HTM_15ZCT79601_5">
	QuickLinks
</A>
</FONT>
<FONT SIZE=3>
	-- Click here to rapidly navigate through this document
</FONT>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<!-- COMMAND=ADD_BASECOLOR,"BLACK" -->
<!-- COMMAND=ADD_DEFAULTFONT,"FONT-FAMILY:TIMES;" -->
<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->
<!-- COMMAND=ADD_STABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;" -->
<!-- COMMAND=ADD_DTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;" -->
<!-- COMMAND=ADD_SCRTABLERULES,"BORDER-BOTTOM:SOLID #000000 1.0PT;MARGIN-BOTTOM:0PT;" -->
<!-- COMMAND=ADD_DCRTABLERULES,"BORDER-BOTTOM:DOUBLE #000000 2.25PT;MARGIN-BOTTOM:0PT;" -->
</FONT>
</P>
<!-- TOC_END -->
<P ALIGN="RIGHT" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZEX-23_1_HTM_KE79601_EXHIBIT_23_1">
</A>
<A NAME="A2228976ZEX-23_1_HTM_TOC_KE79601_1">
</A>
<BR>
</FONT>
<FONT SIZE=2>
<B>
	Exhibit 23.1
<BR>
</B>
</FONT>
</P>
<P ALIGN="CENTER" STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
<A NAME="A2228976ZEX-23_1_HTM_KE79601_CONSENT_OF_INDEPENDENT__KE702323">
</A>
<A NAME="A2228976ZEX-23_1_HTM_TOC_KE79601_2">
</A>
</FONT>
<FONT SIZE=2>
<B>
	Consent of Independent Registered Public Accounting Firm
<BR>
</B>
</FONT>
</P>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" and to the use of our report dated April&nbsp;18, 2016 (except
	for Note 16(B), as to which the date is June&nbsp;20, 2016), in Amendment No.&nbsp;1 to the Registration Statement (Form&nbsp;S-1 No.&nbsp;333-211818) and related Prospectus of Syros
	Pharmaceuticals,&nbsp;Inc. dated June&nbsp;20, 2016.
</FONT>
</P>
<DIV STYLE="PADDING:0PT;POSITION:RELATIVE;WIDTH:80%;MARGIN-LEFT:10%;">
<P STYLE="FONT-FAMILY:TIMES;">
</FONT>
</P>
<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- USER-SPECIFIED TAGGED TABLE -->
<DIV ALIGN="CENTER">
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="12PT" STYLE="FONT-FAMILY:TIMES;">
</TD>
<TD WIDTH="48%" STYLE="FONT-FAMILY:TIMES;">
</TD>
<!-- TABLE COLUMN WIDTHS END -->
</TR>
<TR VALIGN="TOP">
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	/s/ Ernst&nbsp;&amp; Young&nbsp;LLP
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- END OF USER-SPECIFIED TAGGED TABLE -->
</DIV>
<P STYLE="FONT-FAMILY:TIMES;">
<FONT SIZE=2>
	Boston,
	Massachusetts
<BR>
	June&nbsp;20, 2016
</FONT>
</P>
<HR NOSHADE>
<P STYLE='FONT-FAMILY:TIMES;PAGE-BREAK-BEFORE:ALWAYS'>
</P>
<!-- ZEQ.=1,SEQ=1,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="5",CHK=87925,FOLIO='BLANK',FILE='DISK124:[15ZCT1.15ZCT79601]KE79601A.;12',USER='PANDERS',CD='18-JUN-2016;15:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P>
<BR>
<A NAME="A2228976ZEX-23_1_HTM_15ZCT79601_5">
	QuickLinks
</A>
<BR>
</P>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZEX-23_1_HTM_TOC_KE79601_1">
	Exhibit 23.1
</A>
</FONT>
<BR>
</UL>
<FONT SIZE=2 STYLE="FONT-FAMILY:TIMES;">
<A HREF="#A2228976ZEX-23_1_HTM_TOC_KE79601_2">
	Consent of Independent Registered Public Accounting Firm
</A>
</FONT>
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JVANGB,SEQ=,EFW="2228976",CP="SYROS PHARMACEUTICALS INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</EFX_EXHIBIT_23>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
